[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fYVpdlKzPVkQxgeiooDXNQuFnVyPE_FAaq_dWFMVEfVM":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":84,"rows":91},"Medical University of Vienna",[4],1086,false,151,67,1836957,68,747,[14,17,20,23,26,28,31,33],{"name":15,"count":16},"Healthy",27,{"name":18,"count":19},"Regional Blood Flow",21,{"name":21,"count":22},"Ocular Physiology",18,{"name":24,"count":25},"Cataract",15,{"name":27,"count":25},"Glaucoma",{"name":29,"count":30},"Dry Eye Syndromes",12,{"name":32,"count":30},"Coronary Artery Disease",{"name":34,"count":35},"Critical Illness",11,[37,42,47,52,57,62,66,71,75,79],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT03617133","Image Guided IMRT, Radiochemotherapy and MRI-based IGABT in Locally Advanced Cervical Cancer","2021-12-31","Systemic application of simultaneous chemotherapy",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT06597916","RSV Vaccination in Immunocompromised Patients.","2025-08-31","Arexvy powder and suspension for",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT05655754","Comparison of Esketamine\u002FPropofol and Methohexital Anesthesia for ECT","2025-10-31","Methohexital",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT02669953","Aflibercept in Recurrent or Persistent CNV","2025-11","Aflibercept",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT02652169","PRF With Topical Antibiotics or Antiseptics in Chronical Wounds Version 1.4","2025-12","PRF mixed with amikacin and teicoplanin",{"nctId":63,"briefTitle":64,"date":60,"intervention":65},"NCT04628429","CGRP Inhibition, Autonomic Function, and Migraine","Erenumab",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT06643403","Age-related Changes in Retinal Oxygen Extraction in Healthy Subjects","2025-12-31","Oxygen 100% Gas for Inhalation",{"nctId":72,"briefTitle":73,"date":69,"intervention":74},"NCT05093374","Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting","anti-VEGF agent",{"nctId":76,"briefTitle":77,"date":69,"intervention":78},"NCT06025487","Meningococcal B Vaccine in Patients with Asplenia","Bexsero",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT05042830","Contribution of Nasal IgE Production to the Boost of Systemic Allergen-specific IgE Upon Nasal Allergen Contact","2026-01","Nasal specimen collection",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,140,181,203,230,248,269,296,319,337,363,381,399,417,435,460,496,532,557,579,600,624,646,683,701,719,737,755,773,791,809,827,892,919,937,963,992,1010,1028,1076,1148,1204,1236,1274,1297,1323,1346,1364,1382,1408,1426,1444,1462,1480,1498,1516,1534,1552,1575,1593,1611,1635,1657,1675,1701,1726,1751,1769,1790,1828,1882,1945,1997,2059,2090,2140,2176,2215,2237,2259,2298,2343,2378,2405,2441,2466,2484,2508,2526,2550,2568,2586,2612,2638,2656,2685,2703,2724,2750,2775,2799,2823,2846,2870,2895,2913,2931,2954,2977,2995,3013,3036,3061,3086,3104,3127,3150,3172,3194,3216,3240,3267,3295,3313,3338,3363,3390,3408,3432,3450,3468,3486,3511,3537,3555,3579,3603,3621,3647,3665,3692,3710,3731,3749,3771,3793,3817,3835,3853,3875,3898,3921,3948,3966,3991,4016,4043,4061,4088,4106,4124,4148,4166,4190,4213,4231,4249,4275,4293,4311,4329,4352,4370,4388,4406,4424,4442,4460,4490,4508,4530,4548,4566,4592,4610,4631,4659,4677,4695,4722,4748,4766,4784,4807,4830,4848,4873,4891,4909,4957,4992,5014,5032,5057,5075,5102,5120,5145,5163,5189,5213,5231,5252,5276,5294,5319,5343,5367,5392,5410,5435,5453,5479,5497,5522,5546,5564,5582,5600,5618,5636,5654,5672,5690,5708,5726,5748,5769,5797,5815,5833,5851,5876,5899,5924,5946,5968,5991,6014,6037,6055,6081,6105,6126,6149,6173,6198,6216,6240,6272,6315,6350,6380,6412,6438,6465,6487,6505,6530,6548,6566,6592,6615,6639,6657,6678,6703,6721,6743,6769,6787,6805,6823,6847,6865,6890,6908,6935,6953,6971,6989,7013,7031,7054,7072,7093,7117,7144,7162,7180,7202,7225,7248,7266,7284,7310,7328,7350,7375,7393,7416,7441,7464,7485,7507,7529,7552,7570,7595,7619,7640,7664,7691,7709,7730,7755,7773,7796,7814,7837,7855,7873,7900,7918,7936,7954,7977,8000,8018,8036,8060,8078,8101,8119,8143,8171,8189,8207,8225,8243,8268,8290,8308,8334,8356,8382,8400,8418,8436,8463,8481,8499,8517,8535,8597,8634,8673,8716,8756,8784,8814,8843,8873,8900,8931,8957,8989,9018,9040,9062,9087,9109,9136,9169,9200,9227,9259,9290,9312,9333,9356,9379,9401,9423,9441,9459,9481,9499,9517,9535,9553,9571,9599,9617,9635,9658,9680,9704,9726,9748,9774,9798,9819,9842,9866,9884,9909,9927,9945,9967,9990,10012,10030,10053,10075,10100,10118,10136,10159,10177,10198,10220,10238,10256,10277,10298,10322,10343,10367,10391,10412,10434,10452,10475,10493,10519,10537,10555,10579,10601,10625,10643,10665,10683,10705,10723,10745,10767,10789,10814,10838,10861,10879,10901],{"intervention":93,"totalTrials":94,"cells":95},"Unfractionated heparin",2,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":118,"NA":138},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":98},[],{"trials":104,"activeCount":98},[105],{"nctId":106,"briefTitle":107,"status":108,"phases":109,"primaryCompletion":110,"completion":110,"start":111,"enrollment":112,"conditions":113,"interventions":116},"NCT05226442","Safety and Feasibility of Argatroban As Anticoagulant in Adults with ECMO","COMPLETED",[87,88],"2024-07-07","2021-12-01",40,[114,115],"Extracorporeal Membrane Oxygenation Complication","Anticoagulants and Bleeding Disorders",[117,93],"Argatroban",{"trials":119,"activeCount":137,"soonestReadout":125},[120],{"nctId":121,"briefTitle":122,"status":123,"phases":124,"primaryCompletion":125,"completion":126,"start":127,"enrollment":128,"conditions":129,"interventions":134},"NCT06442267","Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support","RECRUITING",[89],"2027-01-30","2027-07-30","2024-07-30",90,[130,131,132,133],"Respiratory Insufficiency","Circulatory Failure","Thromboembolism","Bleeding",[135,136,93],"Enoxaparin Injectable Solution","Argatroban, 1 Mg\u002FmL Intravenous Solution",1,{"trials":139,"activeCount":98},[],{"intervention":141,"totalTrials":94,"cells":142},"Desflurane",{"EARLY_PHASE1":143,"PHASE1":145,"PHASE2":147,"PHASE3":149,"PHASE4":151,"NA":179},{"trials":144,"activeCount":98},[],{"trials":146,"activeCount":98},[],{"trials":148,"activeCount":98},[],{"trials":150,"activeCount":98},[],{"trials":152,"activeCount":137,"soonestReadout":170},[153,166],{"nctId":154,"briefTitle":155,"status":108,"phases":156,"primaryCompletion":157,"completion":157,"start":158,"enrollment":159,"conditions":160,"interventions":164},"NCT05331027","The Effect of Desflurane Versus Sevoflurane on Postoperative Recovery",[89],"2023-06-01","2022-05-01",190,[161,162,163],"Postoperative Recovery","Postoperative Delirium","Difference in Pharmakokinetics of Volatile Anesthetics",[141,165],"Sevoflurane",{"nctId":167,"briefTitle":168,"status":123,"phases":169,"primaryCompletion":170,"completion":171,"start":172,"enrollment":173,"conditions":174,"interventions":177},"NCT05990790","The Effect of Desflurane Versus Sevoflurane Versus Propofol on Postoperative Delirium",[89],"2027-12-31","2028-12-31","2023-09-03",1332,[162,175,176],"Major Noncardiac Surgery","Postoperative Cognitive Dysfunction",[141,165,178],"Propofol",{"trials":180,"activeCount":98},[],{"intervention":165,"totalTrials":94,"cells":182},{"EARLY_PHASE1":183,"PHASE1":185,"PHASE2":187,"PHASE3":189,"PHASE4":191,"NA":201},{"trials":184,"activeCount":98},[],{"trials":186,"activeCount":98},[],{"trials":188,"activeCount":98},[],{"trials":190,"activeCount":98},[],{"trials":192,"activeCount":137,"soonestReadout":170},[193,197],{"nctId":154,"briefTitle":155,"status":108,"phases":194,"primaryCompletion":157,"completion":157,"start":158,"enrollment":159,"conditions":195,"interventions":196},[89],[161,162,163],[141,165],{"nctId":167,"briefTitle":168,"status":123,"phases":198,"primaryCompletion":170,"completion":171,"start":172,"enrollment":173,"conditions":199,"interventions":200},[89],[162,175,176],[141,165,178],{"trials":202,"activeCount":98},[],{"intervention":204,"totalTrials":137,"cells":205},"Platelet Concentrate",{"EARLY_PHASE1":206,"PHASE1":208,"PHASE2":210,"PHASE3":212,"PHASE4":214,"NA":228},{"trials":207,"activeCount":98},[],{"trials":209,"activeCount":98},[],{"trials":211,"activeCount":98},[],{"trials":213,"activeCount":98},[],{"trials":215,"activeCount":137,"soonestReadout":220},[216],{"nctId":217,"briefTitle":218,"status":123,"phases":219,"primaryCompletion":220,"completion":221,"start":222,"enrollment":223,"conditions":224,"interventions":226},"NCT05667805","Coagulation in Cirrhosis",[89],"2027-01-01","2027-03-01","2023-01-19",400,[225],"Liver Cirrhosis",[204,227],"Prothrombin Complex Concentrate",{"trials":229,"activeCount":98},[],{"intervention":227,"totalTrials":137,"cells":231},{"EARLY_PHASE1":232,"PHASE1":234,"PHASE2":236,"PHASE3":238,"PHASE4":240,"NA":246},{"trials":233,"activeCount":98},[],{"trials":235,"activeCount":98},[],{"trials":237,"activeCount":98},[],{"trials":239,"activeCount":98},[],{"trials":241,"activeCount":137,"soonestReadout":220},[242],{"nctId":217,"briefTitle":218,"status":123,"phases":243,"primaryCompletion":220,"completion":221,"start":222,"enrollment":223,"conditions":244,"interventions":245},[89],[225],[204,227],{"trials":247,"activeCount":98},[],{"intervention":74,"totalTrials":137,"cells":249},{"EARLY_PHASE1":250,"PHASE1":252,"PHASE2":254,"PHASE3":256,"PHASE4":258,"NA":267},{"trials":251,"activeCount":98},[],{"trials":253,"activeCount":98},[],{"trials":255,"activeCount":98},[],{"trials":257,"activeCount":98},[],{"trials":259,"activeCount":137,"soonestReadout":69},[260],{"nctId":72,"briefTitle":73,"status":123,"phases":261,"primaryCompletion":69,"completion":69,"start":262,"enrollment":263,"conditions":264,"interventions":266},[89],"2021-03-01",290,[265],"Exudative Macular Degeneration",[74,74],{"trials":268,"activeCount":98},[],{"intervention":270,"totalTrials":137,"cells":271},"Liraglutide daily (0.6-3.0mg, highest tolerable dose) additional to dietological measures and lifestyle optimization suggestions",{"EARLY_PHASE1":272,"PHASE1":274,"PHASE2":276,"PHASE3":278,"PHASE4":280,"NA":294},{"trials":273,"activeCount":98},[],{"trials":275,"activeCount":98},[],{"trials":277,"activeCount":98},[],{"trials":279,"activeCount":98},[],{"trials":281,"activeCount":137,"soonestReadout":287},[282],{"nctId":283,"briefTitle":284,"status":285,"phases":286,"primaryCompletion":287,"completion":288,"start":289,"enrollment":290,"conditions":291,"interventions":293},"NCT06865365","Preoperative Use of Liraglutide Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone","NOT_YET_RECRUITING",[89],"2027-02-01","2028-02-01","2025-05-01",72,[292],"Obesity, Adolescent",[270],{"trials":295,"activeCount":98},[],{"intervention":51,"totalTrials":137,"cells":297},{"EARLY_PHASE1":298,"PHASE1":300,"PHASE2":302,"PHASE3":304,"PHASE4":306,"NA":317},{"trials":299,"activeCount":98},[],{"trials":301,"activeCount":98},[],{"trials":303,"activeCount":98},[],{"trials":305,"activeCount":98},[],{"trials":307,"activeCount":137,"soonestReadout":50},[308],{"nctId":48,"briefTitle":49,"status":123,"phases":309,"primaryCompletion":50,"completion":50,"start":310,"enrollment":311,"conditions":312,"interventions":315},[89],"2022-11-01",100,[313,314],"ECT","Depression",[51,316],"Ketofol",{"trials":318,"activeCount":98},[],{"intervention":316,"totalTrials":137,"cells":320},{"EARLY_PHASE1":321,"PHASE1":323,"PHASE2":325,"PHASE3":327,"PHASE4":329,"NA":335},{"trials":322,"activeCount":98},[],{"trials":324,"activeCount":98},[],{"trials":326,"activeCount":98},[],{"trials":328,"activeCount":98},[],{"trials":330,"activeCount":137,"soonestReadout":50},[331],{"nctId":48,"briefTitle":49,"status":123,"phases":332,"primaryCompletion":50,"completion":50,"start":310,"enrollment":311,"conditions":333,"interventions":334},[89],[313,314],[51,316],{"trials":336,"activeCount":98},[],{"intervention":338,"totalTrials":137,"cells":339},"WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline",{"EARLY_PHASE1":340,"PHASE1":342,"PHASE2":344,"PHASE3":346,"PHASE4":348,"NA":361},{"trials":341,"activeCount":98},[],{"trials":343,"activeCount":98},[],{"trials":345,"activeCount":98},[],{"trials":347,"activeCount":98},[],{"trials":349,"activeCount":137,"soonestReadout":354},[350],{"nctId":351,"briefTitle":352,"status":123,"phases":353,"primaryCompletion":354,"completion":354,"start":355,"enrollment":356,"conditions":357,"interventions":359},"NCT06675851","Reward-specific Changes of the Chemical Messenger Dopamine in the Brain of Healthy and Depressed People",[89],"2026-12","2022-12-01",120,[358],"Major Depressive Disorder (MDD)",[338,360],"Cipralex",{"trials":362,"activeCount":98},[],{"intervention":360,"totalTrials":137,"cells":364},{"EARLY_PHASE1":365,"PHASE1":367,"PHASE2":369,"PHASE3":371,"PHASE4":373,"NA":379},{"trials":366,"activeCount":98},[],{"trials":368,"activeCount":98},[],{"trials":370,"activeCount":98},[],{"trials":372,"activeCount":98},[],{"trials":374,"activeCount":137,"soonestReadout":354},[375],{"nctId":351,"briefTitle":352,"status":123,"phases":376,"primaryCompletion":354,"completion":354,"start":355,"enrollment":356,"conditions":377,"interventions":378},[89],[358],[338,360],{"trials":380,"activeCount":98},[],{"intervention":178,"totalTrials":137,"cells":382},{"EARLY_PHASE1":383,"PHASE1":385,"PHASE2":387,"PHASE3":389,"PHASE4":391,"NA":397},{"trials":384,"activeCount":98},[],{"trials":386,"activeCount":98},[],{"trials":388,"activeCount":98},[],{"trials":390,"activeCount":98},[],{"trials":392,"activeCount":137,"soonestReadout":170},[393],{"nctId":167,"briefTitle":168,"status":123,"phases":394,"primaryCompletion":170,"completion":171,"start":172,"enrollment":173,"conditions":395,"interventions":396},[89],[162,175,176],[141,165,178],{"trials":398,"activeCount":98},[],{"intervention":135,"totalTrials":137,"cells":400},{"EARLY_PHASE1":401,"PHASE1":403,"PHASE2":405,"PHASE3":407,"PHASE4":409,"NA":415},{"trials":402,"activeCount":98},[],{"trials":404,"activeCount":98},[],{"trials":406,"activeCount":98},[],{"trials":408,"activeCount":98},[],{"trials":410,"activeCount":137,"soonestReadout":125},[411],{"nctId":121,"briefTitle":122,"status":123,"phases":412,"primaryCompletion":125,"completion":126,"start":127,"enrollment":128,"conditions":413,"interventions":414},[89],[130,131,132,133],[135,136,93],{"trials":416,"activeCount":98},[],{"intervention":136,"totalTrials":137,"cells":418},{"EARLY_PHASE1":419,"PHASE1":421,"PHASE2":423,"PHASE3":425,"PHASE4":427,"NA":433},{"trials":420,"activeCount":98},[],{"trials":422,"activeCount":98},[],{"trials":424,"activeCount":98},[],{"trials":426,"activeCount":98},[],{"trials":428,"activeCount":137,"soonestReadout":125},[429],{"nctId":121,"briefTitle":122,"status":123,"phases":430,"primaryCompletion":125,"completion":126,"start":127,"enrollment":128,"conditions":431,"interventions":432},[89],[130,131,132,133],[135,136,93],{"trials":434,"activeCount":98},[],{"intervention":436,"totalTrials":137,"cells":437},"Methotrexate",{"EARLY_PHASE1":438,"PHASE1":440,"PHASE2":442,"PHASE3":444,"PHASE4":446,"NA":458},{"trials":439,"activeCount":98},[],{"trials":441,"activeCount":98},[],{"trials":443,"activeCount":98},[],{"trials":445,"activeCount":98},[],{"trials":447,"activeCount":137,"soonestReadout":452},[448],{"nctId":449,"briefTitle":450,"status":123,"phases":451,"primaryCompletion":452,"completion":452,"start":453,"enrollment":454,"conditions":455,"interventions":457},"NCT06649136","MethMax Trial: MAXimising the METHotrexate Therapy Potential in Patients with Active Rheumatoid Arthritis",[89],"2026-09-30","2024-08-12",182,[456],"Rheumatoid Arthritis",[436],{"trials":459,"activeCount":98},[],{"intervention":461,"totalTrials":94,"cells":462},"[177Lu]Lu-PSMA I&T",{"EARLY_PHASE1":463,"PHASE1":465,"PHASE2":467,"PHASE3":490,"PHASE4":492,"NA":494},{"trials":464,"activeCount":98},[],{"trials":466,"activeCount":98},[],{"trials":468,"activeCount":94,"soonestReadout":473},[469,480],{"nctId":470,"briefTitle":471,"status":123,"phases":472,"primaryCompletion":473,"completion":474,"start":475,"enrollment":476,"conditions":477,"interventions":479},"NCT06220188","PSMA-RLT in Biochemically Recurrent PCa",[87],"2026-06","2027-01","2024-01-15",20,[478],"Prostate Cancer Recurrent",[461],{"nctId":481,"briefTitle":482,"status":123,"phases":483,"primaryCompletion":474,"completion":484,"start":485,"enrollment":486,"conditions":487,"interventions":489},"NCT06259123","Neoadjuvant PSMA-RLT in Oligometastatic PCa",[87],"2027-06","2024-02-01",10,[488],"Prostate Cancer",[461],{"trials":491,"activeCount":98},[],{"trials":493,"activeCount":98},[],{"trials":495,"activeCount":98},[],{"intervention":497,"totalTrials":94,"cells":498},"BT200",{"EARLY_PHASE1":499,"PHASE1":501,"PHASE2":503,"PHASE3":526,"PHASE4":528,"NA":530},{"trials":500,"activeCount":98},[],{"trials":502,"activeCount":98},[],{"trials":504,"activeCount":137,"soonestReadout":520},[505,516],{"nctId":506,"briefTitle":507,"status":108,"phases":508,"primaryCompletion":509,"completion":509,"start":510,"enrollment":511,"conditions":512,"interventions":515},"NCT04677803","BT200 in Hereditary Bleeding Disorders",[87],"2021-09-10","2020-12-14",26,[513,514],"Von Willebrand Diseases","Hemophilia A",[497],{"nctId":517,"briefTitle":518,"status":123,"phases":519,"primaryCompletion":520,"completion":520,"start":521,"enrollment":522,"conditions":523,"interventions":525},"NCT07273721","Efficacy and Safety of BT200 (Rondaptivon Pegol) in Patients With Type 2B Von Willebrand Disease",[87],"2026-07-31","2025-08-14",6,[524],"Von Willebrand Disease (VWD), Type 2",[497],{"trials":527,"activeCount":98},[],{"trials":529,"activeCount":98},[],{"trials":531,"activeCount":98},[],{"intervention":533,"totalTrials":137,"cells":534},"Polatuzumab, bendamustin und rituximab",{"EARLY_PHASE1":535,"PHASE1":537,"PHASE2":539,"PHASE3":551,"PHASE4":553,"NA":555},{"trials":536,"activeCount":98},[],{"trials":538,"activeCount":98},[],{"trials":540,"activeCount":137,"soonestReadout":545},[541],{"nctId":542,"briefTitle":543,"status":123,"phases":544,"primaryCompletion":545,"completion":545,"start":546,"enrollment":547,"conditions":548,"interventions":550},"NCT05868395","Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed\u002F Refractory Mantle Cell Lymphoma",[87],"2027-05-24","2024-01-02",16,[549],"Mantle-cell Lymphoma",[533],{"trials":552,"activeCount":98},[],{"trials":554,"activeCount":98},[],{"trials":556,"activeCount":98},[],{"intervention":46,"totalTrials":137,"cells":558},{"EARLY_PHASE1":559,"PHASE1":561,"PHASE2":563,"PHASE3":573,"PHASE4":575,"NA":577},{"trials":560,"activeCount":98},[],{"trials":562,"activeCount":98},[],{"trials":564,"activeCount":137,"soonestReadout":45},[565],{"nctId":43,"briefTitle":44,"status":123,"phases":566,"primaryCompletion":45,"completion":567,"start":568,"enrollment":569,"conditions":570,"interventions":572},[87],"2026-03-31","2024-09-19",200,[571],"RSV Infection",[46],{"trials":574,"activeCount":98},[],{"trials":576,"activeCount":98},[],{"trials":578,"activeCount":98},[],{"intervention":78,"totalTrials":137,"cells":580},{"EARLY_PHASE1":581,"PHASE1":583,"PHASE2":585,"PHASE3":594,"PHASE4":596,"NA":598},{"trials":582,"activeCount":98},[],{"trials":584,"activeCount":98},[],{"trials":586,"activeCount":137,"soonestReadout":69},[587],{"nctId":76,"briefTitle":77,"status":123,"phases":588,"primaryCompletion":69,"completion":69,"start":589,"enrollment":590,"conditions":591,"interventions":593},[87],"2024-03-12",80,[592],"Splenectomy; Status",[78],{"trials":595,"activeCount":98},[],{"trials":597,"activeCount":98},[],{"trials":599,"activeCount":98},[],{"intervention":601,"totalTrials":137,"cells":602},"Datopotamab deruxtecan",{"EARLY_PHASE1":603,"PHASE1":605,"PHASE2":607,"PHASE3":618,"PHASE4":620,"NA":622},{"trials":604,"activeCount":98},[],{"trials":606,"activeCount":98},[],{"trials":608,"activeCount":137,"soonestReadout":613},[609],{"nctId":610,"briefTitle":611,"status":123,"phases":612,"primaryCompletion":613,"completion":613,"start":614,"enrollment":476,"conditions":615,"interventions":617},"NCT05866432","Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases",[87],"2026-05-23","2023-07-01",[616],"Breast Cancer Stage IV",[601],{"trials":619,"activeCount":98},[],{"trials":621,"activeCount":98},[],{"trials":623,"activeCount":98},[],{"intervention":41,"totalTrials":137,"cells":625},{"EARLY_PHASE1":626,"PHASE1":628,"PHASE2":630,"PHASE3":640,"PHASE4":642,"NA":644},{"trials":627,"activeCount":98},[],{"trials":629,"activeCount":98},[],{"trials":631,"activeCount":137,"soonestReadout":40},[632],{"nctId":38,"briefTitle":39,"status":123,"phases":633,"primaryCompletion":40,"completion":634,"start":635,"enrollment":636,"conditions":637,"interventions":639},[87],"2031-04","2016-04",1000,[638],"Uterine Cervical Neoplasms",[41],{"trials":641,"activeCount":98},[],{"trials":643,"activeCount":98},[],{"trials":645,"activeCount":98},[],{"intervention":647,"totalTrials":137,"cells":648},"Thalidomide",{"EARLY_PHASE1":649,"PHASE1":651,"PHASE2":653,"PHASE3":677,"PHASE4":679,"NA":681},{"trials":650,"activeCount":98},[],{"trials":652,"activeCount":98},[],{"trials":654,"activeCount":137,"soonestReadout":659},[655],{"nctId":656,"briefTitle":657,"status":123,"phases":658,"primaryCompletion":659,"completion":659,"start":660,"enrollment":661,"conditions":662,"interventions":667},"NCT01356290","Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors",[87],"2030-04","2014-04",232,[663,664,665,666],"Medulloblastoma Recurrent","Ependymoma Recurrent","ATRT Recurrent","Rare CNS Tumor Recurrent",[668,647,669,670,671,672,673,674,675,676],"Bevacizumab","Celecoxib","Fenofibric acid","Etoposide","Cyclophosphamide","Etoposide phosphate","Cytarabine","Temozolomide","Irinotecan",{"trials":678,"activeCount":98},[],{"trials":680,"activeCount":98},[],{"trials":682,"activeCount":98},[],{"intervention":669,"totalTrials":137,"cells":684},{"EARLY_PHASE1":685,"PHASE1":687,"PHASE2":689,"PHASE3":695,"PHASE4":697,"NA":699},{"trials":686,"activeCount":98},[],{"trials":688,"activeCount":98},[],{"trials":690,"activeCount":137,"soonestReadout":659},[691],{"nctId":656,"briefTitle":657,"status":123,"phases":692,"primaryCompletion":659,"completion":659,"start":660,"enrollment":661,"conditions":693,"interventions":694},[87],[663,664,665,666],[668,647,669,670,671,672,673,674,675,676],{"trials":696,"activeCount":98},[],{"trials":698,"activeCount":98},[],{"trials":700,"activeCount":98},[],{"intervention":670,"totalTrials":137,"cells":702},{"EARLY_PHASE1":703,"PHASE1":705,"PHASE2":707,"PHASE3":713,"PHASE4":715,"NA":717},{"trials":704,"activeCount":98},[],{"trials":706,"activeCount":98},[],{"trials":708,"activeCount":137,"soonestReadout":659},[709],{"nctId":656,"briefTitle":657,"status":123,"phases":710,"primaryCompletion":659,"completion":659,"start":660,"enrollment":661,"conditions":711,"interventions":712},[87],[663,664,665,666],[668,647,669,670,671,672,673,674,675,676],{"trials":714,"activeCount":98},[],{"trials":716,"activeCount":98},[],{"trials":718,"activeCount":98},[],{"intervention":671,"totalTrials":137,"cells":720},{"EARLY_PHASE1":721,"PHASE1":723,"PHASE2":725,"PHASE3":731,"PHASE4":733,"NA":735},{"trials":722,"activeCount":98},[],{"trials":724,"activeCount":98},[],{"trials":726,"activeCount":137,"soonestReadout":659},[727],{"nctId":656,"briefTitle":657,"status":123,"phases":728,"primaryCompletion":659,"completion":659,"start":660,"enrollment":661,"conditions":729,"interventions":730},[87],[663,664,665,666],[668,647,669,670,671,672,673,674,675,676],{"trials":732,"activeCount":98},[],{"trials":734,"activeCount":98},[],{"trials":736,"activeCount":98},[],{"intervention":672,"totalTrials":137,"cells":738},{"EARLY_PHASE1":739,"PHASE1":741,"PHASE2":743,"PHASE3":749,"PHASE4":751,"NA":753},{"trials":740,"activeCount":98},[],{"trials":742,"activeCount":98},[],{"trials":744,"activeCount":137,"soonestReadout":659},[745],{"nctId":656,"briefTitle":657,"status":123,"phases":746,"primaryCompletion":659,"completion":659,"start":660,"enrollment":661,"conditions":747,"interventions":748},[87],[663,664,665,666],[668,647,669,670,671,672,673,674,675,676],{"trials":750,"activeCount":98},[],{"trials":752,"activeCount":98},[],{"trials":754,"activeCount":98},[],{"intervention":673,"totalTrials":137,"cells":756},{"EARLY_PHASE1":757,"PHASE1":759,"PHASE2":761,"PHASE3":767,"PHASE4":769,"NA":771},{"trials":758,"activeCount":98},[],{"trials":760,"activeCount":98},[],{"trials":762,"activeCount":137,"soonestReadout":659},[763],{"nctId":656,"briefTitle":657,"status":123,"phases":764,"primaryCompletion":659,"completion":659,"start":660,"enrollment":661,"conditions":765,"interventions":766},[87],[663,664,665,666],[668,647,669,670,671,672,673,674,675,676],{"trials":768,"activeCount":98},[],{"trials":770,"activeCount":98},[],{"trials":772,"activeCount":98},[],{"intervention":674,"totalTrials":137,"cells":774},{"EARLY_PHASE1":775,"PHASE1":777,"PHASE2":779,"PHASE3":785,"PHASE4":787,"NA":789},{"trials":776,"activeCount":98},[],{"trials":778,"activeCount":98},[],{"trials":780,"activeCount":137,"soonestReadout":659},[781],{"nctId":656,"briefTitle":657,"status":123,"phases":782,"primaryCompletion":659,"completion":659,"start":660,"enrollment":661,"conditions":783,"interventions":784},[87],[663,664,665,666],[668,647,669,670,671,672,673,674,675,676],{"trials":786,"activeCount":98},[],{"trials":788,"activeCount":98},[],{"trials":790,"activeCount":98},[],{"intervention":675,"totalTrials":137,"cells":792},{"EARLY_PHASE1":793,"PHASE1":795,"PHASE2":797,"PHASE3":803,"PHASE4":805,"NA":807},{"trials":794,"activeCount":98},[],{"trials":796,"activeCount":98},[],{"trials":798,"activeCount":137,"soonestReadout":659},[799],{"nctId":656,"briefTitle":657,"status":123,"phases":800,"primaryCompletion":659,"completion":659,"start":660,"enrollment":661,"conditions":801,"interventions":802},[87],[663,664,665,666],[668,647,669,670,671,672,673,674,675,676],{"trials":804,"activeCount":98},[],{"trials":806,"activeCount":98},[],{"trials":808,"activeCount":98},[],{"intervention":676,"totalTrials":137,"cells":810},{"EARLY_PHASE1":811,"PHASE1":813,"PHASE2":815,"PHASE3":821,"PHASE4":823,"NA":825},{"trials":812,"activeCount":98},[],{"trials":814,"activeCount":98},[],{"trials":816,"activeCount":137,"soonestReadout":659},[817],{"nctId":656,"briefTitle":657,"status":123,"phases":818,"primaryCompletion":659,"completion":659,"start":660,"enrollment":661,"conditions":819,"interventions":820},[87],[663,664,665,666],[668,647,669,670,671,672,673,674,675,676],{"trials":822,"activeCount":98},[],{"trials":824,"activeCount":98},[],{"trials":826,"activeCount":98},[],{"intervention":668,"totalTrials":828,"cells":829},5,{"EARLY_PHASE1":830,"PHASE1":832,"PHASE2":834,"PHASE3":865,"PHASE4":867,"NA":880},{"trials":831,"activeCount":98},[],{"trials":833,"activeCount":98},[],{"trials":835,"activeCount":137,"soonestReadout":659},[836,849,861],{"nctId":837,"briefTitle":838,"status":839,"phases":840,"primaryCompletion":841,"completion":842,"start":843,"enrollment":844,"conditions":845,"interventions":847},"NCT00280007","Transarterial Chemoembolisation Plus Bevacizumab for Treatment of Hepatocellular Carcinoma","TERMINATED",[87],"2009-12","2010-12","2006-01",32,[846],"Hepatocellular Carcinoma",[848],"bevacizumab",{"nctId":850,"briefTitle":851,"status":108,"phases":852,"primaryCompletion":853,"completion":853,"start":854,"enrollment":25,"conditions":855,"interventions":859},"NCT01314274","Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)",[87],"2013-06","2011-03",[856,857,858],"HHT","Morbus Osler","Epistaxis",[668,860],"NaCl",{"nctId":656,"briefTitle":657,"status":123,"phases":862,"primaryCompletion":659,"completion":659,"start":660,"enrollment":661,"conditions":863,"interventions":864},[87],[663,664,665,666],[668,647,669,670,671,672,673,674,675,676],{"trials":866,"activeCount":98},[],{"trials":868,"activeCount":98},[869],{"nctId":870,"briefTitle":871,"status":108,"phases":872,"primaryCompletion":873,"completion":873,"start":874,"enrollment":875,"conditions":876,"interventions":878},"NCT00682539","Intraocular Anti-VEGF Compared With Intraocular Triamcinolone in Patients With Diabetic Macular Edema",[89],"2014-07","2007-10",71,[877],"Diabetic Macular Edema",[668,879],"Triamcinolone",{"trials":881,"activeCount":98},[882],{"nctId":883,"briefTitle":884,"status":108,"phases":885,"primaryCompletion":886,"completion":841,"start":887,"enrollment":888,"conditions":889,"interventions":891},"NCT01027468","Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration",[90],"2009-11","2009-08",160,[890],"Neovascular Age-related Macular Degeneration",[668],{"intervention":893,"totalTrials":137,"cells":894},"Psilocybin",{"EARLY_PHASE1":895,"PHASE1":897,"PHASE2":911,"PHASE3":913,"PHASE4":915,"NA":917},{"trials":896,"activeCount":98},[],{"trials":898,"activeCount":137,"soonestReadout":903},[899],{"nctId":900,"briefTitle":901,"status":123,"phases":902,"primaryCompletion":903,"completion":903,"start":904,"enrollment":905,"conditions":906,"interventions":909},"NCT07490353","Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects",[86],"2028-05-31","2025-11-01",85,[907,908],"Depression - Major Depressive Disorder","Anhedonia",[893,910],"Risperidone 1 MG",{"trials":912,"activeCount":98},[],{"trials":914,"activeCount":98},[],{"trials":916,"activeCount":98},[],{"trials":918,"activeCount":98},[],{"intervention":910,"totalTrials":137,"cells":920},{"EARLY_PHASE1":921,"PHASE1":923,"PHASE2":929,"PHASE3":931,"PHASE4":933,"NA":935},{"trials":922,"activeCount":98},[],{"trials":924,"activeCount":137,"soonestReadout":903},[925],{"nctId":900,"briefTitle":901,"status":123,"phases":926,"primaryCompletion":903,"completion":903,"start":904,"enrollment":905,"conditions":927,"interventions":928},[86],[907,908],[893,910],{"trials":930,"activeCount":98},[],{"trials":932,"activeCount":98},[],{"trials":934,"activeCount":98},[],{"trials":936,"activeCount":98},[],{"intervention":938,"totalTrials":137,"cells":939},"MRI contrast-enhancing agents",{"EARLY_PHASE1":940,"PHASE1":953,"PHASE2":955,"PHASE3":957,"PHASE4":959,"NA":961},{"trials":941,"activeCount":137,"soonestReadout":946},[942],{"nctId":943,"briefTitle":944,"status":285,"phases":945,"primaryCompletion":946,"completion":947,"start":948,"enrollment":949,"conditions":950,"interventions":952},"NCT07066436","ImmunoMRI for Assessment of Tumor-associated Macrophages",[85],"2028-03","2028-09","2025-10",60,[951],"DLBCL - Diffuse Large B Cell Lymphoma",[938],{"trials":954,"activeCount":98},[],{"trials":956,"activeCount":98},[],{"trials":958,"activeCount":98},[],{"trials":960,"activeCount":98},[],{"trials":962,"activeCount":98},[],{"intervention":964,"totalTrials":137,"cells":965},"Suzetrigine",{"EARLY_PHASE1":966,"PHASE1":982,"PHASE2":984,"PHASE3":986,"PHASE4":988,"NA":990},{"trials":967,"activeCount":137,"soonestReadout":972},[968],{"nctId":969,"briefTitle":970,"status":123,"phases":971,"primaryCompletion":972,"completion":972,"start":973,"enrollment":974,"conditions":975,"interventions":979},"NCT07511400","The Role of NaV1.8 in Human Pain Models",[85],"2026-10-12","2026-04-21",66,[976,977,978],"Pain","Acute Pain","Healthy Volunteer Study",[964,980,981],"Lidocaine","Control Solution",{"trials":983,"activeCount":98},[],{"trials":985,"activeCount":98},[],{"trials":987,"activeCount":98},[],{"trials":989,"activeCount":98},[],{"trials":991,"activeCount":98},[],{"intervention":980,"totalTrials":137,"cells":993},{"EARLY_PHASE1":994,"PHASE1":1000,"PHASE2":1002,"PHASE3":1004,"PHASE4":1006,"NA":1008},{"trials":995,"activeCount":137,"soonestReadout":972},[996],{"nctId":969,"briefTitle":970,"status":123,"phases":997,"primaryCompletion":972,"completion":972,"start":973,"enrollment":974,"conditions":998,"interventions":999},[85],[976,977,978],[964,980,981],{"trials":1001,"activeCount":98},[],{"trials":1003,"activeCount":98},[],{"trials":1005,"activeCount":98},[],{"trials":1007,"activeCount":98},[],{"trials":1009,"activeCount":98},[],{"intervention":981,"totalTrials":137,"cells":1011},{"EARLY_PHASE1":1012,"PHASE1":1018,"PHASE2":1020,"PHASE3":1022,"PHASE4":1024,"NA":1026},{"trials":1013,"activeCount":137,"soonestReadout":972},[1014],{"nctId":969,"briefTitle":970,"status":123,"phases":1015,"primaryCompletion":972,"completion":972,"start":973,"enrollment":974,"conditions":1016,"interventions":1017},[85],[976,977,978],[964,980,981],{"trials":1019,"activeCount":98},[],{"trials":1021,"activeCount":98},[],{"trials":1023,"activeCount":98},[],{"trials":1025,"activeCount":98},[],{"trials":1027,"activeCount":98},[],{"intervention":1029,"totalTrials":1030,"cells":1031},"Fluid bolus",3,{"EARLY_PHASE1":1032,"PHASE1":1034,"PHASE2":1036,"PHASE3":1038,"PHASE4":1040,"NA":1054},{"trials":1033,"activeCount":98},[],{"trials":1035,"activeCount":98},[],{"trials":1037,"activeCount":98},[],{"trials":1039,"activeCount":98},[],{"trials":1041,"activeCount":98},[1042],{"nctId":1043,"briefTitle":1044,"status":839,"phases":1045,"primaryCompletion":1046,"completion":1046,"start":1047,"enrollment":949,"conditions":1048,"interventions":1049},"NCT02414555","Perioperative Fluid Management in Patients Receiving Major Abdominal Surgery - Effects of Normal Saline Versus an Acetate Buffered Balanced Infusion Solution on the Necessity of Catecholamines for Cardiocirculatory Support",[89],"2016-03","2015-03",[34],[1050,1051,1052,1053],"vasopressor","fluid bolus","Normal Saline","Elo-Mel Isoton",{"trials":1055,"activeCount":94,"soonestReadout":474},[1056,1070],{"nctId":1057,"briefTitle":1058,"status":123,"phases":1059,"primaryCompletion":474,"completion":474,"start":1060,"enrollment":1061,"conditions":1062,"interventions":1069},"NCT06593717","Hemodynamic Monitoring and Fluid Responsiveness in Venovenous Extracorporeal Membrane Oxygenation (VV ECMO) - \"HemodynamECMOnitoring-VV Study\"",[90],"2024-05-03",30,[1063,1064,1065,1066,1067,1068],"ECMO Treatment","ARDS","Pneumonia","Intensive Care","Hemodynamic Monitoring","Fluid Responsiveness",[1029],{"nctId":1071,"briefTitle":1072,"status":123,"phases":1073,"primaryCompletion":474,"completion":474,"start":1060,"enrollment":1061,"conditions":1074,"interventions":1075},"NCT06593756","Hemodynamic Monitoring and Fluid Responsiveness in Venoarterial Extracorporeal Membrane Oxygenation (VA ECMO) - \"HemodynamECMOnitoring-VA Study\"",[90],[1063,1064,1065,1066,1067,1068],[1029],{"intervention":1077,"totalTrials":522,"cells":1078},"Midazolam",{"EARLY_PHASE1":1079,"PHASE1":1081,"PHASE2":1083,"PHASE3":1085,"PHASE4":1087,"NA":1135},{"trials":1080,"activeCount":98},[],{"trials":1082,"activeCount":98},[],{"trials":1084,"activeCount":98},[],{"trials":1086,"activeCount":98},[],{"trials":1088,"activeCount":98},[1089,1102,1110,1117,1127],{"nctId":1090,"briefTitle":1091,"status":1092,"phases":1093,"primaryCompletion":1094,"completion":1095,"start":1096,"enrollment":1097,"conditions":1098,"interventions":1100},"NCT00811837","The Effect of Remifentanil on Established Sunburn-induced Hyperalgesia in Human Volunteers","UNKNOWN",[89],"2009-07","2009-09","2009-01",24,[1099],"Hyperalgesia",[1077,1101],"Remifentanil",{"nctId":1103,"briefTitle":1104,"status":1092,"phases":1105,"primaryCompletion":841,"completion":1106,"start":1107,"enrollment":1097,"conditions":1108,"interventions":1109},"NCT00886106","The Effect of High-dose Remifentanil on Established Capsaicin-induced Hyperalgesia in Human Volunteers",[89],"2010-03","2009-06",[1099],[1101,1077],{"nctId":1111,"briefTitle":1112,"status":1092,"phases":1113,"primaryCompletion":1106,"completion":1114,"start":886,"enrollment":1097,"conditions":1115,"interventions":1116},"NCT01015482","The Effect of High-dose Remifentanil on Established Sunburn-induced Hyperalgesia in Human Volunteers (HighDose RemiSun)",[89],"2010-04",[1099],[1101,1077],{"nctId":1118,"briefTitle":1119,"status":108,"phases":1120,"primaryCompletion":1121,"completion":1121,"start":1122,"enrollment":590,"conditions":1123,"interventions":1125},"NCT03931057","The Use of ADV6209 for Premedication in Pediatric Anesthesia",[89],"2021-09-17","2020-11-16",[1124],"Preanesthetic Medication",[1126,1077],"ADV6209",{"nctId":1128,"briefTitle":1129,"status":1092,"phases":1130,"primaryCompletion":1131,"completion":841,"start":1132,"enrollment":1097,"conditions":1133,"interventions":1134},"NCT00789386","The Effect of Remifentanil on Established Capsaicin-Induced Hyperalgesia in Human Volunteers",[89],"2009-10","2008-11",[1099],[1101,1077],{"trials":1136,"activeCount":137,"soonestReadout":473},[1137],{"nctId":1138,"briefTitle":1139,"status":123,"phases":1140,"primaryCompletion":473,"completion":473,"start":1141,"enrollment":949,"conditions":1142,"interventions":1145},"NCT05577585","Ketamine in OCD: Efficacy and Effects on Stress and Cognition",[90],"2022-10-01",[1143,1144],"Obsessive-Compulsive Disorder","Psychiatric Disorder",[1146,1077,1147],"Ketamine 50 MG\u002FML Blinded","Ketamine 50 MG\u002FML Open Label",{"intervention":1149,"totalTrials":1030,"cells":1150},"Docetaxel",{"EARLY_PHASE1":1151,"PHASE1":1153,"PHASE2":1155,"PHASE3":1177,"PHASE4":1179,"NA":1181},{"trials":1152,"activeCount":98},[],{"trials":1154,"activeCount":98},[],{"trials":1156,"activeCount":98},[1157,1167],{"nctId":1158,"briefTitle":1159,"status":108,"phases":1160,"primaryCompletion":1161,"completion":1161,"start":1046,"enrollment":1162,"conditions":1163,"interventions":1165},"NCT02718820","Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer",[86,87],"2021-12",22,[1164],"Head and Neck Carcinoma",[1149,1166],"Pembrolizumab",{"nctId":1168,"briefTitle":1169,"status":1092,"phases":1170,"primaryCompletion":1171,"completion":1172,"start":1132,"enrollment":949,"conditions":1173,"interventions":1175},"NCT00795171","Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer",[87],"2011-04","2011-07",[1174],"Hormone Refractory Prostate Cancer",[1176,1149,1149],"Docetaxel * Sunitinib",{"trials":1178,"activeCount":98},[],{"trials":1180,"activeCount":98},[],{"trials":1182,"activeCount":137,"soonestReadout":1187},[1183],{"nctId":1184,"briefTitle":1185,"status":285,"phases":1186,"primaryCompletion":1187,"completion":1188,"start":1189,"enrollment":1190,"conditions":1191,"interventions":1197},"NCT06430411","Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study",[],"2031-01-01","2031-12-31","2024-05-31",500,[1192,1193,488,1194,1195,1196],"Prostate Cancer Metastatic","Prostate Cancer Metastatic to Bone","Prostate Neoplasm","Oligometastatic Disease","Oligometastasis",[1198,1199,1200,1201,1149,1202,1203],"Abiraterone acetate","Enzalutamide","Darolutamide","Apalutamide","Lutetium-PSMA","Androgen deprivation treatment",{"intervention":1205,"totalTrials":94,"cells":1206},"Dupilumab",{"EARLY_PHASE1":1207,"PHASE1":1209,"PHASE2":1211,"PHASE3":1213,"PHASE4":1215,"NA":1226},{"trials":1208,"activeCount":98},[],{"trials":1210,"activeCount":98},[],{"trials":1212,"activeCount":98},[],{"trials":1214,"activeCount":98},[],{"trials":1216,"activeCount":98},[1217],{"nctId":1218,"briefTitle":1219,"status":1092,"phases":1220,"primaryCompletion":1221,"completion":1221,"start":1222,"enrollment":1061,"conditions":1223,"interventions":1225},"NCT04442256","Effect of Dupilumab on Aspirin Intolerance",[89],"2022-12-31","2020-06-01",[1224],"AERD - Aspirin Exacerbated Respiratory Disease",[1205],{"trials":1227,"activeCount":137,"soonestReadout":473},[1228],{"nctId":1229,"briefTitle":1230,"status":123,"phases":1231,"primaryCompletion":473,"completion":354,"start":1232,"enrollment":486,"conditions":1233,"interventions":1235},"NCT07025200","DETACT sEvere asThmAtiC paTients - a Pilot Study",[],"2023-02-16",[1234],"Asthma",[1205],{"intervention":1237,"totalTrials":94,"cells":1238},"Azithromycin",{"EARLY_PHASE1":1239,"PHASE1":1241,"PHASE2":1243,"PHASE3":1245,"PHASE4":1247,"NA":1261},{"trials":1240,"activeCount":98},[],{"trials":1242,"activeCount":98},[],{"trials":1244,"activeCount":98},[],{"trials":1246,"activeCount":98},[],{"trials":1248,"activeCount":98},[1249],{"nctId":1250,"briefTitle":1251,"status":108,"phases":1252,"primaryCompletion":1253,"completion":1254,"start":1255,"enrollment":1256,"conditions":1257,"interventions":1259},"NCT03162497","Effect of Topical Azithromycin on Tear Film Thickness in Patients With Meibomian Gland Dysfunction",[89],"2022-09-09","2022-09-23","2018-01-08",23,[29,1258],"Meibomian Gland Dysfunction",[1237,1260],"Doxycycline",{"trials":1262,"activeCount":137,"soonestReadout":1267},[1263],{"nctId":1264,"briefTitle":1265,"status":285,"phases":1266,"primaryCompletion":1267,"completion":1268,"start":1269,"enrollment":1270,"conditions":1271,"interventions":1273},"NCT06170983","Skin Inflammation and PK of Azithromycin",[90],"2026-01-01","2026-07-01","2024-01-01",36,[1272],"Skin Infection",[1237],{"intervention":70,"totalTrials":137,"cells":1275},{"EARLY_PHASE1":1276,"PHASE1":1278,"PHASE2":1280,"PHASE3":1282,"PHASE4":1284,"NA":1286},{"trials":1277,"activeCount":98},[],{"trials":1279,"activeCount":98},[],{"trials":1281,"activeCount":98},[],{"trials":1283,"activeCount":98},[],{"trials":1285,"activeCount":98},[],{"trials":1287,"activeCount":137,"soonestReadout":69},[1288],{"nctId":67,"briefTitle":68,"status":123,"phases":1289,"primaryCompletion":69,"completion":1290,"start":1291,"enrollment":1292,"conditions":1293,"interventions":1296},[90],"2026-01-31","2024-09-30",50,[1294,1295],"Healthy Participants","Retinal Oxygen Extraction",[70],{"intervention":1298,"totalTrials":137,"cells":1299},"gender-affirming hormone therapy",{"EARLY_PHASE1":1300,"PHASE1":1302,"PHASE2":1304,"PHASE3":1306,"PHASE4":1308,"NA":1310},{"trials":1301,"activeCount":98},[],{"trials":1303,"activeCount":98},[],{"trials":1305,"activeCount":98},[],{"trials":1307,"activeCount":98},[],{"trials":1309,"activeCount":98},[],{"trials":1311,"activeCount":137,"soonestReadout":1316},[1312],{"nctId":1313,"briefTitle":1314,"status":123,"phases":1315,"primaryCompletion":1316,"completion":1317,"start":1318,"enrollment":1292,"conditions":1319,"interventions":1322},"NCT06291675","Gender-Affirming Hormone Therapy and Its Impact on Myocardial Mass and Cardiac Function, Heart, Liver and Pancreatic Fat Content",[],"2027-03-03","2033-03-03","2023-03-03",[1320,1321],"Gender Dysphoria","Hormone Therapy Induced Morphologic Change",[1298],{"intervention":61,"totalTrials":137,"cells":1324},{"EARLY_PHASE1":1325,"PHASE1":1327,"PHASE2":1329,"PHASE3":1331,"PHASE4":1333,"NA":1335},{"trials":1326,"activeCount":98},[],{"trials":1328,"activeCount":98},[],{"trials":1330,"activeCount":98},[],{"trials":1332,"activeCount":98},[],{"trials":1334,"activeCount":98},[],{"trials":1336,"activeCount":137,"soonestReadout":60},[1337],{"nctId":58,"briefTitle":59,"status":123,"phases":1338,"primaryCompletion":60,"completion":1339,"start":1340,"enrollment":356,"conditions":1341,"interventions":1343},[90],"2027-04","2014-06",[1342],"Chronic Skin Ulcer",[61,1344,1345],"PRF mixed with PHMB plus Macrogolol","PRF plus normal saline",{"intervention":1344,"totalTrials":137,"cells":1347},{"EARLY_PHASE1":1348,"PHASE1":1350,"PHASE2":1352,"PHASE3":1354,"PHASE4":1356,"NA":1358},{"trials":1349,"activeCount":98},[],{"trials":1351,"activeCount":98},[],{"trials":1353,"activeCount":98},[],{"trials":1355,"activeCount":98},[],{"trials":1357,"activeCount":98},[],{"trials":1359,"activeCount":137,"soonestReadout":60},[1360],{"nctId":58,"briefTitle":59,"status":123,"phases":1361,"primaryCompletion":60,"completion":1339,"start":1340,"enrollment":356,"conditions":1362,"interventions":1363},[90],[1342],[61,1344,1345],{"intervention":1345,"totalTrials":137,"cells":1365},{"EARLY_PHASE1":1366,"PHASE1":1368,"PHASE2":1370,"PHASE3":1372,"PHASE4":1374,"NA":1376},{"trials":1367,"activeCount":98},[],{"trials":1369,"activeCount":98},[],{"trials":1371,"activeCount":98},[],{"trials":1373,"activeCount":98},[],{"trials":1375,"activeCount":98},[],{"trials":1377,"activeCount":137,"soonestReadout":60},[1378],{"nctId":58,"briefTitle":59,"status":123,"phases":1379,"primaryCompletion":60,"completion":1339,"start":1340,"enrollment":356,"conditions":1380,"interventions":1381},[90],[1342],[61,1344,1345],{"intervention":1383,"totalTrials":137,"cells":1384},"Tezepelumab",{"EARLY_PHASE1":1385,"PHASE1":1387,"PHASE2":1389,"PHASE3":1391,"PHASE4":1393,"NA":1395},{"trials":1386,"activeCount":98},[],{"trials":1388,"activeCount":98},[],{"trials":1390,"activeCount":98},[],{"trials":1392,"activeCount":98},[],{"trials":1394,"activeCount":98},[],{"trials":1396,"activeCount":137,"soonestReadout":1401},[1397],{"nctId":1398,"briefTitle":1399,"status":285,"phases":1400,"primaryCompletion":1401,"completion":1402,"start":1403,"enrollment":476,"conditions":1404,"interventions":1407},"NCT07046117","Effect of Tezepelumab on Barrier Function in Severe Asthmatic Patients With and Without Comorbid Chronic Rhinosinusitis With Nasal Polyps",[90],"2028-01-31","2028-08-01","2025-10-01",[1405,1406],"Asthma Bronchiale","Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)",[1383],{"intervention":1146,"totalTrials":137,"cells":1409},{"EARLY_PHASE1":1410,"PHASE1":1412,"PHASE2":1414,"PHASE3":1416,"PHASE4":1418,"NA":1420},{"trials":1411,"activeCount":98},[],{"trials":1413,"activeCount":98},[],{"trials":1415,"activeCount":98},[],{"trials":1417,"activeCount":98},[],{"trials":1419,"activeCount":98},[],{"trials":1421,"activeCount":137,"soonestReadout":473},[1422],{"nctId":1138,"briefTitle":1139,"status":123,"phases":1423,"primaryCompletion":473,"completion":473,"start":1141,"enrollment":949,"conditions":1424,"interventions":1425},[90],[1143,1144],[1146,1077,1147],{"intervention":1147,"totalTrials":137,"cells":1427},{"EARLY_PHASE1":1428,"PHASE1":1430,"PHASE2":1432,"PHASE3":1434,"PHASE4":1436,"NA":1438},{"trials":1429,"activeCount":98},[],{"trials":1431,"activeCount":98},[],{"trials":1433,"activeCount":98},[],{"trials":1435,"activeCount":98},[],{"trials":1437,"activeCount":98},[],{"trials":1439,"activeCount":137,"soonestReadout":473},[1440],{"nctId":1138,"briefTitle":1139,"status":123,"phases":1441,"primaryCompletion":473,"completion":473,"start":1141,"enrollment":949,"conditions":1442,"interventions":1443},[90],[1143,1144],[1146,1077,1147],{"intervention":1198,"totalTrials":137,"cells":1445},{"EARLY_PHASE1":1446,"PHASE1":1448,"PHASE2":1450,"PHASE3":1452,"PHASE4":1454,"NA":1456},{"trials":1447,"activeCount":98},[],{"trials":1449,"activeCount":98},[],{"trials":1451,"activeCount":98},[],{"trials":1453,"activeCount":98},[],{"trials":1455,"activeCount":98},[],{"trials":1457,"activeCount":137,"soonestReadout":1187},[1458],{"nctId":1184,"briefTitle":1185,"status":285,"phases":1459,"primaryCompletion":1187,"completion":1188,"start":1189,"enrollment":1190,"conditions":1460,"interventions":1461},[],[1192,1193,488,1194,1195,1196],[1198,1199,1200,1201,1149,1202,1203],{"intervention":1199,"totalTrials":137,"cells":1463},{"EARLY_PHASE1":1464,"PHASE1":1466,"PHASE2":1468,"PHASE3":1470,"PHASE4":1472,"NA":1474},{"trials":1465,"activeCount":98},[],{"trials":1467,"activeCount":98},[],{"trials":1469,"activeCount":98},[],{"trials":1471,"activeCount":98},[],{"trials":1473,"activeCount":98},[],{"trials":1475,"activeCount":137,"soonestReadout":1187},[1476],{"nctId":1184,"briefTitle":1185,"status":285,"phases":1477,"primaryCompletion":1187,"completion":1188,"start":1189,"enrollment":1190,"conditions":1478,"interventions":1479},[],[1192,1193,488,1194,1195,1196],[1198,1199,1200,1201,1149,1202,1203],{"intervention":1200,"totalTrials":137,"cells":1481},{"EARLY_PHASE1":1482,"PHASE1":1484,"PHASE2":1486,"PHASE3":1488,"PHASE4":1490,"NA":1492},{"trials":1483,"activeCount":98},[],{"trials":1485,"activeCount":98},[],{"trials":1487,"activeCount":98},[],{"trials":1489,"activeCount":98},[],{"trials":1491,"activeCount":98},[],{"trials":1493,"activeCount":137,"soonestReadout":1187},[1494],{"nctId":1184,"briefTitle":1185,"status":285,"phases":1495,"primaryCompletion":1187,"completion":1188,"start":1189,"enrollment":1190,"conditions":1496,"interventions":1497},[],[1192,1193,488,1194,1195,1196],[1198,1199,1200,1201,1149,1202,1203],{"intervention":1201,"totalTrials":137,"cells":1499},{"EARLY_PHASE1":1500,"PHASE1":1502,"PHASE2":1504,"PHASE3":1506,"PHASE4":1508,"NA":1510},{"trials":1501,"activeCount":98},[],{"trials":1503,"activeCount":98},[],{"trials":1505,"activeCount":98},[],{"trials":1507,"activeCount":98},[],{"trials":1509,"activeCount":98},[],{"trials":1511,"activeCount":137,"soonestReadout":1187},[1512],{"nctId":1184,"briefTitle":1185,"status":285,"phases":1513,"primaryCompletion":1187,"completion":1188,"start":1189,"enrollment":1190,"conditions":1514,"interventions":1515},[],[1192,1193,488,1194,1195,1196],[1198,1199,1200,1201,1149,1202,1203],{"intervention":1202,"totalTrials":137,"cells":1517},{"EARLY_PHASE1":1518,"PHASE1":1520,"PHASE2":1522,"PHASE3":1524,"PHASE4":1526,"NA":1528},{"trials":1519,"activeCount":98},[],{"trials":1521,"activeCount":98},[],{"trials":1523,"activeCount":98},[],{"trials":1525,"activeCount":98},[],{"trials":1527,"activeCount":98},[],{"trials":1529,"activeCount":137,"soonestReadout":1187},[1530],{"nctId":1184,"briefTitle":1185,"status":285,"phases":1531,"primaryCompletion":1187,"completion":1188,"start":1189,"enrollment":1190,"conditions":1532,"interventions":1533},[],[1192,1193,488,1194,1195,1196],[1198,1199,1200,1201,1149,1202,1203],{"intervention":1203,"totalTrials":137,"cells":1535},{"EARLY_PHASE1":1536,"PHASE1":1538,"PHASE2":1540,"PHASE3":1542,"PHASE4":1544,"NA":1546},{"trials":1537,"activeCount":98},[],{"trials":1539,"activeCount":98},[],{"trials":1541,"activeCount":98},[],{"trials":1543,"activeCount":98},[],{"trials":1545,"activeCount":98},[],{"trials":1547,"activeCount":137,"soonestReadout":1187},[1548],{"nctId":1184,"briefTitle":1185,"status":285,"phases":1549,"primaryCompletion":1187,"completion":1188,"start":1189,"enrollment":1190,"conditions":1550,"interventions":1551},[],[1192,1193,488,1194,1195,1196],[1198,1199,1200,1201,1149,1202,1203],{"intervention":65,"totalTrials":137,"cells":1553},{"EARLY_PHASE1":1554,"PHASE1":1556,"PHASE2":1558,"PHASE3":1560,"PHASE4":1562,"NA":1564},{"trials":1555,"activeCount":98},[],{"trials":1557,"activeCount":98},[],{"trials":1559,"activeCount":98},[],{"trials":1561,"activeCount":98},[],{"trials":1563,"activeCount":98},[],{"trials":1565,"activeCount":137,"soonestReadout":60},[1566],{"nctId":63,"briefTitle":64,"status":123,"phases":1567,"primaryCompletion":60,"completion":354,"start":1568,"enrollment":356,"conditions":1569,"interventions":1572},[],"2020-10-01",[1570,1571],"Episodic Migraine","Chronic Migraine",[65,1573,1574],"Galcanezumab","Fremanezumab",{"intervention":1573,"totalTrials":137,"cells":1576},{"EARLY_PHASE1":1577,"PHASE1":1579,"PHASE2":1581,"PHASE3":1583,"PHASE4":1585,"NA":1587},{"trials":1578,"activeCount":98},[],{"trials":1580,"activeCount":98},[],{"trials":1582,"activeCount":98},[],{"trials":1584,"activeCount":98},[],{"trials":1586,"activeCount":98},[],{"trials":1588,"activeCount":137,"soonestReadout":60},[1589],{"nctId":63,"briefTitle":64,"status":123,"phases":1590,"primaryCompletion":60,"completion":354,"start":1568,"enrollment":356,"conditions":1591,"interventions":1592},[],[1570,1571],[65,1573,1574],{"intervention":1574,"totalTrials":137,"cells":1594},{"EARLY_PHASE1":1595,"PHASE1":1597,"PHASE2":1599,"PHASE3":1601,"PHASE4":1603,"NA":1605},{"trials":1596,"activeCount":98},[],{"trials":1598,"activeCount":98},[],{"trials":1600,"activeCount":98},[],{"trials":1602,"activeCount":98},[],{"trials":1604,"activeCount":98},[],{"trials":1606,"activeCount":137,"soonestReadout":60},[1607],{"nctId":63,"briefTitle":64,"status":123,"phases":1608,"primaryCompletion":60,"completion":354,"start":1568,"enrollment":356,"conditions":1609,"interventions":1610},[],[1570,1571],[65,1573,1574],{"intervention":1612,"totalTrials":137,"cells":1613},"gender affirming hormone therapy",{"EARLY_PHASE1":1614,"PHASE1":1616,"PHASE2":1618,"PHASE3":1620,"PHASE4":1622,"NA":1624},{"trials":1615,"activeCount":98},[],{"trials":1617,"activeCount":98},[],{"trials":1619,"activeCount":98},[],{"trials":1621,"activeCount":98},[],{"trials":1623,"activeCount":98},[],{"trials":1625,"activeCount":137,"soonestReadout":1630},[1626],{"nctId":1627,"briefTitle":1628,"status":123,"phases":1629,"primaryCompletion":1630,"completion":1631,"start":1632,"enrollment":112,"conditions":1633,"interventions":1634},"NCT06245681","Effects of Cross-sex Hormone Treatment on Cardiac Function, Myocardial and Hepatic Fat Content",[],"2027-10-20","2028-10-20","2017-10-20",[1320],[1612],{"intervention":83,"totalTrials":137,"cells":1636},{"EARLY_PHASE1":1637,"PHASE1":1639,"PHASE2":1641,"PHASE3":1643,"PHASE4":1645,"NA":1647},{"trials":1638,"activeCount":98},[],{"trials":1640,"activeCount":98},[],{"trials":1642,"activeCount":98},[],{"trials":1644,"activeCount":98},[],{"trials":1646,"activeCount":98},[],{"trials":1648,"activeCount":137,"soonestReadout":82},[1649],{"nctId":80,"briefTitle":81,"status":123,"phases":1650,"primaryCompletion":82,"completion":1651,"start":1652,"enrollment":1061,"conditions":1653,"interventions":1655},[90],"2026-09","2021-11-11",[1654],"Allergy",[83,1656],"Pregnancy test",{"intervention":1656,"totalTrials":137,"cells":1658},{"EARLY_PHASE1":1659,"PHASE1":1661,"PHASE2":1663,"PHASE3":1665,"PHASE4":1667,"NA":1669},{"trials":1660,"activeCount":98},[],{"trials":1662,"activeCount":98},[],{"trials":1664,"activeCount":98},[],{"trials":1666,"activeCount":98},[],{"trials":1668,"activeCount":98},[],{"trials":1670,"activeCount":137,"soonestReadout":82},[1671],{"nctId":80,"briefTitle":81,"status":123,"phases":1672,"primaryCompletion":82,"completion":1651,"start":1652,"enrollment":1061,"conditions":1673,"interventions":1674},[90],[1654],[83,1656],{"intervention":1676,"totalTrials":137,"cells":1677},"Dupilumab 300 MG\u002F2 ML Subcutaneous Solution [DUPIXENT]",{"EARLY_PHASE1":1678,"PHASE1":1680,"PHASE2":1682,"PHASE3":1684,"PHASE4":1686,"NA":1688},{"trials":1679,"activeCount":98},[],{"trials":1681,"activeCount":98},[],{"trials":1683,"activeCount":98},[],{"trials":1685,"activeCount":98},[],{"trials":1687,"activeCount":98},[],{"trials":1689,"activeCount":137,"soonestReadout":1694},[1690],{"nctId":1691,"briefTitle":1692,"status":123,"phases":1693,"primaryCompletion":1694,"completion":1695,"start":1696,"enrollment":590,"conditions":1697,"interventions":1700},"NCT06398873","Effect of Dupilumab on Nasal Epithelial Barrier Function in Patients With CRSwNP",[],"2026-09-01","2027-09-01","2024-06-06",[1698,1699],"Chronic Rhinosinusitis With Nasal Polyps","Chronic Rhinosinusitis Without Nasal Polyps",[1676],{"intervention":1702,"totalTrials":137,"cells":1703},"Mavacamten in clinical routine use",{"EARLY_PHASE1":1704,"PHASE1":1706,"PHASE2":1708,"PHASE3":1710,"PHASE4":1712,"NA":1714},{"trials":1705,"activeCount":98},[],{"trials":1707,"activeCount":98},[],{"trials":1709,"activeCount":98},[],{"trials":1711,"activeCount":98},[],{"trials":1713,"activeCount":98},[],{"trials":1715,"activeCount":137,"soonestReadout":1720},[1716],{"nctId":1717,"briefTitle":1718,"status":123,"phases":1719,"primaryCompletion":1720,"completion":1721,"start":1722,"enrollment":476,"conditions":1723,"interventions":1725},"NCT07150299","Myocardial Perfusion Changes Following Optimal Medical Treatment in Symptomatic Hypertrophic Cardiomyopathy",[],"2027-05","2027-09","2025-09-05",[1724],"Hypertrophic Obstructive Cardiomyopathy \\(HOCM\\)",[1702],{"intervention":1727,"totalTrials":137,"cells":1728},"Intranasal Insulin",{"EARLY_PHASE1":1729,"PHASE1":1731,"PHASE2":1733,"PHASE3":1735,"PHASE4":1737,"NA":1739},{"trials":1730,"activeCount":98},[],{"trials":1732,"activeCount":98},[],{"trials":1734,"activeCount":98},[],{"trials":1736,"activeCount":98},[],{"trials":1738,"activeCount":98},[],{"trials":1740,"activeCount":137,"soonestReadout":1745},[1741],{"nctId":1742,"briefTitle":1743,"status":285,"phases":1744,"primaryCompletion":1745,"completion":1745,"start":1267,"enrollment":1746,"conditions":1747,"interventions":1749},"NCT07252752","Dopamine and Insulin in Psychosis",[90],"2029-01-01",46,[1748],"First Episode Psychosis (FEP)",[1727,1750],"Low dose insulin",{"intervention":1750,"totalTrials":137,"cells":1752},{"EARLY_PHASE1":1753,"PHASE1":1755,"PHASE2":1757,"PHASE3":1759,"PHASE4":1761,"NA":1763},{"trials":1754,"activeCount":98},[],{"trials":1756,"activeCount":98},[],{"trials":1758,"activeCount":98},[],{"trials":1760,"activeCount":98},[],{"trials":1762,"activeCount":98},[],{"trials":1764,"activeCount":137,"soonestReadout":1745},[1765],{"nctId":1742,"briefTitle":1743,"status":285,"phases":1766,"primaryCompletion":1745,"completion":1745,"start":1267,"enrollment":1746,"conditions":1767,"interventions":1768},[90],[1748],[1727,1750],{"intervention":56,"totalTrials":137,"cells":1770},{"EARLY_PHASE1":1771,"PHASE1":1773,"PHASE2":1775,"PHASE3":1777,"PHASE4":1779,"NA":1781},{"trials":1772,"activeCount":98},[],{"trials":1774,"activeCount":98},[],{"trials":1776,"activeCount":98},[],{"trials":1778,"activeCount":98},[],{"trials":1780,"activeCount":98},[],{"trials":1782,"activeCount":137,"soonestReadout":55},[1783],{"nctId":53,"briefTitle":54,"status":123,"phases":1784,"primaryCompletion":55,"completion":60,"start":1785,"enrollment":590,"conditions":1786,"interventions":1789},[],"2015-12",[1787,1788,877],"Age Related Macular Degeneration","Intravitreal Injections",[56],{"intervention":1101,"totalTrials":828,"cells":1791},{"EARLY_PHASE1":1792,"PHASE1":1794,"PHASE2":1796,"PHASE3":1798,"PHASE4":1808,"NA":1826},{"trials":1793,"activeCount":98},[],{"trials":1795,"activeCount":98},[],{"trials":1797,"activeCount":98},[],{"trials":1799,"activeCount":98},[1800],{"nctId":1801,"briefTitle":1802,"status":1092,"phases":1803,"primaryCompletion":854,"completion":854,"start":1804,"enrollment":1061,"conditions":1805,"interventions":1807},"NCT01102101","Effect of Opioids in Neuropathic Pain in Postherpetic Patients",[88],"2010-08",[1806],"Neuralgia, Postherpetic",[1101],{"trials":1809,"activeCount":98},[1810,1814,1818,1822],{"nctId":1090,"briefTitle":1091,"status":1092,"phases":1811,"primaryCompletion":1094,"completion":1095,"start":1096,"enrollment":1097,"conditions":1812,"interventions":1813},[89],[1099],[1077,1101],{"nctId":1103,"briefTitle":1104,"status":1092,"phases":1815,"primaryCompletion":841,"completion":1106,"start":1107,"enrollment":1097,"conditions":1816,"interventions":1817},[89],[1099],[1101,1077],{"nctId":1111,"briefTitle":1112,"status":1092,"phases":1819,"primaryCompletion":1106,"completion":1114,"start":886,"enrollment":1097,"conditions":1820,"interventions":1821},[89],[1099],[1101,1077],{"nctId":1128,"briefTitle":1129,"status":1092,"phases":1823,"primaryCompletion":1131,"completion":841,"start":1132,"enrollment":1097,"conditions":1824,"interventions":1825},[89],[1099],[1101,1077],{"trials":1827,"activeCount":98},[],{"intervention":1829,"totalTrials":1830,"cells":1831},"Tacrolimus",4,{"EARLY_PHASE1":1832,"PHASE1":1834,"PHASE2":1836,"PHASE3":1846,"PHASE4":1848,"NA":1880},{"trials":1833,"activeCount":98},[],{"trials":1835,"activeCount":98},[],{"trials":1837,"activeCount":98},[1838],{"nctId":1839,"briefTitle":1840,"status":839,"phases":1841,"completion":842,"start":1095,"enrollment":844,"conditions":1842,"interventions":1844},"NCT01268995","Improving Secretion of Insulin in New Onset Diabetes After Renal Transplantation",[87],[1843],"New Onset Diabetes Mellitus After Renal Transplantation",[1845,1829],"Cyclosporine A",{"trials":1847,"activeCount":98},[],{"trials":1849,"activeCount":98},[1850,1861,1869],{"nctId":1851,"briefTitle":1852,"status":108,"phases":1853,"primaryCompletion":1854,"completion":1854,"start":1855,"enrollment":1856,"conditions":1857,"interventions":1860},"NCT03751332","The Vienna Prograf and Endothelial Progenitor Cell Extension Study",[89],"2010-10","2008-03",87,[1858,1859],"Immunosuppression","Renal Failure",[1829],{"nctId":1862,"briefTitle":1863,"status":108,"phases":1864,"primaryCompletion":842,"completion":842,"start":1865,"enrollment":511,"conditions":1866,"interventions":1868},"NCT00609388","Tacrolimus During the Implantation and the Effect on Ischemia-reperfusion Injury in Liver Transplantation",[89],"2008-01",[1867],"Ischemia Reperfusion Injury",[1829],{"nctId":1870,"briefTitle":1871,"status":108,"phases":1872,"primaryCompletion":1873,"completion":1873,"start":1874,"enrollment":1875,"conditions":1876,"interventions":1878},"NCT00182559","The Vienna Prograf and Endothelial Progenitor Cell Study",[89],"2009-05","2004-04",148,[1877],"End Stage Renal Disease",[1879,1829],"Ciclosporin",{"trials":1881,"activeCount":98},[],{"intervention":1883,"totalTrials":1830,"cells":1884},"Ticagrelor",{"EARLY_PHASE1":1885,"PHASE1":1887,"PHASE2":1889,"PHASE3":1915,"PHASE4":1917,"NA":1943},{"trials":1886,"activeCount":98},[],{"trials":1888,"activeCount":98},[],{"trials":1890,"activeCount":98},[1891,1902],{"nctId":1892,"briefTitle":1893,"status":108,"phases":1894,"primaryCompletion":1895,"completion":1895,"start":1854,"enrollment":1896,"conditions":1897,"interventions":1899},"NCT02120092","The Effect of Clopidogrel and Ticagrelor With and Without Acetylsalicylic Acid (ASA) on Hemostatic System Activation at the Site of Plug Formation in Vivo in Man",[87],"2013-12",89,[1898],"Acute Coronary Syndrome",[1900,1883,1901],"Clopidogrel","ASA",{"nctId":1903,"briefTitle":1904,"status":1092,"phases":1905,"primaryCompletion":1906,"completion":1907,"start":1908,"enrollment":569,"conditions":1909,"interventions":1910},"NCT02285751","High \"on Treatment\" Platelet Reactivity in the Intensive Care Unit",[87],"2020-07","2020-08","2012-11",[34],[1911,1912,1913,1914],"acetylsalicylic acid","clopidogrel","prasugrel","ticagrelor",{"trials":1916,"activeCount":98},[],{"trials":1918,"activeCount":98},[1919,1932],{"nctId":1920,"briefTitle":1921,"status":1092,"phases":1922,"primaryCompletion":1923,"completion":1161,"start":1924,"enrollment":949,"conditions":1925,"interventions":1929},"NCT03273075","Add-on Cangrelor in STEMI-triggered Cardiac Arrest",[89],"2021-05","2017-09",[1926,1927,1928],"Cardiopulmonary Arrest With Successful Resuscitation","ACS - Acute Coronary Syndrome","Hypothermia, Induced",[1930,1931,1883],"Cangrelor","Prasugrel",{"nctId":1933,"briefTitle":1934,"status":108,"phases":1935,"primaryCompletion":1936,"completion":1937,"start":1938,"enrollment":844,"conditions":1939,"interventions":1941},"NCT02910778","The Effect of Ticagrelor With or Without Atorvastatin on Endothelial Function in Healthy Males",[89],"2017-02","2017-03","2016-10",[1940],"Ischemia",[1942,1883],"Atorvastatin",{"trials":1944,"activeCount":98},[],{"intervention":1946,"totalTrials":1830,"cells":1947},"Escitalopram",{"EARLY_PHASE1":1948,"PHASE1":1950,"PHASE2":1952,"PHASE3":1954,"PHASE4":1956,"NA":1995},{"trials":1949,"activeCount":98},[],{"trials":1951,"activeCount":98},[],{"trials":1953,"activeCount":98},[],{"trials":1955,"activeCount":98},[],{"trials":1957,"activeCount":98},[1958,1968,1978,1988],{"nctId":1959,"briefTitle":1960,"status":1092,"phases":1961,"primaryCompletion":1962,"start":1963,"enrollment":590,"conditions":1964,"interventions":1967},"NCT02753738","Enhancement of Learning Associated Neural Plasticity by Selective Serotonin Reuptake Inhibitors",[89],"2019-08","2016-08",[1965,1966],"Ssri","Neuronal Plasticity",[1946],{"nctId":1969,"briefTitle":1970,"status":1092,"phases":1971,"primaryCompletion":1972,"completion":1972,"start":1973,"enrollment":590,"conditions":1974,"interventions":1976},"NCT02711215","Patient Stratification and Treatment Response Prediction in Neuropharmacotherapy Using Hybrid Positron Emmission Tomography\u002FMagnetic Resconance Imaging (PET\u002FMR)",[89],"2020-01","2015-05",[1975],"Major Depressive Disorder",[1977,1946],"Citalopram",{"nctId":1979,"briefTitle":1980,"status":108,"phases":1981,"primaryCompletion":1982,"completion":1982,"start":1983,"enrollment":1984,"conditions":1985,"interventions":1987},"NCT01477203","Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders",[89],"2016-09","2011-11",289,[358,1986],"Anxiety Disorder",[1946],{"nctId":1989,"briefTitle":1990,"status":108,"phases":1991,"primaryCompletion":873,"completion":1047,"start":1992,"enrollment":511,"conditions":1993,"interventions":1994},"NCT01251471","Neural, Genetic, and Peripheral Correlates of SSRI Pharmaco-Response",[89],"2011-08",[314],[1946],{"trials":1996,"activeCount":98},[],{"intervention":1998,"totalTrials":1830,"cells":1999},"Teriparatide",{"EARLY_PHASE1":2000,"PHASE1":2002,"PHASE2":2004,"PHASE3":2006,"PHASE4":2018,"NA":2057},{"trials":2001,"activeCount":98},[],{"trials":2003,"activeCount":98},[],{"trials":2005,"activeCount":98},[],{"trials":2007,"activeCount":98},[2008],{"nctId":2009,"briefTitle":2010,"status":2011,"phases":2012,"primaryCompletion":2013,"completion":2013,"start":1340,"enrollment":98,"conditions":2014,"interventions":2017},"NCT02091492","Teriparatide for Fracture Repair in Humans","WITHDRAWN",[88],"2015-09",[2015,2016],"Osteoporosis, Age-Related","Humeral Fractures",[1998],{"trials":2019,"activeCount":98},[2020,2032,2045],{"nctId":2021,"briefTitle":2022,"status":2023,"phases":2024,"primaryCompletion":2013,"completion":2013,"start":2025,"enrollment":128,"conditions":2026,"interventions":2030},"NCT01734824","Treatment of Atraumatic Bone Marrow Edema With Denosumab and Teriparatide vs Placebo","SUSPENDED",[89],"2012-05",[2027,2028,2029],"Bone Marrow Oedema Syndrome","High Turnover Bone Disease","Quality of Life",[2031,1998],"Denosumab",{"nctId":2033,"briefTitle":2034,"status":108,"phases":2035,"primaryCompletion":2036,"completion":2036,"start":2037,"enrollment":2038,"conditions":2039,"interventions":2041},"NCT01535027","Combined Administration of Teripapartide and Antiresorptive Agents in Postmenopausal Osteoporosis",[89],"2012-12","2006-03",125,[2040],"Osteoporosis",[2042,2043,2044],"teriparatide","teriparatide and raloxifene","teriparatide and alendronate",{"nctId":2046,"briefTitle":2047,"status":108,"phases":2048,"primaryCompletion":2049,"completion":2050,"start":2051,"enrollment":511,"conditions":2052,"interventions":2055},"NCT03472846","MiDeTe - microRNA Levels Under Denosumab and Teriparatide Therapy in Postmenopausal Osteoporosis",[89],"2022-09-01","2022-09-30","2017-03-01",[2053,2054],"Postmenopausal Osteoporosis","Diabetes Type 2",[2056,1998],"Prolia, 60 Mg\u002FmL Subcutaneous Solution",{"trials":2058,"activeCount":98},[],{"intervention":1931,"totalTrials":1030,"cells":2060},{"EARLY_PHASE1":2061,"PHASE1":2063,"PHASE2":2065,"PHASE3":2071,"PHASE4":2073,"NA":2088},{"trials":2062,"activeCount":98},[],{"trials":2064,"activeCount":98},[],{"trials":2066,"activeCount":98},[2067],{"nctId":1903,"briefTitle":1904,"status":1092,"phases":2068,"primaryCompletion":1906,"completion":1907,"start":1908,"enrollment":569,"conditions":2069,"interventions":2070},[87],[34],[1911,1912,1913,1914],{"trials":2072,"activeCount":98},[],{"trials":2074,"activeCount":98},[2075,2084],{"nctId":2076,"briefTitle":2077,"status":108,"phases":2078,"primaryCompletion":1854,"completion":2079,"start":886,"enrollment":476,"conditions":2080,"interventions":2083},"NCT01099566","The Role of the P2Y12 Receptor in Tissue Factor Induced Coagulation",[89],"2010-11",[2081,2082],"Healthy Volunteers","Sepsis",[1931],{"nctId":1920,"briefTitle":1921,"status":1092,"phases":2085,"primaryCompletion":1923,"completion":1161,"start":1924,"enrollment":949,"conditions":2086,"interventions":2087},[89],[1926,1927,1928],[1930,1931,1883],{"trials":2089,"activeCount":98},[],{"intervention":2091,"totalTrials":1030,"cells":2092},"Dapagliflozin",{"EARLY_PHASE1":2093,"PHASE1":2095,"PHASE2":2097,"PHASE3":2110,"PHASE4":2112,"NA":2138},{"trials":2094,"activeCount":98},[],{"trials":2096,"activeCount":98},[],{"trials":2098,"activeCount":98},[2099],{"nctId":2100,"briefTitle":2101,"status":1092,"phases":2102,"primaryCompletion":2103,"completion":2104,"start":2105,"enrollment":476,"conditions":2106,"interventions":2109},"NCT02558270","Effects of SGLT-2 Inhibition on Hepatic Glucose and Energy Metabolism",[87],"2017-12","2018-06","2016-06",[2107,2108],"Type 2 Diabetes","Metabolically Healthy Controls",[2091],{"trials":2111,"activeCount":98},[],{"trials":2113,"activeCount":98},[2114,2127],{"nctId":2115,"briefTitle":2116,"status":108,"phases":2117,"primaryCompletion":2118,"completion":2119,"start":2120,"enrollment":2121,"conditions":2122,"interventions":2125},"NCT03007329","Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus.",[89],"2019-11-26","2020-01-16","2017-03-08",34,[2123,2124],"Steatosis, Liver","Type2 Diabetes",[2126,2091],"Exenatide",{"nctId":2128,"briefTitle":2129,"status":1092,"phases":2130,"primaryCompletion":2131,"completion":69,"start":2132,"enrollment":844,"conditions":2133,"interventions":2136},"NCT05443932","Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone Patients",[89],"2024-12-31","2024-03-04",[2134,2135],"Urolithiasis","Hyperoxaluria",[2091,2137],"Hydrochlorothiazide",{"trials":2139,"activeCount":98},[],{"intervention":2141,"totalTrials":94,"cells":2142},"Atropine",{"EARLY_PHASE1":2143,"PHASE1":2145,"PHASE2":2147,"PHASE3":2160,"PHASE4":2162,"NA":2174},{"trials":2144,"activeCount":98},[],{"trials":2146,"activeCount":98},[],{"trials":2148,"activeCount":98},[2149],{"nctId":2150,"briefTitle":2151,"status":108,"phases":2152,"start":2153,"enrollment":2154,"conditions":2155,"interventions":2156},"NCT00431392","Mechanisms of Choroidal Blood Flow Changes During Dark\u002FLight Transitions",[87],"2001-09",42,[18,21],[2157,2158,2159,2141],"Phenylephrine","NG-Monomethyl-L-Arginine","Propanolol",{"trials":2161,"activeCount":98},[],{"trials":2163,"activeCount":98},[2164],{"nctId":2165,"briefTitle":2166,"status":108,"phases":2167,"completion":1865,"start":2168,"enrollment":2169,"conditions":2170,"interventions":2173},"NCT00575523","Atropine for Prevention of Dysrhythmias Caused by Percutaneous Ethanol Instillation for Hepatoma Therapy",[89],"2003-10",31,[2171,2172],"Arrhythmia","Respiratory Arrest",[2141],{"trials":2175,"activeCount":98},[],{"intervention":2177,"totalTrials":94,"cells":2178},"Lynestrenol",{"EARLY_PHASE1":2179,"PHASE1":2181,"PHASE2":2183,"PHASE3":2185,"PHASE4":2187,"NA":2213},{"trials":2180,"activeCount":98},[],{"trials":2182,"activeCount":98},[],{"trials":2184,"activeCount":98},[],{"trials":2186,"activeCount":98},[],{"trials":2188,"activeCount":98},[2189,2202],{"nctId":2190,"briefTitle":2191,"status":1092,"phases":2192,"primaryCompletion":2193,"completion":2193,"start":2194,"enrollment":2195,"conditions":2196,"interventions":2197},"NCT02715232","Effects of Sex Steroids on the Serotonin System",[89],"2020-12","2017-02-06",92,[1320],[2198,2177,2199,2200,2201],"Testosterone","Cyproterone Acetate","Estradiol","Triptorelin acetate",{"nctId":2203,"briefTitle":2204,"status":108,"phases":2205,"primaryCompletion":2206,"completion":2206,"start":2207,"enrollment":844,"conditions":2208,"interventions":2210},"NCT01065220","Sex Steroids and the Serotonin Transporter",[89],"2014-01","2010-02",[2209],"Transsexualism",[2211,2177,2199,2200,2212],"Testolactone undecanoate","5-alpha reductase inhibitor",{"trials":2214,"activeCount":98},[],{"intervention":2199,"totalTrials":94,"cells":2216},{"EARLY_PHASE1":2217,"PHASE1":2219,"PHASE2":2221,"PHASE3":2223,"PHASE4":2225,"NA":2235},{"trials":2218,"activeCount":98},[],{"trials":2220,"activeCount":98},[],{"trials":2222,"activeCount":98},[],{"trials":2224,"activeCount":98},[],{"trials":2226,"activeCount":98},[2227,2231],{"nctId":2190,"briefTitle":2191,"status":1092,"phases":2228,"primaryCompletion":2193,"completion":2193,"start":2194,"enrollment":2195,"conditions":2229,"interventions":2230},[89],[1320],[2198,2177,2199,2200,2201],{"nctId":2203,"briefTitle":2204,"status":108,"phases":2232,"primaryCompletion":2206,"completion":2206,"start":2207,"enrollment":844,"conditions":2233,"interventions":2234},[89],[2209],[2211,2177,2199,2200,2212],{"trials":2236,"activeCount":98},[],{"intervention":2200,"totalTrials":94,"cells":2238},{"EARLY_PHASE1":2239,"PHASE1":2241,"PHASE2":2243,"PHASE3":2245,"PHASE4":2247,"NA":2257},{"trials":2240,"activeCount":98},[],{"trials":2242,"activeCount":98},[],{"trials":2244,"activeCount":98},[],{"trials":2246,"activeCount":98},[],{"trials":2248,"activeCount":98},[2249,2253],{"nctId":2190,"briefTitle":2191,"status":1092,"phases":2250,"primaryCompletion":2193,"completion":2193,"start":2194,"enrollment":2195,"conditions":2251,"interventions":2252},[89],[1320],[2198,2177,2199,2200,2201],{"nctId":2203,"briefTitle":2204,"status":108,"phases":2254,"primaryCompletion":2206,"completion":2206,"start":2207,"enrollment":844,"conditions":2255,"interventions":2256},[89],[2209],[2211,2177,2199,2200,2212],{"trials":2258,"activeCount":98},[],{"intervention":2260,"totalTrials":94,"cells":2261},"Esomeprazole",{"EARLY_PHASE1":2262,"PHASE1":2264,"PHASE2":2266,"PHASE3":2268,"PHASE4":2281,"NA":2296},{"trials":2263,"activeCount":98},[],{"trials":2265,"activeCount":98},[],{"trials":2267,"activeCount":98},[],{"trials":2269,"activeCount":98},[2270],{"nctId":2271,"briefTitle":2272,"status":108,"phases":2273,"primaryCompletion":2274,"completion":2274,"start":2275,"enrollment":22,"conditions":2276,"interventions":2279},"NCT01579539","The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy",[88],"2017-05-18","2013-06-27",[2277,2278],"Thyroid-associated Ophthalmopathy","Dry Eye Syndrome",[2280,2260],"Methylprednisolone",{"trials":2282,"activeCount":98},[2283],{"nctId":2284,"briefTitle":2285,"status":108,"phases":2286,"primaryCompletion":2287,"completion":2287,"start":2288,"enrollment":2289,"conditions":2290,"interventions":2293},"NCT00590928","Gastric pH in Critically Ill Patients",[89],"2006-06","2004-07",75,[2291,2292],"Critically Ill Patients","Indication for Stress Ulcer Prophylaxis",[2294,2295],"esomeprazole","ranitidine",{"trials":2297,"activeCount":98},[],{"intervention":2299,"totalTrials":94,"cells":2300},"Candesartan",{"EARLY_PHASE1":2301,"PHASE1":2303,"PHASE2":2305,"PHASE3":2307,"PHASE4":2328,"NA":2341},{"trials":2302,"activeCount":98},[],{"trials":2304,"activeCount":98},[],{"trials":2306,"activeCount":98},[],{"trials":2308,"activeCount":98},[2309],{"nctId":2310,"briefTitle":2311,"status":1092,"phases":2312,"primaryCompletion":111,"completion":2313,"start":2314,"enrollment":1190,"conditions":2315,"interventions":2317},"NCT04351724","Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)",[87,88],"2022-03-31","2020-04-16",[2316],"COVID-19",[2318,2319,2320,2321,2299,2322,2323,2324,2325,2326,2327],"Chloroquine or Hydroxychloroquine","Lopinavir\u002FRitonavir","Rivaroxaban","Thromboprophylaxis","non-RAS blocking antihypertensives","Remdesivir","Asunercept 400mg","Asunercept 100mg","Asunercept 25mg","Pentaglobin",{"trials":2329,"activeCount":98},[2330],{"nctId":2331,"briefTitle":2332,"status":108,"phases":2333,"primaryCompletion":2334,"completion":2334,"start":2036,"enrollment":1097,"conditions":2335,"interventions":2339},"NCT01827202","RAS Quantification in Patients With Aliskiren or Candesartan",[89],"2016-02",[2336,2337,2338],"Hypertension","Chronic Kidney Disease","Proteinuria",[2340,2299],"Aliskiren",{"trials":2342,"activeCount":98},[],{"intervention":2344,"totalTrials":94,"cells":2345},"erythropoietin",{"EARLY_PHASE1":2346,"PHASE1":2348,"PHASE2":2350,"PHASE3":2352,"PHASE4":2364,"NA":2376},{"trials":2347,"activeCount":98},[],{"trials":2349,"activeCount":98},[],{"trials":2351,"activeCount":98},[],{"trials":2353,"activeCount":98},[2354],{"nctId":2355,"briefTitle":2356,"status":1092,"phases":2357,"completion":1094,"start":2358,"enrollment":2359,"conditions":2360,"interventions":2362},"NCT00348738","Impact of Erythropoietin Administration During Definitive Cervix Cancer Radiotherapy on Treatment Outcome",[88],"2000-07",300,[2361],"Cervix Cancer",[2363],"Erythropoietin",{"trials":2365,"activeCount":98},[2366],{"nctId":2367,"briefTitle":2368,"status":108,"phases":2369,"primaryCompletion":2370,"completion":2371,"start":2372,"enrollment":30,"conditions":2373,"interventions":2375},"NCT01392612","Erythropoietin and Platelet Activation Markers",[89],"2007-02","2007-07","2006-11",[2374,2336],"Thrombosis",[2344],{"trials":2377,"activeCount":98},[],{"intervention":1260,"totalTrials":94,"cells":2379},{"EARLY_PHASE1":2380,"PHASE1":2382,"PHASE2":2393,"PHASE3":2395,"PHASE4":2397,"NA":2403},{"trials":2381,"activeCount":98},[],{"trials":2383,"activeCount":98},[2384],{"nctId":2385,"briefTitle":2386,"status":108,"phases":2387,"primaryCompletion":2388,"completion":2388,"start":2389,"enrollment":522,"conditions":2390,"interventions":2392},"NCT03478436","Pharmacokinetics of Doxycycline in Skin of Healthy Volunteers",[86],"2016-10-25","2016-07",[2391],"Rosacea",[1260],{"trials":2394,"activeCount":98},[],{"trials":2396,"activeCount":98},[],{"trials":2398,"activeCount":98},[2399],{"nctId":1250,"briefTitle":1251,"status":108,"phases":2400,"primaryCompletion":1253,"completion":1254,"start":1255,"enrollment":1256,"conditions":2401,"interventions":2402},[89],[29,1258],[1237,1260],{"trials":2404,"activeCount":98},[],{"intervention":2406,"totalTrials":94,"cells":2407},"Morphine",{"EARLY_PHASE1":2408,"PHASE1":2410,"PHASE2":2412,"PHASE3":2414,"PHASE4":2416,"NA":2439},{"trials":2409,"activeCount":98},[],{"trials":2411,"activeCount":98},[],{"trials":2413,"activeCount":98},[],{"trials":2415,"activeCount":98},[],{"trials":2417,"activeCount":98},[2418,2428],{"nctId":2419,"briefTitle":2420,"status":108,"phases":2421,"primaryCompletion":2025,"completion":2422,"start":1172,"enrollment":1292,"conditions":2423,"interventions":2425},"NCT01816581","Oral Oxycodone After Major Cardiac Surgery",[89],"2013-03",[2424],"Heart; Dysfunction Postoperative, Cardiac Surgery",[2426,2427,2406],"Targin","Oxynorm",{"nctId":2429,"briefTitle":2430,"status":108,"phases":2431,"primaryCompletion":2432,"completion":2432,"start":2433,"enrollment":2434,"conditions":2435,"interventions":2438},"NCT01369186","Drug Drug Interactions of Aspirin and P2Y12-inhibitors",[89],"2015-01","2011-05",95,[2436,2437],"Drug Interaction Potentiation","Myocardial Infarction",[2406],{"trials":2440,"activeCount":98},[],{"intervention":2442,"totalTrials":137,"cells":2443},"Brinavess",{"EARLY_PHASE1":2444,"PHASE1":2446,"PHASE2":2448,"PHASE3":2450,"PHASE4":2452,"NA":2464},{"trials":2445,"activeCount":98},[],{"trials":2447,"activeCount":98},[],{"trials":2449,"activeCount":98},[],{"trials":2451,"activeCount":98},[],{"trials":2453,"activeCount":98},[2454],{"nctId":2455,"briefTitle":2456,"status":108,"phases":2457,"primaryCompletion":1973,"completion":1973,"start":2458,"enrollment":2459,"conditions":2460,"interventions":2462},"NCT01447862","Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation",[89],"2011-10",101,[2461],"Atrial Fibrillation",[2442,2463],"Corvert",{"trials":2465,"activeCount":98},[],{"intervention":2463,"totalTrials":137,"cells":2467},{"EARLY_PHASE1":2468,"PHASE1":2470,"PHASE2":2472,"PHASE3":2474,"PHASE4":2476,"NA":2482},{"trials":2469,"activeCount":98},[],{"trials":2471,"activeCount":98},[],{"trials":2473,"activeCount":98},[],{"trials":2475,"activeCount":98},[],{"trials":2477,"activeCount":98},[2478],{"nctId":2455,"briefTitle":2456,"status":108,"phases":2479,"primaryCompletion":1973,"completion":1973,"start":2458,"enrollment":2459,"conditions":2480,"interventions":2481},[89],[2461],[2442,2463],{"trials":2483,"activeCount":98},[],{"intervention":2485,"totalTrials":137,"cells":2486},"Liraglutide",{"EARLY_PHASE1":2487,"PHASE1":2489,"PHASE2":2491,"PHASE3":2493,"PHASE4":2495,"NA":2506},{"trials":2488,"activeCount":98},[],{"trials":2490,"activeCount":98},[],{"trials":2492,"activeCount":98},[],{"trials":2494,"activeCount":98},[],{"trials":2496,"activeCount":98},[2497],{"nctId":2498,"briefTitle":2499,"status":108,"phases":2500,"primaryCompletion":2501,"completion":2502,"start":2079,"enrollment":547,"conditions":2503,"interventions":2505},"NCT01695109","The Influence of Liraglutide on the Reward Properties of Food: an fMRI Study on Healthy Volunteers",[89],"2012-02","2012-03",[2504],"Healthy Human Male Subjects",[2485],{"trials":2507,"activeCount":98},[],{"intervention":879,"totalTrials":137,"cells":2509},{"EARLY_PHASE1":2510,"PHASE1":2512,"PHASE2":2514,"PHASE3":2516,"PHASE4":2518,"NA":2524},{"trials":2511,"activeCount":98},[],{"trials":2513,"activeCount":98},[],{"trials":2515,"activeCount":98},[],{"trials":2517,"activeCount":98},[],{"trials":2519,"activeCount":98},[2520],{"nctId":870,"briefTitle":871,"status":108,"phases":2521,"primaryCompletion":873,"completion":873,"start":874,"enrollment":875,"conditions":2522,"interventions":2523},[89],[877],[668,879],{"trials":2525,"activeCount":98},[],{"intervention":2527,"totalTrials":137,"cells":2528},"Omalizumab",{"EARLY_PHASE1":2529,"PHASE1":2531,"PHASE2":2533,"PHASE3":2535,"PHASE4":2537,"NA":2548},{"trials":2530,"activeCount":98},[],{"trials":2532,"activeCount":98},[],{"trials":2534,"activeCount":98},[],{"trials":2536,"activeCount":98},[],{"trials":2538,"activeCount":98},[2539],{"nctId":2540,"briefTitle":2541,"status":108,"phases":2542,"completion":2543,"start":2544,"conditions":2545,"interventions":2547},"NCT00822783","Study to Determine the Effect of an Anti-IgE Agent on Inflammatory Cells in the Skin of Atopic Dermatitis Patients",[89],"2003-04","2001-10",[2546],"Atopic Dermatitis",[2527],{"trials":2549,"activeCount":98},[],{"intervention":2198,"totalTrials":137,"cells":2551},{"EARLY_PHASE1":2552,"PHASE1":2554,"PHASE2":2556,"PHASE3":2558,"PHASE4":2560,"NA":2566},{"trials":2553,"activeCount":98},[],{"trials":2555,"activeCount":98},[],{"trials":2557,"activeCount":98},[],{"trials":2559,"activeCount":98},[],{"trials":2561,"activeCount":98},[2562],{"nctId":2190,"briefTitle":2191,"status":1092,"phases":2563,"primaryCompletion":2193,"completion":2193,"start":2194,"enrollment":2195,"conditions":2564,"interventions":2565},[89],[1320],[2198,2177,2199,2200,2201],{"trials":2567,"activeCount":98},[],{"intervention":2201,"totalTrials":137,"cells":2569},{"EARLY_PHASE1":2570,"PHASE1":2572,"PHASE2":2574,"PHASE3":2576,"PHASE4":2578,"NA":2584},{"trials":2571,"activeCount":98},[],{"trials":2573,"activeCount":98},[],{"trials":2575,"activeCount":98},[],{"trials":2577,"activeCount":98},[],{"trials":2579,"activeCount":98},[2580],{"nctId":2190,"briefTitle":2191,"status":1092,"phases":2581,"primaryCompletion":2193,"completion":2193,"start":2194,"enrollment":2195,"conditions":2582,"interventions":2583},[89],[1320],[2198,2177,2199,2200,2201],{"trials":2585,"activeCount":98},[],{"intervention":2587,"totalTrials":137,"cells":2588},"ziprasidone",{"EARLY_PHASE1":2589,"PHASE1":2591,"PHASE2":2593,"PHASE3":2595,"PHASE4":2597,"NA":2610},{"trials":2590,"activeCount":98},[],{"trials":2592,"activeCount":98},[],{"trials":2594,"activeCount":98},[],{"trials":2596,"activeCount":98},[],{"trials":2598,"activeCount":98},[2599],{"nctId":2600,"briefTitle":2601,"status":108,"phases":2602,"primaryCompletion":2603,"completion":2603,"start":2604,"enrollment":547,"conditions":2605,"interventions":2608},"NCT01185743","Antipsychotics and Gene Expression in Soft Tissues",[89],"2017-01-01","2010-07",[2606,2607],"Schizophrenia","Diabetes",[2609,2587],"olanzapine",{"trials":2611,"activeCount":98},[],{"intervention":2613,"totalTrials":137,"cells":2614},"Supplementation of ferric carboxymaltose",{"EARLY_PHASE1":2615,"PHASE1":2617,"PHASE2":2619,"PHASE3":2621,"PHASE4":2623,"NA":2636},{"trials":2616,"activeCount":98},[],{"trials":2618,"activeCount":98},[],{"trials":2620,"activeCount":98},[],{"trials":2622,"activeCount":98},[],{"trials":2624,"activeCount":98},[2625],{"nctId":2626,"briefTitle":2627,"status":108,"phases":2628,"primaryCompletion":2629,"completion":2629,"start":2630,"enrollment":2631,"conditions":2632,"interventions":2634},"NCT02198495","Comparison Study of Two Iron Compounds for Treatment of Anemia in Hemodialysis Patients",[89],"2019-05","2014-09",143,[2633],"Anemia of Chronic Kidney Disease",[2613,2635],"Supplementation of iron sucrose",{"trials":2637,"activeCount":98},[],{"intervention":2635,"totalTrials":137,"cells":2639},{"EARLY_PHASE1":2640,"PHASE1":2642,"PHASE2":2644,"PHASE3":2646,"PHASE4":2648,"NA":2654},{"trials":2641,"activeCount":98},[],{"trials":2643,"activeCount":98},[],{"trials":2645,"activeCount":98},[],{"trials":2647,"activeCount":98},[],{"trials":2649,"activeCount":98},[2650],{"nctId":2626,"briefTitle":2627,"status":108,"phases":2651,"primaryCompletion":2629,"completion":2629,"start":2630,"enrollment":2631,"conditions":2652,"interventions":2653},[89],[2633],[2613,2635],{"trials":2655,"activeCount":98},[],{"intervention":2657,"totalTrials":137,"cells":2658},"LG-group",{"EARLY_PHASE1":2659,"PHASE1":2661,"PHASE2":2663,"PHASE3":2665,"PHASE4":2667,"NA":2683},{"trials":2660,"activeCount":98},[],{"trials":2662,"activeCount":98},[],{"trials":2664,"activeCount":98},[],{"trials":2666,"activeCount":98},[],{"trials":2668,"activeCount":98},[2669],{"nctId":2670,"briefTitle":2671,"status":108,"phases":2672,"primaryCompletion":2673,"completion":2674,"start":2675,"enrollment":16,"conditions":2676,"interventions":2681},"NCT01144039","Glutamate and Diastolic Function in Patients Undergoing Aortic Valve Repair",[89],"2007-11","2008-09","2006-02",[2677,2678,2679,2680],"Hypertrophy, Left Ventricular","Aortic Stenosis","Myocardial Ischemia","Cardiopulmonary Bypass",[2657,2682],"HG-group",{"trials":2684,"activeCount":98},[],{"intervention":2682,"totalTrials":137,"cells":2686},{"EARLY_PHASE1":2687,"PHASE1":2689,"PHASE2":2691,"PHASE3":2693,"PHASE4":2695,"NA":2701},{"trials":2688,"activeCount":98},[],{"trials":2690,"activeCount":98},[],{"trials":2692,"activeCount":98},[],{"trials":2694,"activeCount":98},[],{"trials":2696,"activeCount":98},[2697],{"nctId":2670,"briefTitle":2671,"status":108,"phases":2698,"primaryCompletion":2673,"completion":2674,"start":2675,"enrollment":16,"conditions":2699,"interventions":2700},[89],[2677,2678,2679,2680],[2657,2682],{"trials":2702,"activeCount":98},[],{"intervention":2704,"totalTrials":137,"cells":2705},"doripenem",{"EARLY_PHASE1":2706,"PHASE1":2708,"PHASE2":2710,"PHASE3":2712,"PHASE4":2714,"NA":2722},{"trials":2707,"activeCount":98},[],{"trials":2709,"activeCount":98},[],{"trials":2711,"activeCount":98},[],{"trials":2713,"activeCount":98},[],{"trials":2715,"activeCount":98},[2716],{"nctId":2717,"briefTitle":2718,"status":108,"phases":2719,"primaryCompletion":854,"completion":854,"start":1804,"enrollment":522,"conditions":2720,"interventions":2721},"NCT01311141","Target Site Pharmacokinetics of Doripenem After a Single Dose of 500mg in Healthy Volunteers Dori_MD_1",[89],[15],[2704],{"trials":2723,"activeCount":98},[],{"intervention":2725,"totalTrials":137,"cells":2726},"FSME-IMMUN Vaccine",{"EARLY_PHASE1":2727,"PHASE1":2729,"PHASE2":2731,"PHASE3":2733,"PHASE4":2735,"NA":2748},{"trials":2728,"activeCount":98},[],{"trials":2730,"activeCount":98},[],{"trials":2732,"activeCount":98},[],{"trials":2734,"activeCount":98},[],{"trials":2736,"activeCount":98},[2737],{"nctId":2738,"briefTitle":2739,"status":1092,"phases":2740,"primaryCompletion":2741,"completion":2742,"start":2743,"enrollment":2744,"conditions":2745,"interventions":2747},"NCT04017052","Application of a TBE-Vaccine in Obese Persons",[89],"2020-02-07","2020-12-30","2015-04-15",73,[2746],"Tick Borne Encephalitis",[2725],{"trials":2749,"activeCount":98},[],{"intervention":2751,"totalTrials":137,"cells":2752},"Thealoz Total® Eye Drops, Laboratoires Thea, Clermont Ferrand, France",{"EARLY_PHASE1":2753,"PHASE1":2755,"PHASE2":2757,"PHASE3":2759,"PHASE4":2761,"NA":2773},{"trials":2754,"activeCount":98},[],{"trials":2756,"activeCount":98},[],{"trials":2758,"activeCount":98},[],{"trials":2760,"activeCount":98},[],{"trials":2762,"activeCount":98},[2763],{"nctId":2764,"briefTitle":2765,"status":839,"phases":2766,"primaryCompletion":2767,"completion":2768,"start":2769,"enrollment":1061,"conditions":2770,"interventions":2772},"NCT07245836","Anti-inflammatory Effects and Clinical Efficacy of Topical Thealoz Total Eye Drops in Patients With Chronic Dry Eye Disease and Associated Ocular Surface Inflammation",[89],"2025-06-03","2025-07-06","2025-01-20",[2771],"Dry Eye Disease (DED)",[2751],{"trials":2774,"activeCount":98},[],{"intervention":2776,"totalTrials":137,"cells":2777},"Nux vomica",{"EARLY_PHASE1":2778,"PHASE1":2780,"PHASE2":2782,"PHASE3":2784,"PHASE4":2786,"NA":2797},{"trials":2779,"activeCount":98},[],{"trials":2781,"activeCount":98},[],{"trials":2783,"activeCount":98},[],{"trials":2785,"activeCount":98},[],{"trials":2787,"activeCount":98},[2788],{"nctId":2789,"briefTitle":2790,"status":839,"phases":2791,"primaryCompletion":2792,"completion":2793,"start":2794,"enrollment":30,"conditions":2795,"interventions":2796},"NCT00861237","Homeopathy for Prevention of Atrial Fibrillation After Aortocoronary Bypass Surgery",[89],"2017-10","2017-11","2008-07",[2461],[2776],{"trials":2798,"activeCount":98},[],{"intervention":2800,"totalTrials":137,"cells":2801},"Linoladiol Estradiol",{"EARLY_PHASE1":2802,"PHASE1":2804,"PHASE2":2806,"PHASE3":2808,"PHASE4":2810,"NA":2821},{"trials":2803,"activeCount":98},[],{"trials":2805,"activeCount":98},[],{"trials":2807,"activeCount":98},[],{"trials":2809,"activeCount":98},[],{"trials":2811,"activeCount":98},[2812],{"nctId":2813,"briefTitle":2814,"status":108,"phases":2815,"primaryCompletion":2816,"completion":2816,"start":2817,"enrollment":356,"conditions":2818,"interventions":2820},"NCT03779633","Preoperative Oestrogen in Postmenopausal Women With Pelvic Organ Prolapse",[89],"2020-08-27","2017-02-02",[2819],"Pelvic Organ Prolapse",[2800],{"trials":2822,"activeCount":98},[],{"intervention":2824,"totalTrials":137,"cells":2825},"TBE vaccination and influenza vaccination",{"EARLY_PHASE1":2826,"PHASE1":2828,"PHASE2":2830,"PHASE3":2832,"PHASE4":2834,"NA":2844},{"trials":2827,"activeCount":98},[],{"trials":2829,"activeCount":98},[],{"trials":2831,"activeCount":98},[],{"trials":2833,"activeCount":98},[],{"trials":2835,"activeCount":98},[2836],{"nctId":2837,"briefTitle":2838,"status":108,"phases":2839,"primaryCompletion":2079,"completion":2079,"start":2840,"enrollment":9,"conditions":2841,"interventions":2843},"NCT00804219","Humoral and Cellular Immunity of Low and High-responders After Tick-borne Encephalitis Vaccination",[89],"2008-12",[2842],"Tick-borne Encephalitis",[2824],{"trials":2845,"activeCount":98},[],{"intervention":2847,"totalTrials":137,"cells":2848},"Taurin 6g per day per oral for 28 days",{"EARLY_PHASE1":2849,"PHASE1":2851,"PHASE2":2853,"PHASE3":2855,"PHASE4":2857,"NA":2868},{"trials":2850,"activeCount":98},[],{"trials":2852,"activeCount":98},[],{"trials":2854,"activeCount":98},[],{"trials":2856,"activeCount":98},[],{"trials":2858,"activeCount":98},[2859],{"nctId":2860,"briefTitle":2861,"status":108,"phases":2862,"primaryCompletion":1973,"completion":2863,"start":1854,"enrollment":1061,"conditions":2864,"interventions":2867},"NCT02344719","Effect of Taurine on Portal Hemodynamics in Patients With Advanced Liver Cirrhosis",[89],"2015-06",[2865,2866],"Cirrhosis","Portal Hypertension",[2847],{"trials":2869,"activeCount":98},[],{"intervention":2871,"totalTrials":137,"cells":2872},"Lidocaine\u002Ftetracaine patch",{"EARLY_PHASE1":2873,"PHASE1":2875,"PHASE2":2877,"PHASE3":2879,"PHASE4":2881,"NA":2893},{"trials":2874,"activeCount":98},[],{"trials":2876,"activeCount":98},[],{"trials":2878,"activeCount":98},[],{"trials":2880,"activeCount":98},[],{"trials":2882,"activeCount":98},[2883],{"nctId":2884,"briefTitle":2885,"status":108,"phases":2886,"primaryCompletion":2887,"completion":2458,"start":854,"enrollment":128,"conditions":2888,"interventions":2890},"NCT01494311","Rapydan Topical Anaesthesia for Arterial Cannulation",[89],"2011-06",[2889],"Arterial Catheterization",[2871,2891,2892],"Subcutaneous injection of 0.5 ml Lidocain 1%","Subcutaneous injection of saline",{"trials":2894,"activeCount":98},[],{"intervention":2891,"totalTrials":137,"cells":2896},{"EARLY_PHASE1":2897,"PHASE1":2899,"PHASE2":2901,"PHASE3":2903,"PHASE4":2905,"NA":2911},{"trials":2898,"activeCount":98},[],{"trials":2900,"activeCount":98},[],{"trials":2902,"activeCount":98},[],{"trials":2904,"activeCount":98},[],{"trials":2906,"activeCount":98},[2907],{"nctId":2884,"briefTitle":2885,"status":108,"phases":2908,"primaryCompletion":2887,"completion":2458,"start":854,"enrollment":128,"conditions":2909,"interventions":2910},[89],[2889],[2871,2891,2892],{"trials":2912,"activeCount":98},[],{"intervention":2892,"totalTrials":137,"cells":2914},{"EARLY_PHASE1":2915,"PHASE1":2917,"PHASE2":2919,"PHASE3":2921,"PHASE4":2923,"NA":2929},{"trials":2916,"activeCount":98},[],{"trials":2918,"activeCount":98},[],{"trials":2920,"activeCount":98},[],{"trials":2922,"activeCount":98},[],{"trials":2924,"activeCount":98},[2925],{"nctId":2884,"briefTitle":2885,"status":108,"phases":2926,"primaryCompletion":2887,"completion":2458,"start":854,"enrollment":128,"conditions":2927,"interventions":2928},[89],[2889],[2871,2891,2892],{"trials":2930,"activeCount":98},[],{"intervention":2932,"totalTrials":137,"cells":2933},"Micafungin",{"EARLY_PHASE1":2934,"PHASE1":2936,"PHASE2":2938,"PHASE3":2940,"PHASE4":2942,"NA":2952},{"trials":2935,"activeCount":98},[],{"trials":2937,"activeCount":98},[],{"trials":2939,"activeCount":98},[],{"trials":2941,"activeCount":98},[],{"trials":2943,"activeCount":98},[2944],{"nctId":2945,"briefTitle":2946,"status":108,"phases":2947,"primaryCompletion":2432,"completion":2948,"start":2025,"enrollment":486,"conditions":2949,"interventions":2951},"NCT02651038","Pharmacokinetics of Micafungin During Continuous Venovenous Hemofiltration",[89],"2016-01",[2950],"Candida Sepsis",[2932],{"trials":2953,"activeCount":98},[],{"intervention":2955,"totalTrials":137,"cells":2956},"Topical High dose Capsaicin",{"EARLY_PHASE1":2957,"PHASE1":2959,"PHASE2":2961,"PHASE3":2963,"PHASE4":2965,"NA":2975},{"trials":2958,"activeCount":98},[],{"trials":2960,"activeCount":98},[],{"trials":2962,"activeCount":98},[],{"trials":2964,"activeCount":98},[],{"trials":2966,"activeCount":98},[2967],{"nctId":2968,"briefTitle":2969,"status":108,"phases":2970,"primaryCompletion":1973,"completion":2013,"start":2971,"enrollment":476,"conditions":2972,"interventions":2973},"NCT02570841","Pain Thresholds Under High-dose Topical Capsaicin",[89],"2015-02",[976],[2955,2974],"Topical Placebo",{"trials":2976,"activeCount":98},[],{"intervention":2974,"totalTrials":137,"cells":2978},{"EARLY_PHASE1":2979,"PHASE1":2981,"PHASE2":2983,"PHASE3":2985,"PHASE4":2987,"NA":2993},{"trials":2980,"activeCount":98},[],{"trials":2982,"activeCount":98},[],{"trials":2984,"activeCount":98},[],{"trials":2986,"activeCount":98},[],{"trials":2988,"activeCount":98},[2989],{"nctId":2968,"briefTitle":2969,"status":108,"phases":2990,"primaryCompletion":1973,"completion":2013,"start":2971,"enrollment":476,"conditions":2991,"interventions":2992},[89],[976],[2955,2974],{"trials":2994,"activeCount":98},[],{"intervention":2126,"totalTrials":137,"cells":2996},{"EARLY_PHASE1":2997,"PHASE1":2999,"PHASE2":3001,"PHASE3":3003,"PHASE4":3005,"NA":3011},{"trials":2998,"activeCount":98},[],{"trials":3000,"activeCount":98},[],{"trials":3002,"activeCount":98},[],{"trials":3004,"activeCount":98},[],{"trials":3006,"activeCount":98},[3007],{"nctId":2115,"briefTitle":2116,"status":108,"phases":3008,"primaryCompletion":2118,"completion":2119,"start":2120,"enrollment":2121,"conditions":3009,"interventions":3010},[89],[2123,2124],[2126,2091],{"trials":3012,"activeCount":98},[],{"intervention":3014,"totalTrials":137,"cells":3015},"Yohimbine hydrochloride",{"EARLY_PHASE1":3016,"PHASE1":3018,"PHASE2":3020,"PHASE3":3022,"PHASE4":3024,"NA":3034},{"trials":3017,"activeCount":98},[],{"trials":3019,"activeCount":98},[],{"trials":3021,"activeCount":98},[],{"trials":3023,"activeCount":98},[],{"trials":3025,"activeCount":98},[3026],{"nctId":3027,"briefTitle":3028,"status":108,"phases":3029,"enrollment":22,"conditions":3030,"interventions":3033},"NCT00814047","The Effect of an α2-Adrenoceptor Antagonist (Yohimbine) on Dynamic Autoregulation in the Human Middle Cerebral Artery and Ophthalmic Artery",[89],[3031,3032,21],"Blood Flow Velocity","Autoregulation",[3014],{"trials":3035,"activeCount":98},[],{"intervention":3037,"totalTrials":137,"cells":3038},"Nicotinic Acid",{"EARLY_PHASE1":3039,"PHASE1":3041,"PHASE2":3043,"PHASE3":3045,"PHASE4":3047,"NA":3059},{"trials":3040,"activeCount":98},[],{"trials":3042,"activeCount":98},[],{"trials":3044,"activeCount":98},[],{"trials":3046,"activeCount":98},[],{"trials":3048,"activeCount":98},[3049],{"nctId":3050,"briefTitle":3051,"status":1092,"phases":3052,"start":3053,"enrollment":569,"conditions":3054,"interventions":3057},"NCT00712049","Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT)",[89],"2008-06",[3055,3056],"Dyslipidemia","Atherosclerosis",[3058,3037],"simvastatin",{"trials":3060,"activeCount":98},[],{"intervention":3062,"totalTrials":137,"cells":3063},"Softacort",{"EARLY_PHASE1":3064,"PHASE1":3066,"PHASE2":3068,"PHASE3":3070,"PHASE4":3072,"NA":3084},{"trials":3065,"activeCount":98},[],{"trials":3067,"activeCount":98},[],{"trials":3069,"activeCount":98},[],{"trials":3071,"activeCount":98},[],{"trials":3073,"activeCount":98},[3074],{"nctId":3075,"briefTitle":3076,"status":108,"phases":3077,"primaryCompletion":3078,"completion":3079,"start":3080,"enrollment":949,"conditions":3081,"interventions":3083},"NCT03907865","Clinical Efficacy of Topical Hydrocortisone 0.335% (Softacort®) in Patients With Chronic Dry Eye Disease and Associated Ocular Surface Inflammation",[89],"2018-11-28","2019-01-02","2018-03-27",[3082],"Dry Eye",[3062],{"trials":3085,"activeCount":98},[],{"intervention":2340,"totalTrials":137,"cells":3087},{"EARLY_PHASE1":3088,"PHASE1":3090,"PHASE2":3092,"PHASE3":3094,"PHASE4":3096,"NA":3102},{"trials":3089,"activeCount":98},[],{"trials":3091,"activeCount":98},[],{"trials":3093,"activeCount":98},[],{"trials":3095,"activeCount":98},[],{"trials":3097,"activeCount":98},[3098],{"nctId":2331,"briefTitle":2332,"status":108,"phases":3099,"primaryCompletion":2334,"completion":2334,"start":2036,"enrollment":1097,"conditions":3100,"interventions":3101},[89],[2336,2337,2338],[2340,2299],{"trials":3103,"activeCount":98},[],{"intervention":3105,"totalTrials":137,"cells":3106},"ziprasidone or olanzapine",{"EARLY_PHASE1":3107,"PHASE1":3109,"PHASE2":3111,"PHASE3":3113,"PHASE4":3115,"NA":3125},{"trials":3108,"activeCount":98},[],{"trials":3110,"activeCount":98},[],{"trials":3112,"activeCount":98},[],{"trials":3114,"activeCount":98},[],{"trials":3116,"activeCount":98},[3117],{"nctId":3118,"briefTitle":3119,"status":108,"phases":3120,"start":3121,"conditions":3122,"interventions":3124},"NCT00297960","Influence of Treatment With Olanzapine or Ziprasidone on Transcapillary Glucose Transport in Human Skeletal Muscle",[89],"2005-04",[3123],"Healthy Male Volunteers",[3105],{"trials":3126,"activeCount":98},[],{"intervention":3128,"totalTrials":137,"cells":3129},"Lucentis",{"EARLY_PHASE1":3130,"PHASE1":3132,"PHASE2":3134,"PHASE3":3136,"PHASE4":3138,"NA":3148},{"trials":3131,"activeCount":98},[],{"trials":3133,"activeCount":98},[],{"trials":3135,"activeCount":98},[],{"trials":3137,"activeCount":98},[],{"trials":3139,"activeCount":98},[3140],{"nctId":3141,"briefTitle":3142,"status":108,"phases":3143,"primaryCompletion":886,"completion":841,"start":3144,"enrollment":1061,"conditions":3145,"interventions":3147},"NCT01027481","Ranibizumab in Patients With Branch Retinal Vein Occlusion",[89],"2007-12",[3146],"Retinal Vein Occlusion",[3128],{"trials":3149,"activeCount":98},[],{"intervention":3151,"totalTrials":137,"cells":3152},"levodopa",{"EARLY_PHASE1":3153,"PHASE1":3155,"PHASE2":3157,"PHASE3":3159,"PHASE4":3161,"NA":3170},{"trials":3154,"activeCount":98},[],{"trials":3156,"activeCount":98},[],{"trials":3158,"activeCount":98},[],{"trials":3160,"activeCount":98},[],{"trials":3162,"activeCount":98},[3163],{"nctId":3164,"briefTitle":3165,"status":108,"phases":3166,"primaryCompletion":2168,"completion":2168,"start":2544,"enrollment":476,"conditions":3167,"interventions":3169},"NCT00812760","Effect of Levodopa on Human Multifocal Electroretinogram",[89],[3168],"Retinal Diseases",[3151],{"trials":3171,"activeCount":98},[],{"intervention":3173,"totalTrials":137,"cells":3174},"sclerotherapy with aethoxysclerol foam",{"EARLY_PHASE1":3175,"PHASE1":3177,"PHASE2":3179,"PHASE3":3181,"PHASE4":3183,"NA":3192},{"trials":3176,"activeCount":98},[],{"trials":3178,"activeCount":98},[],{"trials":3180,"activeCount":98},[],{"trials":3182,"activeCount":98},[],{"trials":3184,"activeCount":98},[3185],{"nctId":3186,"briefTitle":3187,"status":108,"phases":3188,"primaryCompletion":2501,"completion":2501,"start":2287,"enrollment":112,"conditions":3189,"interventions":3191},"NCT02010723","Surgery Versus Sclerotherapy for Isolated Accessory Great Saphenous Vein Varicosis",[89],[3190],"Varicose Veins",[3173],{"trials":3193,"activeCount":98},[],{"intervention":3195,"totalTrials":137,"cells":3196},"Rosuvastatin",{"EARLY_PHASE1":3197,"PHASE1":3199,"PHASE2":3201,"PHASE3":3203,"PHASE4":3205,"NA":3214},{"trials":3198,"activeCount":98},[],{"trials":3200,"activeCount":98},[],{"trials":3202,"activeCount":98},[],{"trials":3204,"activeCount":98},[],{"trials":3206,"activeCount":98},[3207],{"nctId":3208,"briefTitle":3209,"status":2011,"phases":3210,"primaryCompletion":3211,"completion":3211,"start":1107,"enrollment":98,"conditions":3212,"interventions":3213},"NCT00913562","Effect of Rosuvastatin on Endothelial Function in Patients With Diabetes and Glaucoma",[89],"2014-11",[27,2607],[3195],{"trials":3215,"activeCount":98},[],{"intervention":3217,"totalTrials":137,"cells":3218},"Clonidin",{"EARLY_PHASE1":3219,"PHASE1":3221,"PHASE2":3223,"PHASE3":3225,"PHASE4":3227,"NA":3238},{"trials":3220,"activeCount":98},[],{"trials":3222,"activeCount":98},[],{"trials":3224,"activeCount":98},[],{"trials":3226,"activeCount":98},[],{"trials":3228,"activeCount":98},[3229],{"nctId":3230,"briefTitle":3231,"status":108,"phases":3232,"completion":3233,"start":3234,"enrollment":22,"conditions":3235,"interventions":3236},"NCT00312416","Effects of Topical Clonidine vs. Brimonidine on Choroidal Blood Flow and Intraocular Pressure During Isometric Exercise",[89],"2004-12","2004-02",[21,18],[3217,3237],"Brimonidine",{"trials":3239,"activeCount":98},[],{"intervention":3241,"totalTrials":137,"cells":3242},"Vitamin B1-ratiopharm",{"EARLY_PHASE1":3243,"PHASE1":3245,"PHASE2":3247,"PHASE3":3249,"PHASE4":3251,"NA":3265},{"trials":3244,"activeCount":98},[],{"trials":3246,"activeCount":98},[],{"trials":3248,"activeCount":98},[],{"trials":3250,"activeCount":98},[],{"trials":3252,"activeCount":98},[3253],{"nctId":3254,"briefTitle":3255,"status":108,"phases":3256,"primaryCompletion":3257,"completion":3258,"start":3259,"enrollment":1061,"conditions":3260,"interventions":3264},"NCT01524315","Preoperative Parenteral Thiamine Supplementation in Patients Undergoing Heart Surgery",[89],"2015-02-01","2015-02-02","2012-02-01",[3261,3262,3263],"Heart Failure","Acidosis, Lactic","Thiamine Deficiency",[3241],{"trials":3266,"activeCount":98},[],{"intervention":3268,"totalTrials":137,"cells":3269},"Adalimumab treatment arm",{"EARLY_PHASE1":3270,"PHASE1":3272,"PHASE2":3274,"PHASE3":3276,"PHASE4":3278,"NA":3293},{"trials":3271,"activeCount":98},[],{"trials":3273,"activeCount":98},[],{"trials":3275,"activeCount":98},[],{"trials":3277,"activeCount":98},[],{"trials":3279,"activeCount":98},[3280],{"nctId":3281,"briefTitle":3282,"status":1092,"phases":3283,"primaryCompletion":3284,"completion":3285,"start":3286,"enrollment":974,"conditions":3287,"interventions":3291},"NCT01088165","The Influence of Adalimumab on Cardiovascular and Metabolic Risk in Psoriasis",[89],"2013-05","2014-05","2010-05",[3288,3289,3290],"Psoriasis","Cardiovascular Diseases","Diabetes Mellitus, Type 2",[3268,3292],"Fumaric acid esters treatment group",{"trials":3294,"activeCount":98},[],{"intervention":3292,"totalTrials":137,"cells":3296},{"EARLY_PHASE1":3297,"PHASE1":3299,"PHASE2":3301,"PHASE3":3303,"PHASE4":3305,"NA":3311},{"trials":3298,"activeCount":98},[],{"trials":3300,"activeCount":98},[],{"trials":3302,"activeCount":98},[],{"trials":3304,"activeCount":98},[],{"trials":3306,"activeCount":98},[3307],{"nctId":3281,"briefTitle":3282,"status":1092,"phases":3308,"primaryCompletion":3284,"completion":3285,"start":3286,"enrollment":974,"conditions":3309,"interventions":3310},[89],[3288,3289,3290],[3268,3292],{"trials":3312,"activeCount":98},[],{"intervention":3314,"totalTrials":137,"cells":3315},"Iron Carboxymaltose",{"EARLY_PHASE1":3316,"PHASE1":3318,"PHASE2":3320,"PHASE3":3322,"PHASE4":3324,"NA":3336},{"trials":3317,"activeCount":98},[],{"trials":3319,"activeCount":98},[],{"trials":3321,"activeCount":98},[],{"trials":3323,"activeCount":98},[],{"trials":3325,"activeCount":98},[3326],{"nctId":3327,"briefTitle":3328,"status":1092,"phases":3329,"primaryCompletion":1221,"completion":3330,"start":3331,"enrollment":949,"conditions":3332,"interventions":3335},"NCT04475887","Treatment of Anemia With Intravenous Iron in Patients Listed for Orthotopic Liver Transplantation",[89],"2023-05-31","2020-07-23",[3333,3334],"Liver Transplantation","Blood Loss",[3314],{"trials":3337,"activeCount":98},[],{"intervention":3339,"totalTrials":137,"cells":3340},"Heparin sodium",{"EARLY_PHASE1":3341,"PHASE1":3343,"PHASE2":3345,"PHASE3":3347,"PHASE4":3349,"NA":3361},{"trials":3342,"activeCount":98},[],{"trials":3344,"activeCount":98},[],{"trials":3346,"activeCount":98},[],{"trials":3348,"activeCount":98},[],{"trials":3350,"activeCount":98},[3351],{"nctId":3352,"briefTitle":3353,"status":1092,"phases":3354,"primaryCompletion":3355,"completion":3356,"start":3357,"enrollment":590,"conditions":3358,"interventions":3360},"NCT05697692","Heparin-free Extracorporeal Membrane Oxygenation Support During Clinical Lung Transplantation",[89],"2024-02-28","2024-06-30","2022-12-20",[3359],"Lung Transplantation",[3339],{"trials":3362,"activeCount":98},[],{"intervention":3364,"totalTrials":137,"cells":3365},"Lactated Ringer's Solution",{"EARLY_PHASE1":3366,"PHASE1":3368,"PHASE2":3370,"PHASE3":3372,"PHASE4":3374,"NA":3388},{"trials":3367,"activeCount":98},[],{"trials":3369,"activeCount":98},[],{"trials":3371,"activeCount":98},[],{"trials":3373,"activeCount":98},[],{"trials":3375,"activeCount":98},[3376],{"nctId":3377,"briefTitle":3378,"status":108,"phases":3379,"primaryCompletion":3380,"completion":3380,"start":3381,"enrollment":3382,"conditions":3383,"interventions":3386},"NCT00517127","Crystalloids Versus Colloids During Surgery",[89],"2016-12-31","2006-09",1109,[3384,3385],"Fluid Overload","Postoperative Complications",[3364,3387],"Hydroxyethylstarch 6% 130\u002F0.4",{"trials":3389,"activeCount":98},[],{"intervention":3387,"totalTrials":137,"cells":3391},{"EARLY_PHASE1":3392,"PHASE1":3394,"PHASE2":3396,"PHASE3":3398,"PHASE4":3400,"NA":3406},{"trials":3393,"activeCount":98},[],{"trials":3395,"activeCount":98},[],{"trials":3397,"activeCount":98},[],{"trials":3399,"activeCount":98},[],{"trials":3401,"activeCount":98},[3402],{"nctId":3377,"briefTitle":3378,"status":108,"phases":3403,"primaryCompletion":3380,"completion":3380,"start":3381,"enrollment":3382,"conditions":3404,"interventions":3405},[89],[3384,3385],[3364,3387],{"trials":3407,"activeCount":98},[],{"intervention":3409,"totalTrials":137,"cells":3410},"IXIARO",{"EARLY_PHASE1":3411,"PHASE1":3413,"PHASE2":3415,"PHASE3":3417,"PHASE4":3419,"NA":3430},{"trials":3412,"activeCount":98},[],{"trials":3414,"activeCount":98},[],{"trials":3416,"activeCount":98},[],{"trials":3418,"activeCount":98},[],{"trials":3420,"activeCount":98},[3421],{"nctId":3422,"briefTitle":3423,"status":108,"phases":3424,"primaryCompletion":3425,"completion":3426,"start":2079,"enrollment":949,"conditions":3427,"interventions":3429},"NCT01398540","Cellular and Humoral Immunity in Elderly After Immunization With a Japanese Encephalitis Vaccine",[89],"2012-10","2013-11",[3428],"Humoral and Cellular Immune Responses",[3409],{"trials":3431,"activeCount":98},[],{"intervention":1050,"totalTrials":137,"cells":3433},{"EARLY_PHASE1":3434,"PHASE1":3436,"PHASE2":3438,"PHASE3":3440,"PHASE4":3442,"NA":3448},{"trials":3435,"activeCount":98},[],{"trials":3437,"activeCount":98},[],{"trials":3439,"activeCount":98},[],{"trials":3441,"activeCount":98},[],{"trials":3443,"activeCount":98},[3444],{"nctId":1043,"briefTitle":1044,"status":839,"phases":3445,"primaryCompletion":1046,"completion":1046,"start":1047,"enrollment":949,"conditions":3446,"interventions":3447},[89],[34],[1050,1051,1052,1053],{"trials":3449,"activeCount":98},[],{"intervention":1052,"totalTrials":137,"cells":3451},{"EARLY_PHASE1":3452,"PHASE1":3454,"PHASE2":3456,"PHASE3":3458,"PHASE4":3460,"NA":3466},{"trials":3453,"activeCount":98},[],{"trials":3455,"activeCount":98},[],{"trials":3457,"activeCount":98},[],{"trials":3459,"activeCount":98},[],{"trials":3461,"activeCount":98},[3462],{"nctId":1043,"briefTitle":1044,"status":839,"phases":3463,"primaryCompletion":1046,"completion":1046,"start":1047,"enrollment":949,"conditions":3464,"interventions":3465},[89],[34],[1050,1051,1052,1053],{"trials":3467,"activeCount":98},[],{"intervention":1053,"totalTrials":137,"cells":3469},{"EARLY_PHASE1":3470,"PHASE1":3472,"PHASE2":3474,"PHASE3":3476,"PHASE4":3478,"NA":3484},{"trials":3471,"activeCount":98},[],{"trials":3473,"activeCount":98},[],{"trials":3475,"activeCount":98},[],{"trials":3477,"activeCount":98},[],{"trials":3479,"activeCount":98},[3480],{"nctId":1043,"briefTitle":1044,"status":839,"phases":3481,"primaryCompletion":1046,"completion":1046,"start":1047,"enrollment":949,"conditions":3482,"interventions":3483},[89],[34],[1050,1051,1052,1053],{"trials":3485,"activeCount":98},[],{"intervention":3487,"totalTrials":137,"cells":3488},"Omega 3 fatty acids",{"EARLY_PHASE1":3489,"PHASE1":3491,"PHASE2":3493,"PHASE3":3495,"PHASE4":3497,"NA":3509},{"trials":3490,"activeCount":98},[],{"trials":3492,"activeCount":98},[],{"trials":3494,"activeCount":98},[],{"trials":3496,"activeCount":98},[],{"trials":3498,"activeCount":98},[3499],{"nctId":3500,"briefTitle":3501,"status":108,"phases":3502,"primaryCompletion":3503,"completion":3503,"start":3504,"enrollment":3505,"conditions":3506,"interventions":3508},"NCT00396643","Indicated Prevention With Omega-3 Fatty Acids in Adolescents With 'At-Risk-Mental-State' for Psychosis",[89],"2007-06","2004-05",81,[2606,3507],"Prodrome",[3487],{"trials":3510,"activeCount":98},[],{"intervention":3512,"totalTrials":137,"cells":3513},"Strontium Ranelate + Ca\u002FVitamin-D",{"EARLY_PHASE1":3514,"PHASE1":3516,"PHASE2":3518,"PHASE3":3520,"PHASE4":3522,"NA":3535},{"trials":3515,"activeCount":98},[],{"trials":3517,"activeCount":98},[],{"trials":3519,"activeCount":98},[],{"trials":3521,"activeCount":98},[],{"trials":3523,"activeCount":98},[3524],{"nctId":3525,"briefTitle":3526,"status":108,"phases":3527,"primaryCompletion":3528,"completion":3528,"start":3529,"enrollment":3530,"conditions":3531,"interventions":3534},"NCT01222026","Systematic Treatment After Successful Surgical Treatment for Primary Hyperparathyroidism With Strontium Ranelate",[89],"2014-12","2010-09",63,[3532,3533,2040],"Primary Hyperparathyroidism","Osteopenia",[3512],{"trials":3536,"activeCount":98},[],{"intervention":1977,"totalTrials":137,"cells":3538},{"EARLY_PHASE1":3539,"PHASE1":3541,"PHASE2":3543,"PHASE3":3545,"PHASE4":3547,"NA":3553},{"trials":3540,"activeCount":98},[],{"trials":3542,"activeCount":98},[],{"trials":3544,"activeCount":98},[],{"trials":3546,"activeCount":98},[],{"trials":3548,"activeCount":98},[3549],{"nctId":1969,"briefTitle":1970,"status":1092,"phases":3550,"primaryCompletion":1972,"completion":1972,"start":1973,"enrollment":590,"conditions":3551,"interventions":3552},[89],[1975],[1977,1946],{"trials":3554,"activeCount":98},[],{"intervention":3556,"totalTrials":137,"cells":3557},"clonidine (drug) intravenously",{"EARLY_PHASE1":3558,"PHASE1":3560,"PHASE2":3562,"PHASE3":3564,"PHASE4":3566,"NA":3577},{"trials":3559,"activeCount":98},[],{"trials":3561,"activeCount":98},[],{"trials":3563,"activeCount":98},[],{"trials":3565,"activeCount":98},[],{"trials":3567,"activeCount":98},[3568],{"nctId":3569,"briefTitle":3570,"status":108,"phases":3571,"completion":3572,"start":3573,"enrollment":30,"conditions":3574,"interventions":3576},"NCT00279253","Effects of Intravenous Clonidine on Ocular Blood Flow and Intraocular Pressure",[89],"2005-01","2004-03",[3575],"Physiology",[3556],{"trials":3578,"activeCount":98},[],{"intervention":3580,"totalTrials":137,"cells":3581},"volume replacement",{"EARLY_PHASE1":3582,"PHASE1":3584,"PHASE2":3586,"PHASE3":3588,"PHASE4":3590,"NA":3601},{"trials":3583,"activeCount":98},[],{"trials":3585,"activeCount":98},[],{"trials":3587,"activeCount":98},[],{"trials":3589,"activeCount":98},[],{"trials":3591,"activeCount":98},[3592],{"nctId":3593,"briefTitle":3594,"status":108,"phases":3595,"primaryCompletion":2207,"completion":1114,"start":2037,"enrollment":3596,"conditions":3597,"interventions":3599},"NCT01174719","Humanalbumin, Hydroxyethylstarch and Ringer Lactate During Cardiac Surgery",[89],240,[3598,32],"Valvular Heart Disease",[3580,3600,3580],"Humanalbumin 5%",{"trials":3602,"activeCount":98},[],{"intervention":3600,"totalTrials":137,"cells":3604},{"EARLY_PHASE1":3605,"PHASE1":3607,"PHASE2":3609,"PHASE3":3611,"PHASE4":3613,"NA":3619},{"trials":3606,"activeCount":98},[],{"trials":3608,"activeCount":98},[],{"trials":3610,"activeCount":98},[],{"trials":3612,"activeCount":98},[],{"trials":3614,"activeCount":98},[3615],{"nctId":3593,"briefTitle":3594,"status":108,"phases":3616,"primaryCompletion":2207,"completion":1114,"start":2037,"enrollment":3596,"conditions":3617,"interventions":3618},[89],[3598,32],[3580,3600,3580],{"trials":3620,"activeCount":98},[],{"intervention":3622,"totalTrials":137,"cells":3623},"Nitrous oxide",{"EARLY_PHASE1":3624,"PHASE1":3626,"PHASE2":3628,"PHASE3":3630,"PHASE4":3632,"NA":3645},{"trials":3625,"activeCount":98},[],{"trials":3627,"activeCount":98},[],{"trials":3629,"activeCount":98},[],{"trials":3631,"activeCount":98},[],{"trials":3633,"activeCount":98},[3634],{"nctId":3635,"briefTitle":3636,"status":108,"phases":3637,"completion":3638,"start":3572,"enrollment":3639,"conditions":3640,"interventions":3644},"NCT00482456","Homocysteine After Nitrous Oxide Anesthesia",[89],"2007-03",140,[3641,3642,3643],"Anesthesia, General","Adverse Effects","Nitrous Oxide",[3622],{"trials":3646,"activeCount":98},[],{"intervention":2031,"totalTrials":137,"cells":3648},{"EARLY_PHASE1":3649,"PHASE1":3651,"PHASE2":3653,"PHASE3":3655,"PHASE4":3657,"NA":3663},{"trials":3650,"activeCount":98},[],{"trials":3652,"activeCount":98},[],{"trials":3654,"activeCount":98},[],{"trials":3656,"activeCount":98},[],{"trials":3658,"activeCount":98},[3659],{"nctId":2021,"briefTitle":2022,"status":2023,"phases":3660,"primaryCompletion":2013,"completion":2013,"start":2025,"enrollment":128,"conditions":3661,"interventions":3662},[89],[2027,2028,2029],[2031,1998],{"trials":3664,"activeCount":98},[],{"intervention":3666,"totalTrials":137,"cells":3667},"Neodolpasse",{"EARLY_PHASE1":3668,"PHASE1":3670,"PHASE2":3672,"PHASE3":3674,"PHASE4":3676,"NA":3690},{"trials":3669,"activeCount":98},[],{"trials":3671,"activeCount":98},[],{"trials":3673,"activeCount":98},[],{"trials":3675,"activeCount":98},[],{"trials":3677,"activeCount":98},[3678],{"nctId":3679,"briefTitle":3680,"status":108,"phases":3681,"primaryCompletion":3682,"completion":3682,"start":3683,"enrollment":290,"conditions":3684,"interventions":3688},"NCT03493490","Neodolpasse® Infusion Solution Versus Diclofenac 75 mg Infusion in the Treatment of Postoperative Pain After Elective Knee Surgery",[89],"2019-05-31","2018-03-01",[3685,3686,3687],"Pain, Postoperative","Analgesic Adverse Reaction","Cruciate Ligament Rupture",[3666,3689],"Diclofenac",{"trials":3691,"activeCount":98},[],{"intervention":3689,"totalTrials":137,"cells":3693},{"EARLY_PHASE1":3694,"PHASE1":3696,"PHASE2":3698,"PHASE3":3700,"PHASE4":3702,"NA":3708},{"trials":3695,"activeCount":98},[],{"trials":3697,"activeCount":98},[],{"trials":3699,"activeCount":98},[],{"trials":3701,"activeCount":98},[],{"trials":3703,"activeCount":98},[3704],{"nctId":3679,"briefTitle":3680,"status":108,"phases":3705,"primaryCompletion":3682,"completion":3682,"start":3683,"enrollment":290,"conditions":3706,"interventions":3707},[89],[3685,3686,3687],[3666,3689],{"trials":3709,"activeCount":98},[],{"intervention":3711,"totalTrials":137,"cells":3712},"ramipril",{"EARLY_PHASE1":3713,"PHASE1":3715,"PHASE2":3717,"PHASE3":3719,"PHASE4":3721,"NA":3729},{"trials":3714,"activeCount":98},[],{"trials":3716,"activeCount":98},[],{"trials":3718,"activeCount":98},[],{"trials":3720,"activeCount":98},[],{"trials":3722,"activeCount":98},[3723],{"nctId":3724,"briefTitle":3725,"status":108,"phases":3726,"primaryCompletion":1106,"completion":1992,"start":1855,"enrollment":22,"conditions":3727,"interventions":3728},"NCT00657865","Gene Expression Profiling in Skeletal Muscle of Healthy Subjects Treated With Ramipril",[89],[15],[3711],{"trials":3730,"activeCount":98},[],{"intervention":1930,"totalTrials":137,"cells":3732},{"EARLY_PHASE1":3733,"PHASE1":3735,"PHASE2":3737,"PHASE3":3739,"PHASE4":3741,"NA":3747},{"trials":3734,"activeCount":98},[],{"trials":3736,"activeCount":98},[],{"trials":3738,"activeCount":98},[],{"trials":3740,"activeCount":98},[],{"trials":3742,"activeCount":98},[3743],{"nctId":1920,"briefTitle":1921,"status":1092,"phases":3744,"primaryCompletion":1923,"completion":1161,"start":1924,"enrollment":949,"conditions":3745,"interventions":3746},[89],[1926,1927,1928],[1930,1931,1883],{"trials":3748,"activeCount":98},[],{"intervention":3750,"totalTrials":137,"cells":3751},"Pioglitazone",{"EARLY_PHASE1":3752,"PHASE1":3754,"PHASE2":3756,"PHASE3":3758,"PHASE4":3760,"NA":3769},{"trials":3753,"activeCount":98},[],{"trials":3755,"activeCount":98},[],{"trials":3757,"activeCount":98},[],{"trials":3759,"activeCount":98},[],{"trials":3761,"activeCount":98},[3762],{"nctId":3763,"briefTitle":3764,"status":108,"phases":3765,"primaryCompletion":1132,"completion":1132,"start":3233,"enrollment":476,"conditions":3766,"interventions":3768},"NCT00570622","Effect of Pioglitazone on Portal and Systemic Hemodynamics in Patients With Advanced Cirrhosis",[89],[2865,3767,2866],"Ascites",[3750],{"trials":3770,"activeCount":98},[],{"intervention":3772,"totalTrials":137,"cells":3773},"Vorapaxar",{"EARLY_PHASE1":3774,"PHASE1":3776,"PHASE2":3778,"PHASE3":3780,"PHASE4":3782,"NA":3791},{"trials":3775,"activeCount":98},[],{"trials":3777,"activeCount":98},[],{"trials":3779,"activeCount":98},[],{"trials":3781,"activeCount":98},[],{"trials":3783,"activeCount":98},[3784],{"nctId":3785,"briefTitle":3786,"status":108,"phases":3787,"primaryCompletion":3788,"completion":3788,"start":2105,"enrollment":547,"conditions":3789,"interventions":3790},"NCT02875028","Vorapaxar in the Human Endotoxemia Model",[89],"2016-11-30",[2081],[3772],{"trials":3792,"activeCount":98},[],{"intervention":3794,"totalTrials":137,"cells":3795},"Dabigatran, Ticagrelor, ASA",{"EARLY_PHASE1":3796,"PHASE1":3798,"PHASE2":3800,"PHASE3":3802,"PHASE4":3804,"NA":3815},{"trials":3797,"activeCount":98},[],{"trials":3799,"activeCount":98},[],{"trials":3801,"activeCount":98},[],{"trials":3803,"activeCount":98},[],{"trials":3805,"activeCount":98},[3806],{"nctId":3807,"briefTitle":3808,"status":108,"phases":3809,"primaryCompletion":3284,"completion":3810,"start":3425,"enrollment":949,"conditions":3811,"interventions":3812},"NCT01812200","Antithrombotic Triple Therapy in Humans",[89],"2013-07",[2461,1898],[3794,3813,3814],"Rivaroxaban, Ticagrelor, ASA","Phenprocoumon, Ticagrelor, ASA",{"trials":3816,"activeCount":98},[],{"intervention":3813,"totalTrials":137,"cells":3818},{"EARLY_PHASE1":3819,"PHASE1":3821,"PHASE2":3823,"PHASE3":3825,"PHASE4":3827,"NA":3833},{"trials":3820,"activeCount":98},[],{"trials":3822,"activeCount":98},[],{"trials":3824,"activeCount":98},[],{"trials":3826,"activeCount":98},[],{"trials":3828,"activeCount":98},[3829],{"nctId":3807,"briefTitle":3808,"status":108,"phases":3830,"primaryCompletion":3284,"completion":3810,"start":3425,"enrollment":949,"conditions":3831,"interventions":3832},[89],[2461,1898],[3794,3813,3814],{"trials":3834,"activeCount":98},[],{"intervention":3814,"totalTrials":137,"cells":3836},{"EARLY_PHASE1":3837,"PHASE1":3839,"PHASE2":3841,"PHASE3":3843,"PHASE4":3845,"NA":3851},{"trials":3838,"activeCount":98},[],{"trials":3840,"activeCount":98},[],{"trials":3842,"activeCount":98},[],{"trials":3844,"activeCount":98},[],{"trials":3846,"activeCount":98},[3847],{"nctId":3807,"briefTitle":3808,"status":108,"phases":3848,"primaryCompletion":3284,"completion":3810,"start":3425,"enrollment":949,"conditions":3849,"interventions":3850},[89],[2461,1898],[3794,3813,3814],{"trials":3852,"activeCount":98},[],{"intervention":3854,"totalTrials":137,"cells":3855},"dalteparin",{"EARLY_PHASE1":3856,"PHASE1":3858,"PHASE2":3860,"PHASE3":3862,"PHASE4":3864,"NA":3873},{"trials":3857,"activeCount":98},[],{"trials":3859,"activeCount":98},[],{"trials":3861,"activeCount":98},[],{"trials":3863,"activeCount":98},[],{"trials":3865,"activeCount":98},[3866],{"nctId":3867,"briefTitle":3868,"status":839,"phases":3869,"completion":3121,"start":2543,"enrollment":128,"conditions":3870,"interventions":3872},"NCT00437697","Thromboprophylaxis in Critically Ill Patients",[89],[3871],"Venous Thromboembolism",[3854],{"trials":3874,"activeCount":98},[],{"intervention":3876,"totalTrials":137,"cells":3877},"cefpirome and moxifloxacin administration",{"EARLY_PHASE1":3878,"PHASE1":3880,"PHASE2":3882,"PHASE3":3884,"PHASE4":3886,"NA":3896},{"trials":3879,"activeCount":98},[],{"trials":3881,"activeCount":98},[],{"trials":3883,"activeCount":98},[],{"trials":3885,"activeCount":98},[],{"trials":3887,"activeCount":98},[3888],{"nctId":3889,"briefTitle":3890,"status":108,"phases":3891,"primaryCompletion":841,"completion":841,"start":843,"enrollment":476,"conditions":3892,"interventions":3895},"NCT00280514","Plasma and Abscess Fluid Pharmacokinetics of Cefpirome and Moxifloxacin After Single and Multiple Dose Administration",[89],[3893,3894],"Abscess","Cysts",[3876],{"trials":3897,"activeCount":98},[],{"intervention":3899,"totalTrials":137,"cells":3900},"imiquimod 5% cream",{"EARLY_PHASE1":3901,"PHASE1":3903,"PHASE2":3905,"PHASE3":3907,"PHASE4":3909,"NA":3919},{"trials":3902,"activeCount":98},[],{"trials":3904,"activeCount":98},[],{"trials":3906,"activeCount":98},[],{"trials":3908,"activeCount":98},[],{"trials":3910,"activeCount":98},[3911],{"nctId":3912,"briefTitle":3913,"status":839,"phases":3914,"primaryCompletion":2630,"completion":2630,"start":3915,"enrollment":486,"conditions":3916,"interventions":3918},"NCT01538901","Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant Recipients",[89],"2012-09",[3917],"Actinic Keratoses",[3899],{"trials":3920,"activeCount":98},[],{"intervention":3922,"totalTrials":137,"cells":3923},"NVX",{"EARLY_PHASE1":3924,"PHASE1":3926,"PHASE2":3928,"PHASE3":3930,"PHASE4":3932,"NA":3946},{"trials":3925,"activeCount":98},[],{"trials":3927,"activeCount":98},[],{"trials":3929,"activeCount":98},[],{"trials":3931,"activeCount":98},[],{"trials":3933,"activeCount":98},[3934],{"nctId":3935,"briefTitle":3936,"status":1092,"phases":3937,"primaryCompletion":3938,"completion":3939,"start":3940,"enrollment":3941,"conditions":3942,"interventions":3944},"NCT05767606","Concomitant Administration of the Novavax Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Adults Aged ≥60 Years",[89],"2023-07","2023-08","2023-03",256,[2316,3943],"Pneumococcal Infections",[3922,3945],"PCV20",{"trials":3947,"activeCount":98},[],{"intervention":3945,"totalTrials":137,"cells":3949},{"EARLY_PHASE1":3950,"PHASE1":3952,"PHASE2":3954,"PHASE3":3956,"PHASE4":3958,"NA":3964},{"trials":3951,"activeCount":98},[],{"trials":3953,"activeCount":98},[],{"trials":3955,"activeCount":98},[],{"trials":3957,"activeCount":98},[],{"trials":3959,"activeCount":98},[3960],{"nctId":3935,"briefTitle":3936,"status":1092,"phases":3961,"primaryCompletion":3938,"completion":3939,"start":3940,"enrollment":3941,"conditions":3962,"interventions":3963},[89],[2316,3943],[3922,3945],{"trials":3965,"activeCount":98},[],{"intervention":3967,"totalTrials":137,"cells":3968},"TBE booster vaccination",{"EARLY_PHASE1":3969,"PHASE1":3971,"PHASE2":3973,"PHASE3":3975,"PHASE4":3977,"NA":3989},{"trials":3970,"activeCount":98},[],{"trials":3972,"activeCount":98},[],{"trials":3974,"activeCount":98},[],{"trials":3976,"activeCount":98},[],{"trials":3978,"activeCount":98},[3979],{"nctId":3980,"briefTitle":3981,"status":108,"phases":3982,"primaryCompletion":2334,"completion":1982,"start":3983,"enrollment":3984,"conditions":3985,"interventions":3988},"NCT02511535","TBE (Tick-borne Encephalitis) Vaccination in Allergic Patients",[89],"2013-09",119,[3986,3987],"Vaccine Responsiveness in Allergy","Vaccine Responsiveness During Allergy De-sensitization Treatment",[3967],{"trials":3990,"activeCount":98},[],{"intervention":3992,"totalTrials":137,"cells":3993},"IXIARO®- Japanese Encephalitis vaccine",{"EARLY_PHASE1":3994,"PHASE1":3996,"PHASE2":3998,"PHASE3":4000,"PHASE4":4002,"NA":4014},{"trials":3995,"activeCount":98},[],{"trials":3997,"activeCount":98},[],{"trials":3999,"activeCount":98},[],{"trials":4001,"activeCount":98},[],{"trials":4003,"activeCount":98},[4004],{"nctId":4005,"briefTitle":4006,"status":1092,"phases":4007,"primaryCompletion":2193,"completion":4008,"start":4009,"enrollment":4010,"conditions":4011,"interventions":4013},"NCT03971058","Immune Responses After a Booster Immunisation With IXIARO® in Elderly Compared to Young Individuals.",[89],"2021-03","2019-03-01",64,[4012],"Japanese Encephalitis Vaccine",[3992],{"trials":4015,"activeCount":98},[],{"intervention":4017,"totalTrials":137,"cells":4018},"Preservative-free latanoprost 50µg\u002Fml",{"EARLY_PHASE1":4019,"PHASE1":4021,"PHASE2":4023,"PHASE3":4025,"PHASE4":4027,"NA":4041},{"trials":4020,"activeCount":98},[],{"trials":4022,"activeCount":98},[],{"trials":4024,"activeCount":98},[],{"trials":4026,"activeCount":98},[],{"trials":4028,"activeCount":98},[4029],{"nctId":4030,"briefTitle":4031,"status":1092,"phases":4032,"primaryCompletion":4033,"completion":4034,"start":4035,"enrollment":4036,"conditions":4037,"interventions":4039},"NCT02585375","Latanoprost Preserved Versus Unpreserved: Effect on Tear Film Thickness as Measured With OCT",[89],"2023-09","2023-09-02","2015-09-17",70,[27,4038],"Ocular Hypertension",[4017,4040],"Preserved latanoprost 0.005%",{"trials":4042,"activeCount":98},[],{"intervention":4040,"totalTrials":137,"cells":4044},{"EARLY_PHASE1":4045,"PHASE1":4047,"PHASE2":4049,"PHASE3":4051,"PHASE4":4053,"NA":4059},{"trials":4046,"activeCount":98},[],{"trials":4048,"activeCount":98},[],{"trials":4050,"activeCount":98},[],{"trials":4052,"activeCount":98},[],{"trials":4054,"activeCount":98},[4055],{"nctId":4030,"briefTitle":4031,"status":1092,"phases":4056,"primaryCompletion":4033,"completion":4034,"start":4035,"enrollment":4036,"conditions":4057,"interventions":4058},[89],[27,4038],[4017,4040],{"trials":4060,"activeCount":98},[],{"intervention":4062,"totalTrials":137,"cells":4063},"SMOFLIPID",{"EARLY_PHASE1":4064,"PHASE1":4066,"PHASE2":4068,"PHASE3":4070,"PHASE4":4072,"NA":4086},{"trials":4065,"activeCount":98},[],{"trials":4067,"activeCount":98},[],{"trials":4069,"activeCount":98},[],{"trials":4071,"activeCount":98},[],{"trials":4073,"activeCount":98},[4074],{"nctId":4075,"briefTitle":4076,"status":108,"phases":4077,"primaryCompletion":2863,"completion":4078,"start":4079,"enrollment":4080,"conditions":4081,"interventions":4084},"NCT01585935","Preventing Cholestasis Using SMOFLipid®",[89],"2017-11-13","2012-06",230,[4082,4083],"Cholestasis","Psychomotor Disorders, Developmental",[4062,4085],"INTRALIPID",{"trials":4087,"activeCount":98},[],{"intervention":4085,"totalTrials":137,"cells":4089},{"EARLY_PHASE1":4090,"PHASE1":4092,"PHASE2":4094,"PHASE3":4096,"PHASE4":4098,"NA":4104},{"trials":4091,"activeCount":98},[],{"trials":4093,"activeCount":98},[],{"trials":4095,"activeCount":98},[],{"trials":4097,"activeCount":98},[],{"trials":4099,"activeCount":98},[4100],{"nctId":4075,"briefTitle":4076,"status":108,"phases":4101,"primaryCompletion":2863,"completion":4078,"start":4079,"enrollment":4080,"conditions":4102,"interventions":4103},[89],[4082,4083],[4062,4085],{"trials":4105,"activeCount":98},[],{"intervention":1126,"totalTrials":137,"cells":4107},{"EARLY_PHASE1":4108,"PHASE1":4110,"PHASE2":4112,"PHASE3":4114,"PHASE4":4116,"NA":4122},{"trials":4109,"activeCount":98},[],{"trials":4111,"activeCount":98},[],{"trials":4113,"activeCount":98},[],{"trials":4115,"activeCount":98},[],{"trials":4117,"activeCount":98},[4118],{"nctId":1118,"briefTitle":1119,"status":108,"phases":4119,"primaryCompletion":1121,"completion":1121,"start":1122,"enrollment":590,"conditions":4120,"interventions":4121},[89],[1124],[1126,1077],{"trials":4123,"activeCount":98},[],{"intervention":4125,"totalTrials":137,"cells":4126},"Prosicca",{"EARLY_PHASE1":4127,"PHASE1":4129,"PHASE2":4131,"PHASE3":4133,"PHASE4":4135,"NA":4146},{"trials":4128,"activeCount":98},[],{"trials":4130,"activeCount":98},[],{"trials":4132,"activeCount":98},[],{"trials":4134,"activeCount":98},[],{"trials":4136,"activeCount":98},[4137],{"nctId":4138,"briefTitle":4139,"status":1092,"phases":4140,"primaryCompletion":4033,"completion":4141,"start":4142,"enrollment":112,"conditions":4143,"interventions":4144},"NCT02533154","Effect of Benzalkonium Chloride Containing Eye Drops on the Conjunctival Bacterial Flora of Dry Eye Patients",[89],"2023-10","2015-07-27",[29],[4125,4145],"Prosicca sine",{"trials":4147,"activeCount":98},[],{"intervention":4145,"totalTrials":137,"cells":4149},{"EARLY_PHASE1":4150,"PHASE1":4152,"PHASE2":4154,"PHASE3":4156,"PHASE4":4158,"NA":4164},{"trials":4151,"activeCount":98},[],{"trials":4153,"activeCount":98},[],{"trials":4155,"activeCount":98},[],{"trials":4157,"activeCount":98},[],{"trials":4159,"activeCount":98},[4160],{"nctId":4138,"briefTitle":4139,"status":1092,"phases":4161,"primaryCompletion":4033,"completion":4141,"start":4142,"enrollment":112,"conditions":4162,"interventions":4163},[89],[29],[4125,4145],{"trials":4165,"activeCount":98},[],{"intervention":4167,"totalTrials":137,"cells":4168},"Prednisolone",{"EARLY_PHASE1":4169,"PHASE1":4171,"PHASE2":4173,"PHASE3":4175,"PHASE4":4177,"NA":4188},{"trials":4170,"activeCount":98},[],{"trials":4172,"activeCount":98},[],{"trials":4174,"activeCount":98},[],{"trials":4176,"activeCount":98},[],{"trials":4178,"activeCount":98},[4179],{"nctId":4180,"briefTitle":4181,"status":108,"phases":4182,"completion":4183,"start":4184,"enrollment":1097,"conditions":4185,"interventions":4187},"NCT00312325","Effect of High-Dose Prednisolone (Solu Dacortin®) Treatment on Choroidal and Optic Nerve Head Blood Flow in Humans",[89],"2005-08","2005-07",[18,4186],"Optic Disk",[4167],{"trials":4189,"activeCount":98},[],{"intervention":4191,"totalTrials":137,"cells":4192},"FSME-Immune vaccination",{"EARLY_PHASE1":4193,"PHASE1":4195,"PHASE2":4197,"PHASE3":4199,"PHASE4":4201,"NA":4211},{"trials":4194,"activeCount":98},[],{"trials":4196,"activeCount":98},[],{"trials":4198,"activeCount":98},[],{"trials":4200,"activeCount":98},[],{"trials":4202,"activeCount":98},[4203],{"nctId":4204,"briefTitle":4205,"status":108,"phases":4206,"primaryCompletion":2863,"completion":2863,"start":3425,"enrollment":4207,"conditions":4208,"interventions":4210},"NCT02511587","Comparison of Vaccination Routes: Subcutaneous Versus Intramuscular Application of FSME-Immun®",[89],116,[4209],"Vaccine Efficacy",[4191],{"trials":4212,"activeCount":98},[],{"intervention":2426,"totalTrials":137,"cells":4214},{"EARLY_PHASE1":4215,"PHASE1":4217,"PHASE2":4219,"PHASE3":4221,"PHASE4":4223,"NA":4229},{"trials":4216,"activeCount":98},[],{"trials":4218,"activeCount":98},[],{"trials":4220,"activeCount":98},[],{"trials":4222,"activeCount":98},[],{"trials":4224,"activeCount":98},[4225],{"nctId":2419,"briefTitle":2420,"status":108,"phases":4226,"primaryCompletion":2025,"completion":2422,"start":1172,"enrollment":1292,"conditions":4227,"interventions":4228},[89],[2424],[2426,2427,2406],{"trials":4230,"activeCount":98},[],{"intervention":2427,"totalTrials":137,"cells":4232},{"EARLY_PHASE1":4233,"PHASE1":4235,"PHASE2":4237,"PHASE3":4239,"PHASE4":4241,"NA":4247},{"trials":4234,"activeCount":98},[],{"trials":4236,"activeCount":98},[],{"trials":4238,"activeCount":98},[],{"trials":4240,"activeCount":98},[],{"trials":4242,"activeCount":98},[4243],{"nctId":2419,"briefTitle":2420,"status":108,"phases":4244,"primaryCompletion":2025,"completion":2422,"start":1172,"enrollment":1292,"conditions":4245,"interventions":4246},[89],[2424],[2426,2427,2406],{"trials":4248,"activeCount":98},[],{"intervention":4250,"totalTrials":137,"cells":4251},"Remicade",{"EARLY_PHASE1":4252,"PHASE1":4254,"PHASE2":4256,"PHASE3":4258,"PHASE4":4260,"NA":4273},{"trials":4253,"activeCount":98},[],{"trials":4255,"activeCount":98},[],{"trials":4257,"activeCount":98},[],{"trials":4259,"activeCount":98},[],{"trials":4261,"activeCount":98},[4262],{"nctId":4263,"briefTitle":4264,"status":108,"phases":4265,"primaryCompletion":4266,"completion":4266,"start":2025,"enrollment":4267,"conditions":4268,"interventions":4269},"NCT01638715","A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action",[89],"2018-08-01",115,[456],[4250,4270,4271,4272],"Orencia","Ro-Actemra","Mabthera",{"trials":4274,"activeCount":98},[],{"intervention":4270,"totalTrials":137,"cells":4276},{"EARLY_PHASE1":4277,"PHASE1":4279,"PHASE2":4281,"PHASE3":4283,"PHASE4":4285,"NA":4291},{"trials":4278,"activeCount":98},[],{"trials":4280,"activeCount":98},[],{"trials":4282,"activeCount":98},[],{"trials":4284,"activeCount":98},[],{"trials":4286,"activeCount":98},[4287],{"nctId":4263,"briefTitle":4264,"status":108,"phases":4288,"primaryCompletion":4266,"completion":4266,"start":2025,"enrollment":4267,"conditions":4289,"interventions":4290},[89],[456],[4250,4270,4271,4272],{"trials":4292,"activeCount":98},[],{"intervention":4271,"totalTrials":137,"cells":4294},{"EARLY_PHASE1":4295,"PHASE1":4297,"PHASE2":4299,"PHASE3":4301,"PHASE4":4303,"NA":4309},{"trials":4296,"activeCount":98},[],{"trials":4298,"activeCount":98},[],{"trials":4300,"activeCount":98},[],{"trials":4302,"activeCount":98},[],{"trials":4304,"activeCount":98},[4305],{"nctId":4263,"briefTitle":4264,"status":108,"phases":4306,"primaryCompletion":4266,"completion":4266,"start":2025,"enrollment":4267,"conditions":4307,"interventions":4308},[89],[456],[4250,4270,4271,4272],{"trials":4310,"activeCount":98},[],{"intervention":4272,"totalTrials":137,"cells":4312},{"EARLY_PHASE1":4313,"PHASE1":4315,"PHASE2":4317,"PHASE3":4319,"PHASE4":4321,"NA":4327},{"trials":4314,"activeCount":98},[],{"trials":4316,"activeCount":98},[],{"trials":4318,"activeCount":98},[],{"trials":4320,"activeCount":98},[],{"trials":4322,"activeCount":98},[4323],{"nctId":4263,"briefTitle":4264,"status":108,"phases":4324,"primaryCompletion":4266,"completion":4266,"start":2025,"enrollment":4267,"conditions":4325,"interventions":4326},[89],[456],[4250,4270,4271,4272],{"trials":4328,"activeCount":98},[],{"intervention":4330,"totalTrials":137,"cells":4331},"estradiol valerate",{"EARLY_PHASE1":4332,"PHASE1":4334,"PHASE2":4336,"PHASE3":4338,"PHASE4":4340,"NA":4350},{"trials":4333,"activeCount":98},[],{"trials":4335,"activeCount":98},[],{"trials":4337,"activeCount":98},[],{"trials":4339,"activeCount":98},[],{"trials":4341,"activeCount":98},[4342],{"nctId":4343,"briefTitle":4344,"status":108,"phases":4345,"primaryCompletion":1172,"completion":1172,"start":1873,"enrollment":1061,"conditions":4346,"interventions":4348},"NCT00755963","Effects of Hormone Replacement Therapy on the Serotonergic System and Mood in Postmenopausal Women",[89],[4347],"Hormone Replacement",[4330,4349],"micronized progesterone",{"trials":4351,"activeCount":98},[],{"intervention":4349,"totalTrials":137,"cells":4353},{"EARLY_PHASE1":4354,"PHASE1":4356,"PHASE2":4358,"PHASE3":4360,"PHASE4":4362,"NA":4368},{"trials":4355,"activeCount":98},[],{"trials":4357,"activeCount":98},[],{"trials":4359,"activeCount":98},[],{"trials":4361,"activeCount":98},[],{"trials":4363,"activeCount":98},[4364],{"nctId":4343,"briefTitle":4344,"status":108,"phases":4365,"primaryCompletion":1172,"completion":1172,"start":1873,"enrollment":1061,"conditions":4366,"interventions":4367},[89],[4347],[4330,4349],{"trials":4369,"activeCount":98},[],{"intervention":1942,"totalTrials":137,"cells":4371},{"EARLY_PHASE1":4372,"PHASE1":4374,"PHASE2":4376,"PHASE3":4378,"PHASE4":4380,"NA":4386},{"trials":4373,"activeCount":98},[],{"trials":4375,"activeCount":98},[],{"trials":4377,"activeCount":98},[],{"trials":4379,"activeCount":98},[],{"trials":4381,"activeCount":98},[4382],{"nctId":1933,"briefTitle":1934,"status":108,"phases":4383,"primaryCompletion":1936,"completion":1937,"start":1938,"enrollment":844,"conditions":4384,"interventions":4385},[89],[1940],[1942,1883],{"trials":4387,"activeCount":98},[],{"intervention":2211,"totalTrials":137,"cells":4389},{"EARLY_PHASE1":4390,"PHASE1":4392,"PHASE2":4394,"PHASE3":4396,"PHASE4":4398,"NA":4404},{"trials":4391,"activeCount":98},[],{"trials":4393,"activeCount":98},[],{"trials":4395,"activeCount":98},[],{"trials":4397,"activeCount":98},[],{"trials":4399,"activeCount":98},[4400],{"nctId":2203,"briefTitle":2204,"status":108,"phases":4401,"primaryCompletion":2206,"completion":2206,"start":2207,"enrollment":844,"conditions":4402,"interventions":4403},[89],[2209],[2211,2177,2199,2200,2212],{"trials":4405,"activeCount":98},[],{"intervention":2212,"totalTrials":137,"cells":4407},{"EARLY_PHASE1":4408,"PHASE1":4410,"PHASE2":4412,"PHASE3":4414,"PHASE4":4416,"NA":4422},{"trials":4409,"activeCount":98},[],{"trials":4411,"activeCount":98},[],{"trials":4413,"activeCount":98},[],{"trials":4415,"activeCount":98},[],{"trials":4417,"activeCount":98},[4418],{"nctId":2203,"briefTitle":2204,"status":108,"phases":4419,"primaryCompletion":2206,"completion":2206,"start":2207,"enrollment":844,"conditions":4420,"interventions":4421},[89],[2209],[2211,2177,2199,2200,2212],{"trials":4423,"activeCount":98},[],{"intervention":2043,"totalTrials":137,"cells":4425},{"EARLY_PHASE1":4426,"PHASE1":4428,"PHASE2":4430,"PHASE3":4432,"PHASE4":4434,"NA":4440},{"trials":4427,"activeCount":98},[],{"trials":4429,"activeCount":98},[],{"trials":4431,"activeCount":98},[],{"trials":4433,"activeCount":98},[],{"trials":4435,"activeCount":98},[4436],{"nctId":2033,"briefTitle":2034,"status":108,"phases":4437,"primaryCompletion":2036,"completion":2036,"start":2037,"enrollment":2038,"conditions":4438,"interventions":4439},[89],[2040],[2042,2043,2044],{"trials":4441,"activeCount":98},[],{"intervention":2044,"totalTrials":137,"cells":4443},{"EARLY_PHASE1":4444,"PHASE1":4446,"PHASE2":4448,"PHASE3":4450,"PHASE4":4452,"NA":4458},{"trials":4445,"activeCount":98},[],{"trials":4447,"activeCount":98},[],{"trials":4449,"activeCount":98},[],{"trials":4451,"activeCount":98},[],{"trials":4453,"activeCount":98},[4454],{"nctId":2033,"briefTitle":2034,"status":108,"phases":4455,"primaryCompletion":2036,"completion":2036,"start":2037,"enrollment":2038,"conditions":4456,"interventions":4457},[89],[2040],[2042,2043,2044],{"trials":4459,"activeCount":98},[],{"intervention":4461,"totalTrials":137,"cells":4462},"Oxygen 30 %",{"EARLY_PHASE1":4463,"PHASE1":4465,"PHASE2":4467,"PHASE3":4469,"PHASE4":4471,"NA":4488},{"trials":4464,"activeCount":98},[],{"trials":4466,"activeCount":98},[],{"trials":4468,"activeCount":98},[],{"trials":4470,"activeCount":98},[],{"trials":4472,"activeCount":98},[4473],{"nctId":4474,"briefTitle":4475,"status":108,"phases":4476,"primaryCompletion":4477,"completion":4478,"start":4479,"enrollment":4480,"conditions":4481,"interventions":4486},"NCT03366857","Effect of Supplemental Oxygen on Perioperative BNP Concentration in Cardiac Risk Patients",[89],"2019-12-31","2020-05-30","2017-12-01",260,[4482,4483,4484,4485],"Supplemental Oxygen","Brain Natriuretic Peptide","Cardiac Risk Patients","Perioperative",[4461,4487],"Oxygen 80 %",{"trials":4489,"activeCount":98},[],{"intervention":4487,"totalTrials":137,"cells":4491},{"EARLY_PHASE1":4492,"PHASE1":4494,"PHASE2":4496,"PHASE3":4498,"PHASE4":4500,"NA":4506},{"trials":4493,"activeCount":98},[],{"trials":4495,"activeCount":98},[],{"trials":4497,"activeCount":98},[],{"trials":4499,"activeCount":98},[],{"trials":4501,"activeCount":98},[4502],{"nctId":4474,"briefTitle":4475,"status":108,"phases":4503,"primaryCompletion":4477,"completion":4478,"start":4479,"enrollment":4480,"conditions":4504,"interventions":4505},[89],[4482,4483,4484,4485],[4461,4487],{"trials":4507,"activeCount":98},[],{"intervention":4509,"totalTrials":137,"cells":4510},"Blood transfusion",{"EARLY_PHASE1":4511,"PHASE1":4513,"PHASE2":4515,"PHASE3":4517,"PHASE4":4519,"NA":4528},{"trials":4512,"activeCount":98},[],{"trials":4514,"activeCount":98},[],{"trials":4516,"activeCount":98},[],{"trials":4518,"activeCount":98},[],{"trials":4520,"activeCount":98},[4521],{"nctId":4522,"briefTitle":4523,"status":839,"phases":4524,"primaryCompletion":2105,"completion":2105,"start":2206,"enrollment":35,"conditions":4525,"interventions":4527},"NCT02050230","Hemodynamic Effects of Stored Blood Transfusion in Intensive Care Patients",[89],[4526],"Pulmonary Hypertension",[4509],{"trials":4529,"activeCount":98},[],{"intervention":2137,"totalTrials":137,"cells":4531},{"EARLY_PHASE1":4532,"PHASE1":4534,"PHASE2":4536,"PHASE3":4538,"PHASE4":4540,"NA":4546},{"trials":4533,"activeCount":98},[],{"trials":4535,"activeCount":98},[],{"trials":4537,"activeCount":98},[],{"trials":4539,"activeCount":98},[],{"trials":4541,"activeCount":98},[4542],{"nctId":2128,"briefTitle":2129,"status":1092,"phases":4543,"primaryCompletion":2131,"completion":69,"start":2132,"enrollment":844,"conditions":4544,"interventions":4545},[89],[2134,2135],[2091,2137],{"trials":4547,"activeCount":98},[],{"intervention":2056,"totalTrials":137,"cells":4549},{"EARLY_PHASE1":4550,"PHASE1":4552,"PHASE2":4554,"PHASE3":4556,"PHASE4":4558,"NA":4564},{"trials":4551,"activeCount":98},[],{"trials":4553,"activeCount":98},[],{"trials":4555,"activeCount":98},[],{"trials":4557,"activeCount":98},[],{"trials":4559,"activeCount":98},[4560],{"nctId":2046,"briefTitle":2047,"status":108,"phases":4561,"primaryCompletion":2049,"completion":2050,"start":2051,"enrollment":511,"conditions":4562,"interventions":4563},[89],[2053,2054],[2056,1998],{"trials":4565,"activeCount":98},[],{"intervention":4567,"totalTrials":137,"cells":4568},"Albumin",{"EARLY_PHASE1":4569,"PHASE1":4571,"PHASE2":4573,"PHASE3":4575,"PHASE4":4577,"NA":4590},{"trials":4570,"activeCount":98},[],{"trials":4572,"activeCount":98},[],{"trials":4574,"activeCount":98},[],{"trials":4576,"activeCount":98},[],{"trials":4578,"activeCount":98},[4579],{"nctId":4580,"briefTitle":4581,"status":108,"phases":4582,"primaryCompletion":4583,"completion":4584,"start":4585,"enrollment":112,"conditions":4586,"interventions":4588},"NCT00708747","Biseko Versus Albumin in Systemic Inflammatory Response Syndrome (SIRS) Patients",[89],"2001-06","2003-09","1996-07",[4587],"Systemic Inflammatory Response Syndrome",[4567,4589],"Biseko",{"trials":4591,"activeCount":98},[],{"intervention":4589,"totalTrials":137,"cells":4593},{"EARLY_PHASE1":4594,"PHASE1":4596,"PHASE2":4598,"PHASE3":4600,"PHASE4":4602,"NA":4608},{"trials":4595,"activeCount":98},[],{"trials":4597,"activeCount":98},[],{"trials":4599,"activeCount":98},[],{"trials":4601,"activeCount":98},[],{"trials":4603,"activeCount":98},[4604],{"nctId":4580,"briefTitle":4581,"status":108,"phases":4605,"primaryCompletion":4583,"completion":4584,"start":4585,"enrollment":112,"conditions":4606,"interventions":4607},[89],[4587],[4567,4589],{"trials":4609,"activeCount":98},[],{"intervention":4611,"totalTrials":137,"cells":4612},"fluidotherapy with ringer-lactate",{"EARLY_PHASE1":4613,"PHASE1":4615,"PHASE2":4617,"PHASE3":4619,"PHASE4":4621,"NA":4629},{"trials":4614,"activeCount":98},[],{"trials":4616,"activeCount":98},[],{"trials":4618,"activeCount":98},[],{"trials":4620,"activeCount":98},[],{"trials":4622,"activeCount":98},[4623],{"nctId":4624,"briefTitle":4625,"status":108,"phases":4626,"primaryCompletion":2036,"completion":2036,"start":2673,"enrollment":128,"conditions":4627,"interventions":4628},"NCT00860704","Goal Directed Fluid Therapy",[89],[4625],[4611],{"trials":4630,"activeCount":98},[],{"intervention":4632,"totalTrials":137,"cells":4633},"Epinephrin",{"EARLY_PHASE1":4634,"PHASE1":4636,"PHASE2":4638,"PHASE3":4640,"PHASE4":4642,"NA":4657},{"trials":4635,"activeCount":98},[],{"trials":4637,"activeCount":98},[],{"trials":4639,"activeCount":98},[],{"trials":4641,"activeCount":98},[],{"trials":4643,"activeCount":98},[4644],{"nctId":4645,"briefTitle":4646,"status":1092,"phases":4647,"primaryCompletion":4648,"completion":4649,"start":2049,"enrollment":4650,"conditions":4651,"interventions":4655},"NCT05492968","The Effect of Epinephrine, Norepinephrine and Phenylephrine on Intraoperative Hemodynamic Performance",[89],"2024-08-01","2024-08-31",225,[4652,4653,4654],"Cardiac Output, Low","Cardiac Output, High","Perfusion; Complications",[4632,4656,2157],"Norepinephrine",{"trials":4658,"activeCount":98},[],{"intervention":4656,"totalTrials":137,"cells":4660},{"EARLY_PHASE1":4661,"PHASE1":4663,"PHASE2":4665,"PHASE3":4667,"PHASE4":4669,"NA":4675},{"trials":4662,"activeCount":98},[],{"trials":4664,"activeCount":98},[],{"trials":4666,"activeCount":98},[],{"trials":4668,"activeCount":98},[],{"trials":4670,"activeCount":98},[4671],{"nctId":4645,"briefTitle":4646,"status":1092,"phases":4672,"primaryCompletion":4648,"completion":4649,"start":2049,"enrollment":4650,"conditions":4673,"interventions":4674},[89],[4652,4653,4654],[4632,4656,2157],{"trials":4676,"activeCount":98},[],{"intervention":1879,"totalTrials":137,"cells":4678},{"EARLY_PHASE1":4679,"PHASE1":4681,"PHASE2":4683,"PHASE3":4685,"PHASE4":4687,"NA":4693},{"trials":4680,"activeCount":98},[],{"trials":4682,"activeCount":98},[],{"trials":4684,"activeCount":98},[],{"trials":4686,"activeCount":98},[],{"trials":4688,"activeCount":98},[4689],{"nctId":1870,"briefTitle":1871,"status":108,"phases":4690,"primaryCompletion":1873,"completion":1873,"start":1874,"enrollment":1875,"conditions":4691,"interventions":4692},[89],[1877],[1879,1829],{"trials":4694,"activeCount":98},[],{"intervention":4696,"totalTrials":137,"cells":4697},"Cannabidiol Oral Product",{"EARLY_PHASE1":4698,"PHASE1":4700,"PHASE2":4702,"PHASE3":4704,"PHASE4":4706,"NA":4720},{"trials":4699,"activeCount":98},[],{"trials":4701,"activeCount":98},[],{"trials":4703,"activeCount":98},[],{"trials":4705,"activeCount":98},[],{"trials":4707,"activeCount":98},[4708],{"nctId":4709,"briefTitle":4710,"status":108,"phases":4711,"primaryCompletion":4712,"completion":4713,"start":4714,"enrollment":4715,"conditions":4716,"interventions":4719},"NCT04607603","Efficacy of Cannabidiol in Knee Osteoarthritis",[89],"2022-02-17","2022-03-29","2020-10-13",86,[4717,4718],"Osteo Arthritis Knee","Pain, Joint",[4696],{"trials":4721,"activeCount":98},[],{"intervention":4723,"totalTrials":137,"cells":4724},"100% oxygen breathing",{"EARLY_PHASE1":4725,"PHASE1":4727,"PHASE2":4729,"PHASE3":4731,"PHASE4":4733,"NA":4746},{"trials":4726,"activeCount":98},[],{"trials":4728,"activeCount":98},[],{"trials":4730,"activeCount":98},[],{"trials":4732,"activeCount":98},[],{"trials":4734,"activeCount":98},[4735],{"nctId":4736,"briefTitle":4737,"status":108,"phases":4738,"primaryCompletion":2036,"completion":4739,"start":4079,"enrollment":1061,"conditions":4740,"interventions":4743},"NCT01692821","Effect of Systemic Hypoxia and Hyperoxia on Retinal Oxygen Saturation",[89],"2013-01",[4741,4742],"Retinal Oxygenation","Retinal Blood Flow",[4723,4744,4745],"15% oxygen in N2 breathing","12% oxygen in N2 breathing",{"trials":4747,"activeCount":98},[],{"intervention":4744,"totalTrials":137,"cells":4749},{"EARLY_PHASE1":4750,"PHASE1":4752,"PHASE2":4754,"PHASE3":4756,"PHASE4":4758,"NA":4764},{"trials":4751,"activeCount":98},[],{"trials":4753,"activeCount":98},[],{"trials":4755,"activeCount":98},[],{"trials":4757,"activeCount":98},[],{"trials":4759,"activeCount":98},[4760],{"nctId":4736,"briefTitle":4737,"status":108,"phases":4761,"primaryCompletion":2036,"completion":4739,"start":4079,"enrollment":1061,"conditions":4762,"interventions":4763},[89],[4741,4742],[4723,4744,4745],{"trials":4765,"activeCount":98},[],{"intervention":4745,"totalTrials":137,"cells":4767},{"EARLY_PHASE1":4768,"PHASE1":4770,"PHASE2":4772,"PHASE3":4774,"PHASE4":4776,"NA":4782},{"trials":4769,"activeCount":98},[],{"trials":4771,"activeCount":98},[],{"trials":4773,"activeCount":98},[],{"trials":4775,"activeCount":98},[],{"trials":4777,"activeCount":98},[4778],{"nctId":4736,"briefTitle":4737,"status":108,"phases":4779,"primaryCompletion":2036,"completion":4739,"start":4079,"enrollment":1061,"conditions":4780,"interventions":4781},[89],[4741,4742],[4723,4744,4745],{"trials":4783,"activeCount":98},[],{"intervention":4785,"totalTrials":137,"cells":4786},"Valganciclovir",{"EARLY_PHASE1":4787,"PHASE1":4789,"PHASE2":4791,"PHASE3":4793,"PHASE4":4795,"NA":4805},{"trials":4788,"activeCount":98},[],{"trials":4790,"activeCount":98},[],{"trials":4792,"activeCount":98},[],{"trials":4794,"activeCount":98},[],{"trials":4796,"activeCount":98},[4797],{"nctId":4798,"briefTitle":4799,"status":108,"phases":4800,"primaryCompletion":4801,"completion":4801,"start":842,"enrollment":476,"conditions":4802,"interventions":4804},"NCT01255644","Antiviral Treatment of Chronic Lymphocytic Leukemia",[89],"2015-07",[4803],"Chronic Lymphocytic Leukemia",[4785],{"trials":4806,"activeCount":98},[],{"intervention":4808,"totalTrials":137,"cells":4809},"Hydrocortisone",{"EARLY_PHASE1":4810,"PHASE1":4812,"PHASE2":4814,"PHASE3":4816,"PHASE4":4818,"NA":4828},{"trials":4811,"activeCount":98},[],{"trials":4813,"activeCount":98},[],{"trials":4815,"activeCount":98},[],{"trials":4817,"activeCount":98},[],{"trials":4819,"activeCount":98},[4820],{"nctId":4821,"briefTitle":4822,"status":108,"phases":4823,"primaryCompletion":4824,"completion":2840,"start":3053,"enrollment":486,"conditions":4825,"interventions":4826},"NCT00709839","Rapid Effects of Hydrocortisone on Glucose-induced Insulin Secretion in Healthy Humans",[89],"2008-10",[15],[4808,4827],"Glucose 33%",{"trials":4829,"activeCount":98},[],{"intervention":4827,"totalTrials":137,"cells":4831},{"EARLY_PHASE1":4832,"PHASE1":4834,"PHASE2":4836,"PHASE3":4838,"PHASE4":4840,"NA":4846},{"trials":4833,"activeCount":98},[],{"trials":4835,"activeCount":98},[],{"trials":4837,"activeCount":98},[],{"trials":4839,"activeCount":98},[],{"trials":4841,"activeCount":98},[4842],{"nctId":4821,"briefTitle":4822,"status":108,"phases":4843,"primaryCompletion":4824,"completion":2840,"start":3053,"enrollment":486,"conditions":4844,"interventions":4845},[89],[15],[4808,4827],{"trials":4847,"activeCount":98},[],{"intervention":4849,"totalTrials":137,"cells":4850},"500mg RTX Group",{"EARLY_PHASE1":4851,"PHASE1":4853,"PHASE2":4855,"PHASE3":4857,"PHASE4":4859,"NA":4871},{"trials":4852,"activeCount":98},[],{"trials":4854,"activeCount":98},[],{"trials":4856,"activeCount":98},[],{"trials":4858,"activeCount":98},[],{"trials":4860,"activeCount":98},[4861],{"nctId":4862,"briefTitle":4863,"status":839,"phases":4864,"primaryCompletion":4865,"completion":4865,"start":4866,"enrollment":19,"conditions":4867,"interventions":4869},"NCT05116228","Non-inferiority of Reduced-dose Rituximab in Rheumatoid Arthritis in Low Disease Activity and Remission",[89],"2021-11-01","2015-09-01",[456,4868],"Remission",[4849,4870],"1000mg RTX Group",{"trials":4872,"activeCount":98},[],{"intervention":4870,"totalTrials":137,"cells":4874},{"EARLY_PHASE1":4875,"PHASE1":4877,"PHASE2":4879,"PHASE3":4881,"PHASE4":4883,"NA":4889},{"trials":4876,"activeCount":98},[],{"trials":4878,"activeCount":98},[],{"trials":4880,"activeCount":98},[],{"trials":4882,"activeCount":98},[],{"trials":4884,"activeCount":98},[4885],{"nctId":4862,"briefTitle":4863,"status":839,"phases":4886,"primaryCompletion":4865,"completion":4865,"start":4866,"enrollment":19,"conditions":4887,"interventions":4888},[89],[456,4868],[4849,4870],{"trials":4890,"activeCount":98},[],{"intervention":2295,"totalTrials":137,"cells":4892},{"EARLY_PHASE1":4893,"PHASE1":4895,"PHASE2":4897,"PHASE3":4899,"PHASE4":4901,"NA":4907},{"trials":4894,"activeCount":98},[],{"trials":4896,"activeCount":98},[],{"trials":4898,"activeCount":98},[],{"trials":4900,"activeCount":98},[],{"trials":4902,"activeCount":98},[4903],{"nctId":2284,"briefTitle":2285,"status":108,"phases":4904,"primaryCompletion":2287,"completion":2287,"start":2288,"enrollment":2289,"conditions":4905,"interventions":4906},[89],[2291,2292],[2294,2295],{"trials":4908,"activeCount":98},[],{"intervention":4910,"totalTrials":1830,"cells":4911},"Moxaverine",{"EARLY_PHASE1":4912,"PHASE1":4914,"PHASE2":4916,"PHASE3":4941,"PHASE4":4953,"NA":4955},{"trials":4913,"activeCount":98},[],{"trials":4915,"activeCount":98},[],{"trials":4917,"activeCount":98},[4918,4927,4934],{"nctId":4919,"briefTitle":4920,"status":108,"phases":4921,"primaryCompletion":4922,"completion":4922,"start":3638,"enrollment":547,"conditions":4923,"interventions":4925},"NCT00709423","Effects of Moxaverine and Placebo on Ocular Blood Flow",[87],"2007-05",[18,21,4924],"Retina",[4910,4926,860],"Moxaverin 150mg",{"nctId":4928,"briefTitle":4929,"status":108,"phases":4930,"completion":2371,"start":3638,"enrollment":547,"conditions":4931,"interventions":4932},"NCT00569621","A Randomized, Double-Masked, Placebo-Controlled Two Cross Over Study Comparing the Effects of Moxaverine and Placebo on Ocular Blood Flow",[87],[1940],[4910,4933],"physiological saline",{"nctId":4935,"briefTitle":4936,"status":108,"phases":4937,"primaryCompletion":854,"completion":2887,"start":1854,"enrollment":547,"conditions":4938,"interventions":4940},"NCT01629680","A Randomized, Placebo-controlled Study Investigating the Effects of Moxaverine on Ocular Blood Flow After Oral Administration in Healthy Subjects",[87],[4939],"Effect of Orally Administrated Moxaverine on Ocular Blood Flow",[4910],{"trials":4942,"activeCount":98},[4943],{"nctId":4944,"briefTitle":4945,"status":108,"phases":4946,"primaryCompletion":4947,"completion":4947,"start":4948,"enrollment":949,"conditions":4949,"interventions":4951},"NCT00709449","An Open Study Comparing the Effects of Moxaverine on Ocular Blood Flow in Patients With Age- Related Macular Degeneration, Primary Open Angle Glaucoma and Healthy Control Subjects",[87,88],"2009-03","2008-05",[4950,27,18],"Macular Degeneration",[4952,4952,4952],"moxaverine",{"trials":4954,"activeCount":98},[],{"trials":4956,"activeCount":98},[],{"intervention":4958,"totalTrials":94,"cells":4959},"Human insulin isophane, Humulin N",{"EARLY_PHASE1":4960,"PHASE1":4962,"PHASE2":4964,"PHASE3":4966,"PHASE4":4988,"NA":4990},{"trials":4961,"activeCount":98},[],{"trials":4963,"activeCount":98},[],{"trials":4965,"activeCount":98},[],{"trials":4967,"activeCount":98},[4968,4980],{"nctId":4969,"briefTitle":4970,"status":108,"phases":4971,"primaryCompletion":4972,"completion":4972,"start":4973,"enrollment":4974,"conditions":4975,"interventions":4977},"NCT03507829","Insulin Therapy for the Prevention of New Onset Diabetes After Transplantation Prospective Study in Non-Diabetic De Novo Kidney Transplant Recipients",[88],"2018-05-22","2012-11-21",263,[4976],"Hyperglycemia",[4958,4978,4979],"Standard of care","Insulin lispro, Humalog (Eli Lilly) in insulin pump",{"nctId":4981,"briefTitle":4982,"status":108,"phases":4983,"primaryCompletion":4984,"completion":4984,"start":4985,"enrollment":905,"conditions":4986,"interventions":4987},"NCT01680185","Sensor-Augmented Insulin-Pump Therapy in New-onset Diabetes After Transplantation",[88],"2018-05","2012-08",[4976],[4979,4958],{"trials":4989,"activeCount":98},[],{"trials":4991,"activeCount":98},[],{"intervention":4979,"totalTrials":94,"cells":4993},{"EARLY_PHASE1":4994,"PHASE1":4996,"PHASE2":4998,"PHASE3":5000,"PHASE4":5010,"NA":5012},{"trials":4995,"activeCount":98},[],{"trials":4997,"activeCount":98},[],{"trials":4999,"activeCount":98},[],{"trials":5001,"activeCount":98},[5002,5006],{"nctId":4969,"briefTitle":4970,"status":108,"phases":5003,"primaryCompletion":4972,"completion":4972,"start":4973,"enrollment":4974,"conditions":5004,"interventions":5005},[88],[4976],[4958,4978,4979],{"nctId":4981,"briefTitle":4982,"status":108,"phases":5007,"primaryCompletion":4984,"completion":4984,"start":4985,"enrollment":905,"conditions":5008,"interventions":5009},[88],[4976],[4979,4958],{"trials":5011,"activeCount":98},[],{"trials":5013,"activeCount":98},[],{"intervention":4978,"totalTrials":137,"cells":5015},{"EARLY_PHASE1":5016,"PHASE1":5018,"PHASE2":5020,"PHASE3":5022,"PHASE4":5028,"NA":5030},{"trials":5017,"activeCount":98},[],{"trials":5019,"activeCount":98},[],{"trials":5021,"activeCount":98},[],{"trials":5023,"activeCount":98},[5024],{"nctId":4969,"briefTitle":4970,"status":108,"phases":5025,"primaryCompletion":4972,"completion":4972,"start":4973,"enrollment":4974,"conditions":5026,"interventions":5027},[88],[4976],[4958,4978,4979],{"trials":5029,"activeCount":98},[],{"trials":5031,"activeCount":98},[],{"intervention":5033,"totalTrials":137,"cells":5034},"Acetylsalicylic acid lysinate",{"EARLY_PHASE1":5035,"PHASE1":5037,"PHASE2":5039,"PHASE3":5041,"PHASE4":5053,"NA":5055},{"trials":5036,"activeCount":98},[],{"trials":5038,"activeCount":98},[],{"trials":5040,"activeCount":98},[],{"trials":5042,"activeCount":98},[5043],{"nctId":5044,"briefTitle":5045,"status":839,"phases":5046,"primaryCompletion":5047,"completion":5048,"start":5049,"enrollment":25,"conditions":5050,"interventions":5051},"NCT02285153","Does Acetylsalicylic Acid Reduce the Mortality of Patients Admitted to an Intensive Care Unit",[88],"2017-09-05","2017-11-10","2011-11-15",[34],[5033,5052],"0.9% sodium-chloride solution",{"trials":5054,"activeCount":98},[],{"trials":5056,"activeCount":98},[],{"intervention":5052,"totalTrials":137,"cells":5058},{"EARLY_PHASE1":5059,"PHASE1":5061,"PHASE2":5063,"PHASE3":5065,"PHASE4":5071,"NA":5073},{"trials":5060,"activeCount":98},[],{"trials":5062,"activeCount":98},[],{"trials":5064,"activeCount":98},[],{"trials":5066,"activeCount":98},[5067],{"nctId":5044,"briefTitle":5045,"status":839,"phases":5068,"primaryCompletion":5047,"completion":5048,"start":5049,"enrollment":25,"conditions":5069,"interventions":5070},[88],[34],[5033,5052],{"trials":5072,"activeCount":98},[],{"trials":5074,"activeCount":98},[],{"intervention":5076,"totalTrials":137,"cells":5077},"Tocilizumab Prefilled Syringe [Actemra]",{"EARLY_PHASE1":5078,"PHASE1":5080,"PHASE2":5082,"PHASE3":5084,"PHASE4":5098,"NA":5100},{"trials":5079,"activeCount":98},[],{"trials":5081,"activeCount":98},[],{"trials":5083,"activeCount":98},[],{"trials":5085,"activeCount":98},[5086],{"nctId":5087,"briefTitle":5088,"status":108,"phases":5089,"primaryCompletion":5090,"completion":5090,"start":5091,"enrollment":5092,"conditions":5093,"interventions":5095},"NCT03263715","A Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects With New-Onset Polymyalgia Rheumatica (PMR- SPARE)",[88],"2020-06-02","2017-11-24",39,[5094],"Polymyalgia Rheumatica",[5076,5096,5097],"Placebos","Glucocorticoids",{"trials":5099,"activeCount":98},[],{"trials":5101,"activeCount":98},[],{"intervention":5096,"totalTrials":137,"cells":5103},{"EARLY_PHASE1":5104,"PHASE1":5106,"PHASE2":5108,"PHASE3":5110,"PHASE4":5116,"NA":5118},{"trials":5105,"activeCount":98},[],{"trials":5107,"activeCount":98},[],{"trials":5109,"activeCount":98},[],{"trials":5111,"activeCount":98},[5112],{"nctId":5087,"briefTitle":5088,"status":108,"phases":5113,"primaryCompletion":5090,"completion":5090,"start":5091,"enrollment":5092,"conditions":5114,"interventions":5115},[88],[5094],[5076,5096,5097],{"trials":5117,"activeCount":98},[],{"trials":5119,"activeCount":98},[],{"intervention":5121,"totalTrials":137,"cells":5122},"Administration of Amoxicillin \u002F clavulanic acid",{"EARLY_PHASE1":5123,"PHASE1":5125,"PHASE2":5127,"PHASE3":5129,"PHASE4":5141,"NA":5143},{"trials":5124,"activeCount":98},[],{"trials":5126,"activeCount":98},[],{"trials":5128,"activeCount":98},[],{"trials":5130,"activeCount":98},[5131],{"nctId":5132,"briefTitle":5133,"status":108,"phases":5134,"primaryCompletion":2971,"completion":5135,"start":5136,"enrollment":547,"conditions":5137,"interventions":5139},"NCT02007603","Concentration of Ampicillin \u002F Sulbactam and Amoxicillin \u002F Clavulanic Acid in the Blood During Renal Replacement Therapy in Longterm Renal Replacement Therapy Patients",[88],"2017-05","2013-08",[5138],"Infection During Hemodialysis",[5121,5140],"Ampicillin \u002F sulbactam",{"trials":5142,"activeCount":98},[],{"trials":5144,"activeCount":98},[],{"intervention":5140,"totalTrials":137,"cells":5146},{"EARLY_PHASE1":5147,"PHASE1":5149,"PHASE2":5151,"PHASE3":5153,"PHASE4":5159,"NA":5161},{"trials":5148,"activeCount":98},[],{"trials":5150,"activeCount":98},[],{"trials":5152,"activeCount":98},[],{"trials":5154,"activeCount":98},[5155],{"nctId":5132,"briefTitle":5133,"status":108,"phases":5156,"primaryCompletion":2971,"completion":5135,"start":5136,"enrollment":547,"conditions":5157,"interventions":5158},[88],[5138],[5121,5140],{"trials":5160,"activeCount":98},[],{"trials":5162,"activeCount":98},[],{"intervention":5164,"totalTrials":137,"cells":5165},"Hydroxychloroquine",{"EARLY_PHASE1":5166,"PHASE1":5168,"PHASE2":5170,"PHASE3":5172,"PHASE4":5185,"NA":5187},{"trials":5167,"activeCount":98},[],{"trials":5169,"activeCount":98},[],{"trials":5171,"activeCount":98},[],{"trials":5173,"activeCount":98},[5174],{"nctId":5175,"briefTitle":5176,"status":2011,"phases":5177,"primaryCompletion":1906,"completion":1907,"start":5178,"enrollment":98,"conditions":5179,"interventions":5184},"NCT04336748","HCQ for Primary Prophylaxis Against COVID19 in Health-care Workers",[88],"2020-04",[5180,5181,5182,5183],"Sars-CoV2","Infection Viral","Healthcare Worker","Prophylaxis",[5164],{"trials":5186,"activeCount":98},[],{"trials":5188,"activeCount":98},[],{"intervention":5190,"totalTrials":137,"cells":5191},"Lixisenatide",{"EARLY_PHASE1":5192,"PHASE1":5194,"PHASE2":5196,"PHASE3":5198,"PHASE4":5209,"NA":5211},{"trials":5193,"activeCount":98},[],{"trials":5195,"activeCount":98},[],{"trials":5197,"activeCount":98},[],{"trials":5199,"activeCount":98},[5200],{"nctId":5201,"briefTitle":5202,"status":108,"phases":5203,"primaryCompletion":4801,"completion":5204,"start":3211,"enrollment":486,"conditions":5205,"interventions":5207},"NCT02168491","Feasibility of Once\u002FDaily Administered GLP\u002F1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin",[88],"2015-08",[5206],"Type 2 Diabetes Mellitus",[5190,5208],"Insulin glargine",{"trials":5210,"activeCount":98},[],{"trials":5212,"activeCount":98},[],{"intervention":5208,"totalTrials":137,"cells":5214},{"EARLY_PHASE1":5215,"PHASE1":5217,"PHASE2":5219,"PHASE3":5221,"PHASE4":5227,"NA":5229},{"trials":5216,"activeCount":98},[],{"trials":5218,"activeCount":98},[],{"trials":5220,"activeCount":98},[],{"trials":5222,"activeCount":98},[5223],{"nctId":5201,"briefTitle":5202,"status":108,"phases":5224,"primaryCompletion":4801,"completion":5204,"start":3211,"enrollment":486,"conditions":5225,"interventions":5226},[88],[5206],[5190,5208],{"trials":5228,"activeCount":98},[],{"trials":5230,"activeCount":98},[],{"intervention":5232,"totalTrials":137,"cells":5233},"5-Methoxypsoralen",{"EARLY_PHASE1":5234,"PHASE1":5236,"PHASE2":5238,"PHASE3":5240,"PHASE4":5248,"NA":5250},{"trials":5235,"activeCount":98},[],{"trials":5237,"activeCount":98},[],{"trials":5239,"activeCount":98},[],{"trials":5241,"activeCount":98},[5242],{"nctId":5243,"briefTitle":5244,"status":108,"phases":5245,"primaryCompletion":1096,"completion":1096,"start":874,"enrollment":476,"conditions":5246,"interventions":5247},"NCT00533195","Comparison of UVA1 Phototherapy Versus Photochemotherapy for Patients With Severe Generalized Atopic Dermatitis",[88],[2546],[5232],{"trials":5249,"activeCount":98},[],{"trials":5251,"activeCount":98},[],{"intervention":5253,"totalTrials":137,"cells":5254},"acipimox",{"EARLY_PHASE1":5255,"PHASE1":5257,"PHASE2":5259,"PHASE3":5261,"PHASE4":5272,"NA":5274},{"trials":5256,"activeCount":98},[],{"trials":5258,"activeCount":98},[],{"trials":5260,"activeCount":98},[],{"trials":5262,"activeCount":98},[5263],{"nctId":5264,"briefTitle":5265,"status":108,"phases":5266,"primaryCompletion":1785,"completion":5267,"start":5268,"enrollment":5269,"conditions":5270,"interventions":5271},"NCT01980524","The Impact of Free Fatty Acid (FFA-) Suppression on Myocardial Lipids and Function in Patients With Type 2 Diabetes",[87,88],"2016-05","2013-10",8,[2107],[5253],{"trials":5273,"activeCount":98},[],{"trials":5275,"activeCount":98},[],{"intervention":117,"totalTrials":137,"cells":5277},{"EARLY_PHASE1":5278,"PHASE1":5280,"PHASE2":5282,"PHASE3":5284,"PHASE4":5290,"NA":5292},{"trials":5279,"activeCount":98},[],{"trials":5281,"activeCount":98},[],{"trials":5283,"activeCount":98},[],{"trials":5285,"activeCount":98},[5286],{"nctId":106,"briefTitle":107,"status":108,"phases":5287,"primaryCompletion":110,"completion":110,"start":111,"enrollment":112,"conditions":5288,"interventions":5289},[87,88],[114,115],[117,93],{"trials":5291,"activeCount":98},[],{"trials":5293,"activeCount":98},[],{"intervention":5295,"totalTrials":137,"cells":5296},"Metformin Glucophage 500mg (IR) tablets M90",{"EARLY_PHASE1":5297,"PHASE1":5299,"PHASE2":5301,"PHASE3":5303,"PHASE4":5315,"NA":5317},{"trials":5298,"activeCount":98},[],{"trials":5300,"activeCount":98},[],{"trials":5302,"activeCount":98},[],{"trials":5304,"activeCount":98},[5305],{"nctId":5306,"briefTitle":5307,"status":1092,"phases":5308,"primaryCompletion":5309,"completion":5309,"start":5310,"enrollment":5311,"conditions":5312,"interventions":5314},"NCT03507413","Metformin Therapy in Non-diabetic AAA Patients",[87,88],"2024-05-01","2018-09-26",170,[5313],"Abdominal Aortic Aneurysm",[5295],{"trials":5316,"activeCount":98},[],{"trials":5318,"activeCount":98},[],{"intervention":5320,"totalTrials":137,"cells":5321},"OMACOR",{"EARLY_PHASE1":5322,"PHASE1":5324,"PHASE2":5326,"PHASE3":5328,"PHASE4":5339,"NA":5341},{"trials":5323,"activeCount":98},[],{"trials":5325,"activeCount":98},[],{"trials":5327,"activeCount":98},[],{"trials":5329,"activeCount":98},[5330],{"nctId":5331,"briefTitle":5332,"status":108,"phases":5333,"primaryCompletion":3426,"completion":5334,"start":5335,"enrollment":875,"conditions":5336,"interventions":5338},"NCT01367145","OMEGA-3-Polyunsaturated Fatty-Acids (N3-Pufa) In Patients With Peripheral Arterial Disease",[88],"2014-03","2011-01",[5337],"Peripheral Arterial Disease",[5320],{"trials":5340,"activeCount":98},[],{"trials":5342,"activeCount":98},[],{"intervention":5344,"totalTrials":137,"cells":5345},"Riboflavin",{"EARLY_PHASE1":5346,"PHASE1":5348,"PHASE2":5350,"PHASE3":5352,"PHASE4":5363,"NA":5365},{"trials":5347,"activeCount":98},[],{"trials":5349,"activeCount":98},[],{"trials":5351,"activeCount":98},[],{"trials":5353,"activeCount":98},[5354],{"nctId":5355,"briefTitle":5356,"status":108,"phases":5357,"primaryCompletion":5358,"completion":5358,"start":5359,"enrollment":949,"conditions":5360,"interventions":5362},"NCT03187912","Accelerated Corneal Cross-linking With Different Riboflavin Solutions",[88],"2020-03-30","2016-09-19",[5361],"Keratoconus",[5344],{"trials":5364,"activeCount":98},[],{"trials":5366,"activeCount":98},[],{"intervention":5368,"totalTrials":137,"cells":5369},"Somatostatin-Analog",{"EARLY_PHASE1":5370,"PHASE1":5372,"PHASE2":5374,"PHASE3":5376,"PHASE4":5388,"NA":5390},{"trials":5371,"activeCount":98},[],{"trials":5373,"activeCount":98},[],{"trials":5375,"activeCount":98},[],{"trials":5377,"activeCount":98},[5378],{"nctId":5379,"briefTitle":5380,"status":1092,"phases":5381,"primaryCompletion":4141,"completion":5382,"start":5383,"enrollment":5384,"conditions":5385,"interventions":5387},"NCT02705651","Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO Treatment",[88],"2024-10","2019-12",180,[5386],"Pancreatic Neuroendocrine Tumors in MEN1",[5368],{"trials":5389,"activeCount":98},[],{"trials":5391,"activeCount":98},[],{"intervention":2280,"totalTrials":137,"cells":5393},{"EARLY_PHASE1":5394,"PHASE1":5396,"PHASE2":5398,"PHASE3":5400,"PHASE4":5406,"NA":5408},{"trials":5395,"activeCount":98},[],{"trials":5397,"activeCount":98},[],{"trials":5399,"activeCount":98},[],{"trials":5401,"activeCount":98},[5402],{"nctId":2271,"briefTitle":2272,"status":108,"phases":5403,"primaryCompletion":2274,"completion":2274,"start":2275,"enrollment":22,"conditions":5404,"interventions":5405},[88],[2277,2278],[2280,2260],{"trials":5407,"activeCount":98},[],{"trials":5409,"activeCount":98},[],{"intervention":5411,"totalTrials":137,"cells":5412},"Additive classical homeopathy",{"EARLY_PHASE1":5413,"PHASE1":5415,"PHASE2":5417,"PHASE3":5419,"PHASE4":5431,"NA":5433},{"trials":5414,"activeCount":98},[],{"trials":5416,"activeCount":98},[],{"trials":5418,"activeCount":98},[],{"trials":5420,"activeCount":98},[5421],{"nctId":5422,"briefTitle":5423,"status":108,"phases":5424,"primaryCompletion":5425,"completion":5425,"start":3259,"enrollment":5426,"conditions":5427,"interventions":5429},"NCT01509612","Additive Homeopathy in Cancer Patients",[88],"2019-07-31",150,[5428],"Malignant Tumors",[5411,5430],"Homeopathic Placebo globules",{"trials":5432,"activeCount":98},[],{"trials":5434,"activeCount":98},[],{"intervention":5430,"totalTrials":137,"cells":5436},{"EARLY_PHASE1":5437,"PHASE1":5439,"PHASE2":5441,"PHASE3":5443,"PHASE4":5449,"NA":5451},{"trials":5438,"activeCount":98},[],{"trials":5440,"activeCount":98},[],{"trials":5442,"activeCount":98},[],{"trials":5444,"activeCount":98},[5445],{"nctId":5422,"briefTitle":5423,"status":108,"phases":5446,"primaryCompletion":5425,"completion":5425,"start":3259,"enrollment":5426,"conditions":5447,"interventions":5448},[88],[5428],[5411,5430],{"trials":5450,"activeCount":98},[],{"trials":5452,"activeCount":98},[],{"intervention":5454,"totalTrials":137,"cells":5455},"Dorzolamide 2%",{"EARLY_PHASE1":5456,"PHASE1":5458,"PHASE2":5460,"PHASE3":5462,"PHASE4":5475,"NA":5477},{"trials":5457,"activeCount":98},[],{"trials":5459,"activeCount":98},[],{"trials":5461,"activeCount":98},[],{"trials":5463,"activeCount":98},[5464],{"nctId":5465,"briefTitle":5466,"status":108,"phases":5467,"primaryCompletion":5468,"completion":5469,"start":5470,"enrollment":888,"conditions":5471,"interventions":5473},"NCT00991822","A Comparison of the Effect of Dorzolamide and Timolol on Optic Disk Blood Flow in Patients With Open Angle Glaucoma",[87,88],"2001-12","2003-12","1999-05",[5472],"Glaucoma, Open-Angle",[5454,5474],"Timolol 0.5%",{"trials":5476,"activeCount":98},[],{"trials":5478,"activeCount":98},[],{"intervention":5474,"totalTrials":137,"cells":5480},{"EARLY_PHASE1":5481,"PHASE1":5483,"PHASE2":5485,"PHASE3":5487,"PHASE4":5493,"NA":5495},{"trials":5482,"activeCount":98},[],{"trials":5484,"activeCount":98},[],{"trials":5486,"activeCount":98},[],{"trials":5488,"activeCount":98},[5489],{"nctId":5465,"briefTitle":5466,"status":108,"phases":5490,"primaryCompletion":5468,"completion":5469,"start":5470,"enrollment":888,"conditions":5491,"interventions":5492},[87,88],[5472],[5454,5474],{"trials":5494,"activeCount":98},[],{"trials":5496,"activeCount":98},[],{"intervention":5498,"totalTrials":137,"cells":5499},"Levosimendan",{"EARLY_PHASE1":5500,"PHASE1":5502,"PHASE2":5504,"PHASE3":5506,"PHASE4":5518,"NA":5520},{"trials":5501,"activeCount":98},[],{"trials":5503,"activeCount":98},[],{"trials":5505,"activeCount":98},[],{"trials":5507,"activeCount":98},[5508],{"nctId":5509,"briefTitle":5510,"status":108,"phases":5511,"primaryCompletion":5512,"completion":5513,"start":5514,"enrollment":4080,"conditions":5515,"interventions":5517},"NCT04329624","Effect Levosimendan Administration on Postoperative NT-proBNP in Cardiac Risk Patients",[88],"2023-11-07","2024-12-18","2020-10-10",[5516],"Cardiovascular Risk Factor",[5498],{"trials":5519,"activeCount":98},[],{"trials":5521,"activeCount":98},[],{"intervention":5523,"totalTrials":137,"cells":5524},"Cholecalciferol",{"EARLY_PHASE1":5525,"PHASE1":5527,"PHASE2":5529,"PHASE3":5531,"PHASE4":5542,"NA":5544},{"trials":5526,"activeCount":98},[],{"trials":5528,"activeCount":98},[],{"trials":5530,"activeCount":98},[],{"trials":5532,"activeCount":98},[5533],{"nctId":5534,"briefTitle":5535,"status":1092,"phases":5536,"primaryCompletion":873,"completion":873,"start":1873,"enrollment":569,"conditions":5537,"interventions":5541},"NCT00752401","Vitamin D3 Substitution in Vitamin D Deficient Kidney Transplant Recipients",[88],[5538,5539,5540],"Kidney Transplantation","Vitamin D Deficiency","Renal Osteodystrophy",[5523],{"trials":5543,"activeCount":98},[],{"trials":5545,"activeCount":98},[],{"intervention":2318,"totalTrials":137,"cells":5547},{"EARLY_PHASE1":5548,"PHASE1":5550,"PHASE2":5552,"PHASE3":5554,"PHASE4":5560,"NA":5562},{"trials":5549,"activeCount":98},[],{"trials":5551,"activeCount":98},[],{"trials":5553,"activeCount":98},[],{"trials":5555,"activeCount":98},[5556],{"nctId":2310,"briefTitle":2311,"status":1092,"phases":5557,"primaryCompletion":111,"completion":2313,"start":2314,"enrollment":1190,"conditions":5558,"interventions":5559},[87,88],[2316],[2318,2319,2320,2321,2299,2322,2323,2324,2325,2326,2327],{"trials":5561,"activeCount":98},[],{"trials":5563,"activeCount":98},[],{"intervention":2319,"totalTrials":137,"cells":5565},{"EARLY_PHASE1":5566,"PHASE1":5568,"PHASE2":5570,"PHASE3":5572,"PHASE4":5578,"NA":5580},{"trials":5567,"activeCount":98},[],{"trials":5569,"activeCount":98},[],{"trials":5571,"activeCount":98},[],{"trials":5573,"activeCount":98},[5574],{"nctId":2310,"briefTitle":2311,"status":1092,"phases":5575,"primaryCompletion":111,"completion":2313,"start":2314,"enrollment":1190,"conditions":5576,"interventions":5577},[87,88],[2316],[2318,2319,2320,2321,2299,2322,2323,2324,2325,2326,2327],{"trials":5579,"activeCount":98},[],{"trials":5581,"activeCount":98},[],{"intervention":2320,"totalTrials":137,"cells":5583},{"EARLY_PHASE1":5584,"PHASE1":5586,"PHASE2":5588,"PHASE3":5590,"PHASE4":5596,"NA":5598},{"trials":5585,"activeCount":98},[],{"trials":5587,"activeCount":98},[],{"trials":5589,"activeCount":98},[],{"trials":5591,"activeCount":98},[5592],{"nctId":2310,"briefTitle":2311,"status":1092,"phases":5593,"primaryCompletion":111,"completion":2313,"start":2314,"enrollment":1190,"conditions":5594,"interventions":5595},[87,88],[2316],[2318,2319,2320,2321,2299,2322,2323,2324,2325,2326,2327],{"trials":5597,"activeCount":98},[],{"trials":5599,"activeCount":98},[],{"intervention":2321,"totalTrials":137,"cells":5601},{"EARLY_PHASE1":5602,"PHASE1":5604,"PHASE2":5606,"PHASE3":5608,"PHASE4":5614,"NA":5616},{"trials":5603,"activeCount":98},[],{"trials":5605,"activeCount":98},[],{"trials":5607,"activeCount":98},[],{"trials":5609,"activeCount":98},[5610],{"nctId":2310,"briefTitle":2311,"status":1092,"phases":5611,"primaryCompletion":111,"completion":2313,"start":2314,"enrollment":1190,"conditions":5612,"interventions":5613},[87,88],[2316],[2318,2319,2320,2321,2299,2322,2323,2324,2325,2326,2327],{"trials":5615,"activeCount":98},[],{"trials":5617,"activeCount":98},[],{"intervention":2322,"totalTrials":137,"cells":5619},{"EARLY_PHASE1":5620,"PHASE1":5622,"PHASE2":5624,"PHASE3":5626,"PHASE4":5632,"NA":5634},{"trials":5621,"activeCount":98},[],{"trials":5623,"activeCount":98},[],{"trials":5625,"activeCount":98},[],{"trials":5627,"activeCount":98},[5628],{"nctId":2310,"briefTitle":2311,"status":1092,"phases":5629,"primaryCompletion":111,"completion":2313,"start":2314,"enrollment":1190,"conditions":5630,"interventions":5631},[87,88],[2316],[2318,2319,2320,2321,2299,2322,2323,2324,2325,2326,2327],{"trials":5633,"activeCount":98},[],{"trials":5635,"activeCount":98},[],{"intervention":2323,"totalTrials":137,"cells":5637},{"EARLY_PHASE1":5638,"PHASE1":5640,"PHASE2":5642,"PHASE3":5644,"PHASE4":5650,"NA":5652},{"trials":5639,"activeCount":98},[],{"trials":5641,"activeCount":98},[],{"trials":5643,"activeCount":98},[],{"trials":5645,"activeCount":98},[5646],{"nctId":2310,"briefTitle":2311,"status":1092,"phases":5647,"primaryCompletion":111,"completion":2313,"start":2314,"enrollment":1190,"conditions":5648,"interventions":5649},[87,88],[2316],[2318,2319,2320,2321,2299,2322,2323,2324,2325,2326,2327],{"trials":5651,"activeCount":98},[],{"trials":5653,"activeCount":98},[],{"intervention":2324,"totalTrials":137,"cells":5655},{"EARLY_PHASE1":5656,"PHASE1":5658,"PHASE2":5660,"PHASE3":5662,"PHASE4":5668,"NA":5670},{"trials":5657,"activeCount":98},[],{"trials":5659,"activeCount":98},[],{"trials":5661,"activeCount":98},[],{"trials":5663,"activeCount":98},[5664],{"nctId":2310,"briefTitle":2311,"status":1092,"phases":5665,"primaryCompletion":111,"completion":2313,"start":2314,"enrollment":1190,"conditions":5666,"interventions":5667},[87,88],[2316],[2318,2319,2320,2321,2299,2322,2323,2324,2325,2326,2327],{"trials":5669,"activeCount":98},[],{"trials":5671,"activeCount":98},[],{"intervention":2325,"totalTrials":137,"cells":5673},{"EARLY_PHASE1":5674,"PHASE1":5676,"PHASE2":5678,"PHASE3":5680,"PHASE4":5686,"NA":5688},{"trials":5675,"activeCount":98},[],{"trials":5677,"activeCount":98},[],{"trials":5679,"activeCount":98},[],{"trials":5681,"activeCount":98},[5682],{"nctId":2310,"briefTitle":2311,"status":1092,"phases":5683,"primaryCompletion":111,"completion":2313,"start":2314,"enrollment":1190,"conditions":5684,"interventions":5685},[87,88],[2316],[2318,2319,2320,2321,2299,2322,2323,2324,2325,2326,2327],{"trials":5687,"activeCount":98},[],{"trials":5689,"activeCount":98},[],{"intervention":2326,"totalTrials":137,"cells":5691},{"EARLY_PHASE1":5692,"PHASE1":5694,"PHASE2":5696,"PHASE3":5698,"PHASE4":5704,"NA":5706},{"trials":5693,"activeCount":98},[],{"trials":5695,"activeCount":98},[],{"trials":5697,"activeCount":98},[],{"trials":5699,"activeCount":98},[5700],{"nctId":2310,"briefTitle":2311,"status":1092,"phases":5701,"primaryCompletion":111,"completion":2313,"start":2314,"enrollment":1190,"conditions":5702,"interventions":5703},[87,88],[2316],[2318,2319,2320,2321,2299,2322,2323,2324,2325,2326,2327],{"trials":5705,"activeCount":98},[],{"trials":5707,"activeCount":98},[],{"intervention":2327,"totalTrials":137,"cells":5709},{"EARLY_PHASE1":5710,"PHASE1":5712,"PHASE2":5714,"PHASE3":5716,"PHASE4":5722,"NA":5724},{"trials":5711,"activeCount":98},[],{"trials":5713,"activeCount":98},[],{"trials":5715,"activeCount":98},[],{"trials":5717,"activeCount":98},[5718],{"nctId":2310,"briefTitle":2311,"status":1092,"phases":5719,"primaryCompletion":111,"completion":2313,"start":2314,"enrollment":1190,"conditions":5720,"interventions":5721},[87,88],[2316],[2318,2319,2320,2321,2299,2322,2323,2324,2325,2326,2327],{"trials":5723,"activeCount":98},[],{"trials":5725,"activeCount":98},[],{"intervention":5727,"totalTrials":137,"cells":5728},"enoxaparin",{"EARLY_PHASE1":5729,"PHASE1":5731,"PHASE2":5733,"PHASE3":5735,"PHASE4":5744,"NA":5746},{"trials":5730,"activeCount":98},[],{"trials":5732,"activeCount":98},[],{"trials":5734,"activeCount":98},[],{"trials":5736,"activeCount":98},[5737],{"nctId":5738,"briefTitle":5739,"status":108,"phases":5740,"completion":4948,"start":2287,"conditions":5741,"interventions":5743},"NCT00375076","Comparison of Two Different Dosages of Low-molecular Weight Heparin in Cancer Patients",[88],[5742],"Cancer",[5727],{"trials":5745,"activeCount":98},[],{"trials":5747,"activeCount":98},[],{"intervention":5749,"totalTrials":137,"cells":5750},"NovoSeven",{"EARLY_PHASE1":5751,"PHASE1":5753,"PHASE2":5755,"PHASE3":5757,"PHASE4":5765,"NA":5767},{"trials":5752,"activeCount":98},[],{"trials":5754,"activeCount":98},[],{"trials":5756,"activeCount":98},[],{"trials":5758,"activeCount":98},[5759],{"nctId":5760,"briefTitle":5761,"status":108,"phases":5762,"conditions":5763,"interventions":5764},"NCT00375323","Recombinant Factor VIIa (NovoSeven) on Restoring Coagulation Activation",[88],[514],[5749],{"trials":5766,"activeCount":98},[],{"trials":5768,"activeCount":98},[],{"intervention":5770,"totalTrials":137,"cells":5771},"Oxybuprocaine MDU",{"EARLY_PHASE1":5772,"PHASE1":5774,"PHASE2":5776,"PHASE3":5778,"PHASE4":5793,"NA":5795},{"trials":5773,"activeCount":98},[],{"trials":5775,"activeCount":98},[],{"trials":5777,"activeCount":98},[],{"trials":5779,"activeCount":98},[5780],{"nctId":5781,"briefTitle":5782,"status":108,"phases":5783,"primaryCompletion":5784,"completion":5784,"start":5785,"enrollment":476,"conditions":5786,"interventions":5789},"NCT07230548","Effect of Four Different Diagnostic Eye Drops on Tear Film Thickness",[88],"2020-10-28","2020-06-10",[5787,5788],"Ocular Surface Disease","Tear Film Characteristics",[5770,5790,5791,5792],"Oxybuprocaine SDU","Oxybuprocaine\u002Ffluorescein SDU","Fluorescein SDU",{"trials":5794,"activeCount":98},[],{"trials":5796,"activeCount":98},[],{"intervention":5790,"totalTrials":137,"cells":5798},{"EARLY_PHASE1":5799,"PHASE1":5801,"PHASE2":5803,"PHASE3":5805,"PHASE4":5811,"NA":5813},{"trials":5800,"activeCount":98},[],{"trials":5802,"activeCount":98},[],{"trials":5804,"activeCount":98},[],{"trials":5806,"activeCount":98},[5807],{"nctId":5781,"briefTitle":5782,"status":108,"phases":5808,"primaryCompletion":5784,"completion":5784,"start":5785,"enrollment":476,"conditions":5809,"interventions":5810},[88],[5787,5788],[5770,5790,5791,5792],{"trials":5812,"activeCount":98},[],{"trials":5814,"activeCount":98},[],{"intervention":5791,"totalTrials":137,"cells":5816},{"EARLY_PHASE1":5817,"PHASE1":5819,"PHASE2":5821,"PHASE3":5823,"PHASE4":5829,"NA":5831},{"trials":5818,"activeCount":98},[],{"trials":5820,"activeCount":98},[],{"trials":5822,"activeCount":98},[],{"trials":5824,"activeCount":98},[5825],{"nctId":5781,"briefTitle":5782,"status":108,"phases":5826,"primaryCompletion":5784,"completion":5784,"start":5785,"enrollment":476,"conditions":5827,"interventions":5828},[88],[5787,5788],[5770,5790,5791,5792],{"trials":5830,"activeCount":98},[],{"trials":5832,"activeCount":98},[],{"intervention":5792,"totalTrials":137,"cells":5834},{"EARLY_PHASE1":5835,"PHASE1":5837,"PHASE2":5839,"PHASE3":5841,"PHASE4":5847,"NA":5849},{"trials":5836,"activeCount":98},[],{"trials":5838,"activeCount":98},[],{"trials":5840,"activeCount":98},[],{"trials":5842,"activeCount":98},[5843],{"nctId":5781,"briefTitle":5782,"status":108,"phases":5844,"primaryCompletion":5784,"completion":5784,"start":5785,"enrollment":476,"conditions":5845,"interventions":5846},[88],[5787,5788],[5770,5790,5791,5792],{"trials":5848,"activeCount":98},[],{"trials":5850,"activeCount":98},[],{"intervention":5852,"totalTrials":137,"cells":5853},"Mannitol",{"EARLY_PHASE1":5854,"PHASE1":5856,"PHASE2":5858,"PHASE3":5860,"PHASE4":5872,"NA":5874},{"trials":5855,"activeCount":98},[],{"trials":5857,"activeCount":98},[],{"trials":5859,"activeCount":98},[],{"trials":5861,"activeCount":98},[5862],{"nctId":5863,"briefTitle":5864,"status":108,"phases":5865,"primaryCompletion":5866,"completion":5867,"start":5868,"enrollment":2121,"conditions":5869,"interventions":5871},"NCT02705573","Effects of Mannitol on Delayed Graft Function After Cadaveric Renal Transplantation",[88],"2018-06-30","2018-07-30","2018-01-01",[5870],"Kidney Transplantation, Mannitol",[5852],{"trials":5873,"activeCount":98},[],{"trials":5875,"activeCount":98},[],{"intervention":5877,"totalTrials":137,"cells":5878},"follicle stimulating hormone",{"EARLY_PHASE1":5879,"PHASE1":5881,"PHASE2":5883,"PHASE3":5885,"PHASE4":5895,"NA":5897},{"trials":5880,"activeCount":98},[],{"trials":5882,"activeCount":98},[],{"trials":5884,"activeCount":98},[],{"trials":5886,"activeCount":98},[5887],{"nctId":5888,"briefTitle":5889,"status":2023,"phases":5890,"primaryCompletion":1973,"completion":2863,"start":1973,"enrollment":5891,"conditions":5892,"interventions":5894},"NCT00749853","Efficacy of Ovarian Stimulation Based on FSHR Genotype Status",[88],165,[5893],"Sterility",[5877,5877],{"trials":5896,"activeCount":98},[],{"trials":5898,"activeCount":98},[],{"intervention":5900,"totalTrials":137,"cells":5901},"Landiolol HCl",{"EARLY_PHASE1":5902,"PHASE1":5904,"PHASE2":5906,"PHASE3":5908,"PHASE4":5920,"NA":5922},{"trials":5903,"activeCount":98},[],{"trials":5905,"activeCount":98},[],{"trials":5907,"activeCount":98},[],{"trials":5909,"activeCount":98},[5910],{"nctId":5911,"briefTitle":5912,"status":1092,"phases":5913,"primaryCompletion":5914,"completion":5915,"start":5916,"enrollment":5917,"conditions":5918,"interventions":5919},"NCT05084118","Landiolol for Prevention of Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery",[88],"2023-11-01","2024-06-01","2021-10-21",164,[2461,3385],[5900],{"trials":5921,"activeCount":98},[],{"trials":5923,"activeCount":98},[],{"intervention":5925,"totalTrials":137,"cells":5926},"Fumaric acid esters",{"EARLY_PHASE1":5927,"PHASE1":5929,"PHASE2":5931,"PHASE3":5933,"PHASE4":5942,"NA":5944},{"trials":5928,"activeCount":98},[],{"trials":5930,"activeCount":98},[],{"trials":5932,"activeCount":98},[],{"trials":5934,"activeCount":98},[5935],{"nctId":5936,"briefTitle":5937,"status":108,"phases":5938,"primaryCompletion":1895,"completion":660,"start":1171,"enrollment":1061,"conditions":5939,"interventions":5941},"NCT01321164","Fumaric Acid Versus Fumaric Acid Plus Narrow Band Type B Ultraviolet (UVB) for Psoriasis",[88],[5940],"Plaque Psoriasis",[5925],{"trials":5943,"activeCount":98},[],{"trials":5945,"activeCount":98},[],{"intervention":5947,"totalTrials":137,"cells":5948},"Dantrolene",{"EARLY_PHASE1":5949,"PHASE1":5951,"PHASE2":5953,"PHASE3":5955,"PHASE4":5964,"NA":5966},{"trials":5950,"activeCount":98},[],{"trials":5952,"activeCount":98},[],{"trials":5954,"activeCount":98},[],{"trials":5956,"activeCount":98},[5957],{"nctId":5958,"briefTitle":5959,"status":839,"phases":5960,"primaryCompletion":854,"completion":854,"start":4948,"enrollment":2121,"conditions":5961,"interventions":5963},"NCT00796900","Dantrolene for Treatment of Hyperthermia in Subarachnoidal Hemorrhage (SAH)",[87,88],[5962],"Hyperthermia",[5947],{"trials":5965,"activeCount":98},[],{"trials":5967,"activeCount":98},[],{"intervention":5969,"totalTrials":137,"cells":5970},"Telmisartan, Bisoprolol",{"EARLY_PHASE1":5971,"PHASE1":5973,"PHASE2":5975,"PHASE3":5977,"PHASE4":5987,"NA":5989},{"trials":5972,"activeCount":98},[],{"trials":5974,"activeCount":98},[],{"trials":5976,"activeCount":98},[],{"trials":5978,"activeCount":98},[5979],{"nctId":5980,"briefTitle":5981,"status":108,"phases":5982,"primaryCompletion":5983,"completion":5983,"start":2673,"enrollment":2359,"conditions":5984,"interventions":5986},"NCT00562952","Nt-proBNP Guided Primary Prevention of CV Events in Diabetic Patients",[87,88],"2011-12",[5985,3261,32],"Diabetes Mellitus",[5969],{"trials":5988,"activeCount":98},[],{"trials":5990,"activeCount":98},[],{"intervention":5992,"totalTrials":137,"cells":5993},"Topical Imiquimod",{"EARLY_PHASE1":5994,"PHASE1":5996,"PHASE2":5998,"PHASE3":6000,"PHASE4":6010,"NA":6012},{"trials":5995,"activeCount":98},[],{"trials":5997,"activeCount":98},[],{"trials":5999,"activeCount":98},[],{"trials":6001,"activeCount":98},[6002],{"nctId":6003,"briefTitle":6004,"status":839,"phases":6005,"primaryCompletion":1924,"completion":6006,"start":3284,"enrollment":2434,"conditions":6007,"interventions":6009},"NCT01283763","Topical Imiquimod Versus Conization to Treat Cervical Intraepithelial Neoplasia",[88],"2018-01",[6008],"Cervical Intraepithelial Neoplasia",[5992],{"trials":6011,"activeCount":98},[],{"trials":6013,"activeCount":98},[],{"intervention":6015,"totalTrials":137,"cells":6016},"Timoptic® 0.5%",{"EARLY_PHASE1":6017,"PHASE1":6019,"PHASE2":6021,"PHASE3":6023,"PHASE4":6033,"NA":6035},{"trials":6018,"activeCount":98},[],{"trials":6020,"activeCount":98},[],{"trials":6022,"activeCount":98},[],{"trials":6024,"activeCount":98},[6025],{"nctId":6026,"briefTitle":6027,"status":839,"phases":6028,"primaryCompletion":3915,"completion":2432,"start":1172,"enrollment":6029,"conditions":6030,"interventions":6031},"NCT01746602","Effect of Topical Glaucoma Therapy on Tear Film Stability in Healthy Subjects",[88],38,[15],[6015,6032],"Timophtal sine® 0.5%",{"trials":6034,"activeCount":98},[],{"trials":6036,"activeCount":98},[],{"intervention":6032,"totalTrials":137,"cells":6038},{"EARLY_PHASE1":6039,"PHASE1":6041,"PHASE2":6043,"PHASE3":6045,"PHASE4":6051,"NA":6053},{"trials":6040,"activeCount":98},[],{"trials":6042,"activeCount":98},[],{"trials":6044,"activeCount":98},[],{"trials":6046,"activeCount":98},[6047],{"nctId":6026,"briefTitle":6027,"status":839,"phases":6048,"primaryCompletion":3915,"completion":2432,"start":1172,"enrollment":6029,"conditions":6049,"interventions":6050},[88],[15],[6015,6032],{"trials":6052,"activeCount":98},[],{"trials":6054,"activeCount":98},[],{"intervention":6056,"totalTrials":137,"cells":6057},"Antithyroid Drug",{"EARLY_PHASE1":6058,"PHASE1":6060,"PHASE2":6062,"PHASE3":6064,"PHASE4":6077,"NA":6079},{"trials":6059,"activeCount":98},[],{"trials":6061,"activeCount":98},[],{"trials":6063,"activeCount":98},[],{"trials":6065,"activeCount":98},[6066],{"nctId":6067,"briefTitle":6068,"status":1092,"phases":6069,"primaryCompletion":6070,"completion":6071,"start":2051,"enrollment":949,"conditions":6072,"interventions":6076},"NCT03066076","Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy",[88],"2019-02-01","2019-06-01",[6073,6074,6075],"Graves Disease","Graves Ophthalmopathy","Graves' Ophthalmopathy Worsened",[6056],{"trials":6078,"activeCount":98},[],{"trials":6080,"activeCount":98},[],{"intervention":6082,"totalTrials":137,"cells":6083},"68Ga- PSMA-HBED-CC",{"EARLY_PHASE1":6084,"PHASE1":6086,"PHASE2":6088,"PHASE3":6090,"PHASE4":6101,"NA":6103},{"trials":6085,"activeCount":98},[],{"trials":6087,"activeCount":98},[],{"trials":6089,"activeCount":98},[],{"trials":6091,"activeCount":98},[6092],{"nctId":6093,"briefTitle":6094,"status":108,"phases":6095,"primaryCompletion":6096,"completion":6097,"start":2948,"enrollment":6098,"conditions":6099,"interventions":6100},"NCT02659527","PET\u002FMRI in Patients With Suspected Prostate Cancer",[88],"2022-05","2022-08",220,[488],[6082],{"trials":6102,"activeCount":98},[],{"trials":6104,"activeCount":98},[],{"intervention":6106,"totalTrials":137,"cells":6107},"Topical imiquimod therapy",{"EARLY_PHASE1":6108,"PHASE1":6110,"PHASE2":6112,"PHASE3":6114,"PHASE4":6122,"NA":6124},{"trials":6109,"activeCount":98},[],{"trials":6111,"activeCount":98},[],{"trials":6113,"activeCount":98},[],{"trials":6115,"activeCount":98},[6116],{"nctId":6117,"briefTitle":6118,"status":108,"phases":6119,"primaryCompletion":5335,"completion":5335,"start":1094,"enrollment":949,"conditions":6120,"interventions":6121},"NCT00941252","ITIC (Imiquimod Therapy in Cervical Intraepithelial Neoplasia)-Trial",[87,88],[6008],[6106],{"trials":6123,"activeCount":98},[],{"trials":6125,"activeCount":98},[],{"intervention":6127,"totalTrials":137,"cells":6128},"infliximab",{"EARLY_PHASE1":6129,"PHASE1":6131,"PHASE2":6133,"PHASE3":6135,"PHASE4":6145,"NA":6147},{"trials":6130,"activeCount":98},[],{"trials":6132,"activeCount":98},[],{"trials":6134,"activeCount":98},[],{"trials":6136,"activeCount":98},[6137],{"nctId":6138,"briefTitle":6139,"status":839,"phases":6140,"primaryCompletion":1107,"completion":1107,"start":3381,"enrollment":137,"conditions":6141,"interventions":6144},"NCT00368264","TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )",[87,88],[6142,6143],"Lupus Erythematosus, Systemic","Lupus Nephritis",[6127],{"trials":6146,"activeCount":98},[],{"trials":6148,"activeCount":98},[],{"intervention":6150,"totalTrials":137,"cells":6151},"Lactobacillus casei rhamnosus",{"EARLY_PHASE1":6152,"PHASE1":6154,"PHASE2":6156,"PHASE3":6158,"PHASE4":6169,"NA":6171},{"trials":6153,"activeCount":98},[],{"trials":6155,"activeCount":98},[],{"trials":6157,"activeCount":98},[],{"trials":6159,"activeCount":98},[6160],{"nctId":6161,"briefTitle":6162,"status":108,"phases":6163,"primaryCompletion":6164,"completion":2742,"start":6165,"enrollment":356,"conditions":6166,"interventions":6168},"NCT02979288","Treatment of the Intermediate Vaginal Microbiota With Vaginal Lactobacillus Casei Rhamnosus to Improve Pregnancy Outcome",[88],"2020-11-01","2017-05-02",[6167],"Lactobacillus Infection",[6150],{"trials":6170,"activeCount":98},[],{"trials":6172,"activeCount":98},[],{"intervention":6174,"totalTrials":137,"cells":6175},"Lucentis intravitreal",{"EARLY_PHASE1":6176,"PHASE1":6178,"PHASE2":6180,"PHASE3":6182,"PHASE4":6194,"NA":6196},{"trials":6177,"activeCount":98},[],{"trials":6179,"activeCount":98},[],{"trials":6181,"activeCount":98},[],{"trials":6183,"activeCount":98},[6184],{"nctId":6185,"briefTitle":6186,"status":108,"phases":6187,"primaryCompletion":1908,"completion":6188,"start":4985,"enrollment":6189,"conditions":6190,"interventions":6192},"NCT02033031","Long-term Treatment Effect of Intravitreal Ant-VEGF in Branch Retinal Vein Occlusion",[88],"2013-02",28,[6191],"Branch Retinal Vein Occlusion",[6174,6193],"Avastin intravitreal",{"trials":6195,"activeCount":98},[],{"trials":6197,"activeCount":98},[],{"intervention":6193,"totalTrials":137,"cells":6199},{"EARLY_PHASE1":6200,"PHASE1":6202,"PHASE2":6204,"PHASE3":6206,"PHASE4":6212,"NA":6214},{"trials":6201,"activeCount":98},[],{"trials":6203,"activeCount":98},[],{"trials":6205,"activeCount":98},[],{"trials":6207,"activeCount":98},[6208],{"nctId":6185,"briefTitle":6186,"status":108,"phases":6209,"primaryCompletion":1908,"completion":6188,"start":4985,"enrollment":6189,"conditions":6210,"interventions":6211},[88],[6191],[6174,6193],{"trials":6213,"activeCount":98},[],{"trials":6215,"activeCount":98},[],{"intervention":6217,"totalTrials":137,"cells":6218},"Nadroparin calcium",{"EARLY_PHASE1":6219,"PHASE1":6221,"PHASE2":6223,"PHASE3":6225,"PHASE4":6236,"NA":6238},{"trials":6220,"activeCount":98},[],{"trials":6222,"activeCount":98},[],{"trials":6224,"activeCount":98},[],{"trials":6226,"activeCount":98},[6227],{"nctId":6228,"briefTitle":6229,"status":1092,"phases":6230,"primaryCompletion":6231,"completion":2036,"start":6232,"enrollment":2359,"conditions":6233,"interventions":6235},"NCT01019655","Heparin for Pregnant Women With Thrombophilia",[88],"2012-01","2010-01",[6234],"Pregnancy and Thrombophilia",[6217],{"trials":6237,"activeCount":98},[],{"trials":6239,"activeCount":98},[],{"intervention":860,"totalTrials":1030,"cells":6241},{"EARLY_PHASE1":6242,"PHASE1":6244,"PHASE2":6246,"PHASE3":6266,"PHASE4":6268,"NA":6270},{"trials":6243,"activeCount":98},[],{"trials":6245,"activeCount":98},[],{"trials":6247,"activeCount":98},[6248,6252,6256],{"nctId":4919,"briefTitle":4920,"status":108,"phases":6249,"primaryCompletion":4922,"completion":4922,"start":3638,"enrollment":547,"conditions":6250,"interventions":6251},[87],[18,21,4924],[4910,4926,860],{"nctId":850,"briefTitle":851,"status":108,"phases":6253,"primaryCompletion":853,"completion":853,"start":854,"enrollment":25,"conditions":6254,"interventions":6255},[87],[856,857,858],[668,860],{"nctId":6257,"briefTitle":6258,"status":1092,"phases":6259,"primaryCompletion":1785,"completion":6260,"start":6261,"enrollment":356,"conditions":6262,"interventions":6264},"NCT01658410","Short-term Endothelin A Receptor Blockade in Patients With On-pump CABG",[87],"2016-12","2012-07",[32,6263],"Aorto-coronary Bypass Grafting",[6265,860],"BQ-123",{"trials":6267,"activeCount":98},[],{"trials":6269,"activeCount":98},[],{"trials":6271,"activeCount":98},[],{"intervention":6273,"totalTrials":1030,"cells":6274},"Bortezomib",{"EARLY_PHASE1":6275,"PHASE1":6277,"PHASE2":6279,"PHASE3":6309,"PHASE4":6311,"NA":6313},{"trials":6276,"activeCount":98},[],{"trials":6278,"activeCount":98},[],{"trials":6280,"activeCount":98},[6281,6288,6298],{"nctId":6282,"briefTitle":6283,"status":108,"phases":6284,"enrollment":547,"conditions":6285,"interventions":6287},"NCT00373906","Velcade in MALT Lymphoma Patients",[87],[6286],"MALT Lymphoma",[6273],{"nctId":6289,"briefTitle":6290,"status":108,"phases":6291,"primaryCompletion":2971,"completion":6292,"start":1895,"enrollment":6293,"conditions":6294,"interventions":6297},"NCT01873157","Bortezomib in Late Antibody-mediated Kidney Transplant Rejection",[87],"2017-02-28",44,[6295,6296],"Late Rejection of Renal Transplant","Antibody-mediated Rejection",[6273],{"nctId":6299,"briefTitle":6300,"status":1092,"phases":6301,"completion":6302,"start":3572,"enrollment":547,"conditions":6303,"interventions":6305},"NCT00261612","Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed\u002FRefractory Mantle Cell Lymphoma",[87],"2007-01",[6304],"Lymphoma, Mantle-Cell",[6306,6307,6308],"bortezomib","rituximab","dexamethasone",{"trials":6310,"activeCount":98},[],{"trials":6312,"activeCount":98},[],{"trials":6314,"activeCount":98},[],{"intervention":6316,"totalTrials":94,"cells":6317},"Cetuximab",{"EARLY_PHASE1":6318,"PHASE1":6320,"PHASE2":6331,"PHASE3":6344,"PHASE4":6346,"NA":6348},{"trials":6319,"activeCount":98},[],{"trials":6321,"activeCount":98},[6322],{"nctId":6323,"briefTitle":6324,"status":1092,"phases":6325,"primaryCompletion":2887,"completion":2887,"start":6326,"enrollment":844,"conditions":6327,"interventions":6329},"NCT00367250","Safety Study of Combined Immunotherapy With Trastuzumab and Cetuximab in Patients With Metastatic Breast Cancer",[86],"2006-07",[6328],"Metastatic Breast Cancer",[6316,6330],"Trastuzumab",{"trials":6332,"activeCount":98},[6333],{"nctId":6334,"briefTitle":6335,"status":108,"phases":6336,"primaryCompletion":6337,"completion":6337,"start":6338,"enrollment":6339,"conditions":6340,"interventions":6342},"NCT04278092","Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure",[87],"2024-10-31","2020-02-10",57,[6341],"Head and Neck Squamous Cell Carcinoma",[6343,6316],"Paclitaxel",{"trials":6345,"activeCount":98},[],{"trials":6347,"activeCount":98},[],{"trials":6349,"activeCount":98},[],{"intervention":6351,"totalTrials":94,"cells":6352},"bosentan",{"EARLY_PHASE1":6353,"PHASE1":6355,"PHASE2":6365,"PHASE3":6374,"PHASE4":6376,"NA":6378},{"trials":6354,"activeCount":98},[],{"trials":6356,"activeCount":98},[6357],{"nctId":6358,"briefTitle":6359,"status":108,"phases":6360,"primaryCompletion":6361,"completion":874,"start":6362,"enrollment":6189,"conditions":6363,"interventions":6364},"NCT00701597","Effects of Non-Specific Endothelin-A Receptor Blockade on Ocular Blood Flow in Patients With Glaucoma",[86],"2007-09","2007-04",[27,3031],[6351],{"trials":6366,"activeCount":98},[6367],{"nctId":6368,"briefTitle":6369,"status":839,"phases":6370,"primaryCompletion":660,"start":2458,"enrollment":522,"conditions":6371,"interventions":6373},"NCT01518595","Bosentan for Treatment of Hepatopulmonary Syndrome in Patients With Liver Cirrhosis",[87],[6372,225],"Hepatopulmonary Syndrome",[6351],{"trials":6375,"activeCount":98},[],{"trials":6377,"activeCount":98},[],{"trials":6379,"activeCount":98},[],{"intervention":6381,"totalTrials":94,"cells":6382},"Ketamine",{"EARLY_PHASE1":6383,"PHASE1":6385,"PHASE2":6395,"PHASE3":6406,"PHASE4":6408,"NA":6410},{"trials":6384,"activeCount":98},[],{"trials":6386,"activeCount":98},[6387],{"nctId":6388,"briefTitle":6389,"status":1092,"phases":6390,"primaryCompletion":6391,"completion":6391,"start":6392,"enrollment":949,"conditions":6393,"interventions":6394},"NCT05320107","The Effect of Ketamine on Aesthetics and Role for Antidepressant Effects",[86],"2025-02-28","2022-06-01",[1975],[6381],{"trials":6396,"activeCount":98},[6397],{"nctId":6398,"briefTitle":6399,"status":1092,"phases":6400,"primaryCompletion":2193,"completion":2193,"start":6401,"enrollment":949,"conditions":6402,"interventions":6404},"NCT02992496","Investigation of Antidepressant Efficacy of Oral Ketamine Treatment",[87],"2017-04-24",[6403],"Major Depressive Episode",[6381,6405],"Midazolam Hydrochloride",{"trials":6407,"activeCount":98},[],{"trials":6409,"activeCount":98},[],{"trials":6411,"activeCount":98},[],{"intervention":6307,"totalTrials":94,"cells":6413},{"EARLY_PHASE1":6414,"PHASE1":6416,"PHASE2":6426,"PHASE3":6432,"PHASE4":6434,"NA":6436},{"trials":6415,"activeCount":98},[],{"trials":6417,"activeCount":98},[6418],{"nctId":6419,"briefTitle":6420,"status":839,"phases":6421,"primaryCompletion":2433,"completion":2433,"start":874,"enrollment":6422,"conditions":6423,"interventions":6425},"NCT01032122","Rituximab in Metastatic Melanoma",[86],9,[6424],"Metastatic Melanoma",[6307],{"trials":6427,"activeCount":98},[6428],{"nctId":6299,"briefTitle":6300,"status":1092,"phases":6429,"completion":6302,"start":3572,"enrollment":547,"conditions":6430,"interventions":6431},[87],[6304],[6306,6307,6308],{"trials":6433,"activeCount":98},[],{"trials":6435,"activeCount":98},[],{"trials":6437,"activeCount":98},[],{"intervention":6439,"totalTrials":94,"cells":6440},"Acetylsalicylic acid",{"EARLY_PHASE1":6441,"PHASE1":6443,"PHASE2":6445,"PHASE3":6459,"PHASE4":6461,"NA":6463},{"trials":6442,"activeCount":98},[],{"trials":6444,"activeCount":98},[],{"trials":6446,"activeCount":98},[6447,6455],{"nctId":6448,"briefTitle":6449,"status":1092,"phases":6450,"primaryCompletion":2036,"completion":853,"start":1171,"enrollment":6451,"conditions":6452,"interventions":6454},"NCT01328145","Acetylic Salicylic Acid for the Treatment of Chronic Obstructive Pulmonary Disease",[87],74,[6453],"COPD",[6439],{"nctId":1903,"briefTitle":1904,"status":1092,"phases":6456,"primaryCompletion":1906,"completion":1907,"start":1908,"enrollment":569,"conditions":6457,"interventions":6458},[87],[34],[1911,1912,1913,1914],{"trials":6460,"activeCount":98},[],{"trials":6462,"activeCount":98},[],{"trials":6464,"activeCount":98},[],{"intervention":6466,"totalTrials":137,"cells":6467},"Syntocinon Nasalspray",{"EARLY_PHASE1":6468,"PHASE1":6470,"PHASE2":6472,"PHASE3":6481,"PHASE4":6483,"NA":6485},{"trials":6469,"activeCount":98},[],{"trials":6471,"activeCount":98},[],{"trials":6473,"activeCount":98},[6474],{"nctId":6475,"briefTitle":6476,"status":108,"phases":6477,"primaryCompletion":5268,"completion":5268,"start":4079,"enrollment":1061,"conditions":6478,"interventions":6480},"NCT02229721","Effect of Chronic Intranasal Oxytocin Administration on Sexual Function in Pre- and Postmenopausal Women",[87],[6479],"Female Sexual Dysfunction",[6466],{"trials":6482,"activeCount":98},[],{"trials":6484,"activeCount":98},[],{"trials":6486,"activeCount":98},[],{"intervention":4926,"totalTrials":137,"cells":6488},{"EARLY_PHASE1":6489,"PHASE1":6491,"PHASE2":6493,"PHASE3":6499,"PHASE4":6501,"NA":6503},{"trials":6490,"activeCount":98},[],{"trials":6492,"activeCount":98},[],{"trials":6494,"activeCount":98},[6495],{"nctId":4919,"briefTitle":4920,"status":108,"phases":6496,"primaryCompletion":4922,"completion":4922,"start":3638,"enrollment":547,"conditions":6497,"interventions":6498},[87],[18,21,4924],[4910,4926,860],{"trials":6500,"activeCount":98},[],{"trials":6502,"activeCount":98},[],{"trials":6504,"activeCount":98},[],{"intervention":6506,"totalTrials":137,"cells":6507},"reesterified long-chain n-3 polyunsaturated fatty acids",{"EARLY_PHASE1":6508,"PHASE1":6510,"PHASE2":6512,"PHASE3":6524,"PHASE4":6526,"NA":6528},{"trials":6509,"activeCount":98},[],{"trials":6511,"activeCount":98},[],{"trials":6513,"activeCount":98},[6514],{"nctId":6515,"briefTitle":6516,"status":108,"phases":6517,"primaryCompletion":2630,"completion":1046,"start":2674,"enrollment":6518,"conditions":6519,"interventions":6522},"NCT00760760","n-3 Polyunsaturated Fatty Acids in Obesity",[87],55,[6520,6521],"Adipose Tissue Inflammation","Morbid Obesity",[6506,6523],"control",{"trials":6525,"activeCount":98},[],{"trials":6527,"activeCount":98},[],{"trials":6529,"activeCount":98},[],{"intervention":6523,"totalTrials":137,"cells":6531},{"EARLY_PHASE1":6532,"PHASE1":6534,"PHASE2":6536,"PHASE3":6542,"PHASE4":6544,"NA":6546},{"trials":6533,"activeCount":98},[],{"trials":6535,"activeCount":98},[],{"trials":6537,"activeCount":98},[6538],{"nctId":6515,"briefTitle":6516,"status":108,"phases":6539,"primaryCompletion":2630,"completion":1046,"start":2674,"enrollment":6518,"conditions":6540,"interventions":6541},[87],[6520,6521],[6506,6523],{"trials":6543,"activeCount":98},[],{"trials":6545,"activeCount":98},[],{"trials":6547,"activeCount":98},[],{"intervention":1845,"totalTrials":137,"cells":6549},{"EARLY_PHASE1":6550,"PHASE1":6552,"PHASE2":6554,"PHASE3":6560,"PHASE4":6562,"NA":6564},{"trials":6551,"activeCount":98},[],{"trials":6553,"activeCount":98},[],{"trials":6555,"activeCount":98},[6556],{"nctId":1839,"briefTitle":1840,"status":839,"phases":6557,"completion":842,"start":1095,"enrollment":844,"conditions":6558,"interventions":6559},[87],[1843],[1845,1829],{"trials":6561,"activeCount":98},[],{"trials":6563,"activeCount":98},[],{"trials":6565,"activeCount":98},[],{"intervention":6567,"totalTrials":137,"cells":6568},"azithromycin plus artesunate",{"EARLY_PHASE1":6569,"PHASE1":6571,"PHASE2":6573,"PHASE3":6586,"PHASE4":6588,"NA":6590},{"trials":6570,"activeCount":98},[],{"trials":6572,"activeCount":98},[],{"trials":6574,"activeCount":98},[6575],{"nctId":6576,"briefTitle":6577,"status":108,"phases":6578,"primaryCompletion":6579,"start":6580,"enrollment":6581,"conditions":6582,"interventions":6584},"NCT00356005","Azithromycin Combination Therapy for the Treatment of Uncomplicated Falciparum Malaria in Bangladesh",[87],"2007-08","2006-08",228,[6583],"Uncomplicated Falciparum Malaria",[6567,6585],"Artesunate",{"trials":6587,"activeCount":98},[],{"trials":6589,"activeCount":98},[],{"trials":6591,"activeCount":98},[],{"intervention":6593,"totalTrials":137,"cells":6594},"FMT combined with Atezolizumab plus Bevacizumab",{"EARLY_PHASE1":6595,"PHASE1":6597,"PHASE2":6599,"PHASE3":6609,"PHASE4":6611,"NA":6613},{"trials":6596,"activeCount":98},[],{"trials":6598,"activeCount":98},[],{"trials":6600,"activeCount":98},[6601],{"nctId":6602,"briefTitle":6603,"status":108,"phases":6604,"primaryCompletion":6605,"completion":6605,"start":6606,"enrollment":30,"conditions":6607,"interventions":6608},"NCT05750030","FMT in IT-refractory HCC - FAB-HCC Pilot Study",[87],"2025-03-17","2023-05-16",[846],[6593],{"trials":6610,"activeCount":98},[],{"trials":6612,"activeCount":98},[],{"trials":6614,"activeCount":98},[],{"intervention":6616,"totalTrials":137,"cells":6617},"Amiloride hydrochlorothiazide",{"EARLY_PHASE1":6618,"PHASE1":6620,"PHASE2":6622,"PHASE3":6633,"PHASE4":6635,"NA":6637},{"trials":6619,"activeCount":98},[],{"trials":6621,"activeCount":98},[],{"trials":6623,"activeCount":98},[6624],{"nctId":6625,"briefTitle":6626,"status":1092,"phases":6627,"primaryCompletion":635,"completion":635,"start":5334,"enrollment":6628,"conditions":6629,"interventions":6631},"NCT01879527","Amiloride Hydrochlorothiazide as Treatment of Acute Inflammation of the Optic Nerve",[87],78,[6630],"Optic; Neuritis, With Demyelination",[6616,6632],"Sugar pill",{"trials":6634,"activeCount":98},[],{"trials":6636,"activeCount":98},[],{"trials":6638,"activeCount":98},[],{"intervention":6632,"totalTrials":137,"cells":6640},{"EARLY_PHASE1":6641,"PHASE1":6643,"PHASE2":6645,"PHASE3":6651,"PHASE4":6653,"NA":6655},{"trials":6642,"activeCount":98},[],{"trials":6644,"activeCount":98},[],{"trials":6646,"activeCount":98},[6647],{"nctId":6625,"briefTitle":6626,"status":1092,"phases":6648,"primaryCompletion":635,"completion":635,"start":5334,"enrollment":6628,"conditions":6649,"interventions":6650},[87],[6630],[6616,6632],{"trials":6652,"activeCount":98},[],{"trials":6654,"activeCount":98},[],{"trials":6656,"activeCount":98},[],{"intervention":6658,"totalTrials":137,"cells":6659},"Sorafenib",{"EARLY_PHASE1":6660,"PHASE1":6662,"PHASE2":6664,"PHASE3":6672,"PHASE4":6674,"NA":6676},{"trials":6661,"activeCount":98},[],{"trials":6663,"activeCount":98},[],{"trials":6665,"activeCount":98},[6666],{"nctId":6667,"briefTitle":6668,"status":108,"phases":6669,"primaryCompletion":1854,"completion":2079,"start":2674,"enrollment":1162,"conditions":6670,"interventions":6671},"NCT00768937","Sorafenib and Transarterial Chemoembolization for Hepatocellular Carcinoma",[86,87],[846],[6658],{"trials":6673,"activeCount":98},[],{"trials":6675,"activeCount":98},[],{"trials":6677,"activeCount":98},[],{"intervention":6679,"totalTrials":137,"cells":6680},"SAUERSTOFF",{"EARLY_PHASE1":6681,"PHASE1":6683,"PHASE2":6685,"PHASE3":6697,"PHASE4":6699,"NA":6701},{"trials":6682,"activeCount":98},[],{"trials":6684,"activeCount":98},[],{"trials":6686,"activeCount":98},[6687],{"nctId":6688,"briefTitle":6689,"status":108,"phases":6690,"primaryCompletion":127,"completion":127,"start":6691,"enrollment":6692,"conditions":6693,"interventions":6695},"NCT04094285","The Effect of Hyperoxia and Hypoxia on Fluorescence Lifetime Imaging Ophthalmoscopy in Healthy Subjects- a Randomized, Double Blind, Crossover Study",[87],"2019-10-24",48,[6694],"To Investigate the Effect of 100% Oxygen Breathing on Fluorescence Lifetime Imaging Ophthalmoscopy (FLIO) in Healthy Subjects",[6679,6696],"STICKSTOFF",{"trials":6698,"activeCount":98},[],{"trials":6700,"activeCount":98},[],{"trials":6702,"activeCount":98},[],{"intervention":6696,"totalTrials":137,"cells":6704},{"EARLY_PHASE1":6705,"PHASE1":6707,"PHASE2":6709,"PHASE3":6715,"PHASE4":6717,"NA":6719},{"trials":6706,"activeCount":98},[],{"trials":6708,"activeCount":98},[],{"trials":6710,"activeCount":98},[6711],{"nctId":6688,"briefTitle":6689,"status":108,"phases":6712,"primaryCompletion":127,"completion":127,"start":6691,"enrollment":6692,"conditions":6713,"interventions":6714},[87],[6694],[6679,6696],{"trials":6716,"activeCount":98},[],{"trials":6718,"activeCount":98},[],{"trials":6720,"activeCount":98},[],{"intervention":6722,"totalTrials":137,"cells":6723},"TBE virus vaccine",{"EARLY_PHASE1":6724,"PHASE1":6726,"PHASE2":6728,"PHASE3":6737,"PHASE4":6739,"NA":6741},{"trials":6725,"activeCount":98},[],{"trials":6727,"activeCount":98},[],{"trials":6729,"activeCount":98},[6730],{"nctId":6731,"briefTitle":6732,"status":108,"phases":6733,"primaryCompletion":6734,"completion":6734,"start":873,"enrollment":2121,"conditions":6735,"interventions":6736},"NCT01991067","Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients",[87],"2018-10-28",[2746],[6722],{"trials":6738,"activeCount":98},[],{"trials":6740,"activeCount":98},[],{"trials":6742,"activeCount":98},[],{"intervention":6744,"totalTrials":137,"cells":6745},"Ad26COVS1",{"EARLY_PHASE1":6746,"PHASE1":6748,"PHASE2":6750,"PHASE3":6763,"PHASE4":6765,"NA":6767},{"trials":6747,"activeCount":98},[],{"trials":6749,"activeCount":98},[],{"trials":6751,"activeCount":98},[6752],{"nctId":6753,"briefTitle":6754,"status":1092,"phases":6755,"primaryCompletion":6756,"completion":1221,"start":6757,"enrollment":569,"conditions":6758,"interventions":6759},"NCT05324319","Homologous vs Heterologous Third Vaccination in Kidney Transplant Recipients Kidney Transplant Recipients",[87],"2022-07-31","2021-06-15",[2316],[6744,6760,6761,6762],"ChAdOx1 SARS2 Vaccine","BNT162B2","mRNA-1273",{"trials":6764,"activeCount":98},[],{"trials":6766,"activeCount":98},[],{"trials":6768,"activeCount":98},[],{"intervention":6760,"totalTrials":137,"cells":6770},{"EARLY_PHASE1":6771,"PHASE1":6773,"PHASE2":6775,"PHASE3":6781,"PHASE4":6783,"NA":6785},{"trials":6772,"activeCount":98},[],{"trials":6774,"activeCount":98},[],{"trials":6776,"activeCount":98},[6777],{"nctId":6753,"briefTitle":6754,"status":1092,"phases":6778,"primaryCompletion":6756,"completion":1221,"start":6757,"enrollment":569,"conditions":6779,"interventions":6780},[87],[2316],[6744,6760,6761,6762],{"trials":6782,"activeCount":98},[],{"trials":6784,"activeCount":98},[],{"trials":6786,"activeCount":98},[],{"intervention":6761,"totalTrials":137,"cells":6788},{"EARLY_PHASE1":6789,"PHASE1":6791,"PHASE2":6793,"PHASE3":6799,"PHASE4":6801,"NA":6803},{"trials":6790,"activeCount":98},[],{"trials":6792,"activeCount":98},[],{"trials":6794,"activeCount":98},[6795],{"nctId":6753,"briefTitle":6754,"status":1092,"phases":6796,"primaryCompletion":6756,"completion":1221,"start":6757,"enrollment":569,"conditions":6797,"interventions":6798},[87],[2316],[6744,6760,6761,6762],{"trials":6800,"activeCount":98},[],{"trials":6802,"activeCount":98},[],{"trials":6804,"activeCount":98},[],{"intervention":6762,"totalTrials":137,"cells":6806},{"EARLY_PHASE1":6807,"PHASE1":6809,"PHASE2":6811,"PHASE3":6817,"PHASE4":6819,"NA":6821},{"trials":6808,"activeCount":98},[],{"trials":6810,"activeCount":98},[],{"trials":6812,"activeCount":98},[6813],{"nctId":6753,"briefTitle":6754,"status":1092,"phases":6814,"primaryCompletion":6756,"completion":1221,"start":6757,"enrollment":569,"conditions":6815,"interventions":6816},[87],[2316],[6744,6760,6761,6762],{"trials":6818,"activeCount":98},[],{"trials":6820,"activeCount":98},[],{"trials":6822,"activeCount":98},[],{"intervention":6824,"totalTrials":137,"cells":6825},"Intravitreal dexamethasone and intravitreal ranibizumab",{"EARLY_PHASE1":6826,"PHASE1":6828,"PHASE2":6830,"PHASE3":6841,"PHASE4":6843,"NA":6845},{"trials":6827,"activeCount":98},[],{"trials":6829,"activeCount":98},[],{"trials":6831,"activeCount":98},[6832],{"nctId":6833,"briefTitle":6834,"status":108,"phases":6835,"primaryCompletion":2863,"completion":1785,"start":2458,"enrollment":112,"conditions":6836,"interventions":6839},"NCT01162746","Comparison of Ranibizumab Monotherapy and Ranibizumab Combination Therapies in Recurrent or Persistent Choroidal Neovascularization Secondary to Age-related Macular Degeneration",[87],[6837,6838],"Age-Related Macular Degeneration","Neovascularization, Choroidal",[6824,6840],"Intravitreal ranibizumab",{"trials":6842,"activeCount":98},[],{"trials":6844,"activeCount":98},[],{"trials":6846,"activeCount":98},[],{"intervention":6840,"totalTrials":137,"cells":6848},{"EARLY_PHASE1":6849,"PHASE1":6851,"PHASE2":6853,"PHASE3":6859,"PHASE4":6861,"NA":6863},{"trials":6850,"activeCount":98},[],{"trials":6852,"activeCount":98},[],{"trials":6854,"activeCount":98},[6855],{"nctId":6833,"briefTitle":6834,"status":108,"phases":6856,"primaryCompletion":2863,"completion":1785,"start":2458,"enrollment":112,"conditions":6857,"interventions":6858},[87],[6837,6838],[6824,6840],{"trials":6860,"activeCount":98},[],{"trials":6862,"activeCount":98},[],{"trials":6864,"activeCount":98},[],{"intervention":6866,"totalTrials":137,"cells":6867},"Methylphenidate modified release",{"EARLY_PHASE1":6868,"PHASE1":6870,"PHASE2":6872,"PHASE3":6884,"PHASE4":6886,"NA":6888},{"trials":6869,"activeCount":98},[],{"trials":6871,"activeCount":98},[],{"trials":6873,"activeCount":98},[6874],{"nctId":6875,"briefTitle":6876,"status":1092,"phases":6877,"primaryCompletion":1936,"completion":1936,"start":2036,"enrollment":6878,"conditions":6879,"interventions":6882},"NCT01879202","Methylphenidate as Treatment Option of Fatigue in Multiple Sclerosis",[87],96,[6880,6881],"Multiple Sclerosis","Fatigue",[6866,6883],"Maltodextrin",{"trials":6885,"activeCount":98},[],{"trials":6887,"activeCount":98},[],{"trials":6889,"activeCount":98},[],{"intervention":6883,"totalTrials":137,"cells":6891},{"EARLY_PHASE1":6892,"PHASE1":6894,"PHASE2":6896,"PHASE3":6902,"PHASE4":6904,"NA":6906},{"trials":6893,"activeCount":98},[],{"trials":6895,"activeCount":98},[],{"trials":6897,"activeCount":98},[6898],{"nctId":6875,"briefTitle":6876,"status":1092,"phases":6899,"primaryCompletion":1936,"completion":1936,"start":2036,"enrollment":6878,"conditions":6900,"interventions":6901},[87],[6880,6881],[6866,6883],{"trials":6903,"activeCount":98},[],{"trials":6905,"activeCount":98},[],{"trials":6907,"activeCount":98},[],{"intervention":6909,"totalTrials":137,"cells":6910},"Gentamicin Ophthalmic",{"EARLY_PHASE1":6911,"PHASE1":6913,"PHASE2":6915,"PHASE3":6929,"PHASE4":6931,"NA":6933},{"trials":6912,"activeCount":98},[],{"trials":6914,"activeCount":98},[],{"trials":6916,"activeCount":98},[6917],{"nctId":6918,"briefTitle":6919,"status":108,"phases":6920,"primaryCompletion":6921,"completion":6921,"start":6922,"enrollment":476,"conditions":6923,"interventions":6925},"NCT05287425","The Effect of Antibiotic Eye Drops on the Nasal Microbiome in Healthy Subjects",[87],"2023-08-28","2019-08-12",[6924],"Nasal and Pharyngeal Microbiome",[6909,6926,6927,6928],"Ciprofloxacin Ophthalmic","Povidone Ophthalmic","Povidone and Benzalkonium Chloride Ophthalmic",{"trials":6930,"activeCount":98},[],{"trials":6932,"activeCount":98},[],{"trials":6934,"activeCount":98},[],{"intervention":6926,"totalTrials":137,"cells":6936},{"EARLY_PHASE1":6937,"PHASE1":6939,"PHASE2":6941,"PHASE3":6947,"PHASE4":6949,"NA":6951},{"trials":6938,"activeCount":98},[],{"trials":6940,"activeCount":98},[],{"trials":6942,"activeCount":98},[6943],{"nctId":6918,"briefTitle":6919,"status":108,"phases":6944,"primaryCompletion":6921,"completion":6921,"start":6922,"enrollment":476,"conditions":6945,"interventions":6946},[87],[6924],[6909,6926,6927,6928],{"trials":6948,"activeCount":98},[],{"trials":6950,"activeCount":98},[],{"trials":6952,"activeCount":98},[],{"intervention":6927,"totalTrials":137,"cells":6954},{"EARLY_PHASE1":6955,"PHASE1":6957,"PHASE2":6959,"PHASE3":6965,"PHASE4":6967,"NA":6969},{"trials":6956,"activeCount":98},[],{"trials":6958,"activeCount":98},[],{"trials":6960,"activeCount":98},[6961],{"nctId":6918,"briefTitle":6919,"status":108,"phases":6962,"primaryCompletion":6921,"completion":6921,"start":6922,"enrollment":476,"conditions":6963,"interventions":6964},[87],[6924],[6909,6926,6927,6928],{"trials":6966,"activeCount":98},[],{"trials":6968,"activeCount":98},[],{"trials":6970,"activeCount":98},[],{"intervention":6928,"totalTrials":137,"cells":6972},{"EARLY_PHASE1":6973,"PHASE1":6975,"PHASE2":6977,"PHASE3":6983,"PHASE4":6985,"NA":6987},{"trials":6974,"activeCount":98},[],{"trials":6976,"activeCount":98},[],{"trials":6978,"activeCount":98},[6979],{"nctId":6918,"briefTitle":6919,"status":108,"phases":6980,"primaryCompletion":6921,"completion":6921,"start":6922,"enrollment":476,"conditions":6981,"interventions":6982},[87],[6924],[6909,6926,6927,6928],{"trials":6984,"activeCount":98},[],{"trials":6986,"activeCount":98},[],{"trials":6988,"activeCount":98},[],{"intervention":6990,"totalTrials":137,"cells":6991},"Ofatumumab",{"EARLY_PHASE1":6992,"PHASE1":6994,"PHASE2":6996,"PHASE3":7007,"PHASE4":7009,"NA":7011},{"trials":6993,"activeCount":98},[],{"trials":6995,"activeCount":98},[],{"trials":6997,"activeCount":98},[6998],{"nctId":6999,"briefTitle":7000,"status":108,"phases":7001,"primaryCompletion":2432,"completion":1973,"start":2887,"enrollment":486,"conditions":7002,"interventions":7005},"NCT01376713","Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma",[87],[7003,7004],"Stage III Melanoma","Stage IV Melanoma",[6990,7006],"Ofatumumab plus Dacarbazine",{"trials":7008,"activeCount":98},[],{"trials":7010,"activeCount":98},[],{"trials":7012,"activeCount":98},[],{"intervention":7006,"totalTrials":137,"cells":7014},{"EARLY_PHASE1":7015,"PHASE1":7017,"PHASE2":7019,"PHASE3":7025,"PHASE4":7027,"NA":7029},{"trials":7016,"activeCount":98},[],{"trials":7018,"activeCount":98},[],{"trials":7020,"activeCount":98},[7021],{"nctId":6999,"briefTitle":7000,"status":108,"phases":7022,"primaryCompletion":2432,"completion":1973,"start":2887,"enrollment":486,"conditions":7023,"interventions":7024},[87],[7003,7004],[6990,7006],{"trials":7026,"activeCount":98},[],{"trials":7028,"activeCount":98},[],{"trials":7030,"activeCount":98},[],{"intervention":7032,"totalTrials":137,"cells":7033},"Clazakizumab \u002F Clazakizumab",{"EARLY_PHASE1":7034,"PHASE1":7036,"PHASE2":7038,"PHASE3":7048,"PHASE4":7050,"NA":7052},{"trials":7035,"activeCount":98},[],{"trials":7037,"activeCount":98},[],{"trials":7039,"activeCount":98},[7040],{"nctId":7041,"briefTitle":7042,"status":108,"phases":7043,"primaryCompletion":7044,"completion":7044,"start":7045,"enrollment":476,"conditions":7046,"interventions":7047},"NCT03444103","A Pilot Trial of Clazakizumab in Late ABMR",[87],"2020-06-30","2018-01-16",[6296],[7032],{"trials":7049,"activeCount":98},[],{"trials":7051,"activeCount":98},[],{"trials":7053,"activeCount":98},[],{"intervention":1901,"totalTrials":137,"cells":7055},{"EARLY_PHASE1":7056,"PHASE1":7058,"PHASE2":7060,"PHASE3":7066,"PHASE4":7068,"NA":7070},{"trials":7057,"activeCount":98},[],{"trials":7059,"activeCount":98},[],{"trials":7061,"activeCount":98},[7062],{"nctId":1892,"briefTitle":1893,"status":108,"phases":7063,"primaryCompletion":1895,"completion":1895,"start":1854,"enrollment":1896,"conditions":7064,"interventions":7065},[87],[1898],[1900,1883,1901],{"trials":7067,"activeCount":98},[],{"trials":7069,"activeCount":98},[],{"trials":7071,"activeCount":98},[],{"intervention":7073,"totalTrials":137,"cells":7074},"Lenalidomide",{"EARLY_PHASE1":7075,"PHASE1":7077,"PHASE2":7079,"PHASE3":7087,"PHASE4":7089,"NA":7091},{"trials":7076,"activeCount":98},[],{"trials":7078,"activeCount":98},[],{"trials":7080,"activeCount":98},[7081],{"nctId":7082,"briefTitle":7083,"status":1092,"phases":7084,"primaryCompletion":2887,"completion":2887,"start":1094,"enrollment":547,"conditions":7085,"interventions":7086},"NCT00923663","Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type",[87],[6286],[7073],{"trials":7088,"activeCount":98},[],{"trials":7090,"activeCount":98},[],{"trials":7092,"activeCount":98},[],{"intervention":7094,"totalTrials":137,"cells":7095},"Anidulafungin",{"EARLY_PHASE1":7096,"PHASE1":7098,"PHASE2":7100,"PHASE3":7111,"PHASE4":7113,"NA":7115},{"trials":7097,"activeCount":98},[],{"trials":7099,"activeCount":98},[],{"trials":7101,"activeCount":98},[7102],{"nctId":7103,"briefTitle":7104,"status":1092,"phases":7105,"primaryCompletion":1114,"start":7106,"enrollment":486,"conditions":7107,"interventions":7110},"NCT00892359","Anidulafungin During Continuous Venovenous Hemofiltration (CVVHF)",[87],"2009-04",[7108,7109],"Acute Renal Failure","Infection",[7094],{"trials":7112,"activeCount":98},[],{"trials":7114,"activeCount":98},[],{"trials":7116,"activeCount":98},[],{"intervention":7118,"totalTrials":137,"cells":7119},"rMal d 1",{"EARLY_PHASE1":7120,"PHASE1":7122,"PHASE2":7124,"PHASE3":7138,"PHASE4":7140,"NA":7142},{"trials":7121,"activeCount":98},[],{"trials":7123,"activeCount":98},[],{"trials":7125,"activeCount":98},[7126],{"nctId":7127,"briefTitle":7128,"status":108,"phases":7129,"primaryCompletion":7130,"completion":7131,"start":7132,"enrollment":949,"conditions":7133,"interventions":7136},"NCT01449786","Sublingual Immunotherapy of Birch Pollen Associated Apple Allergy",[87],"2014-02-28","2016-12-20","2012-03-14",[7134,7135],"Birch Pollen Related Apple Allergy","Birch Pollen Allergy",[7118,7137],"rBet v 1",{"trials":7139,"activeCount":98},[],{"trials":7141,"activeCount":98},[],{"trials":7143,"activeCount":98},[],{"intervention":7137,"totalTrials":137,"cells":7145},{"EARLY_PHASE1":7146,"PHASE1":7148,"PHASE2":7150,"PHASE3":7156,"PHASE4":7158,"NA":7160},{"trials":7147,"activeCount":98},[],{"trials":7149,"activeCount":98},[],{"trials":7151,"activeCount":98},[7152],{"nctId":7127,"briefTitle":7128,"status":108,"phases":7153,"primaryCompletion":7130,"completion":7131,"start":7132,"enrollment":949,"conditions":7154,"interventions":7155},[87],[7134,7135],[7118,7137],{"trials":7157,"activeCount":98},[],{"trials":7159,"activeCount":98},[],{"trials":7161,"activeCount":98},[],{"intervention":1166,"totalTrials":137,"cells":7163},{"EARLY_PHASE1":7164,"PHASE1":7166,"PHASE2":7168,"PHASE3":7174,"PHASE4":7176,"NA":7178},{"trials":7165,"activeCount":98},[],{"trials":7167,"activeCount":98},[],{"trials":7169,"activeCount":98},[7170],{"nctId":1158,"briefTitle":1159,"status":108,"phases":7171,"primaryCompletion":1161,"completion":1161,"start":1046,"enrollment":1162,"conditions":7172,"interventions":7173},[86,87],[1164],[1149,1166],{"trials":7175,"activeCount":98},[],{"trials":7177,"activeCount":98},[],{"trials":7179,"activeCount":98},[],{"intervention":7181,"totalTrials":137,"cells":7182},"Azithromycin + Artesunate",{"EARLY_PHASE1":7183,"PHASE1":7185,"PHASE2":7187,"PHASE3":7196,"PHASE4":7198,"NA":7200},{"trials":7184,"activeCount":98},[],{"trials":7186,"activeCount":98},[],{"trials":7188,"activeCount":98},[7189],{"nctId":7190,"briefTitle":7191,"status":108,"phases":7192,"primaryCompletion":1908,"completion":1908,"start":1172,"enrollment":2289,"conditions":7193,"interventions":7195},"NCT01374126","Azithromycin Combination Therapy for the Treatment of Severe Malaria",[87],[7194],"Falciparum Malaria",[6585,7181],{"trials":7197,"activeCount":98},[],{"trials":7199,"activeCount":98},[],{"trials":7201,"activeCount":98},[],{"intervention":7203,"totalTrials":137,"cells":7204},"Inhaled nitric oxide",{"EARLY_PHASE1":7205,"PHASE1":7207,"PHASE2":7209,"PHASE3":7219,"PHASE4":7221,"NA":7223},{"trials":7206,"activeCount":98},[],{"trials":7208,"activeCount":98},[],{"trials":7210,"activeCount":98},[7211],{"nctId":7212,"briefTitle":7213,"status":108,"phases":7214,"primaryCompletion":1094,"completion":841,"start":7215,"enrollment":1061,"conditions":7216,"interventions":7218},"NCT00565253","Inhaled Nitric Oxide in Pulmonary Embolism",[87],"2005-03",[7217],"Pulmonary Embolism",[7203],{"trials":7220,"activeCount":98},[],{"trials":7222,"activeCount":98},[],{"trials":7224,"activeCount":98},[],{"intervention":7226,"totalTrials":137,"cells":7227},"Silibinin",{"EARLY_PHASE1":7228,"PHASE1":7230,"PHASE2":7232,"PHASE3":7242,"PHASE4":7244,"NA":7246},{"trials":7229,"activeCount":98},[],{"trials":7231,"activeCount":98},[],{"trials":7233,"activeCount":98},[7234],{"nctId":7235,"briefTitle":7236,"status":108,"phases":7237,"primaryCompletion":7238,"completion":2887,"start":874,"enrollment":4036,"conditions":7239,"interventions":7241},"NCT00684268","Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders",[87],"2011-02",[7240],"Hepatitis C",[7226,7226],{"trials":7243,"activeCount":98},[],{"trials":7245,"activeCount":98},[],{"trials":7247,"activeCount":98},[],{"intervention":6405,"totalTrials":137,"cells":7249},{"EARLY_PHASE1":7250,"PHASE1":7252,"PHASE2":7254,"PHASE3":7260,"PHASE4":7262,"NA":7264},{"trials":7251,"activeCount":98},[],{"trials":7253,"activeCount":98},[],{"trials":7255,"activeCount":98},[7256],{"nctId":6398,"briefTitle":6399,"status":1092,"phases":7257,"primaryCompletion":2193,"completion":2193,"start":6401,"enrollment":949,"conditions":7258,"interventions":7259},[87],[6403],[6381,6405],{"trials":7261,"activeCount":98},[],{"trials":7263,"activeCount":98},[],{"trials":7265,"activeCount":98},[],{"intervention":4933,"totalTrials":137,"cells":7267},{"EARLY_PHASE1":7268,"PHASE1":7270,"PHASE2":7272,"PHASE3":7278,"PHASE4":7280,"NA":7282},{"trials":7269,"activeCount":98},[],{"trials":7271,"activeCount":98},[],{"trials":7273,"activeCount":98},[7274],{"nctId":4928,"briefTitle":4929,"status":108,"phases":7275,"completion":2371,"start":3638,"enrollment":547,"conditions":7276,"interventions":7277},[87],[1940],[4910,4933],{"trials":7279,"activeCount":98},[],{"trials":7281,"activeCount":98},[],{"trials":7283,"activeCount":98},[],{"intervention":7285,"totalTrials":137,"cells":7286},"Dapagliflozin 10 MG",{"EARLY_PHASE1":7287,"PHASE1":7289,"PHASE2":7291,"PHASE3":7304,"PHASE4":7306,"NA":7308},{"trials":7288,"activeCount":98},[],{"trials":7290,"activeCount":98},[],{"trials":7292,"activeCount":98},[7293],{"nctId":7294,"briefTitle":7295,"status":108,"phases":7296,"primaryCompletion":7297,"completion":7298,"start":1141,"enrollment":6098,"conditions":7299,"interventions":7303},"NCT05179668","SGLT2 Inhibition in Hemodialysis",[87],"2025-07-11","2026-02-28",[7300,7301,3290,2337,7302],"Kidney Failure","Hemodialysis","Left Ventricular Hypertrophy",[7285],{"trials":7305,"activeCount":98},[],{"trials":7307,"activeCount":98},[],{"trials":7309,"activeCount":98},[],{"intervention":6343,"totalTrials":137,"cells":7311},{"EARLY_PHASE1":7312,"PHASE1":7314,"PHASE2":7316,"PHASE3":7322,"PHASE4":7324,"NA":7326},{"trials":7313,"activeCount":98},[],{"trials":7315,"activeCount":98},[],{"trials":7317,"activeCount":98},[7318],{"nctId":6334,"briefTitle":6335,"status":108,"phases":7319,"primaryCompletion":6337,"completion":6337,"start":6338,"enrollment":6339,"conditions":7320,"interventions":7321},[87],[6341],[6343,6316],{"trials":7323,"activeCount":98},[],{"trials":7325,"activeCount":98},[],{"trials":7327,"activeCount":98},[],{"intervention":7329,"totalTrials":137,"cells":7330},"progesterone",{"EARLY_PHASE1":7331,"PHASE1":7333,"PHASE2":7335,"PHASE3":7344,"PHASE4":7346,"NA":7348},{"trials":7332,"activeCount":98},[],{"trials":7334,"activeCount":98},[],{"trials":7336,"activeCount":98},[7337],{"nctId":7338,"briefTitle":7339,"status":108,"phases":7340,"primaryCompletion":7106,"completion":1114,"start":7341,"enrollment":112,"conditions":7342,"interventions":7343},"NCT00247169","Vaginal Progesterone in the Treatment of Cervical Dysplasia Grade I and II",[87],"2004-08",[6008],[7329],{"trials":7345,"activeCount":98},[],{"trials":7347,"activeCount":98},[],{"trials":7349,"activeCount":98},[],{"intervention":7351,"totalTrials":137,"cells":7352},"Dronabinol 5 MG",{"EARLY_PHASE1":7353,"PHASE1":7355,"PHASE2":7357,"PHASE3":7369,"PHASE4":7371,"NA":7373},{"trials":7354,"activeCount":98},[],{"trials":7356,"activeCount":98},[],{"trials":7358,"activeCount":98},[7359],{"nctId":7360,"briefTitle":7361,"status":108,"phases":7362,"primaryCompletion":7363,"completion":7363,"start":7364,"enrollment":7365,"conditions":7366,"interventions":7367},"NCT04596826","The Effect of Dronabinol on Ocular Hemodynamics in Patients With Primary Open Angle Glaucoma",[87],"2024-10-02","2020-11-11",51,[4742],[7351,7368],"Dronabinol 10 MG",{"trials":7370,"activeCount":98},[],{"trials":7372,"activeCount":98},[],{"trials":7374,"activeCount":98},[],{"intervention":7368,"totalTrials":137,"cells":7376},{"EARLY_PHASE1":7377,"PHASE1":7379,"PHASE2":7381,"PHASE3":7387,"PHASE4":7389,"NA":7391},{"trials":7378,"activeCount":98},[],{"trials":7380,"activeCount":98},[],{"trials":7382,"activeCount":98},[7383],{"nctId":7360,"briefTitle":7361,"status":108,"phases":7384,"primaryCompletion":7363,"completion":7363,"start":7364,"enrollment":7365,"conditions":7385,"interventions":7386},[87],[4742],[7351,7368],{"trials":7388,"activeCount":98},[],{"trials":7390,"activeCount":98},[],{"trials":7392,"activeCount":98},[],{"intervention":7394,"totalTrials":137,"cells":7395},"Aspirin 500Mg Tab",{"EARLY_PHASE1":7396,"PHASE1":7398,"PHASE2":7400,"PHASE3":7410,"PHASE4":7412,"NA":7414},{"trials":7397,"activeCount":98},[],{"trials":7399,"activeCount":98},[],{"trials":7401,"activeCount":98},[7402],{"nctId":7403,"briefTitle":7404,"status":108,"phases":7405,"primaryCompletion":7406,"completion":7406,"start":7407,"enrollment":844,"conditions":7408,"interventions":7409},"NCT05775536","Detection of Acetylsalicylic Acid and Omega-3 Fatty Acids in Schirmers' Test Strips Using Mass Spectrometry",[87],"2021-11-30","2021-01-21",[3082],[7394],{"trials":7411,"activeCount":98},[],{"trials":7413,"activeCount":98},[],{"trials":7415,"activeCount":98},[],{"intervention":7417,"totalTrials":137,"cells":7418},"Empagliflozin 10 mg",{"EARLY_PHASE1":7419,"PHASE1":7421,"PHASE2":7423,"PHASE3":7435,"PHASE4":7437,"NA":7439},{"trials":7420,"activeCount":98},[],{"trials":7422,"activeCount":98},[],{"trials":7424,"activeCount":98},[7425],{"nctId":7426,"briefTitle":7427,"status":108,"phases":7428,"primaryCompletion":7429,"completion":7430,"start":7431,"enrollment":547,"conditions":7432,"interventions":7434},"NCT03113110","Empagliflozin in Post-Transplantation Diabetes Mellitus",[87],"2017-06-13","2018-05-31","2017-01-15",[7433],"Posttransplant Diabetes Mellitus",[7417],{"trials":7436,"activeCount":98},[],{"trials":7438,"activeCount":98},[],{"trials":7440,"activeCount":98},[],{"intervention":7442,"totalTrials":137,"cells":7443},"Endothelin-1",{"EARLY_PHASE1":7444,"PHASE1":7446,"PHASE2":7448,"PHASE3":7458,"PHASE4":7460,"NA":7462},{"trials":7445,"activeCount":98},[],{"trials":7447,"activeCount":98},[],{"trials":7449,"activeCount":98},[7450],{"nctId":7451,"briefTitle":7452,"status":2011,"phases":7453,"primaryCompletion":3211,"completion":3211,"start":1865,"enrollment":98,"conditions":7454,"interventions":7455},"NCT00406731","Role of Endothelin- and Nitric Oxide-system in the Regulation of Optic Nerve Head Blood Flow During Changes in Ocular Perfusion Pressure",[87],[21,4186,18],[7456,7442,7457],"NG-monomethyl-L-arginine","Physiologic saline solution",{"trials":7459,"activeCount":98},[],{"trials":7461,"activeCount":98},[],{"trials":7463,"activeCount":98},[],{"intervention":7465,"totalTrials":137,"cells":7466},"Vildagliptin",{"EARLY_PHASE1":7467,"PHASE1":7469,"PHASE2":7471,"PHASE3":7479,"PHASE4":7481,"NA":7483},{"trials":7468,"activeCount":98},[],{"trials":7470,"activeCount":98},[],{"trials":7472,"activeCount":98},[7473],{"nctId":7474,"briefTitle":7475,"status":108,"phases":7476,"primaryCompletion":4985,"completion":2036,"start":1095,"enrollment":844,"conditions":7477,"interventions":7478},"NCT00980356","Vildagliptin in New Onset Diabetes After Transplantation",[87],[5985],[7465],{"trials":7480,"activeCount":98},[],{"trials":7482,"activeCount":98},[],{"trials":7484,"activeCount":98},[],{"intervention":7486,"totalTrials":137,"cells":7487},"Imiquimod",{"EARLY_PHASE1":7488,"PHASE1":7490,"PHASE2":7492,"PHASE3":7501,"PHASE4":7503,"NA":7505},{"trials":7489,"activeCount":98},[],{"trials":7491,"activeCount":98},[],{"trials":7493,"activeCount":98},[7494],{"nctId":7495,"briefTitle":7496,"status":108,"phases":7497,"primaryCompletion":841,"completion":3286,"start":2840,"enrollment":828,"conditions":7498,"interventions":7500},"NCT00941811","Immunevasion of Human Papillomavirus (HPV) in Vulvar Intraepithelial Neoplasia 2\u002F3 and Anogenital Warts and Efficiency and Mechanisms of Imiquimod Treatment",[87],[7499],"HPV",[7486],{"trials":7502,"activeCount":98},[],{"trials":7504,"activeCount":98},[],{"trials":7506,"activeCount":98},[],{"intervention":7508,"totalTrials":137,"cells":7509},"Calcium and vitamin D",{"EARLY_PHASE1":7510,"PHASE1":7512,"PHASE2":7514,"PHASE3":7523,"PHASE4":7525,"NA":7527},{"trials":7511,"activeCount":98},[],{"trials":7513,"activeCount":98},[],{"trials":7515,"activeCount":98},[7516],{"nctId":7517,"briefTitle":7518,"status":1092,"phases":7519,"primaryCompletion":1924,"completion":1924,"start":1095,"enrollment":590,"conditions":7520,"interventions":7522},"NCT00973336","Primary Hyperparathyroidism: Does a Systematic Treatment Improve the Calcium and Bone Metabolism After Surgery?",[87],[3532,7521],"Bone Metabolism",[7508],{"trials":7524,"activeCount":98},[],{"trials":7526,"activeCount":98},[],{"trials":7528,"activeCount":98},[],{"intervention":7530,"totalTrials":137,"cells":7531},"Intranasal insulin administration",{"EARLY_PHASE1":7532,"PHASE1":7534,"PHASE2":7536,"PHASE3":7546,"PHASE4":7548,"NA":7550},{"trials":7533,"activeCount":98},[],{"trials":7535,"activeCount":98},[],{"trials":7537,"activeCount":98},[7538],{"nctId":7539,"briefTitle":7540,"status":1092,"phases":7541,"primaryCompletion":2389,"completion":6260,"start":2630,"enrollment":476,"conditions":7542,"interventions":7544},"NCT02164032","The Role of IntraNasal Insulin in Regulating HepaTic Lipid COntent in HUMANS",[87],[7543],"Healthy Subjects",[7530,7545],"Insulin Dilution Buffer",{"trials":7547,"activeCount":98},[],{"trials":7549,"activeCount":98},[],{"trials":7551,"activeCount":98},[],{"intervention":7545,"totalTrials":137,"cells":7553},{"EARLY_PHASE1":7554,"PHASE1":7556,"PHASE2":7558,"PHASE3":7564,"PHASE4":7566,"NA":7568},{"trials":7555,"activeCount":98},[],{"trials":7557,"activeCount":98},[],{"trials":7559,"activeCount":98},[7560],{"nctId":7539,"briefTitle":7540,"status":1092,"phases":7561,"primaryCompletion":2389,"completion":6260,"start":2630,"enrollment":476,"conditions":7562,"interventions":7563},[87],[7543],[7530,7545],{"trials":7565,"activeCount":98},[],{"trials":7567,"activeCount":98},[],{"trials":7569,"activeCount":98},[],{"intervention":7571,"totalTrials":137,"cells":7572},"Neoadjuvant chemotherapy with FOLFOXIRI + bevacizumab",{"EARLY_PHASE1":7573,"PHASE1":7575,"PHASE2":7577,"PHASE3":7589,"PHASE4":7591,"NA":7593},{"trials":7574,"activeCount":98},[],{"trials":7576,"activeCount":98},[],{"trials":7578,"activeCount":98},[7579],{"nctId":7580,"briefTitle":7581,"status":1092,"phases":7582,"primaryCompletion":7583,"completion":7584,"start":1046,"enrollment":1061,"conditions":7585,"interventions":7588},"NCT02591667","Histopathological Response to FOLFOXIRI + Bevacizumab in Peritoneal Metastasis From Colorectal Cancer",[87],"2019-02","2020-02",[7586,7587],"Colorectal Cancer","Peritoneal Metastasis",[7571],{"trials":7590,"activeCount":98},[],{"trials":7592,"activeCount":98},[],{"trials":7594,"activeCount":98},[],{"intervention":7596,"totalTrials":137,"cells":7597},"Calciferol, calcium carbonate",{"EARLY_PHASE1":7598,"PHASE1":7600,"PHASE2":7602,"PHASE3":7613,"PHASE4":7615,"NA":7617},{"trials":7599,"activeCount":98},[],{"trials":7601,"activeCount":98},[],{"trials":7603,"activeCount":98},[7604],{"nctId":7605,"briefTitle":7606,"status":108,"phases":7607,"primaryCompletion":873,"completion":7608,"start":1908,"enrollment":888,"conditions":7609,"interventions":7612},"NCT01739855","Bone Metabolism After Laparoscopic Gastric Bypass Surgery (BABS)",[87],"2014-08",[7610,7611],"Evaluation of Expected Bone Loss After Bariatric Surgery","Possible Prevention of Bone Loss After Surgery by Calcium and Vitamin D Supplementation",[7596],{"trials":7614,"activeCount":98},[],{"trials":7616,"activeCount":98},[],{"trials":7618,"activeCount":98},[],{"intervention":7620,"totalTrials":137,"cells":7621},"Alpha lipoic acid",{"EARLY_PHASE1":7622,"PHASE1":7624,"PHASE2":7626,"PHASE3":7634,"PHASE4":7636,"NA":7638},{"trials":7623,"activeCount":98},[],{"trials":7625,"activeCount":98},[],{"trials":7627,"activeCount":98},[7628],{"nctId":7629,"briefTitle":7630,"status":108,"phases":7631,"completion":6579,"start":2288,"enrollment":1061,"conditions":7632,"interventions":7633},"NCT00490867","Effect of Long Term α-Lipoic Acid Treatment on Endothelial Function in Patients With Type 2 Diabetes",[87],[2107],[7620],{"trials":7635,"activeCount":98},[],{"trials":7637,"activeCount":98},[],{"trials":7639,"activeCount":98},[],{"intervention":7641,"totalTrials":137,"cells":7642},"NiMODipine Injectable Solution",{"EARLY_PHASE1":7643,"PHASE1":7645,"PHASE2":7647,"PHASE3":7658,"PHASE4":7660,"NA":7662},{"trials":7644,"activeCount":98},[],{"trials":7646,"activeCount":98},[],{"trials":7648,"activeCount":98},[7649],{"nctId":7650,"briefTitle":7651,"status":1092,"phases":7652,"primaryCompletion":7653,"completion":7653,"start":7654,"enrollment":1061,"conditions":7655,"interventions":7657},"NCT04801953","Nimodipine in Vestibular Schwanommas",[87],"2024-04-09","2021-05-04",[7656],"Vestibular Schwannoma",[7641],{"trials":7659,"activeCount":98},[],{"trials":7661,"activeCount":98},[],{"trials":7663,"activeCount":98},[],{"intervention":7665,"totalTrials":137,"cells":7666},"Empagliflozin 10 MG [Jardiance]",{"EARLY_PHASE1":7667,"PHASE1":7669,"PHASE2":7671,"PHASE3":7685,"PHASE4":7687,"NA":7689},{"trials":7668,"activeCount":98},[],{"trials":7670,"activeCount":98},[],{"trials":7672,"activeCount":98},[7673],{"nctId":7674,"briefTitle":7675,"status":108,"phases":7676,"primaryCompletion":7677,"completion":7678,"start":7679,"enrollment":7365,"conditions":7680,"interventions":7684},"NCT03078101","EMPRA (EMPagliflozin and RAs in Kidney Disease)",[87],"2019-06-18","2019-08-07","2017-04-15",[7681,3290,7682,7683],"Diabetic Kidney Disease","Chronic Kidney Disease stage3","Chronic Kidney Disease stage4",[7665],{"trials":7686,"activeCount":98},[],{"trials":7688,"activeCount":98},[],{"trials":7690,"activeCount":98},[],{"intervention":1176,"totalTrials":137,"cells":7692},{"EARLY_PHASE1":7693,"PHASE1":7695,"PHASE2":7697,"PHASE3":7703,"PHASE4":7705,"NA":7707},{"trials":7694,"activeCount":98},[],{"trials":7696,"activeCount":98},[],{"trials":7698,"activeCount":98},[7699],{"nctId":1168,"briefTitle":1169,"status":1092,"phases":7700,"primaryCompletion":1171,"completion":1172,"start":1132,"enrollment":949,"conditions":7701,"interventions":7702},[87],[1174],[1176,1149,1149],{"trials":7704,"activeCount":98},[],{"trials":7706,"activeCount":98},[],{"trials":7708,"activeCount":98},[],{"intervention":7710,"totalTrials":137,"cells":7711},"Thalidomide, Pharmion",{"EARLY_PHASE1":7712,"PHASE1":7714,"PHASE2":7716,"PHASE3":7724,"PHASE4":7726,"NA":7728},{"trials":7713,"activeCount":98},[],{"trials":7715,"activeCount":98},[],{"trials":7717,"activeCount":98},[7718],{"nctId":7719,"briefTitle":7720,"status":108,"phases":7721,"primaryCompletion":1096,"completion":1096,"start":2287,"enrollment":5269,"conditions":7722,"interventions":7723},"NCT00373646","Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients",[87],[6286],[7710],{"trials":7725,"activeCount":98},[],{"trials":7727,"activeCount":98},[],{"trials":7729,"activeCount":98},[],{"intervention":7731,"totalTrials":137,"cells":7732},"Landiolol",{"EARLY_PHASE1":7733,"PHASE1":7735,"PHASE2":7737,"PHASE3":7749,"PHASE4":7751,"NA":7753},{"trials":7734,"activeCount":98},[],{"trials":7736,"activeCount":98},[],{"trials":7738,"activeCount":98},[7739],{"nctId":7740,"briefTitle":7741,"status":1092,"phases":7742,"primaryCompletion":7743,"completion":7743,"start":7744,"enrollment":844,"conditions":7745,"interventions":7747},"NCT05554978","Beta-blockade With Landiolol in Out-of-hospital Cardiac Arrest",[86,87],"2023-12-31","2021-03-03",[7746],"Cardiac Arrest",[7731,7748],"Sodium Chloride (NaCl) 0.9%",{"trials":7750,"activeCount":98},[],{"trials":7752,"activeCount":98},[],{"trials":7754,"activeCount":98},[],{"intervention":7748,"totalTrials":137,"cells":7756},{"EARLY_PHASE1":7757,"PHASE1":7759,"PHASE2":7761,"PHASE3":7767,"PHASE4":7769,"NA":7771},{"trials":7758,"activeCount":98},[],{"trials":7760,"activeCount":98},[],{"trials":7762,"activeCount":98},[7763],{"nctId":7740,"briefTitle":7741,"status":1092,"phases":7764,"primaryCompletion":7743,"completion":7743,"start":7744,"enrollment":844,"conditions":7765,"interventions":7766},[86,87],[7746],[7731,7748],{"trials":7768,"activeCount":98},[],{"trials":7770,"activeCount":98},[],{"trials":7772,"activeCount":98},[],{"intervention":7774,"totalTrials":137,"cells":7775},"Trastuzumab deruxtecan",{"EARLY_PHASE1":7776,"PHASE1":7778,"PHASE2":7780,"PHASE3":7790,"PHASE4":7792,"NA":7794},{"trials":7777,"activeCount":98},[],{"trials":7779,"activeCount":98},[],{"trials":7781,"activeCount":98},[7782],{"nctId":7783,"briefTitle":7784,"status":108,"phases":7785,"primaryCompletion":7786,"completion":7786,"start":7787,"enrollment":25,"conditions":7788,"interventions":7789},"NCT04752059","Phase II Study of T-DX in HER2-positive Breast Cancer Brain Metastases",[87],"2023-05-01","2020-07-28",[616],[7774],{"trials":7791,"activeCount":98},[],{"trials":7793,"activeCount":98},[],{"trials":7795,"activeCount":98},[],{"intervention":2159,"totalTrials":137,"cells":7797},{"EARLY_PHASE1":7798,"PHASE1":7800,"PHASE2":7802,"PHASE3":7808,"PHASE4":7810,"NA":7812},{"trials":7799,"activeCount":98},[],{"trials":7801,"activeCount":98},[],{"trials":7803,"activeCount":98},[7804],{"nctId":2150,"briefTitle":2151,"status":108,"phases":7805,"start":2153,"enrollment":2154,"conditions":7806,"interventions":7807},[87],[18,21],[2157,2158,2159,2141],{"trials":7809,"activeCount":98},[],{"trials":7811,"activeCount":98},[],{"trials":7813,"activeCount":98},[],{"intervention":7815,"totalTrials":137,"cells":7816},"IgM-enriched Intravenous Immunoglobulins",{"EARLY_PHASE1":7817,"PHASE1":7819,"PHASE2":7829,"PHASE3":7831,"PHASE4":7833,"NA":7835},{"trials":7818,"activeCount":98},[],{"trials":7820,"activeCount":98},[7821],{"nctId":7822,"briefTitle":7823,"status":839,"phases":7824,"primaryCompletion":7106,"completion":1171,"start":3233,"enrollment":6029,"conditions":7825,"interventions":7827},"NCT01867645","The Impact of IVIG Treatment on Critical Illness Polyneuropathy and\u002For Myopathy in Patients With MOF and SIRS\u002FSepsis",[86],[7826],"Polyneuropathies",[7815,7828],"Human Albumin",{"trials":7830,"activeCount":98},[],{"trials":7832,"activeCount":98},[],{"trials":7834,"activeCount":98},[],{"trials":7836,"activeCount":98},[],{"intervention":7828,"totalTrials":137,"cells":7838},{"EARLY_PHASE1":7839,"PHASE1":7841,"PHASE2":7847,"PHASE3":7849,"PHASE4":7851,"NA":7853},{"trials":7840,"activeCount":98},[],{"trials":7842,"activeCount":98},[7843],{"nctId":7822,"briefTitle":7823,"status":839,"phases":7844,"primaryCompletion":7106,"completion":1171,"start":3233,"enrollment":6029,"conditions":7845,"interventions":7846},[86],[7826],[7815,7828],{"trials":7848,"activeCount":98},[],{"trials":7850,"activeCount":98},[],{"trials":7852,"activeCount":98},[],{"trials":7854,"activeCount":98},[],{"intervention":6330,"totalTrials":137,"cells":7856},{"EARLY_PHASE1":7857,"PHASE1":7859,"PHASE2":7865,"PHASE3":7867,"PHASE4":7869,"NA":7871},{"trials":7858,"activeCount":98},[],{"trials":7860,"activeCount":98},[7861],{"nctId":6323,"briefTitle":6324,"status":1092,"phases":7862,"primaryCompletion":2887,"completion":2887,"start":6326,"enrollment":844,"conditions":7863,"interventions":7864},[86],[6328],[6316,6330],{"trials":7866,"activeCount":98},[],{"trials":7868,"activeCount":98},[],{"trials":7870,"activeCount":98},[],{"trials":7872,"activeCount":98},[],{"intervention":7874,"totalTrials":137,"cells":7875},"Ketamine Hydrochloride",{"EARLY_PHASE1":7876,"PHASE1":7878,"PHASE2":7892,"PHASE3":7894,"PHASE4":7896,"NA":7898},{"trials":7877,"activeCount":98},[],{"trials":7879,"activeCount":98},[7880],{"nctId":7881,"briefTitle":7882,"status":1092,"phases":7883,"primaryCompletion":7884,"completion":7884,"start":7885,"enrollment":7886,"conditions":7887,"interventions":7888},"NCT04587778","Imaging Neural Correlates of Ketamine Using PET\u002FMR",[86],"2025-03-31","2020-10-05",65,[1975],[7874,7889,7890,7891],"Esketamine","Pilot study II: Esketamine","Pilot study II: Placebo",{"trials":7893,"activeCount":98},[],{"trials":7895,"activeCount":98},[],{"trials":7897,"activeCount":98},[],{"trials":7899,"activeCount":98},[],{"intervention":7889,"totalTrials":137,"cells":7901},{"EARLY_PHASE1":7902,"PHASE1":7904,"PHASE2":7910,"PHASE3":7912,"PHASE4":7914,"NA":7916},{"trials":7903,"activeCount":98},[],{"trials":7905,"activeCount":98},[7906],{"nctId":7881,"briefTitle":7882,"status":1092,"phases":7907,"primaryCompletion":7884,"completion":7884,"start":7885,"enrollment":7886,"conditions":7908,"interventions":7909},[86],[1975],[7874,7889,7890,7891],{"trials":7911,"activeCount":98},[],{"trials":7913,"activeCount":98},[],{"trials":7915,"activeCount":98},[],{"trials":7917,"activeCount":98},[],{"intervention":7890,"totalTrials":137,"cells":7919},{"EARLY_PHASE1":7920,"PHASE1":7922,"PHASE2":7928,"PHASE3":7930,"PHASE4":7932,"NA":7934},{"trials":7921,"activeCount":98},[],{"trials":7923,"activeCount":98},[7924],{"nctId":7881,"briefTitle":7882,"status":1092,"phases":7925,"primaryCompletion":7884,"completion":7884,"start":7885,"enrollment":7886,"conditions":7926,"interventions":7927},[86],[1975],[7874,7889,7890,7891],{"trials":7929,"activeCount":98},[],{"trials":7931,"activeCount":98},[],{"trials":7933,"activeCount":98},[],{"trials":7935,"activeCount":98},[],{"intervention":7891,"totalTrials":137,"cells":7937},{"EARLY_PHASE1":7938,"PHASE1":7940,"PHASE2":7946,"PHASE3":7948,"PHASE4":7950,"NA":7952},{"trials":7939,"activeCount":98},[],{"trials":7941,"activeCount":98},[7942],{"nctId":7881,"briefTitle":7882,"status":1092,"phases":7943,"primaryCompletion":7884,"completion":7884,"start":7885,"enrollment":7886,"conditions":7944,"interventions":7945},[86],[1975],[7874,7889,7890,7891],{"trials":7947,"activeCount":98},[],{"trials":7949,"activeCount":98},[],{"trials":7951,"activeCount":98},[],{"trials":7953,"activeCount":98},[],{"intervention":7955,"totalTrials":137,"cells":7956},"LPS",{"EARLY_PHASE1":7957,"PHASE1":7959,"PHASE2":7969,"PHASE3":7971,"PHASE4":7973,"NA":7975},{"trials":7958,"activeCount":98},[],{"trials":7960,"activeCount":98},[7961],{"nctId":7962,"briefTitle":7963,"status":108,"phases":7964,"completion":7965,"start":843,"enrollment":844,"conditions":7966,"interventions":7968},"NCT00284869","Ethnic Differences in the Inflammatory Response in Systemic Inflammation",[86],"2006-04",[7967],"Endotoxemia",[7955],{"trials":7970,"activeCount":98},[],{"trials":7972,"activeCount":98},[],{"trials":7974,"activeCount":98},[],{"trials":7976,"activeCount":98},[],{"intervention":7978,"totalTrials":137,"cells":7979},"LPS 2ng\u002Fkg intravenous bolus",{"EARLY_PHASE1":7980,"PHASE1":7982,"PHASE2":7992,"PHASE3":7994,"PHASE4":7996,"NA":7998},{"trials":7981,"activeCount":98},[],{"trials":7983,"activeCount":98},[7984],{"nctId":7985,"briefTitle":7986,"status":108,"phases":7987,"completion":6326,"start":2037,"enrollment":522,"conditions":7988,"interventions":7989},"NCT00309374","Anti-Inflammatory Effect of Statins in the Human Endotoxin Model",[86],[7967],[7978,7990,7991],"Simvastatin 80mg; administered daily p.o. over 5 days","Rosuvastatin 40mg; administered daily p.o. over 5 days",{"trials":7993,"activeCount":98},[],{"trials":7995,"activeCount":98},[],{"trials":7997,"activeCount":98},[],{"trials":7999,"activeCount":98},[],{"intervention":7990,"totalTrials":137,"cells":8001},{"EARLY_PHASE1":8002,"PHASE1":8004,"PHASE2":8010,"PHASE3":8012,"PHASE4":8014,"NA":8016},{"trials":8003,"activeCount":98},[],{"trials":8005,"activeCount":98},[8006],{"nctId":7985,"briefTitle":7986,"status":108,"phases":8007,"completion":6326,"start":2037,"enrollment":522,"conditions":8008,"interventions":8009},[86],[7967],[7978,7990,7991],{"trials":8011,"activeCount":98},[],{"trials":8013,"activeCount":98},[],{"trials":8015,"activeCount":98},[],{"trials":8017,"activeCount":98},[],{"intervention":7991,"totalTrials":137,"cells":8019},{"EARLY_PHASE1":8020,"PHASE1":8022,"PHASE2":8028,"PHASE3":8030,"PHASE4":8032,"NA":8034},{"trials":8021,"activeCount":98},[],{"trials":8023,"activeCount":98},[8024],{"nctId":7985,"briefTitle":7986,"status":108,"phases":8025,"completion":6326,"start":2037,"enrollment":522,"conditions":8026,"interventions":8027},[86],[7967],[7978,7990,7991],{"trials":8029,"activeCount":98},[],{"trials":8031,"activeCount":98},[],{"trials":8033,"activeCount":98},[],{"trials":8035,"activeCount":98},[],{"intervention":8037,"totalTrials":137,"cells":8038},"Ciprofloxacin",{"EARLY_PHASE1":8039,"PHASE1":8041,"PHASE2":8052,"PHASE3":8054,"PHASE4":8056,"NA":8058},{"trials":8040,"activeCount":98},[],{"trials":8042,"activeCount":98},[8043],{"nctId":8044,"briefTitle":8045,"status":108,"phases":8046,"primaryCompletion":8047,"completion":8047,"start":8048,"enrollment":486,"conditions":8049,"interventions":8050},"NCT03177720","Evaluation of Innovative Tools in Development of Antibiotics",[86],"2021-07-31","2016-05-29",[1065],[8037,8051],"Imipenem",{"trials":8053,"activeCount":98},[],{"trials":8055,"activeCount":98},[],{"trials":8057,"activeCount":98},[],{"trials":8059,"activeCount":98},[],{"intervention":8051,"totalTrials":137,"cells":8061},{"EARLY_PHASE1":8062,"PHASE1":8064,"PHASE2":8070,"PHASE3":8072,"PHASE4":8074,"NA":8076},{"trials":8063,"activeCount":98},[],{"trials":8065,"activeCount":98},[8066],{"nctId":8044,"briefTitle":8045,"status":108,"phases":8067,"primaryCompletion":8047,"completion":8047,"start":8048,"enrollment":486,"conditions":8068,"interventions":8069},[86],[1065],[8037,8051],{"trials":8071,"activeCount":98},[],{"trials":8073,"activeCount":98},[],{"trials":8075,"activeCount":98},[],{"trials":8077,"activeCount":98},[],{"intervention":8079,"totalTrials":137,"cells":8080},"Ticagrelor + Apixaban + ASA",{"EARLY_PHASE1":8081,"PHASE1":8083,"PHASE2":8093,"PHASE3":8095,"PHASE4":8097,"NA":8099},{"trials":8082,"activeCount":98},[],{"trials":8084,"activeCount":98},[8085],{"nctId":8086,"briefTitle":8087,"status":108,"phases":8088,"primaryCompletion":8089,"completion":2971,"start":3285,"enrollment":112,"conditions":8090,"interventions":8091},"NCT02080858","Triple vs. Dual Therapy",[86],"2014-10",[2461,1898],[8079,8092],"Ticagrelor + Apixaban",{"trials":8094,"activeCount":98},[],{"trials":8096,"activeCount":98},[],{"trials":8098,"activeCount":98},[],{"trials":8100,"activeCount":98},[],{"intervention":8092,"totalTrials":137,"cells":8102},{"EARLY_PHASE1":8103,"PHASE1":8105,"PHASE2":8111,"PHASE3":8113,"PHASE4":8115,"NA":8117},{"trials":8104,"activeCount":98},[],{"trials":8106,"activeCount":98},[8107],{"nctId":8086,"briefTitle":8087,"status":108,"phases":8108,"primaryCompletion":8089,"completion":2971,"start":3285,"enrollment":112,"conditions":8109,"interventions":8110},[86],[2461,1898],[8079,8092],{"trials":8112,"activeCount":98},[],{"trials":8114,"activeCount":98},[],{"trials":8116,"activeCount":98},[],{"trials":8118,"activeCount":98},[],{"intervention":8120,"totalTrials":137,"cells":8121},"Triamcinolone Acetonide 40mg\u002FmL",{"EARLY_PHASE1":8122,"PHASE1":8124,"PHASE2":8135,"PHASE3":8137,"PHASE4":8139,"NA":8141},{"trials":8123,"activeCount":98},[],{"trials":8125,"activeCount":98},[8126],{"nctId":8127,"briefTitle":8128,"status":108,"phases":8129,"primaryCompletion":8130,"completion":8131,"start":8132,"enrollment":19,"conditions":8133,"interventions":8134},"NCT04658836","Triamcinolone Levels in Cochlear Perilymph, Lateral Canal and CSF",[86],"2021-08-31","2021-10-31","2020-02-01",[7656],[8120],{"trials":8136,"activeCount":98},[],{"trials":8138,"activeCount":98},[],{"trials":8140,"activeCount":98},[],{"trials":8142,"activeCount":98},[],{"intervention":8144,"totalTrials":137,"cells":8145},"LPS 2 ng\u002Fkg intravenous (IV) bolus",{"EARLY_PHASE1":8146,"PHASE1":8148,"PHASE2":8163,"PHASE3":8165,"PHASE4":8167,"NA":8169},{"trials":8147,"activeCount":98},[],{"trials":8149,"activeCount":98},[8150],{"nctId":8151,"briefTitle":8152,"status":108,"phases":8153,"start":8154,"enrollment":8155,"conditions":8156,"interventions":8158},"NCT00264186","Recombinant Human Superoxide Dismutase (rhSOD) and Vascular Reactivity",[86],"2005-06",43,[8157],"Inflammation",[8144,8159,8160,8161,8162],"rhSOD 82,000 IU (8.2 mg)\u002Fmin intraarterially","Norepinephrine 60, 120, 240 pmol\u002Fmin intraarterially over 5 min\u002Fdose level","Acetylcholine 6.25, 12.5, 25 nmol\u002Fmin intraarterially over 3 min\u002Fdose level","Glyceroltrinitrate",{"trials":8164,"activeCount":98},[],{"trials":8166,"activeCount":98},[],{"trials":8168,"activeCount":98},[],{"trials":8170,"activeCount":98},[],{"intervention":8159,"totalTrials":137,"cells":8172},{"EARLY_PHASE1":8173,"PHASE1":8175,"PHASE2":8181,"PHASE3":8183,"PHASE4":8185,"NA":8187},{"trials":8174,"activeCount":98},[],{"trials":8176,"activeCount":98},[8177],{"nctId":8151,"briefTitle":8152,"status":108,"phases":8178,"start":8154,"enrollment":8155,"conditions":8179,"interventions":8180},[86],[8157],[8144,8159,8160,8161,8162],{"trials":8182,"activeCount":98},[],{"trials":8184,"activeCount":98},[],{"trials":8186,"activeCount":98},[],{"trials":8188,"activeCount":98},[],{"intervention":8160,"totalTrials":137,"cells":8190},{"EARLY_PHASE1":8191,"PHASE1":8193,"PHASE2":8199,"PHASE3":8201,"PHASE4":8203,"NA":8205},{"trials":8192,"activeCount":98},[],{"trials":8194,"activeCount":98},[8195],{"nctId":8151,"briefTitle":8152,"status":108,"phases":8196,"start":8154,"enrollment":8155,"conditions":8197,"interventions":8198},[86],[8157],[8144,8159,8160,8161,8162],{"trials":8200,"activeCount":98},[],{"trials":8202,"activeCount":98},[],{"trials":8204,"activeCount":98},[],{"trials":8206,"activeCount":98},[],{"intervention":8161,"totalTrials":137,"cells":8208},{"EARLY_PHASE1":8209,"PHASE1":8211,"PHASE2":8217,"PHASE3":8219,"PHASE4":8221,"NA":8223},{"trials":8210,"activeCount":98},[],{"trials":8212,"activeCount":98},[8213],{"nctId":8151,"briefTitle":8152,"status":108,"phases":8214,"start":8154,"enrollment":8155,"conditions":8215,"interventions":8216},[86],[8157],[8144,8159,8160,8161,8162],{"trials":8218,"activeCount":98},[],{"trials":8220,"activeCount":98},[],{"trials":8222,"activeCount":98},[],{"trials":8224,"activeCount":98},[],{"intervention":8162,"totalTrials":137,"cells":8226},{"EARLY_PHASE1":8227,"PHASE1":8229,"PHASE2":8235,"PHASE3":8237,"PHASE4":8239,"NA":8241},{"trials":8228,"activeCount":98},[],{"trials":8230,"activeCount":98},[8231],{"nctId":8151,"briefTitle":8152,"status":108,"phases":8232,"start":8154,"enrollment":8155,"conditions":8233,"interventions":8234},[86],[8157],[8144,8159,8160,8161,8162],{"trials":8236,"activeCount":98},[],{"trials":8238,"activeCount":98},[],{"trials":8240,"activeCount":98},[],{"trials":8242,"activeCount":98},[],{"intervention":8244,"totalTrials":137,"cells":8245},"BQ-123 and BQ-788",{"EARLY_PHASE1":8246,"PHASE1":8248,"PHASE2":8260,"PHASE3":8262,"PHASE4":8264,"NA":8266},{"trials":8247,"activeCount":98},[],{"trials":8249,"activeCount":98},[8250],{"nctId":8251,"briefTitle":8252,"status":108,"phases":8253,"completion":6580,"start":8254,"enrollment":511,"conditions":8255,"interventions":8259},"NCT00427232","Endothelin-Receptor Blockade in Coronary Heart Disease",[86],"2003-05",[8256,8257,8258],"Coronary Vessels","Endothelins","Vascular Resistance",[8244],{"trials":8261,"activeCount":98},[],{"trials":8263,"activeCount":98},[],{"trials":8265,"activeCount":98},[],{"trials":8267,"activeCount":98},[],{"intervention":8269,"totalTrials":137,"cells":8270},"Bet v 1aF1-Alum + Bet v 1aF2-Alum",{"EARLY_PHASE1":8271,"PHASE1":8273,"PHASE2":8282,"PHASE3":8284,"PHASE4":8286,"NA":8288},{"trials":8272,"activeCount":98},[],{"trials":8274,"activeCount":98},[8275],{"nctId":8276,"briefTitle":8277,"status":1092,"phases":8278,"primaryCompletion":4985,"completion":1895,"start":1992,"enrollment":476,"conditions":8279,"interventions":8280},"NCT01353924","Immune Response of Individuals Vaccinated With Hypoallergenic Derivatives of the Major Birch Pollen Allergen, Bet v 1",[86],[1654],[8269,8281],"Alum-Placebo",{"trials":8283,"activeCount":98},[],{"trials":8285,"activeCount":98},[],{"trials":8287,"activeCount":98},[],{"trials":8289,"activeCount":98},[],{"intervention":8281,"totalTrials":137,"cells":8291},{"EARLY_PHASE1":8292,"PHASE1":8294,"PHASE2":8300,"PHASE3":8302,"PHASE4":8304,"NA":8306},{"trials":8293,"activeCount":98},[],{"trials":8295,"activeCount":98},[8296],{"nctId":8276,"briefTitle":8277,"status":1092,"phases":8297,"primaryCompletion":4985,"completion":1895,"start":1992,"enrollment":476,"conditions":8298,"interventions":8299},[86],[1654],[8269,8281],{"trials":8301,"activeCount":98},[],{"trials":8303,"activeCount":98},[],{"trials":8305,"activeCount":98},[],{"trials":8307,"activeCount":98},[],{"intervention":8309,"totalTrials":137,"cells":8310},"Dapagliflozin 10mg",{"EARLY_PHASE1":8311,"PHASE1":8313,"PHASE2":8326,"PHASE3":8328,"PHASE4":8330,"NA":8332},{"trials":8312,"activeCount":98},[],{"trials":8314,"activeCount":98},[8315],{"nctId":8316,"briefTitle":8317,"status":1092,"phases":8318,"primaryCompletion":8319,"completion":8320,"start":8321,"enrollment":844,"conditions":8322,"interventions":8325},"NCT05217654","Trial to Investigate the Effect of Dapagliflozin on Ischemia Reperfusion Induced Endothelial Dysfunction",[86],"2023-02-01","2023-08-01","2022-02-18",[8323,8324],"Reperfusion Injury","Vascular Complications",[8309],{"trials":8327,"activeCount":98},[],{"trials":8329,"activeCount":98},[],{"trials":8331,"activeCount":98},[],{"trials":8333,"activeCount":98},[],{"intervention":8335,"totalTrials":137,"cells":8336},"APOSEC™ for cutaneous use",{"EARLY_PHASE1":8337,"PHASE1":8339,"PHASE2":8348,"PHASE3":8350,"PHASE4":8352,"NA":8354},{"trials":8338,"activeCount":98},[],{"trials":8340,"activeCount":98},[8341],{"nctId":8342,"briefTitle":8343,"status":108,"phases":8344,"primaryCompletion":2863,"completion":2863,"start":8089,"enrollment":486,"conditions":8345,"interventions":8347},"NCT02284360","A Prospective Randomized Double-Blinded Placebo Controlled, Explorative Phase I Trial to Investigate the Safety and Tolerability of Two Different Doses of Topically Administered APOSEC™ in Healthy Male Subjects With Artificial Dermal Wounds",[86],[15,8346],"Artificial Dermal Wound",[8335],{"trials":8349,"activeCount":98},[],{"trials":8351,"activeCount":98},[],{"trials":8353,"activeCount":98},[],{"trials":8355,"activeCount":98},[],{"intervention":8357,"totalTrials":137,"cells":8358},"TRPA1-inhibitor",{"EARLY_PHASE1":8359,"PHASE1":8372,"PHASE2":8374,"PHASE3":8376,"PHASE4":8378,"NA":8380},{"trials":8360,"activeCount":98},[8361],{"nctId":8362,"briefTitle":8363,"status":108,"phases":8364,"primaryCompletion":8365,"completion":8365,"start":8366,"enrollment":7365,"conditions":8367,"interventions":8368},"NCT05275751","Mechanisms of Human Heat Perception - Involvement of TRPA1, TRPV1 and TRPM3",[85],"2022-11-30","2022-06-13",[976],[8357,8369,8370,8371],"TRPV1-inhibitor","TRPM3-inhibitor","Chloride-channel inhibitor",{"trials":8373,"activeCount":98},[],{"trials":8375,"activeCount":98},[],{"trials":8377,"activeCount":98},[],{"trials":8379,"activeCount":98},[],{"trials":8381,"activeCount":98},[],{"intervention":8369,"totalTrials":137,"cells":8383},{"EARLY_PHASE1":8384,"PHASE1":8390,"PHASE2":8392,"PHASE3":8394,"PHASE4":8396,"NA":8398},{"trials":8385,"activeCount":98},[8386],{"nctId":8362,"briefTitle":8363,"status":108,"phases":8387,"primaryCompletion":8365,"completion":8365,"start":8366,"enrollment":7365,"conditions":8388,"interventions":8389},[85],[976],[8357,8369,8370,8371],{"trials":8391,"activeCount":98},[],{"trials":8393,"activeCount":98},[],{"trials":8395,"activeCount":98},[],{"trials":8397,"activeCount":98},[],{"trials":8399,"activeCount":98},[],{"intervention":8370,"totalTrials":137,"cells":8401},{"EARLY_PHASE1":8402,"PHASE1":8408,"PHASE2":8410,"PHASE3":8412,"PHASE4":8414,"NA":8416},{"trials":8403,"activeCount":98},[8404],{"nctId":8362,"briefTitle":8363,"status":108,"phases":8405,"primaryCompletion":8365,"completion":8365,"start":8366,"enrollment":7365,"conditions":8406,"interventions":8407},[85],[976],[8357,8369,8370,8371],{"trials":8409,"activeCount":98},[],{"trials":8411,"activeCount":98},[],{"trials":8413,"activeCount":98},[],{"trials":8415,"activeCount":98},[],{"trials":8417,"activeCount":98},[],{"intervention":8371,"totalTrials":137,"cells":8419},{"EARLY_PHASE1":8420,"PHASE1":8426,"PHASE2":8428,"PHASE3":8430,"PHASE4":8432,"NA":8434},{"trials":8421,"activeCount":98},[8422],{"nctId":8362,"briefTitle":8363,"status":108,"phases":8423,"primaryCompletion":8365,"completion":8365,"start":8366,"enrollment":7365,"conditions":8424,"interventions":8425},[85],[976],[8357,8369,8370,8371],{"trials":8427,"activeCount":98},[],{"trials":8429,"activeCount":98},[],{"trials":8431,"activeCount":98},[],{"trials":8433,"activeCount":98},[],{"trials":8435,"activeCount":98},[],{"intervention":8437,"totalTrials":137,"cells":8438},"Lidocain",{"EARLY_PHASE1":8439,"PHASE1":8453,"PHASE2":8455,"PHASE3":8457,"PHASE4":8459,"NA":8461},{"trials":8440,"activeCount":98},[8441],{"nctId":8442,"briefTitle":8443,"status":108,"phases":8444,"primaryCompletion":8445,"completion":8445,"start":8446,"enrollment":1270,"conditions":8447,"interventions":8448},"NCT05935280","Mechanism of Human Cold Pain Perception - Involvement of TRPA1, TRPM8, Nav1.7 and Nav1.8",[85],"2023-09-01","2023-07-07",[976],[8437,8449,8450,8451,8452],"PF-05105679","A967079","PF-05089771","PF-06305591",{"trials":8454,"activeCount":98},[],{"trials":8456,"activeCount":98},[],{"trials":8458,"activeCount":98},[],{"trials":8460,"activeCount":98},[],{"trials":8462,"activeCount":98},[],{"intervention":8449,"totalTrials":137,"cells":8464},{"EARLY_PHASE1":8465,"PHASE1":8471,"PHASE2":8473,"PHASE3":8475,"PHASE4":8477,"NA":8479},{"trials":8466,"activeCount":98},[8467],{"nctId":8442,"briefTitle":8443,"status":108,"phases":8468,"primaryCompletion":8445,"completion":8445,"start":8446,"enrollment":1270,"conditions":8469,"interventions":8470},[85],[976],[8437,8449,8450,8451,8452],{"trials":8472,"activeCount":98},[],{"trials":8474,"activeCount":98},[],{"trials":8476,"activeCount":98},[],{"trials":8478,"activeCount":98},[],{"trials":8480,"activeCount":98},[],{"intervention":8450,"totalTrials":137,"cells":8482},{"EARLY_PHASE1":8483,"PHASE1":8489,"PHASE2":8491,"PHASE3":8493,"PHASE4":8495,"NA":8497},{"trials":8484,"activeCount":98},[8485],{"nctId":8442,"briefTitle":8443,"status":108,"phases":8486,"primaryCompletion":8445,"completion":8445,"start":8446,"enrollment":1270,"conditions":8487,"interventions":8488},[85],[976],[8437,8449,8450,8451,8452],{"trials":8490,"activeCount":98},[],{"trials":8492,"activeCount":98},[],{"trials":8494,"activeCount":98},[],{"trials":8496,"activeCount":98},[],{"trials":8498,"activeCount":98},[],{"intervention":8451,"totalTrials":137,"cells":8500},{"EARLY_PHASE1":8501,"PHASE1":8507,"PHASE2":8509,"PHASE3":8511,"PHASE4":8513,"NA":8515},{"trials":8502,"activeCount":98},[8503],{"nctId":8442,"briefTitle":8443,"status":108,"phases":8504,"primaryCompletion":8445,"completion":8445,"start":8446,"enrollment":1270,"conditions":8505,"interventions":8506},[85],[976],[8437,8449,8450,8451,8452],{"trials":8508,"activeCount":98},[],{"trials":8510,"activeCount":98},[],{"trials":8512,"activeCount":98},[],{"trials":8514,"activeCount":98},[],{"trials":8516,"activeCount":98},[],{"intervention":8452,"totalTrials":137,"cells":8518},{"EARLY_PHASE1":8519,"PHASE1":8525,"PHASE2":8527,"PHASE3":8529,"PHASE4":8531,"NA":8533},{"trials":8520,"activeCount":98},[8521],{"nctId":8442,"briefTitle":8443,"status":108,"phases":8522,"primaryCompletion":8445,"completion":8445,"start":8446,"enrollment":1270,"conditions":8523,"interventions":8524},[85],[976],[8437,8449,8450,8451,8452],{"trials":8526,"activeCount":98},[],{"trials":8528,"activeCount":98},[],{"trials":8530,"activeCount":98},[],{"trials":8532,"activeCount":98},[],{"trials":8534,"activeCount":98},[],{"intervention":7456,"totalTrials":522,"cells":8536},{"EARLY_PHASE1":8537,"PHASE1":8546,"PHASE2":8548,"PHASE3":8558,"PHASE4":8560,"NA":8562},{"trials":8538,"activeCount":98},[8539],{"nctId":8540,"briefTitle":8541,"status":839,"phases":8542,"primaryCompletion":841,"completion":4739,"start":8543,"enrollment":30,"conditions":8544,"interventions":8545},"NCT00708357","Does eNOS Gene Polymorphism Play a Role in the Maintenance of Basal Vascular Tone in the Choroid or Optic Nerve Head?",[85],"2005-05",[21,18],[7456],{"trials":8547,"activeCount":98},[],{"trials":8549,"activeCount":98},[8550,8554],{"nctId":7451,"briefTitle":7452,"status":2011,"phases":8551,"primaryCompletion":3211,"completion":3211,"start":1865,"enrollment":98,"conditions":8552,"interventions":8553},[87],[21,4186,18],[7456,7442,7457],{"nctId":2150,"briefTitle":2151,"status":108,"phases":8555,"start":2153,"enrollment":2154,"conditions":8556,"interventions":8557},[87],[18,21],[2157,2158,2159,2141],{"trials":8559,"activeCount":98},[],{"trials":8561,"activeCount":98},[],{"trials":8563,"activeCount":98},[8564,8584,8591],{"nctId":8565,"briefTitle":8566,"status":108,"phases":8567,"completion":8568,"start":8569,"enrollment":6422,"conditions":8570,"interventions":8575},"NCT00431665","Effect of Elevated Plasma-Free-Fatty-Acids on Renal Hemodynamic Parameters",[90],"2000-06","1999-07",[8571,8572,8573,8574],"Renal Circulation","Renal Plasma Flow","Glomerular Filtration Rate","Fatty Acids, Nonesterified",[8576,8577,8578,8579,8580,8581,8582,8583],"NG-monomethyl-L-Arginine","triglycerides","heparin","somatostatin","insulin","glucose","inulin","paraamino hippurate",{"nctId":8585,"briefTitle":8586,"status":839,"phases":8587,"primaryCompletion":1172,"start":1854,"enrollment":30,"conditions":8588,"interventions":8589},"NCT00914394","Role of Nitric Oxide in Optic Nerve Head Blood Flow Regulation During Experimental Increase of Intraocular Pressure in Healthy Humans",[90],[15],[7456,2157,8590],"Physiological saline solution",{"nctId":8592,"briefTitle":8593,"status":108,"phases":8594,"primaryCompletion":1106,"completion":3915,"start":1095,"enrollment":22,"conditions":8595,"interventions":8596},"NCT00806741","Role of Nitric Oxide in Optic Nerve Head Blood Flow Regulation During Isometric Exercise in Healthy Humans",[90],[15],[7456,2157,8590],{"intervention":2157,"totalTrials":828,"cells":8598},{"EARLY_PHASE1":8599,"PHASE1":8601,"PHASE2":8603,"PHASE3":8609,"PHASE4":8611,"NA":8617},{"trials":8600,"activeCount":98},[],{"trials":8602,"activeCount":98},[],{"trials":8604,"activeCount":98},[8605],{"nctId":2150,"briefTitle":2151,"status":108,"phases":8606,"start":2153,"enrollment":2154,"conditions":8607,"interventions":8608},[87],[18,21],[2157,2158,2159,2141],{"trials":8610,"activeCount":98},[],{"trials":8612,"activeCount":98},[8613],{"nctId":4645,"briefTitle":4646,"status":1092,"phases":8614,"primaryCompletion":4648,"completion":4649,"start":2049,"enrollment":4650,"conditions":8615,"interventions":8616},[89],[4652,4653,4654],[4632,4656,2157],{"trials":8618,"activeCount":98},[8619,8626,8630],{"nctId":8620,"briefTitle":8621,"status":839,"phases":8622,"primaryCompletion":2036,"start":2036,"enrollment":137,"conditions":8623,"interventions":8624},"NCT01333891","Choroidal Thickness During Changes in Intraocular Pressure and Arterial Blood Pressure",[90],[15],[2157,8625],"Sodium-Nitroprusside",{"nctId":8585,"briefTitle":8586,"status":839,"phases":8627,"primaryCompletion":1172,"start":1854,"enrollment":30,"conditions":8628,"interventions":8629},[90],[15],[7456,2157,8590],{"nctId":8592,"briefTitle":8593,"status":108,"phases":8631,"primaryCompletion":1106,"completion":3915,"start":1095,"enrollment":22,"conditions":8632,"interventions":8633},[90],[15],[7456,2157,8590],{"intervention":6585,"totalTrials":1830,"cells":8635},{"EARLY_PHASE1":8636,"PHASE1":8638,"PHASE2":8640,"PHASE3":8650,"PHASE4":8652,"NA":8654},{"trials":8637,"activeCount":98},[],{"trials":8639,"activeCount":98},[],{"trials":8641,"activeCount":98},[8642,8646],{"nctId":6576,"briefTitle":6577,"status":108,"phases":8643,"primaryCompletion":6579,"start":6580,"enrollment":6581,"conditions":8644,"interventions":8645},[87],[6583],[6567,6585],{"nctId":7190,"briefTitle":7191,"status":108,"phases":8647,"primaryCompletion":1908,"completion":1908,"start":1172,"enrollment":2289,"conditions":8648,"interventions":8649},[87],[7194],[6585,7181],{"trials":8651,"activeCount":98},[],{"trials":8653,"activeCount":98},[],{"trials":8655,"activeCount":98},[8656,8664],{"nctId":8657,"briefTitle":8658,"status":108,"phases":8659,"completion":2370,"start":8660,"conditions":8661,"interventions":8663},"NCT00479206","Artemisinin Resistance in Cambodia",[90],"2006-10",[8662],"Malaria, Falciparum",[6585],{"nctId":8665,"briefTitle":8666,"status":108,"phases":8667,"primaryCompletion":886,"completion":886,"start":3053,"enrollment":8668,"conditions":8669,"interventions":8671},"NCT00639873","Artemisinin Resistance in Bangladesh",[90],126,[8670],"Malaria",[6585,8672],"quinine-doxycycline",{"intervention":8674,"totalTrials":1830,"cells":8675},"Simvastatin",{"EARLY_PHASE1":8676,"PHASE1":8678,"PHASE2":8680,"PHASE3":8682,"PHASE4":8684,"NA":8705},{"trials":8677,"activeCount":98},[],{"trials":8679,"activeCount":98},[],{"trials":8681,"activeCount":98},[],{"trials":8683,"activeCount":98},[],{"trials":8685,"activeCount":98},[8686,8693,8701],{"nctId":8687,"briefTitle":8688,"status":1092,"phases":8689,"conditions":8690,"interventions":8692},"NCT00450840","Simvastatin in Patients With Septic Shock",[89],[8691],"Septic Shock",[8674],{"nctId":8694,"briefTitle":8695,"status":2011,"phases":8696,"primaryCompletion":8697,"completion":2193,"start":8698,"enrollment":98,"conditions":8699,"interventions":8700},"NCT02533141","Effect of Simvastatin Withdrawal on Ocular Endothelial Function",[89],"2020-09","2019-10",[15],[8674],{"nctId":3050,"briefTitle":3051,"status":1092,"phases":8702,"start":3053,"enrollment":569,"conditions":8703,"interventions":8704},[89],[3055,3056],[3058,3037],{"trials":8706,"activeCount":98},[8707],{"nctId":8708,"briefTitle":8709,"status":108,"phases":8710,"primaryCompletion":4184,"completion":4184,"start":8711,"enrollment":476,"conditions":8712,"interventions":8715},"NCT00704314","Does Simvastatin Affect Insulin Sensitivity in Dyslipidemic Type 2 Diabetic Patients?",[90],"2002-10",[8713,2607,8714],"Hypercholesterolemia","Cardiovascular Disease",[8674],{"intervention":8717,"totalTrials":1030,"cells":8718},"Escherichia coli Endotoxin",{"EARLY_PHASE1":8719,"PHASE1":8721,"PHASE2":8723,"PHASE3":8725,"PHASE4":8727,"NA":8739},{"trials":8720,"activeCount":98},[],{"trials":8722,"activeCount":98},[],{"trials":8724,"activeCount":98},[],{"trials":8726,"activeCount":98},[],{"trials":8728,"activeCount":98},[8729],{"nctId":8730,"briefTitle":8731,"status":108,"phases":8732,"primaryCompletion":3144,"completion":3144,"start":3381,"enrollment":1162,"conditions":8733,"interventions":8735},"NCT00431691","Effect of Antioxidants on Ocular Blood Flow, Endothelial Function, and Cytokine Levels in LPS Induced Inflammatory Model in Humans.",[89],[4924,18,8734],"Endotoxin, Escherichia Coli",[8736,8717,8737,8738],"vitamin and mineral supplement","100% O2","nitroglycerin",{"trials":8740,"activeCount":98},[8741,8748],{"nctId":8742,"briefTitle":8743,"status":108,"phases":8744,"primaryCompletion":1895,"completion":873,"start":4739,"enrollment":112,"conditions":8745,"interventions":8747},"NCT02221089","Effect of Retaron® on Oxygen Induced Retinal Vasoconstriction in LPS Induced Inflammatory Model in Humans",[90],[8746,7543],"Imparied Retinal Vascular Reactivity",[8717],{"nctId":8749,"briefTitle":8750,"status":108,"phases":8751,"primaryCompletion":3810,"completion":3810,"start":1171,"enrollment":112,"conditions":8752,"interventions":8753},"NCT00914576","Effect of Antioxidants on Oxygen Induced Vasoconstriction in Lipopolysaccharide (LPS) Induced Inflammatory Model in Humans",[90],[15],[8754,8754,8755,8717],"Vitamin and mineral supplement","100% Oxygen",{"intervention":8590,"totalTrials":1030,"cells":8757},{"EARLY_PHASE1":8758,"PHASE1":8760,"PHASE2":8762,"PHASE3":8764,"PHASE4":8766,"NA":8768},{"trials":8759,"activeCount":98},[],{"trials":8761,"activeCount":98},[],{"trials":8763,"activeCount":98},[],{"trials":8765,"activeCount":98},[],{"trials":8767,"activeCount":98},[],{"trials":8769,"activeCount":98},[8770,8774,8778],{"nctId":8585,"briefTitle":8586,"status":839,"phases":8771,"primaryCompletion":1172,"start":1854,"enrollment":30,"conditions":8772,"interventions":8773},[90],[15],[7456,2157,8590],{"nctId":8592,"briefTitle":8593,"status":108,"phases":8775,"primaryCompletion":1106,"completion":3915,"start":1095,"enrollment":22,"conditions":8776,"interventions":8777},[90],[15],[7456,2157,8590],{"nctId":8779,"briefTitle":8780,"status":108,"phases":8781,"primaryCompletion":2433,"completion":5983,"start":1854,"enrollment":547,"conditions":8782,"interventions":8783},"NCT00915070","Role of Endothelin-1 in Optic Nerve Head Blood Flow Regulation During Isometric Exercise in Healthy Humans",[90],[15],[6265,8590],{"intervention":1912,"totalTrials":1030,"cells":8785},{"EARLY_PHASE1":8786,"PHASE1":8788,"PHASE2":8790,"PHASE3":8800,"PHASE4":8802,"NA":8804},{"trials":8787,"activeCount":98},[],{"trials":8789,"activeCount":98},[],{"trials":8791,"activeCount":98},[8792,8796],{"nctId":1892,"briefTitle":1893,"status":108,"phases":8793,"primaryCompletion":1895,"completion":1895,"start":1854,"enrollment":1896,"conditions":8794,"interventions":8795},[87],[1898],[1900,1883,1901],{"nctId":1903,"briefTitle":1904,"status":1092,"phases":8797,"primaryCompletion":1906,"completion":1907,"start":1908,"enrollment":569,"conditions":8798,"interventions":8799},[87],[34],[1911,1912,1913,1914],{"trials":8801,"activeCount":98},[],{"trials":8803,"activeCount":98},[],{"trials":8805,"activeCount":98},[8806],{"nctId":8807,"briefTitle":8808,"status":108,"phases":8809,"primaryCompletion":2025,"completion":2025,"start":4948,"enrollment":1746,"conditions":8810,"interventions":8812},"NCT00858715","Resistance to Antithrombotic Therapy",[90],[3056,8811],"Angioplasty",[8813,1912],"aspirin",{"intervention":6265,"totalTrials":1030,"cells":8815},{"EARLY_PHASE1":8816,"PHASE1":8818,"PHASE2":8820,"PHASE3":8833,"PHASE4":8835,"NA":8837},{"trials":8817,"activeCount":98},[],{"trials":8819,"activeCount":98},[],{"trials":8821,"activeCount":98},[8822,8829],{"nctId":8823,"briefTitle":8824,"status":108,"phases":8825,"primaryCompletion":887,"completion":4985,"start":4922,"enrollment":6339,"conditions":8826,"interventions":8828},"NCT00502528","Endothelin Receptor Blockade in Acute ST-elevation Myocardial Infarction",[87],[8827],"ST-Elevation Myocardial Infarction",[6265],{"nctId":6257,"briefTitle":6258,"status":1092,"phases":8830,"primaryCompletion":1785,"completion":6260,"start":6261,"enrollment":356,"conditions":8831,"interventions":8832},[87],[32,6263],[6265,860],{"trials":8834,"activeCount":98},[],{"trials":8836,"activeCount":98},[],{"trials":8838,"activeCount":98},[8839],{"nctId":8779,"briefTitle":8780,"status":108,"phases":8840,"primaryCompletion":2433,"completion":5983,"start":1854,"enrollment":547,"conditions":8841,"interventions":8842},[90],[15],[6265,8590],{"intervention":8625,"totalTrials":94,"cells":8844},{"EARLY_PHASE1":8845,"PHASE1":8847,"PHASE2":8849,"PHASE3":8851,"PHASE4":8853,"NA":8855},{"trials":8846,"activeCount":98},[],{"trials":8848,"activeCount":98},[],{"trials":8850,"activeCount":98},[],{"trials":8852,"activeCount":98},[],{"trials":8854,"activeCount":98},[],{"trials":8856,"activeCount":98},[8857,8861],{"nctId":8620,"briefTitle":8621,"status":839,"phases":8858,"primaryCompletion":2036,"start":2036,"enrollment":137,"conditions":8859,"interventions":8860},[90],[15],[2157,8625],{"nctId":8862,"briefTitle":8863,"status":108,"phases":8864,"primaryCompletion":8865,"completion":8865,"start":8866,"enrollment":8867,"conditions":8868,"interventions":8869},"NCT00810381","Ocular Hemodynamic Effects of Nitrovasodilators in Healthy Subjects",[90],"1999-06","1999-01",14,[27],[8870,8871,8872,7457],"Nitroglycerin","Isosorbide-Dinitrate","Sodium-nitroprusside",{"intervention":5097,"totalTrials":94,"cells":8874},{"EARLY_PHASE1":8875,"PHASE1":8877,"PHASE2":8879,"PHASE3":8881,"PHASE4":8887,"NA":8889},{"trials":8876,"activeCount":98},[],{"trials":8878,"activeCount":98},[],{"trials":8880,"activeCount":98},[],{"trials":8882,"activeCount":98},[8883],{"nctId":5087,"briefTitle":5088,"status":108,"phases":8884,"primaryCompletion":5090,"completion":5090,"start":5091,"enrollment":5092,"conditions":8885,"interventions":8886},[88],[5094],[5076,5096,5097],{"trials":8888,"activeCount":98},[],{"trials":8890,"activeCount":98},[8891],{"nctId":8892,"briefTitle":8893,"status":108,"phases":8894,"primaryCompletion":8895,"completion":8895,"start":8896,"enrollment":569,"conditions":8897,"interventions":8899},"NCT04042220","Glucocorticoids, Immunotherapy and Radiosurgery for Brain Metastases",[],"2024-01-04","2019-11-01",[8898],"Brain Metastases",[5097],{"intervention":2609,"totalTrials":94,"cells":8901},{"EARLY_PHASE1":8902,"PHASE1":8904,"PHASE2":8906,"PHASE3":8908,"PHASE4":8910,"NA":8916},{"trials":8903,"activeCount":98},[],{"trials":8905,"activeCount":98},[],{"trials":8907,"activeCount":98},[],{"trials":8909,"activeCount":98},[],{"trials":8911,"activeCount":98},[8912],{"nctId":2600,"briefTitle":2601,"status":108,"phases":8913,"primaryCompletion":2603,"completion":2603,"start":2604,"enrollment":547,"conditions":8914,"interventions":8915},[89],[2606,2607],[2609,2587],{"trials":8917,"activeCount":98},[8918],{"nctId":8919,"briefTitle":8920,"status":108,"phases":8921,"primaryCompletion":8922,"completion":8922,"start":6232,"enrollment":569,"conditions":8923,"interventions":8926},"NCT01057329","Therapeutic Drug Monitoring in Child and Adolescent Psychiatry",[],"2019-03-05",[314,8924,8925],"Anorexia Nervosa","ADHD",[8927,8928,8929,8930],"Atomoxetine","Duloxetine","Olanzapine","Aripiprazole",{"intervention":8928,"totalTrials":94,"cells":8932},{"EARLY_PHASE1":8933,"PHASE1":8935,"PHASE2":8937,"PHASE3":8939,"PHASE4":8941,"NA":8951},{"trials":8934,"activeCount":98},[],{"trials":8936,"activeCount":98},[],{"trials":8938,"activeCount":98},[],{"trials":8940,"activeCount":98},[],{"trials":8942,"activeCount":98},[8943],{"nctId":8944,"briefTitle":8945,"status":108,"phases":8946,"primaryCompletion":1340,"completion":1340,"start":3286,"enrollment":8947,"conditions":8948,"interventions":8950},"NCT01166048","Comparison of the Efficacy of Duloxetine With Placebo in Patients With Chronic Low Back Pain With a Radicular Component",[89],41,[8949],"Chronic Low Back Pain",[8928,8928],{"trials":8952,"activeCount":98},[8953],{"nctId":8919,"briefTitle":8920,"status":108,"phases":8954,"primaryCompletion":8922,"completion":8922,"start":6232,"enrollment":569,"conditions":8955,"interventions":8956},[],[314,8924,8925],[8927,8928,8929,8930],{"intervention":8958,"totalTrials":94,"cells":8959},"Sirolimus",{"EARLY_PHASE1":8960,"PHASE1":8962,"PHASE2":8964,"PHASE3":8966,"PHASE4":8977,"NA":8979},{"trials":8961,"activeCount":98},[],{"trials":8963,"activeCount":98},[],{"trials":8965,"activeCount":98},[],{"trials":8967,"activeCount":98},[8968],{"nctId":8969,"briefTitle":8970,"status":1092,"phases":8971,"primaryCompletion":8972,"completion":5383,"start":660,"enrollment":11,"conditions":8973,"interventions":8976},"NCT02055079","Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease",[88],"2019-04",[8974,8975],"Polycystic Kidney, Type 1 Autosomal Dominant Disease","Polycystic Kidney, Type 2 Autosomal Dominant Disease",[8958],{"trials":8978,"activeCount":98},[],{"trials":8980,"activeCount":98},[8981],{"nctId":8982,"briefTitle":8983,"status":108,"phases":8984,"primaryCompletion":8985,"completion":8985,"start":886,"enrollment":5269,"conditions":8986,"interventions":8988},"NCT01632605","The Vienna RAP Pilot Study",[90],"2012-04",[8987],"ADPKD",[8958],{"intervention":8580,"totalTrials":94,"cells":8990},{"EARLY_PHASE1":8991,"PHASE1":8993,"PHASE2":8995,"PHASE3":9008,"PHASE4":9010,"NA":9012},{"trials":8992,"activeCount":98},[],{"trials":8994,"activeCount":98},[],{"trials":8996,"activeCount":98},[8997],{"nctId":8998,"briefTitle":8999,"status":108,"phases":9000,"primaryCompletion":9001,"completion":5469,"start":9002,"enrollment":4010,"conditions":9003,"interventions":9006},"NCT00814008","The Relationship Between Stage of Diabetic Retinopathy and Retinal Blood Flow in Patients With IDDM During Euglycemic Clamp",[87],"2000-04","1999-03",[9004,9005,4924,18],"Diabetes Mellitus, Type 1","Insulin",[9005,9007],"Glucose",{"trials":9009,"activeCount":98},[],{"trials":9011,"activeCount":98},[],{"trials":9013,"activeCount":98},[9014],{"nctId":8565,"briefTitle":8566,"status":108,"phases":9015,"completion":8568,"start":8569,"enrollment":6422,"conditions":9016,"interventions":9017},[90],[8571,8572,8573,8574],[8576,8577,8578,8579,8580,8581,8582,8583],{"intervention":8581,"totalTrials":94,"cells":9019},{"EARLY_PHASE1":9020,"PHASE1":9022,"PHASE2":9024,"PHASE3":9030,"PHASE4":9032,"NA":9034},{"trials":9021,"activeCount":98},[],{"trials":9023,"activeCount":98},[],{"trials":9025,"activeCount":98},[9026],{"nctId":8998,"briefTitle":8999,"status":108,"phases":9027,"primaryCompletion":9001,"completion":5469,"start":9002,"enrollment":4010,"conditions":9028,"interventions":9029},[87],[9004,9005,4924,18],[9005,9007],{"trials":9031,"activeCount":98},[],{"trials":9033,"activeCount":98},[],{"trials":9035,"activeCount":98},[9036],{"nctId":8565,"briefTitle":8566,"status":108,"phases":9037,"completion":8568,"start":8569,"enrollment":6422,"conditions":9038,"interventions":9039},[90],[8571,8572,8573,8574],[8576,8577,8578,8579,8580,8581,8582,8583],{"intervention":8736,"totalTrials":94,"cells":9041},{"EARLY_PHASE1":9042,"PHASE1":9044,"PHASE2":9046,"PHASE3":9048,"PHASE4":9050,"NA":9056},{"trials":9043,"activeCount":98},[],{"trials":9045,"activeCount":98},[],{"trials":9047,"activeCount":98},[],{"trials":9049,"activeCount":98},[],{"trials":9051,"activeCount":98},[9052],{"nctId":8730,"briefTitle":8731,"status":108,"phases":9053,"primaryCompletion":3144,"completion":3144,"start":3381,"enrollment":1162,"conditions":9054,"interventions":9055},[89],[4924,18,8734],[8736,8717,8737,8738],{"trials":9057,"activeCount":98},[9058],{"nctId":8749,"briefTitle":8750,"status":108,"phases":9059,"primaryCompletion":3810,"completion":3810,"start":1171,"enrollment":112,"conditions":9060,"interventions":9061},[90],[15],[8754,8754,8755,8717],{"intervention":8737,"totalTrials":94,"cells":9063},{"EARLY_PHASE1":9064,"PHASE1":9066,"PHASE2":9068,"PHASE3":9070,"PHASE4":9072,"NA":9078},{"trials":9065,"activeCount":98},[],{"trials":9067,"activeCount":98},[],{"trials":9069,"activeCount":98},[],{"trials":9071,"activeCount":98},[],{"trials":9073,"activeCount":98},[9074],{"nctId":8730,"briefTitle":8731,"status":108,"phases":9075,"primaryCompletion":3144,"completion":3144,"start":3381,"enrollment":1162,"conditions":9076,"interventions":9077},[89],[4924,18,8734],[8736,8717,8737,8738],{"trials":9079,"activeCount":98},[9080],{"nctId":9081,"briefTitle":9082,"status":108,"phases":9083,"enrollment":1061,"conditions":9084,"interventions":9086},"NCT00431548","Retinal Oxygen Reactivity in Patients Infected With Human Immunodeficiency Virus (HIV)",[90],[9085,4924,21],"HIV Infections",[8737],{"intervention":8738,"totalTrials":94,"cells":9088},{"EARLY_PHASE1":9089,"PHASE1":9091,"PHASE2":9093,"PHASE3":9095,"PHASE4":9097,"NA":9103},{"trials":9090,"activeCount":98},[],{"trials":9092,"activeCount":98},[],{"trials":9094,"activeCount":98},[],{"trials":9096,"activeCount":98},[],{"trials":9098,"activeCount":98},[9099],{"nctId":8730,"briefTitle":8731,"status":108,"phases":9100,"primaryCompletion":3144,"completion":3144,"start":3381,"enrollment":1162,"conditions":9101,"interventions":9102},[89],[4924,18,8734],[8736,8717,8737,8738],{"trials":9104,"activeCount":98},[9105],{"nctId":8862,"briefTitle":8863,"status":108,"phases":9106,"primaryCompletion":8865,"completion":8865,"start":8866,"enrollment":8867,"conditions":9107,"interventions":9108},[90],[27],[8870,8871,8872,7457],{"intervention":9110,"totalTrials":94,"cells":9111},"Dexamethasone",{"EARLY_PHASE1":9112,"PHASE1":9114,"PHASE2":9116,"PHASE3":9122,"PHASE4":9124,"NA":9126},{"trials":9113,"activeCount":98},[],{"trials":9115,"activeCount":98},[],{"trials":9117,"activeCount":98},[9118],{"nctId":6299,"briefTitle":6300,"status":1092,"phases":9119,"completion":6302,"start":3572,"enrollment":547,"conditions":9120,"interventions":9121},[87],[6304],[6306,6307,6308],{"trials":9123,"activeCount":98},[],{"trials":9125,"activeCount":98},[],{"trials":9127,"activeCount":98},[9128],{"nctId":9129,"briefTitle":9130,"status":108,"phases":9131,"primaryCompletion":4079,"completion":4079,"start":1172,"enrollment":1270,"conditions":9132,"interventions":9134},"NCT01714427","Validation of a Lung Inflammation Model in Healthy Volunteers by Radiological Tools and Glucocorticoid Treatment",[90],[9133],"Experimental Lung Inflammation",[9110,9135],"Sterile isotonic saline",{"intervention":9137,"totalTrials":94,"cells":9138},"Riociguat",{"EARLY_PHASE1":9139,"PHASE1":9141,"PHASE2":9143,"PHASE3":9154,"PHASE4":9156,"NA":9158},{"trials":9140,"activeCount":98},[],{"trials":9142,"activeCount":98},[],{"trials":9144,"activeCount":98},[9145],{"nctId":9146,"briefTitle":9147,"status":108,"phases":9148,"primaryCompletion":1907,"completion":8697,"start":1046,"enrollment":9149,"conditions":9150,"interventions":9153},"NCT02744339","Pharmacodynamic Effects of Riociguat in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction",[87],118,[9151,9152],"Hypertension, Pulmonary","Heart Failure With Normal Ejection Fraction",[9137],{"trials":9155,"activeCount":98},[],{"trials":9157,"activeCount":98},[],{"trials":9159,"activeCount":98},[9160],{"nctId":9161,"briefTitle":9162,"status":108,"phases":9163,"primaryCompletion":1221,"completion":1221,"start":9164,"enrollment":1292,"conditions":9165,"interventions":9168},"NCT03074539","Sleep-Disordered Breathing in Chronic Thromboembolic Pulmonary Hypertension",[90],"2017-02-01",[9166,9167],"Chronic Thromboembolic Pulmonary Hypertension","Sleep Disordered Breathing",[9137],{"intervention":9170,"totalTrials":94,"cells":9171},"Vardenafil",{"EARLY_PHASE1":9172,"PHASE1":9174,"PHASE2":9176,"PHASE3":9178,"PHASE4":9180,"NA":9189},{"trials":9173,"activeCount":98},[],{"trials":9175,"activeCount":98},[],{"trials":9177,"activeCount":98},[],{"trials":9179,"activeCount":98},[],{"trials":9181,"activeCount":98},[9182],{"nctId":9183,"briefTitle":9184,"status":1092,"phases":9185,"primaryCompletion":2105,"start":4079,"enrollment":1061,"conditions":9186,"interventions":9188},"NCT02344823","Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis",[89],[2865,9187],"Erectile Dysfunction",[9170],{"trials":9190,"activeCount":98},[9191],{"nctId":9192,"briefTitle":9193,"status":9194,"phases":9195,"conditions":9196,"interventions":9199},"NCT01406535","Improvement of Myocardial Blood Flow by PhosphoDiesterase 5 Inhibition in Coronary Artery Disease","TEMPORARILY_NOT_AVAILABLE",[],[9197,32,9198],"Therapy Refractory Myocardial Ischemia","Unsuitable for Surgical or Percutaneous Revascularisation",[9170],{"intervention":3237,"totalTrials":94,"cells":9201},{"EARLY_PHASE1":9202,"PHASE1":9204,"PHASE2":9206,"PHASE3":9208,"PHASE4":9210,"NA":9216},{"trials":9203,"activeCount":98},[],{"trials":9205,"activeCount":98},[],{"trials":9207,"activeCount":98},[],{"trials":9209,"activeCount":98},[],{"trials":9211,"activeCount":98},[9212],{"nctId":3230,"briefTitle":3231,"status":108,"phases":9213,"completion":3233,"start":3234,"enrollment":22,"conditions":9214,"interventions":9215},[89],[21,18],[3217,3237],{"trials":9217,"activeCount":98},[9218],{"nctId":9219,"briefTitle":9220,"status":2011,"phases":9221,"primaryCompletion":3211,"completion":3211,"start":2674,"enrollment":98,"conditions":9222,"interventions":9223},"NCT00275756","Effects of Common Topical Glaucoma Therapy on Optic Nerve Head Blood Flow Autoregulation During Increased Arterial Blood Pressure and Artificially Elevated Intraocular Pressure in Healthy Humans",[90],[27],[9224,9225,9226],"Timolol","dorzolamide","brimonidine",{"intervention":9228,"totalTrials":94,"cells":9229},"Rocuronium",{"EARLY_PHASE1":9230,"PHASE1":9232,"PHASE2":9234,"PHASE3":9236,"PHASE4":9249,"NA":9251},{"trials":9231,"activeCount":98},[],{"trials":9233,"activeCount":98},[],{"trials":9235,"activeCount":98},[],{"trials":9237,"activeCount":98},[9238],{"nctId":9239,"briefTitle":9240,"status":108,"phases":9241,"primaryCompletion":5268,"completion":9242,"start":2079,"enrollment":949,"conditions":9243,"interventions":9247},"NCT01719770","Skeletal Muscle Paralysis in Hypothermic Patients After Cardiac Arrest",[88],"2015-04",[9244,9245,9246],"Cardiac Arrest With Successful Resuscitation","Hypothermia","Skeletal Muscle Relaxant Overdose",[9248],"rocuronium",{"trials":9250,"activeCount":98},[],{"trials":9252,"activeCount":98},[9253],{"nctId":9254,"briefTitle":9255,"status":108,"phases":9256,"primaryCompletion":3285,"completion":3211,"start":8985,"enrollment":8155,"conditions":9257,"interventions":9258},"NCT01683006","Influence of Skeletal Muscle Paralysis on Metabolism in Hypothermic Patients After Cardiac Arrest",[90],[34,7746],[9228],{"intervention":9260,"totalTrials":94,"cells":9261},"Teduglutide",{"EARLY_PHASE1":9262,"PHASE1":9264,"PHASE2":9266,"PHASE3":9268,"PHASE4":9270,"NA":9272},{"trials":9263,"activeCount":98},[],{"trials":9265,"activeCount":98},[],{"trials":9267,"activeCount":98},[],{"trials":9269,"activeCount":98},[],{"trials":9271,"activeCount":98},[],{"trials":9273,"activeCount":98},[9274,9283],{"nctId":9275,"briefTitle":9276,"status":108,"phases":9277,"primaryCompletion":1222,"completion":1222,"start":9278,"enrollment":9279,"conditions":9280,"interventions":9282},"NCT04857801","Teduglutide in Short Bowel Syndrome Patients",[],"2016-06-01",17,[9281],"Short Bowel Syndrome",[9260],{"nctId":9284,"briefTitle":9285,"status":108,"phases":9286,"primaryCompletion":4477,"completion":4477,"start":9287,"enrollment":137,"conditions":9288,"interventions":9289},"NCT04916665","Bridging Intestinal Failure With Teduglutide - a Case Report",[],"2019-01-01",[9281],[9260],{"intervention":7457,"totalTrials":94,"cells":9291},{"EARLY_PHASE1":9292,"PHASE1":9294,"PHASE2":9296,"PHASE3":9302,"PHASE4":9304,"NA":9306},{"trials":9293,"activeCount":98},[],{"trials":9295,"activeCount":98},[],{"trials":9297,"activeCount":98},[9298],{"nctId":7451,"briefTitle":7452,"status":2011,"phases":9299,"primaryCompletion":3211,"completion":3211,"start":1865,"enrollment":98,"conditions":9300,"interventions":9301},[87],[21,4186,18],[7456,7442,7457],{"trials":9303,"activeCount":98},[],{"trials":9305,"activeCount":98},[],{"trials":9307,"activeCount":98},[9308],{"nctId":8862,"briefTitle":8863,"status":108,"phases":9309,"primaryCompletion":8865,"completion":8865,"start":8866,"enrollment":8867,"conditions":9310,"interventions":9311},[90],[27],[8870,8871,8872,7457],{"intervention":9313,"totalTrials":137,"cells":9314},"anti-IgE",{"EARLY_PHASE1":9315,"PHASE1":9317,"PHASE2":9319,"PHASE3":9321,"PHASE4":9323,"NA":9325},{"trials":9316,"activeCount":98},[],{"trials":9318,"activeCount":98},[],{"trials":9320,"activeCount":98},[],{"trials":9322,"activeCount":98},[],{"trials":9324,"activeCount":98},[],{"trials":9326,"activeCount":98},[9327],{"nctId":9328,"briefTitle":9329,"status":108,"phases":9330,"primaryCompletion":3284,"completion":3284,"start":1908,"enrollment":25,"conditions":9331,"interventions":9332},"NCT03019237","Effect of Intranasal Anti-IgE Antibodies on IgE Production",[90],[1654],[9313],{"intervention":9334,"totalTrials":137,"cells":9335},"ngFDS selected treatment",{"EARLY_PHASE1":9336,"PHASE1":9338,"PHASE2":9340,"PHASE3":9342,"PHASE4":9344,"NA":9346},{"trials":9337,"activeCount":98},[],{"trials":9339,"activeCount":98},[],{"trials":9341,"activeCount":98},[],{"trials":9343,"activeCount":98},[],{"trials":9345,"activeCount":98},[],{"trials":9347,"activeCount":98},[9348],{"nctId":9349,"briefTitle":9350,"status":108,"phases":9351,"primaryCompletion":9352,"completion":9352,"start":2013,"enrollment":2631,"conditions":9353,"interventions":9355},"NCT03096821","Extended Analysis for Leukemia\u002FLymphoma Treatment",[],"2020-01-30",[9354],"Relapsed Hematologic Malignancy",[9334],{"intervention":9357,"totalTrials":137,"cells":9358},"Elo-mel®",{"EARLY_PHASE1":9359,"PHASE1":9361,"PHASE2":9363,"PHASE3":9365,"PHASE4":9367,"NA":9369},{"trials":9360,"activeCount":98},[],{"trials":9362,"activeCount":98},[],{"trials":9364,"activeCount":98},[],{"trials":9366,"activeCount":98},[],{"trials":9368,"activeCount":98},[],{"trials":9370,"activeCount":98},[9371],{"nctId":9372,"briefTitle":9373,"status":108,"phases":9374,"primaryCompletion":2389,"completion":2389,"start":8089,"enrollment":25,"conditions":9375,"interventions":9378},"NCT02296294","Body Composition Monitoring for Determination of the Fluid Status in Volunteers Undergoing Intravenous Fluid Therapy",[90],[9376,9377],"Fluid Shifts","Body Fluid Compartments",[9357],{"intervention":9380,"totalTrials":137,"cells":9381},"breathing 100% oxygen",{"EARLY_PHASE1":9382,"PHASE1":9384,"PHASE2":9386,"PHASE3":9388,"PHASE4":9390,"NA":9392},{"trials":9383,"activeCount":98},[],{"trials":9385,"activeCount":98},[],{"trials":9387,"activeCount":98},[],{"trials":9389,"activeCount":98},[],{"trials":9391,"activeCount":98},[],{"trials":9393,"activeCount":98},[9394],{"nctId":9395,"briefTitle":9396,"status":108,"phases":9397,"completion":5469,"start":9398,"conditions":9399,"interventions":9400},"NCT00406224","Effect of Oxygen Breathing on Flicker Induced Blood Flow Changes in the Optic Nerve Head",[90],"2002-12",[15],[9380],{"intervention":9402,"totalTrials":137,"cells":9403},"Brimonidine 0.2 %",{"EARLY_PHASE1":9404,"PHASE1":9406,"PHASE2":9408,"PHASE3":9410,"PHASE4":9412,"NA":9414},{"trials":9405,"activeCount":98},[],{"trials":9407,"activeCount":98},[],{"trials":9409,"activeCount":98},[],{"trials":9411,"activeCount":98},[],{"trials":9413,"activeCount":98},[],{"trials":9415,"activeCount":98},[9416],{"nctId":9417,"briefTitle":9418,"status":2011,"phases":9419,"primaryCompletion":3211,"completion":3211,"start":1855,"enrollment":98,"conditions":9420,"interventions":9422},"NCT00712777","Relation Between Intraocular Pressure Lowering Effects of Topical Brimonidine and Alpha 2 Receptor Polymorphism",[90],[21,9421],"Intraocular Pressure",[9402],{"intervention":8927,"totalTrials":137,"cells":9424},{"EARLY_PHASE1":9425,"PHASE1":9427,"PHASE2":9429,"PHASE3":9431,"PHASE4":9433,"NA":9435},{"trials":9426,"activeCount":98},[],{"trials":9428,"activeCount":98},[],{"trials":9430,"activeCount":98},[],{"trials":9432,"activeCount":98},[],{"trials":9434,"activeCount":98},[],{"trials":9436,"activeCount":98},[9437],{"nctId":8919,"briefTitle":8920,"status":108,"phases":9438,"primaryCompletion":8922,"completion":8922,"start":6232,"enrollment":569,"conditions":9439,"interventions":9440},[],[314,8924,8925],[8927,8928,8929,8930],{"intervention":8930,"totalTrials":137,"cells":9442},{"EARLY_PHASE1":9443,"PHASE1":9445,"PHASE2":9447,"PHASE3":9449,"PHASE4":9451,"NA":9453},{"trials":9444,"activeCount":98},[],{"trials":9446,"activeCount":98},[],{"trials":9448,"activeCount":98},[],{"trials":9450,"activeCount":98},[],{"trials":9452,"activeCount":98},[],{"trials":9454,"activeCount":98},[9455],{"nctId":8919,"briefTitle":8920,"status":108,"phases":9456,"primaryCompletion":8922,"completion":8922,"start":6232,"enrollment":569,"conditions":9457,"interventions":9458},[],[314,8924,8925],[8927,8928,8929,8930],{"intervention":9460,"totalTrials":137,"cells":9461},"Adenosine",{"EARLY_PHASE1":9462,"PHASE1":9464,"PHASE2":9466,"PHASE3":9468,"PHASE4":9470,"NA":9472},{"trials":9463,"activeCount":98},[],{"trials":9465,"activeCount":98},[],{"trials":9467,"activeCount":98},[],{"trials":9469,"activeCount":98},[],{"trials":9471,"activeCount":98},[],{"trials":9473,"activeCount":98},[9474],{"nctId":9475,"briefTitle":9476,"status":108,"phases":9477,"primaryCompletion":3121,"completion":3121,"start":3572,"enrollment":476,"conditions":9478,"interventions":9480},"NCT00712764","Role of Adenosine in the Control of Choroidal Blood Flow During Changes in Ocular Perfusion Pressure.",[90],[21,9479],"Microcirculation",[9460],{"intervention":8577,"totalTrials":137,"cells":9482},{"EARLY_PHASE1":9483,"PHASE1":9485,"PHASE2":9487,"PHASE3":9489,"PHASE4":9491,"NA":9493},{"trials":9484,"activeCount":98},[],{"trials":9486,"activeCount":98},[],{"trials":9488,"activeCount":98},[],{"trials":9490,"activeCount":98},[],{"trials":9492,"activeCount":98},[],{"trials":9494,"activeCount":98},[9495],{"nctId":8565,"briefTitle":8566,"status":108,"phases":9496,"completion":8568,"start":8569,"enrollment":6422,"conditions":9497,"interventions":9498},[90],[8571,8572,8573,8574],[8576,8577,8578,8579,8580,8581,8582,8583],{"intervention":8578,"totalTrials":137,"cells":9500},{"EARLY_PHASE1":9501,"PHASE1":9503,"PHASE2":9505,"PHASE3":9507,"PHASE4":9509,"NA":9511},{"trials":9502,"activeCount":98},[],{"trials":9504,"activeCount":98},[],{"trials":9506,"activeCount":98},[],{"trials":9508,"activeCount":98},[],{"trials":9510,"activeCount":98},[],{"trials":9512,"activeCount":98},[9513],{"nctId":8565,"briefTitle":8566,"status":108,"phases":9514,"completion":8568,"start":8569,"enrollment":6422,"conditions":9515,"interventions":9516},[90],[8571,8572,8573,8574],[8576,8577,8578,8579,8580,8581,8582,8583],{"intervention":8579,"totalTrials":137,"cells":9518},{"EARLY_PHASE1":9519,"PHASE1":9521,"PHASE2":9523,"PHASE3":9525,"PHASE4":9527,"NA":9529},{"trials":9520,"activeCount":98},[],{"trials":9522,"activeCount":98},[],{"trials":9524,"activeCount":98},[],{"trials":9526,"activeCount":98},[],{"trials":9528,"activeCount":98},[],{"trials":9530,"activeCount":98},[9531],{"nctId":8565,"briefTitle":8566,"status":108,"phases":9532,"completion":8568,"start":8569,"enrollment":6422,"conditions":9533,"interventions":9534},[90],[8571,8572,8573,8574],[8576,8577,8578,8579,8580,8581,8582,8583],{"intervention":8582,"totalTrials":137,"cells":9536},{"EARLY_PHASE1":9537,"PHASE1":9539,"PHASE2":9541,"PHASE3":9543,"PHASE4":9545,"NA":9547},{"trials":9538,"activeCount":98},[],{"trials":9540,"activeCount":98},[],{"trials":9542,"activeCount":98},[],{"trials":9544,"activeCount":98},[],{"trials":9546,"activeCount":98},[],{"trials":9548,"activeCount":98},[9549],{"nctId":8565,"briefTitle":8566,"status":108,"phases":9550,"completion":8568,"start":8569,"enrollment":6422,"conditions":9551,"interventions":9552},[90],[8571,8572,8573,8574],[8576,8577,8578,8579,8580,8581,8582,8583],{"intervention":8583,"totalTrials":137,"cells":9554},{"EARLY_PHASE1":9555,"PHASE1":9557,"PHASE2":9559,"PHASE3":9561,"PHASE4":9563,"NA":9565},{"trials":9556,"activeCount":98},[],{"trials":9558,"activeCount":98},[],{"trials":9560,"activeCount":98},[],{"trials":9562,"activeCount":98},[],{"trials":9564,"activeCount":98},[],{"trials":9566,"activeCount":98},[9567],{"nctId":8565,"briefTitle":8566,"status":108,"phases":9568,"completion":8568,"start":8569,"enrollment":6422,"conditions":9569,"interventions":9570},[90],[8571,8572,8573,8574],[8576,8577,8578,8579,8580,8581,8582,8583],{"intervention":9572,"totalTrials":137,"cells":9573},"Enteral Dose Form",{"EARLY_PHASE1":9574,"PHASE1":9576,"PHASE2":9578,"PHASE3":9580,"PHASE4":9582,"NA":9584},{"trials":9575,"activeCount":98},[],{"trials":9577,"activeCount":98},[],{"trials":9579,"activeCount":98},[],{"trials":9581,"activeCount":98},[],{"trials":9583,"activeCount":98},[],{"trials":9585,"activeCount":98},[9586],{"nctId":9587,"briefTitle":9588,"status":1092,"phases":9589,"primaryCompletion":9590,"completion":9591,"start":9592,"enrollment":4010,"conditions":9593,"interventions":9597},"NCT05595395","The Enteral Resuscitation In Intensive Care Pilot- Study",[90],"2024-12-01","2025-06-01","2023-02-13",[9594,9595,9596],"Electrolyte Imbalance","Volume Overload","Hyperosmolality",[9572,9598],"Intravenous",{"intervention":9598,"totalTrials":137,"cells":9600},{"EARLY_PHASE1":9601,"PHASE1":9603,"PHASE2":9605,"PHASE3":9607,"PHASE4":9609,"NA":9611},{"trials":9602,"activeCount":98},[],{"trials":9604,"activeCount":98},[],{"trials":9606,"activeCount":98},[],{"trials":9608,"activeCount":98},[],{"trials":9610,"activeCount":98},[],{"trials":9612,"activeCount":98},[9613],{"nctId":9587,"briefTitle":9588,"status":1092,"phases":9614,"primaryCompletion":9590,"completion":9591,"start":9592,"enrollment":4010,"conditions":9615,"interventions":9616},[90],[9594,9595,9596],[9572,9598],{"intervention":9135,"totalTrials":137,"cells":9618},{"EARLY_PHASE1":9619,"PHASE1":9621,"PHASE2":9623,"PHASE3":9625,"PHASE4":9627,"NA":9629},{"trials":9620,"activeCount":98},[],{"trials":9622,"activeCount":98},[],{"trials":9624,"activeCount":98},[],{"trials":9626,"activeCount":98},[],{"trials":9628,"activeCount":98},[],{"trials":9630,"activeCount":98},[9631],{"nctId":9129,"briefTitle":9130,"status":108,"phases":9632,"primaryCompletion":4079,"completion":4079,"start":1172,"enrollment":1270,"conditions":9633,"interventions":9634},[90],[9133],[9110,9135],{"intervention":9636,"totalTrials":137,"cells":9637},"Anti-Bacterial Agents",{"EARLY_PHASE1":9638,"PHASE1":9640,"PHASE2":9642,"PHASE3":9644,"PHASE4":9646,"NA":9648},{"trials":9639,"activeCount":98},[],{"trials":9641,"activeCount":98},[],{"trials":9643,"activeCount":98},[],{"trials":9645,"activeCount":98},[],{"trials":9647,"activeCount":98},[],{"trials":9649,"activeCount":98},[9650],{"nctId":9651,"briefTitle":9652,"status":108,"phases":9653,"primaryCompletion":9654,"completion":9654,"start":2105,"enrollment":476,"conditions":9655,"interventions":9657},"NCT02912520","Comparison of IgA Levels in the Bronchoalveolar Lavage Fluid of Patients With and Without Antibiotic Therapy",[],"2017-04-23",[9656],"Immunoglobulin A",[9636],{"intervention":9659,"totalTrials":137,"cells":9660},"Hormones",{"EARLY_PHASE1":9661,"PHASE1":9663,"PHASE2":9665,"PHASE3":9667,"PHASE4":9669,"NA":9671},{"trials":9662,"activeCount":98},[],{"trials":9664,"activeCount":98},[],{"trials":9666,"activeCount":98},[],{"trials":9668,"activeCount":98},[],{"trials":9670,"activeCount":98},[],{"trials":9672,"activeCount":98},[9673],{"nctId":9674,"briefTitle":9675,"status":108,"phases":9676,"primaryCompletion":9242,"completion":9242,"start":5335,"enrollment":590,"conditions":9677,"interventions":9679},"NCT01292785","Effects of Sex Steroid Hormones on Human Brain Function, Structure and Connectivity",[],[9678],"Gender Identity Disorder",[9659],{"intervention":9681,"totalTrials":137,"cells":9682},"Cyclopentolatehydrochloride 0,5% eye drops",{"EARLY_PHASE1":9683,"PHASE1":9685,"PHASE2":9687,"PHASE3":9689,"PHASE4":9691,"NA":9693},{"trials":9684,"activeCount":98},[],{"trials":9686,"activeCount":98},[],{"trials":9688,"activeCount":98},[],{"trials":9690,"activeCount":98},[],{"trials":9692,"activeCount":98},[],{"trials":9694,"activeCount":98},[9695],{"nctId":9696,"briefTitle":9697,"status":108,"phases":9698,"primaryCompletion":9242,"completion":9242,"start":2971,"enrollment":1061,"conditions":9699,"interventions":9703},"NCT02409641","A Pilot Study Investigating the Impact of Different IOL Designs on Subjective 2D and 3D Image Quality",[90],[9700,9701,9702],"Lenses","Intraocular Sensitivity","Visual Acuity",[9681],{"intervention":9705,"totalTrials":137,"cells":9706},"ranibizumab, bevacizumab or pegaptanib",{"EARLY_PHASE1":9707,"PHASE1":9709,"PHASE2":9711,"PHASE3":9713,"PHASE4":9715,"NA":9717},{"trials":9708,"activeCount":98},[],{"trials":9710,"activeCount":98},[],{"trials":9712,"activeCount":98},[],{"trials":9714,"activeCount":98},[],{"trials":9716,"activeCount":98},[],{"trials":9718,"activeCount":98},[9719],{"nctId":9720,"briefTitle":9721,"status":839,"phases":9722,"primaryCompletion":2604,"completion":1983,"start":1855,"enrollment":5269,"conditions":9723,"interventions":9725},"NCT00709657","The Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head Perfusion",[90],[4950,18,9724],"Vascular Endothelial Growth Factor",[9705],{"intervention":9727,"totalTrials":137,"cells":9728},"human BNP-32",{"EARLY_PHASE1":9729,"PHASE1":9731,"PHASE2":9733,"PHASE3":9735,"PHASE4":9737,"NA":9739},{"trials":9730,"activeCount":98},[],{"trials":9732,"activeCount":98},[],{"trials":9734,"activeCount":98},[],{"trials":9736,"activeCount":98},[],{"trials":9738,"activeCount":98},[],{"trials":9740,"activeCount":98},[9741],{"nctId":9742,"briefTitle":9743,"status":108,"phases":9744,"primaryCompletion":1854,"completion":1854,"start":3286,"enrollment":486,"conditions":9745,"interventions":9747},"NCT01324739","B-type Natriuretic Peptide and Glucose Metabolism",[90],[5985,9746],"Cardiomyopathy",[9727],{"intervention":9749,"totalTrials":137,"cells":9750},"Nimodipine",{"EARLY_PHASE1":9751,"PHASE1":9753,"PHASE2":9755,"PHASE3":9757,"PHASE4":9759,"NA":9761},{"trials":9752,"activeCount":98},[],{"trials":9754,"activeCount":98},[],{"trials":9756,"activeCount":98},[],{"trials":9758,"activeCount":98},[],{"trials":9760,"activeCount":98},[],{"trials":9762,"activeCount":98},[9763],{"nctId":9764,"briefTitle":9765,"status":1092,"phases":9766,"primaryCompletion":9767,"completion":69,"start":9768,"enrollment":1061,"conditions":9769,"interventions":9773},"NCT04649398","Cerebral Nimodipine Concentrations Following Oral, Intra-venous and Intra-arterial Administration",[],"2024-07-31","2020-11-25",[9770,9771,9772],"Subarachnoid Hemorrhage, Aneurysmal","Delayed Cerebral Ischemia","Vasospasm, Cerebral",[9749],{"intervention":9775,"totalTrials":137,"cells":9776},"Single oral dose of selected medicines, respectively",{"EARLY_PHASE1":9777,"PHASE1":9779,"PHASE2":9781,"PHASE3":9783,"PHASE4":9785,"NA":9787},{"trials":9778,"activeCount":98},[],{"trials":9780,"activeCount":98},[],{"trials":9782,"activeCount":98},[],{"trials":9784,"activeCount":98},[],{"trials":9786,"activeCount":98},[],{"trials":9788,"activeCount":98},[9789],{"nctId":9790,"briefTitle":9791,"status":108,"phases":9792,"primaryCompletion":7653,"completion":9793,"start":9794,"enrollment":30,"conditions":9795,"interventions":9797},"NCT06710600","Phototoxicity of Frequently Prescribed Medicines",[90],"2024-10-03","2022-09-22",[9796],"Phototoxicity",[9775,9775],{"intervention":9799,"totalTrials":137,"cells":9800},"indometacine (drug) effect on ocular blood flow",{"EARLY_PHASE1":9801,"PHASE1":9803,"PHASE2":9805,"PHASE3":9807,"PHASE4":9809,"NA":9811},{"trials":9802,"activeCount":98},[],{"trials":9804,"activeCount":98},[],{"trials":9806,"activeCount":98},[],{"trials":9808,"activeCount":98},[],{"trials":9810,"activeCount":98},[],{"trials":9812,"activeCount":98},[9813],{"nctId":9814,"briefTitle":9815,"status":108,"phases":9816,"completion":6580,"start":843,"enrollment":30,"conditions":9817,"interventions":9818},"NCT00275730","Effects of Indomethacin on Retinal and Choroidal Blood Flow in Healthy Volunteers",[90],[21,18],[9799],{"intervention":9820,"totalTrials":137,"cells":9821},"Amyloid-specific treatment",{"EARLY_PHASE1":9822,"PHASE1":9824,"PHASE2":9826,"PHASE3":9828,"PHASE4":9830,"NA":9832},{"trials":9823,"activeCount":98},[],{"trials":9825,"activeCount":98},[],{"trials":9827,"activeCount":98},[],{"trials":9829,"activeCount":98},[],{"trials":9831,"activeCount":98},[],{"trials":9833,"activeCount":98},[9834],{"nctId":9835,"briefTitle":9836,"status":1092,"phases":9837,"primaryCompletion":2131,"completion":2131,"start":9838,"enrollment":2359,"conditions":9839,"interventions":9841},"NCT06129331","Aortic Stenosis and Cardiac Amyloidosis",[],"2023-03-01",[9840,2678],"Cardiac Amyloidosis",[9820],{"intervention":9843,"totalTrials":137,"cells":9844},"Keflex",{"EARLY_PHASE1":9845,"PHASE1":9847,"PHASE2":9849,"PHASE3":9851,"PHASE4":9853,"NA":9855},{"trials":9846,"activeCount":98},[],{"trials":9848,"activeCount":98},[],{"trials":9850,"activeCount":98},[],{"trials":9852,"activeCount":98},[],{"trials":9854,"activeCount":98},[],{"trials":9856,"activeCount":98},[9857],{"nctId":9858,"briefTitle":9859,"status":108,"phases":9860,"primaryCompletion":6232,"completion":6232,"start":3573,"enrollment":9861,"conditions":9862,"interventions":9864},"NCT01248078","Antibiotic Prophylaxis Before Surgery Versus After Cord Clamping in Elective Cesarean Delivery - a Double-blind, Prospective, Randomized Placebo-controlled Trial",[90],1112,[9863],"Elective Cesarean Section",[9843,9843,9865],"saline solution",{"intervention":9865,"totalTrials":137,"cells":9867},{"EARLY_PHASE1":9868,"PHASE1":9870,"PHASE2":9872,"PHASE3":9874,"PHASE4":9876,"NA":9878},{"trials":9869,"activeCount":98},[],{"trials":9871,"activeCount":98},[],{"trials":9873,"activeCount":98},[],{"trials":9875,"activeCount":98},[],{"trials":9877,"activeCount":98},[],{"trials":9879,"activeCount":98},[9880],{"nctId":9858,"briefTitle":9859,"status":108,"phases":9881,"primaryCompletion":6232,"completion":6232,"start":3573,"enrollment":9861,"conditions":9882,"interventions":9883},[90],[9863],[9843,9843,9865],{"intervention":9885,"totalTrials":137,"cells":9886},"Comparator 1",{"EARLY_PHASE1":9887,"PHASE1":9889,"PHASE2":9891,"PHASE3":9893,"PHASE4":9895,"NA":9897},{"trials":9888,"activeCount":98},[],{"trials":9890,"activeCount":98},[],{"trials":9892,"activeCount":98},[],{"trials":9894,"activeCount":98},[],{"trials":9896,"activeCount":98},[],{"trials":9898,"activeCount":98},[9899],{"nctId":9900,"briefTitle":9901,"status":1092,"phases":9902,"primaryCompletion":2025,"completion":2025,"start":5335,"enrollment":9903,"conditions":9904,"interventions":9906},"NCT01350089","Possible Effects of Energy Drink Ingestion on Perceived Alcohol Intoxication",[90],52,[9905],"Perceived Alcohol Intoxication",[9885,9907,9908],"Comparator 2","Comparator 3",{"intervention":9907,"totalTrials":137,"cells":9910},{"EARLY_PHASE1":9911,"PHASE1":9913,"PHASE2":9915,"PHASE3":9917,"PHASE4":9919,"NA":9921},{"trials":9912,"activeCount":98},[],{"trials":9914,"activeCount":98},[],{"trials":9916,"activeCount":98},[],{"trials":9918,"activeCount":98},[],{"trials":9920,"activeCount":98},[],{"trials":9922,"activeCount":98},[9923],{"nctId":9900,"briefTitle":9901,"status":1092,"phases":9924,"primaryCompletion":2025,"completion":2025,"start":5335,"enrollment":9903,"conditions":9925,"interventions":9926},[90],[9905],[9885,9907,9908],{"intervention":9908,"totalTrials":137,"cells":9928},{"EARLY_PHASE1":9929,"PHASE1":9931,"PHASE2":9933,"PHASE3":9935,"PHASE4":9937,"NA":9939},{"trials":9930,"activeCount":98},[],{"trials":9932,"activeCount":98},[],{"trials":9934,"activeCount":98},[],{"trials":9936,"activeCount":98},[],{"trials":9938,"activeCount":98},[],{"trials":9940,"activeCount":98},[9941],{"nctId":9900,"briefTitle":9901,"status":1092,"phases":9942,"primaryCompletion":2025,"completion":2025,"start":5335,"enrollment":9903,"conditions":9943,"interventions":9944},[90],[9905],[9885,9907,9908],{"intervention":9946,"totalTrials":137,"cells":9947},"intensive insulin therapy",{"EARLY_PHASE1":9948,"PHASE1":9950,"PHASE2":9952,"PHASE3":9954,"PHASE4":9956,"NA":9958},{"trials":9949,"activeCount":98},[],{"trials":9951,"activeCount":98},[],{"trials":9953,"activeCount":98},[],{"trials":9955,"activeCount":98},[],{"trials":9957,"activeCount":98},[],{"trials":9959,"activeCount":98},[9960],{"nctId":9961,"briefTitle":9962,"status":108,"phases":9963,"primaryCompletion":9964,"completion":9964,"start":2287,"enrollment":356,"conditions":9965,"interventions":9966},"NCT00494078","Efficiency of Continuous Glucose Monitoring in Critically Ill Patients",[90],"2008-08",[34],[9946],{"intervention":9968,"totalTrials":137,"cells":9969},"Cationorm MD sine eye drops",{"EARLY_PHASE1":9970,"PHASE1":9972,"PHASE2":9974,"PHASE3":9976,"PHASE4":9978,"NA":9980},{"trials":9971,"activeCount":98},[],{"trials":9973,"activeCount":98},[],{"trials":9975,"activeCount":98},[],{"trials":9977,"activeCount":98},[],{"trials":9979,"activeCount":98},[],{"trials":9981,"activeCount":98},[9982],{"nctId":9983,"briefTitle":9984,"status":108,"phases":9985,"primaryCompletion":9986,"completion":9986,"start":9987,"enrollment":30,"conditions":9988,"interventions":9989},"NCT03399292","Effect of Lipid Based Eye Drops on Tear Film Lipid Layer Thickness",[],"2024-11-26","2017-04-12",[29],[9968],{"intervention":9991,"totalTrials":137,"cells":9992},"Nifedipine",{"EARLY_PHASE1":9993,"PHASE1":9995,"PHASE2":9997,"PHASE3":9999,"PHASE4":10001,"NA":10003},{"trials":9994,"activeCount":98},[],{"trials":9996,"activeCount":98},[],{"trials":9998,"activeCount":98},[],{"trials":10000,"activeCount":98},[],{"trials":10002,"activeCount":98},[],{"trials":10004,"activeCount":98},[10005],{"nctId":10006,"briefTitle":10007,"status":108,"phases":10008,"primaryCompletion":7965,"completion":7965,"start":4183,"enrollment":19,"conditions":10009,"interventions":10010},"NCT00280462","Choroidal Blood Flow Regulation During Isometric Exercise: Effects of Ca2+-Channel Blockade",[90],[21,18],[9991,10011],"L-Arginin",{"intervention":10011,"totalTrials":137,"cells":10013},{"EARLY_PHASE1":10014,"PHASE1":10016,"PHASE2":10018,"PHASE3":10020,"PHASE4":10022,"NA":10024},{"trials":10015,"activeCount":98},[],{"trials":10017,"activeCount":98},[],{"trials":10019,"activeCount":98},[],{"trials":10021,"activeCount":98},[],{"trials":10023,"activeCount":98},[],{"trials":10025,"activeCount":98},[10026],{"nctId":10006,"briefTitle":10007,"status":108,"phases":10027,"primaryCompletion":7965,"completion":7965,"start":4183,"enrollment":19,"conditions":10028,"interventions":10029},[90],[21,18],[9991,10011],{"intervention":10031,"totalTrials":137,"cells":10032},"Anesthetics",{"EARLY_PHASE1":10033,"PHASE1":10035,"PHASE2":10037,"PHASE3":10039,"PHASE4":10041,"NA":10043},{"trials":10034,"activeCount":98},[],{"trials":10036,"activeCount":98},[],{"trials":10038,"activeCount":98},[],{"trials":10040,"activeCount":98},[],{"trials":10042,"activeCount":98},[],{"trials":10044,"activeCount":98},[10045],{"nctId":10046,"briefTitle":10047,"status":2011,"phases":10048,"primaryCompletion":10049,"completion":10049,"start":10049,"enrollment":98,"conditions":10050,"interventions":10052},"NCT03239236","Modified Rapid Sequence Induction in Morbidly Obese Patients",[90],"2021-02",[10051],"Anesthesia Intubation Complication",[10031],{"intervention":10054,"totalTrials":137,"cells":10055},"Vasoactive Intestinal Peptide",{"EARLY_PHASE1":10056,"PHASE1":10058,"PHASE2":10060,"PHASE3":10062,"PHASE4":10064,"NA":10066},{"trials":10057,"activeCount":98},[],{"trials":10059,"activeCount":98},[],{"trials":10061,"activeCount":98},[],{"trials":10063,"activeCount":98},[],{"trials":10065,"activeCount":98},[],{"trials":10067,"activeCount":98},[10068],{"nctId":10069,"briefTitle":10070,"status":108,"phases":10071,"completion":6326,"start":10072,"enrollment":2121,"conditions":10073,"interventions":10074},"NCT00464932","Vasoactive Intestinal Peptide in COPD",[],"2003-06",[6453,4526],[10054],{"intervention":10076,"totalTrials":137,"cells":10077},"TNF-alpha inhibitors",{"EARLY_PHASE1":10078,"PHASE1":10080,"PHASE2":10082,"PHASE3":10084,"PHASE4":10086,"NA":10088},{"trials":10079,"activeCount":98},[],{"trials":10081,"activeCount":98},[],{"trials":10083,"activeCount":98},[],{"trials":10085,"activeCount":98},[],{"trials":10087,"activeCount":98},[],{"trials":10089,"activeCount":98},[10090],{"nctId":10091,"briefTitle":10092,"status":108,"phases":10093,"primaryCompletion":5335,"completion":5335,"start":841,"enrollment":10094,"conditions":10095,"interventions":10097},"NCT02376478","On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection",[],222,[3288,10096],"Inflammatory Bowel Diseases",[10076,10098,10099],"Alternative\u002Fno medication","Purine\u002Ffolic acid analogues",{"intervention":10098,"totalTrials":137,"cells":10101},{"EARLY_PHASE1":10102,"PHASE1":10104,"PHASE2":10106,"PHASE3":10108,"PHASE4":10110,"NA":10112},{"trials":10103,"activeCount":98},[],{"trials":10105,"activeCount":98},[],{"trials":10107,"activeCount":98},[],{"trials":10109,"activeCount":98},[],{"trials":10111,"activeCount":98},[],{"trials":10113,"activeCount":98},[10114],{"nctId":10091,"briefTitle":10092,"status":108,"phases":10115,"primaryCompletion":5335,"completion":5335,"start":841,"enrollment":10094,"conditions":10116,"interventions":10117},[],[3288,10096],[10076,10098,10099],{"intervention":10099,"totalTrials":137,"cells":10119},{"EARLY_PHASE1":10120,"PHASE1":10122,"PHASE2":10124,"PHASE3":10126,"PHASE4":10128,"NA":10130},{"trials":10121,"activeCount":98},[],{"trials":10123,"activeCount":98},[],{"trials":10125,"activeCount":98},[],{"trials":10127,"activeCount":98},[],{"trials":10129,"activeCount":98},[],{"trials":10131,"activeCount":98},[10132],{"nctId":10091,"briefTitle":10092,"status":108,"phases":10133,"primaryCompletion":5335,"completion":5335,"start":841,"enrollment":10094,"conditions":10134,"interventions":10135},[],[3288,10096],[10076,10098,10099],{"intervention":10137,"totalTrials":137,"cells":10138},"Dronabinol",{"EARLY_PHASE1":10139,"PHASE1":10141,"PHASE2":10143,"PHASE3":10145,"PHASE4":10147,"NA":10149},{"trials":10140,"activeCount":98},[],{"trials":10142,"activeCount":98},[],{"trials":10144,"activeCount":98},[],{"trials":10146,"activeCount":98},[],{"trials":10148,"activeCount":98},[],{"trials":10150,"activeCount":98},[10151],{"nctId":10152,"briefTitle":10153,"status":108,"phases":10154,"primaryCompletion":10155,"completion":10155,"start":10156,"enrollment":1097,"conditions":10157,"interventions":10158},"NCT03907163","The Effect of Tetrahydrocannabinol on Ocular Hemodynamics in Healthy Subjects",[90],"2018-11-27","2018-07-02",[4742],[10137],{"intervention":8813,"totalTrials":137,"cells":10160},{"EARLY_PHASE1":10161,"PHASE1":10163,"PHASE2":10165,"PHASE3":10167,"PHASE4":10169,"NA":10171},{"trials":10162,"activeCount":98},[],{"trials":10164,"activeCount":98},[],{"trials":10166,"activeCount":98},[],{"trials":10168,"activeCount":98},[],{"trials":10170,"activeCount":98},[],{"trials":10172,"activeCount":98},[10173],{"nctId":8807,"briefTitle":8808,"status":108,"phases":10174,"primaryCompletion":2025,"completion":2025,"start":4948,"enrollment":1746,"conditions":10175,"interventions":10176},[90],[3056,8811],[8813,1912],{"intervention":10178,"totalTrials":137,"cells":10179},"Esketamine hydrochloride",{"EARLY_PHASE1":10180,"PHASE1":10182,"PHASE2":10184,"PHASE3":10186,"PHASE4":10188,"NA":10190},{"trials":10181,"activeCount":98},[],{"trials":10183,"activeCount":98},[],{"trials":10185,"activeCount":98},[],{"trials":10187,"activeCount":98},[],{"trials":10189,"activeCount":98},[],{"trials":10191,"activeCount":98},[10192],{"nctId":10193,"briefTitle":10194,"status":108,"phases":10195,"primaryCompletion":4985,"completion":4985,"start":1992,"enrollment":9903,"conditions":10196,"interventions":10197},"NCT01394757","Network Dysfunction, Schizophrenia and Pharmacological Magnetic Resonance Imaging (phMRI)",[90],[2081],[10178],{"intervention":10199,"totalTrials":137,"cells":10200},"18F Fluoroazomycin Arabinoside",{"EARLY_PHASE1":10201,"PHASE1":10203,"PHASE2":10205,"PHASE3":10207,"PHASE4":10209,"NA":10211},{"trials":10202,"activeCount":98},[],{"trials":10204,"activeCount":98},[],{"trials":10206,"activeCount":98},[],{"trials":10208,"activeCount":98},[],{"trials":10210,"activeCount":98},[],{"trials":10212,"activeCount":98},[10213],{"nctId":10214,"briefTitle":10215,"status":1092,"phases":10216,"completion":2371,"start":6326,"enrollment":10217,"conditions":10218,"interventions":10219},"NCT00388687","Hypoxia Imaging With 18F FAZA. Prognostic Impact in Cervical Cancer",[],25,[638],[10199],{"intervention":9224,"totalTrials":137,"cells":10221},{"EARLY_PHASE1":10222,"PHASE1":10224,"PHASE2":10226,"PHASE3":10228,"PHASE4":10230,"NA":10232},{"trials":10223,"activeCount":98},[],{"trials":10225,"activeCount":98},[],{"trials":10227,"activeCount":98},[],{"trials":10229,"activeCount":98},[],{"trials":10231,"activeCount":98},[],{"trials":10233,"activeCount":98},[10234],{"nctId":9219,"briefTitle":9220,"status":2011,"phases":10235,"primaryCompletion":3211,"completion":3211,"start":2674,"enrollment":98,"conditions":10236,"interventions":10237},[90],[27],[9224,9225,9226],{"intervention":9225,"totalTrials":137,"cells":10239},{"EARLY_PHASE1":10240,"PHASE1":10242,"PHASE2":10244,"PHASE3":10246,"PHASE4":10248,"NA":10250},{"trials":10241,"activeCount":98},[],{"trials":10243,"activeCount":98},[],{"trials":10245,"activeCount":98},[],{"trials":10247,"activeCount":98},[],{"trials":10249,"activeCount":98},[],{"trials":10251,"activeCount":98},[10252],{"nctId":9219,"briefTitle":9220,"status":2011,"phases":10253,"primaryCompletion":3211,"completion":3211,"start":2674,"enrollment":98,"conditions":10254,"interventions":10255},[90],[27],[9224,9225,9226],{"intervention":10257,"totalTrials":137,"cells":10258},"oxytocin",{"EARLY_PHASE1":10259,"PHASE1":10261,"PHASE2":10263,"PHASE3":10265,"PHASE4":10267,"NA":10269},{"trials":10260,"activeCount":98},[],{"trials":10262,"activeCount":98},[],{"trials":10264,"activeCount":98},[],{"trials":10266,"activeCount":98},[],{"trials":10268,"activeCount":98},[],{"trials":10270,"activeCount":98},[10271],{"nctId":10272,"briefTitle":10273,"status":108,"phases":10274,"start":6580,"enrollment":486,"conditions":10275,"interventions":10276},"NCT00360048","Oxytocin Effects on Cytokines and Endocrine Parameters After LPS Induced Systemic Inflammatory Effects in Healthy Volunteers",[],[2082],[10257],{"intervention":10278,"totalTrials":137,"cells":10279},"Vit C",{"EARLY_PHASE1":10280,"PHASE1":10282,"PHASE2":10284,"PHASE3":10286,"PHASE4":10288,"NA":10290},{"trials":10281,"activeCount":98},[],{"trials":10283,"activeCount":98},[],{"trials":10285,"activeCount":98},[],{"trials":10287,"activeCount":98},[],{"trials":10289,"activeCount":98},[],{"trials":10291,"activeCount":98},[10292],{"nctId":10293,"briefTitle":10294,"status":1092,"phases":10295,"start":6579,"conditions":10296,"interventions":10297},"NCT00534924","The Effects of Post-Conditioning and Administration of Vitamin C on Intramuscular High Energy Phosphate Levels",[90],[1867],[10278],{"intervention":10299,"totalTrials":137,"cells":10300},"Cyclopentolatehydrochloride",{"EARLY_PHASE1":10301,"PHASE1":10303,"PHASE2":10305,"PHASE3":10307,"PHASE4":10309,"NA":10311},{"trials":10302,"activeCount":98},[],{"trials":10304,"activeCount":98},[],{"trials":10306,"activeCount":98},[],{"trials":10308,"activeCount":98},[],{"trials":10310,"activeCount":98},[],{"trials":10312,"activeCount":98},[10313],{"nctId":10314,"briefTitle":10315,"status":108,"phases":10316,"primaryCompletion":3810,"completion":3810,"start":10317,"enrollment":1061,"conditions":10318,"interventions":10321},"NCT01873781","A Pilot Study Simulating Multifocal Intraocular Lenses in Healthy Subjects",[],"2013-04",[10319,10320,9702],"Lenses, Intraocular","Contrast Sensitivity",[10299],{"intervention":10323,"totalTrials":137,"cells":10324},"the polymerase chain reaction",{"EARLY_PHASE1":10325,"PHASE1":10327,"PHASE2":10329,"PHASE3":10331,"PHASE4":10333,"NA":10335},{"trials":10326,"activeCount":98},[],{"trials":10328,"activeCount":98},[],{"trials":10330,"activeCount":98},[],{"trials":10332,"activeCount":98},[],{"trials":10334,"activeCount":98},[],{"trials":10336,"activeCount":98},[10337],{"nctId":10338,"briefTitle":10339,"status":1092,"phases":10340,"primaryCompletion":4034,"completion":4034,"start":1047,"enrollment":6098,"conditions":10341,"interventions":10342},"NCT02102880","The Role of Complement Factor H Polymorphism in the Regulation of Choroidal Vascular Tone in Young Healthy Subjects",[90],[6837],[10323],{"intervention":10344,"totalTrials":137,"cells":10345},"Darvadstrocel",{"EARLY_PHASE1":10346,"PHASE1":10348,"PHASE2":10350,"PHASE3":10352,"PHASE4":10354,"NA":10356},{"trials":10347,"activeCount":98},[],{"trials":10349,"activeCount":98},[],{"trials":10351,"activeCount":98},[],{"trials":10353,"activeCount":98},[],{"trials":10355,"activeCount":98},[],{"trials":10357,"activeCount":98},[10358],{"nctId":10359,"briefTitle":10360,"status":108,"phases":10361,"primaryCompletion":111,"completion":111,"start":10362,"enrollment":8867,"conditions":10363,"interventions":10366},"NCT05322057","Efficacy of Cx601 (Darvadstrocel) for the Treatment of Perianal Fistulizing Crohn's Disease",[],"2018-10-01",[10364,10365],"Crohn Disease","Fistula Perianal",[10344],{"intervention":10368,"totalTrials":137,"cells":10369},"Oxygen",{"EARLY_PHASE1":10370,"PHASE1":10372,"PHASE2":10374,"PHASE3":10376,"PHASE4":10378,"NA":10380},{"trials":10371,"activeCount":98},[],{"trials":10373,"activeCount":98},[],{"trials":10375,"activeCount":98},[],{"trials":10377,"activeCount":98},[],{"trials":10379,"activeCount":98},[],{"trials":10381,"activeCount":98},[10382],{"nctId":10383,"briefTitle":10384,"status":108,"phases":10385,"primaryCompletion":10386,"completion":2051,"start":1114,"enrollment":6692,"conditions":10387,"interventions":10390},"NCT00914407","Measurement of Retinal Blood Flow, Retinal Oxygenation and Retinal Oxygen Extraction in Healthy Subjects During Normoxia and Systemic Hyperoxia",[90],"2016-12-10",[15,10388,10389],"Normoxia","Systemic Hypoxia",[10368],{"intervention":10392,"totalTrials":137,"cells":10393},"Latanoprost 0.005%, Xalatan®",{"EARLY_PHASE1":10394,"PHASE1":10396,"PHASE2":10398,"PHASE3":10400,"PHASE4":10402,"NA":10404},{"trials":10395,"activeCount":98},[],{"trials":10397,"activeCount":98},[],{"trials":10399,"activeCount":98},[],{"trials":10401,"activeCount":98},[],{"trials":10403,"activeCount":98},[],{"trials":10405,"activeCount":98},[10406],{"nctId":10407,"briefTitle":10408,"status":108,"phases":10409,"primaryCompletion":1095,"completion":6232,"start":8154,"enrollment":1097,"conditions":10410,"interventions":10411},"NCT00712400","Effects of Latanoprost on Choroidal Blood Flow Regulation in Human Subjects",[90],[21,9421,18],[10392],{"intervention":10413,"totalTrials":137,"cells":10414},"BNP",{"EARLY_PHASE1":10415,"PHASE1":10417,"PHASE2":10419,"PHASE3":10421,"PHASE4":10423,"NA":10425},{"trials":10416,"activeCount":98},[],{"trials":10418,"activeCount":98},[],{"trials":10420,"activeCount":98},[],{"trials":10422,"activeCount":98},[],{"trials":10424,"activeCount":98},[],{"trials":10426,"activeCount":98},[10427],{"nctId":10428,"briefTitle":10429,"status":108,"phases":10430,"primaryCompletion":854,"completion":2433,"start":2079,"enrollment":486,"conditions":10431,"interventions":10432},"NCT01375153","Brain Natriuretic Peptide Effects on Appetite Regulating Hormones and Endothelial Derived Peptides",[90],[15],[10413,10433],"0.9% NaCl",{"intervention":10433,"totalTrials":137,"cells":10435},{"EARLY_PHASE1":10436,"PHASE1":10438,"PHASE2":10440,"PHASE3":10442,"PHASE4":10444,"NA":10446},{"trials":10437,"activeCount":98},[],{"trials":10439,"activeCount":98},[],{"trials":10441,"activeCount":98},[],{"trials":10443,"activeCount":98},[],{"trials":10445,"activeCount":98},[],{"trials":10447,"activeCount":98},[10448],{"nctId":10428,"briefTitle":10429,"status":108,"phases":10449,"primaryCompletion":854,"completion":2433,"start":2079,"enrollment":486,"conditions":10450,"interventions":10451},[90],[15],[10413,10433],{"intervention":10453,"totalTrials":137,"cells":10454},"Eplerenone",{"EARLY_PHASE1":10455,"PHASE1":10457,"PHASE2":10459,"PHASE3":10461,"PHASE4":10463,"NA":10465},{"trials":10456,"activeCount":98},[],{"trials":10458,"activeCount":98},[],{"trials":10460,"activeCount":98},[],{"trials":10462,"activeCount":98},[],{"trials":10464,"activeCount":98},[],{"trials":10466,"activeCount":98},[10467],{"nctId":10468,"briefTitle":10469,"status":1092,"phases":10470,"primaryCompletion":10471,"completion":40,"start":1908,"enrollment":1097,"conditions":10472,"interventions":10474},"NCT01832558","The EPOCH Study (Eplerenone on Top of ACE Inhibition in Chronic Kidney Disease Patients With Hypertension)",[90],"2020-12-31",[10473],"CKD II-III",[10453],{"intervention":8755,"totalTrials":137,"cells":10476},{"EARLY_PHASE1":10477,"PHASE1":10479,"PHASE2":10481,"PHASE3":10483,"PHASE4":10485,"NA":10487},{"trials":10478,"activeCount":98},[],{"trials":10480,"activeCount":98},[],{"trials":10482,"activeCount":98},[],{"trials":10484,"activeCount":98},[],{"trials":10486,"activeCount":98},[],{"trials":10488,"activeCount":98},[10489],{"nctId":8749,"briefTitle":8750,"status":108,"phases":10490,"primaryCompletion":3810,"completion":3810,"start":1171,"enrollment":112,"conditions":10491,"interventions":10492},[90],[15],[8754,8754,8755,8717],{"intervention":10494,"totalTrials":137,"cells":10495},"itraconazole",{"EARLY_PHASE1":10496,"PHASE1":10498,"PHASE2":10500,"PHASE3":10502,"PHASE4":10504,"NA":10506},{"trials":10497,"activeCount":98},[],{"trials":10499,"activeCount":98},[],{"trials":10501,"activeCount":98},[],{"trials":10503,"activeCount":98},[],{"trials":10505,"activeCount":98},[],{"trials":10507,"activeCount":98},[10508],{"nctId":10509,"briefTitle":10510,"status":108,"phases":10511,"primaryCompletion":2675,"completion":2675,"start":10512,"enrollment":10513,"conditions":10514,"interventions":10516},"NCT00895453","Monthly Itraconazole Versus Classic Homeopathy for Treatment of Recurrent Vulvovaginal Candidiasis (RVVC)",[90],"2000-05",144,[10515],"Vulvovaginal Candidiasis",[10494,10517,10518],"lactobacillus gasseri","classic homeopathy",{"intervention":10517,"totalTrials":137,"cells":10520},{"EARLY_PHASE1":10521,"PHASE1":10523,"PHASE2":10525,"PHASE3":10527,"PHASE4":10529,"NA":10531},{"trials":10522,"activeCount":98},[],{"trials":10524,"activeCount":98},[],{"trials":10526,"activeCount":98},[],{"trials":10528,"activeCount":98},[],{"trials":10530,"activeCount":98},[],{"trials":10532,"activeCount":98},[10533],{"nctId":10509,"briefTitle":10510,"status":108,"phases":10534,"primaryCompletion":2675,"completion":2675,"start":10512,"enrollment":10513,"conditions":10535,"interventions":10536},[90],[10515],[10494,10517,10518],{"intervention":10518,"totalTrials":137,"cells":10538},{"EARLY_PHASE1":10539,"PHASE1":10541,"PHASE2":10543,"PHASE3":10545,"PHASE4":10547,"NA":10549},{"trials":10540,"activeCount":98},[],{"trials":10542,"activeCount":98},[],{"trials":10544,"activeCount":98},[],{"trials":10546,"activeCount":98},[],{"trials":10548,"activeCount":98},[],{"trials":10550,"activeCount":98},[10551],{"nctId":10509,"briefTitle":10510,"status":108,"phases":10552,"primaryCompletion":2675,"completion":2675,"start":10512,"enrollment":10513,"conditions":10553,"interventions":10554},[90],[10515],[10494,10517,10518],{"intervention":10556,"totalTrials":137,"cells":10557},"Blood sampling",{"EARLY_PHASE1":10558,"PHASE1":10560,"PHASE2":10562,"PHASE3":10564,"PHASE4":10566,"NA":10568},{"trials":10559,"activeCount":98},[],{"trials":10561,"activeCount":98},[],{"trials":10563,"activeCount":98},[],{"trials":10565,"activeCount":98},[],{"trials":10567,"activeCount":98},[],{"trials":10569,"activeCount":98},[10570],{"nctId":10571,"briefTitle":10572,"status":1092,"phases":10573,"primaryCompletion":5866,"completion":10574,"start":10575,"enrollment":1292,"conditions":10576,"interventions":10578},"NCT03306719","mtDNA as Novel Biomarker for Intra-amniotic Infection",[],"2018-12-31","2017-04-05",[10577],"Preterm Premature Rupture of Membrane",[10556],{"intervention":10580,"totalTrials":137,"cells":10581},"VEGF genotyping",{"EARLY_PHASE1":10582,"PHASE1":10584,"PHASE2":10586,"PHASE3":10588,"PHASE4":10590,"NA":10592},{"trials":10583,"activeCount":98},[],{"trials":10585,"activeCount":98},[],{"trials":10587,"activeCount":98},[],{"trials":10589,"activeCount":98},[],{"trials":10591,"activeCount":98},[],{"trials":10593,"activeCount":98},[10594],{"nctId":10595,"briefTitle":10596,"status":2011,"phases":10597,"primaryCompletion":3211,"completion":3211,"start":1096,"enrollment":98,"conditions":10598,"interventions":10600},"NCT00813514","Does Vascular Endothelial Growth Factor (VEGF) or Complement Factor H Gene Polymorphism Play a Role in the Treatment Success With VEGF Inhibitors in Patients With Choroidal NeoVascularization (CNV)?",[90],[10599,6837],"Choroidal NeoVascularization",[10580],{"intervention":10602,"totalTrials":137,"cells":10603},"Dextroamphetamine Sulfate",{"EARLY_PHASE1":10604,"PHASE1":10606,"PHASE2":10608,"PHASE3":10610,"PHASE4":10612,"NA":10614},{"trials":10605,"activeCount":98},[],{"trials":10607,"activeCount":98},[],{"trials":10609,"activeCount":98},[],{"trials":10611,"activeCount":98},[],{"trials":10613,"activeCount":98},[],{"trials":10615,"activeCount":98},[10616],{"nctId":10617,"briefTitle":10618,"status":1092,"phases":10619,"primaryCompletion":10620,"completion":1161,"start":5868,"enrollment":1162,"conditions":10621,"interventions":10624},"NCT03223844","Influence of Amphetamine-induced Sensitization on Dopamine Synthesis and Release",[90],"2021-08",[2606,10622,10623],"Psychosis","Sensitisation",[10602],{"intervention":8871,"totalTrials":137,"cells":10626},{"EARLY_PHASE1":10627,"PHASE1":10629,"PHASE2":10631,"PHASE3":10633,"PHASE4":10635,"NA":10637},{"trials":10628,"activeCount":98},[],{"trials":10630,"activeCount":98},[],{"trials":10632,"activeCount":98},[],{"trials":10634,"activeCount":98},[],{"trials":10636,"activeCount":98},[],{"trials":10638,"activeCount":98},[10639],{"nctId":8862,"briefTitle":8863,"status":108,"phases":10640,"primaryCompletion":8865,"completion":8865,"start":8866,"enrollment":8867,"conditions":10641,"interventions":10642},[90],[27],[8870,8871,8872,7457],{"intervention":10644,"totalTrials":137,"cells":10645},"Quetiapine",{"EARLY_PHASE1":10646,"PHASE1":10648,"PHASE2":10650,"PHASE3":10652,"PHASE4":10654,"NA":10656},{"trials":10647,"activeCount":98},[],{"trials":10649,"activeCount":98},[],{"trials":10651,"activeCount":98},[],{"trials":10653,"activeCount":98},[],{"trials":10655,"activeCount":98},[],{"trials":10657,"activeCount":98},[10658],{"nctId":10659,"briefTitle":10660,"status":108,"phases":10661,"primaryCompletion":6580,"completion":6580,"start":4183,"enrollment":19,"conditions":10662,"interventions":10663},"NCT00280501","Dopaminergic Modulation of Choroidal Blood Flow Changes During Dark\u002FLight Transitions",[90],[18,21],[10644,10664],"Sulpiride",{"intervention":10664,"totalTrials":137,"cells":10666},{"EARLY_PHASE1":10667,"PHASE1":10669,"PHASE2":10671,"PHASE3":10673,"PHASE4":10675,"NA":10677},{"trials":10668,"activeCount":98},[],{"trials":10670,"activeCount":98},[],{"trials":10672,"activeCount":98},[],{"trials":10674,"activeCount":98},[],{"trials":10676,"activeCount":98},[],{"trials":10678,"activeCount":98},[10679],{"nctId":10659,"briefTitle":10660,"status":108,"phases":10680,"primaryCompletion":6580,"completion":6580,"start":4183,"enrollment":19,"conditions":10681,"interventions":10682},[90],[18,21],[10644,10664],{"intervention":10684,"totalTrials":137,"cells":10685},"latanoprost 0.005% + timolol 0,5% fixed combination",{"EARLY_PHASE1":10686,"PHASE1":10688,"PHASE2":10690,"PHASE3":10692,"PHASE4":10694,"NA":10696},{"trials":10687,"activeCount":98},[],{"trials":10689,"activeCount":98},[],{"trials":10691,"activeCount":98},[],{"trials":10693,"activeCount":98},[],{"trials":10695,"activeCount":98},[],{"trials":10697,"activeCount":98},[10698],{"nctId":10699,"briefTitle":10700,"status":108,"phases":10701,"primaryCompletion":1804,"completion":3529,"start":843,"enrollment":547,"conditions":10702,"interventions":10703},"NCT00706927","Effect of Xalacom® (Latanoprost\u002FTimolol) and Combigan® (Brimonidine\u002FTimolol) Fixed Combination on Intraocular Pressure and Ocular Blood Flow in Patients With Primary Open Angle Glaucoma or Ocular Hypertension",[90],[4924,21],[10684,10704],"brimonidine 0,2% + timolol 0,5% fixed combination",{"intervention":10704,"totalTrials":137,"cells":10706},{"EARLY_PHASE1":10707,"PHASE1":10709,"PHASE2":10711,"PHASE3":10713,"PHASE4":10715,"NA":10717},{"trials":10708,"activeCount":98},[],{"trials":10710,"activeCount":98},[],{"trials":10712,"activeCount":98},[],{"trials":10714,"activeCount":98},[],{"trials":10716,"activeCount":98},[],{"trials":10718,"activeCount":98},[10719],{"nctId":10699,"briefTitle":10700,"status":108,"phases":10720,"primaryCompletion":1804,"completion":3529,"start":843,"enrollment":547,"conditions":10721,"interventions":10722},[90],[4924,21],[10684,10704],{"intervention":10724,"totalTrials":137,"cells":10725},"Oxygen + Carbondioxide",{"EARLY_PHASE1":10726,"PHASE1":10728,"PHASE2":10730,"PHASE3":10732,"PHASE4":10734,"NA":10736},{"trials":10727,"activeCount":98},[],{"trials":10729,"activeCount":98},[],{"trials":10731,"activeCount":98},[],{"trials":10733,"activeCount":98},[],{"trials":10735,"activeCount":98},[],{"trials":10737,"activeCount":98},[10738],{"nctId":10739,"briefTitle":10740,"status":108,"phases":10741,"primaryCompletion":1873,"completion":841,"start":2794,"enrollment":1097,"conditions":10742,"interventions":10744},"NCT00719342","Effect of Breathing a Mixture of 92% Oxygen (O2) + 8% Carbon Dioxide (CO2) on Flicker Induced Blood Flow Changes in Ocular Perfusion",[90],[10743],"Flicker-induced Vasodilatation",[10724],{"intervention":10746,"totalTrials":137,"cells":10747},"Zoledronate",{"EARLY_PHASE1":10748,"PHASE1":10750,"PHASE2":10752,"PHASE3":10754,"PHASE4":10756,"NA":10758},{"trials":10749,"activeCount":98},[],{"trials":10751,"activeCount":98},[],{"trials":10753,"activeCount":98},[],{"trials":10755,"activeCount":98},[],{"trials":10757,"activeCount":98},[],{"trials":10759,"activeCount":98},[10760],{"nctId":10761,"briefTitle":10762,"status":1092,"phases":10763,"start":10764,"enrollment":6878,"conditions":10765,"interventions":10766},"NCT00302484","Use of Bisphosphonates in the Treatment of Osteopathy After Liver Transplantation",[90],"2002-04",[2040,3333],[10746],{"intervention":10768,"totalTrials":137,"cells":10769},"analyze systematically morphological and molecular changes associated with glioblastoma progression and therapy-resistance",{"EARLY_PHASE1":10770,"PHASE1":10772,"PHASE2":10774,"PHASE3":10776,"PHASE4":10778,"NA":10780},{"trials":10771,"activeCount":98},[],{"trials":10773,"activeCount":98},[],{"trials":10775,"activeCount":98},[],{"trials":10777,"activeCount":98},[],{"trials":10779,"activeCount":98},[],{"trials":10781,"activeCount":98},[10782],{"nctId":10783,"briefTitle":10784,"status":1092,"phases":10785,"primaryCompletion":2103,"completion":2103,"start":660,"enrollment":949,"conditions":10786,"interventions":10788},"NCT02152748","Disease Progression and Treatment-induced Alterations in Glioblastoma",[],[10787],"Brain Tumor",[10768],{"intervention":10790,"totalTrials":137,"cells":10791},"Belantamab mafodotin",{"EARLY_PHASE1":10792,"PHASE1":10794,"PHASE2":10796,"PHASE3":10798,"PHASE4":10800,"NA":10802},{"trials":10793,"activeCount":98},[],{"trials":10795,"activeCount":98},[],{"trials":10797,"activeCount":98},[],{"trials":10799,"activeCount":98},[],{"trials":10801,"activeCount":98},[],{"trials":10803,"activeCount":98},[10804],{"nctId":10805,"briefTitle":10806,"status":839,"phases":10807,"primaryCompletion":10808,"completion":10808,"start":157,"enrollment":30,"conditions":10809,"interventions":10813},"NCT05833737","Corneal Findings in Patients Treated With Belantamab Mafodotin",[],"2025-01-01",[10810,10811,10812],"Multiple Myeloma","Corneal Diseases","Corneal Cyst",[10790],{"intervention":10815,"totalTrials":137,"cells":10816},"MPA SNP",{"EARLY_PHASE1":10817,"PHASE1":10819,"PHASE2":10821,"PHASE3":10823,"PHASE4":10825,"NA":10827},{"trials":10818,"activeCount":98},[],{"trials":10820,"activeCount":98},[],{"trials":10822,"activeCount":98},[],{"trials":10824,"activeCount":98},[],{"trials":10826,"activeCount":98},[],{"trials":10828,"activeCount":98},[10829],{"nctId":10830,"briefTitle":10831,"status":108,"phases":10832,"primaryCompletion":10833,"completion":10833,"start":1131,"enrollment":10834,"conditions":10835,"interventions":10837},"NCT00978965","Identification of Patients With High Probability of Poorly Responding to Therapy With Mycophenolic Acid Prodrugs",[],"2020-09-09",277,[10836],"Renal Transplantation",[10815],{"intervention":10839,"totalTrials":137,"cells":10840},"Pilocarpine",{"EARLY_PHASE1":10841,"PHASE1":10843,"PHASE2":10845,"PHASE3":10847,"PHASE4":10849,"NA":10851},{"trials":10842,"activeCount":98},[],{"trials":10844,"activeCount":98},[],{"trials":10846,"activeCount":98},[],{"trials":10848,"activeCount":98},[],{"trials":10850,"activeCount":98},[],{"trials":10852,"activeCount":98},[10853],{"nctId":10854,"briefTitle":10855,"status":1092,"phases":10856,"primaryCompletion":10857,"completion":10857,"start":10858,"enrollment":128,"conditions":10859,"interventions":10860},"NCT02865473","Anterior Segment Imaging With Ultrahigh-resolution OCT in Patients With Glaucoma and PEX - a Pilot Study",[90],"2023-12","2016-04-20",[27],[10839],{"intervention":8672,"totalTrials":137,"cells":10862},{"EARLY_PHASE1":10863,"PHASE1":10865,"PHASE2":10867,"PHASE3":10869,"PHASE4":10871,"NA":10873},{"trials":10864,"activeCount":98},[],{"trials":10866,"activeCount":98},[],{"trials":10868,"activeCount":98},[],{"trials":10870,"activeCount":98},[],{"trials":10872,"activeCount":98},[],{"trials":10874,"activeCount":98},[10875],{"nctId":8665,"briefTitle":8666,"status":108,"phases":10876,"primaryCompletion":886,"completion":886,"start":3053,"enrollment":8668,"conditions":10877,"interventions":10878},[90],[8670],[6585,8672],{"intervention":10880,"totalTrials":137,"cells":10881},"Fluticasone propionate",{"EARLY_PHASE1":10882,"PHASE1":10884,"PHASE2":10886,"PHASE3":10888,"PHASE4":10890,"NA":10892},{"trials":10883,"activeCount":98},[],{"trials":10885,"activeCount":98},[],{"trials":10887,"activeCount":98},[],{"trials":10889,"activeCount":98},[],{"trials":10891,"activeCount":98},[],{"trials":10893,"activeCount":98},[10894],{"nctId":10895,"briefTitle":10896,"status":108,"phases":10897,"enrollment":6692,"conditions":10898,"interventions":10900},"NCT00755066","Effect of Intranasal Corticosteroids on Systemic Allergen Specific IgE",[90],[10899],"Seasonal Allergic Rhinitis",[10880],{"intervention":10902,"totalTrials":137,"cells":10903},"Swabs for microbiome analysis",{"EARLY_PHASE1":10904,"PHASE1":10906,"PHASE2":10908,"PHASE3":10910,"PHASE4":10912,"NA":10914},{"trials":10905,"activeCount":98},[],{"trials":10907,"activeCount":98},[],{"trials":10909,"activeCount":98},[],{"trials":10911,"activeCount":98},[],{"trials":10913,"activeCount":98},[],{"trials":10915,"activeCount":98},[10916],{"nctId":10917,"briefTitle":10918,"status":1092,"phases":10919,"primaryCompletion":10920,"completion":1161,"start":10921,"enrollment":311,"conditions":10922,"interventions":10924},"NCT04489056","Microbiome in Preterm Birth",[],"2021-07","2020-07-27",[10923],"Vaginal Microbiome",[10902]]